返回首页 在线留言 联系我们
首页 > 产品展示 > > 所有 > LKT Labs I5208 INCB-28060 c-MET

产品中心

LKT Labs I5208 INCB-28060 c-MET

  • 型   号:
  • 价   格:

LKT Labs 是一家专注于防癌抗癌特殊化学品研究和开发的公司。主要提供:癌症药物、药物发现试剂盒、天然产物、广泛的生命科学研究试剂、定制合成。
美国LKT Labs 是1988年在美国成立的,为全球提供先端的药物研发试剂、试剂盒、委托合成,并为药物生产企业提供原料,最近几年在农药、水产养殖业有很大程度的开发。LKT Labs I5208 INCB-28060 c-MET

分享到:

LKT Labs 是一家专注于防癌抗癌特殊化学品研究和开发的公司。主要提供:癌症药物、药物发现试剂盒、天然产物、广泛的生命科学研究试剂、定制合成。
美国LKT Labs 是1988年在美国成立的,为全球提供先端的药物研发试剂、试剂盒、委托合成,并为药物生产企业提供原料,最近几年在农药、水产养殖业有很大程度的开发。在LKT Labs 可以找到在其他地方找不到的产品。

LKT Labs I5208 INCB-28060 c-MET

LKT Labs I5208 INCB-28060 c-MET

 

LKT C0366 Carvedilol Phosphate Hemihydrate 5 g 407.7 FIASMA; α1- and β1/2-adrenergic antagonist. (2RS)-1-(9H-Carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]propan-2-ol phosphate salt (1:1) hemihydrate 610309-89-2 ≥98% 513.47 C24H26N2O4 H3O4P 1/2H2O COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O.COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O.O.OP(=O)(O)O.OP(=O)(O)O Ambient 4°C "Arab HH, El-Sawalhi MM. Carvedilol alleviates adjuvant-induced arthritis and subcutaneous air pouch edema: modulation of oxidative stress and inflammatory mediators. Toxicol Appl Pharmacol. 2013 Apr 15;268(2):241-8. PMID: 23360886.

 

Kornhuber J, Muehlbacher M, Trapp S, et al. Identification of novel functional inhibitors of acid sphingomyelinase. PLoS One. 2011;6(8):e23852. PMID: 21909365.

 

Stafylas PC, Sarafidis PA. Carvedilol in hypertension treatment. Vasc Health Risk Manag. 2008;4(1):23-30. PMID: 18629377.

" Not dangerous goods.

LKT C0366 Carvedilol Phosphate Hemihydrate 10 g 652.3 FIASMA; α1- and β1/2-adrenergic antagonist. (2RS)-1-(9H-Carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]propan-2-ol phosphate salt (1:1) hemihydrate 610309-89-2 ≥98% 513.47 C24H26N2O4 H3O4P 1/2H2O COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O.COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O.O.OP(=O)(O)O.OP(=O)(O)O Ambient 4°C "Arab HH, El-Sawalhi MM. Carvedilol alleviates adjuvant-induced arthritis and subcutaneous air pouch edema: modulation of oxidative stress and inflammatory mediators. Toxicol Appl Pharmacol. 2013 Apr 15;268(2):241-8. PMID: 23360886.

 

Kornhuber J, Muehlbacher M, Trapp S, et al. Identification of novel functional inhibitors of acid sphingomyelinase. PLoS One. 2011;6(8):e23852. PMID: 21909365.

 

Stafylas PC, Sarafidis PA. Carvedilol in hypertension treatment. Vasc Health Risk Manag. 2008;4(1):23-30. PMID: 18629377.

" Not dangerous goods.

LKT D1874 DesvenlaFAine Succinate 100 mg 106.1 VenlaFAine metabolite; SERT and NET inhibitor. 4-[2-(Dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]-phenol succinate Pristiq 386750-22-7 ≥98% 395.49 C16H25NO2 C5H8O4 CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O.C(CC(=O)O)C(=O)O.O Ambient Ambient "Song J, Yin J, Chen JD. Acute and chronic effects of desvenlaFAine on gastrointestinal transit and motility in dogs. Neurogastroenterol Motil. 2013 Jul 19. [Epub ahead of print]. PMID: 23865827.

 

Sun Z, Hao Y, Zhang M. Efficacy and safety of desvenlaFAine treatment for hot flashes associated with menopause: a meta-analysis of randomized controlled trials. Gynecol Obstet Invest. 2013;75(4):255-62. PMID: 23548358.

 

DeMartinis NA, Yeung PP, Entsuah R, et al. A double-blind, placebo-controlled study of the efficacy and safety of desvenlaFAine succinate in the treatment of major depressive disorder. J Clin Psychiatry. 2007 May;68(5):677-88. PMID: 17503976.

 

Deecher DC, Beyer CE, Johnston G, et al. DesvenlaFAine succinate: A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006 Aug;318(2):657-65. PMID: 16675639.

" Not dangerous goods

LKT D1874 DesvenlaFAine Succinate 250 mg 203.8 VenlaFAine metabolite; SERT and NET inhibitor. 4-[2-(Dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]-phenol succinate Pristiq 386750-22-7 ≥98% 395.49 C16H25NO2 C5H8O4 CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O.C(CC(=O)O)C(=O)O.O Ambient Ambient "Song J, Yin J, Chen JD. Acute and chronic effects of desvenlaFAine on gastrointestinal transit and motility in dogs. Neurogastroenterol Motil. 2013 Jul 19. [Epub ahead of print]. PMID: 23865827.

 

Sun Z, Hao Y, Zhang M. Efficacy and safety of desvenlaFAine treatment for hot flashes associated with menopause: a meta-analysis of randomized controlled trials. Gynecol Obstet Invest. 2013;75(4):255-62. PMID: 23548358.

 

DeMartinis NA, Yeung PP, Entsuah R, et al. A double-blind, placebo-controlled study of the efficacy and safety of desvenlaFAine succinate in the treatment of major depressive disorder. J Clin Psychiatry. 2007 May;68(5):677-88. PMID: 17503976.

 

Deecher DC, Beyer CE, Johnston G, et al. DesvenlaFAine succinate: A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006 Aug;318(2):657-65. PMID: 16675639.

" Not dangerous goods

LKT D1874 DesvenlaFAine Succinate 1 g 611.5 VenlaFAine metabolite; SERT and NET inhibitor. 4-[2-(Dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]-phenol succinate Pristiq 386750-22-7 ≥98% 395.49 C16H25NO2 C5H8O4 CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O.C(CC(=O)O)C(=O)O.O Ambient Ambient "Song J, Yin J, Chen JD. Acute and chronic effects of desvenlaFAine on gastrointestinal transit and motility in dogs. Neurogastroenterol Motil. 2013 Jul 19. [Epub ahead of print]. PMID: 23865827.

 

Sun Z, Hao Y, Zhang M. Efficacy and safety of desvenlaFAine treatment for hot flashes associated with menopause: a meta-analysis of randomized controlled trials. Gynecol Obstet Invest. 2013;75(4):255-62. PMID: 23548358.

 

DeMartinis NA, Yeung PP, Entsuah R, et al. A double-blind, placebo-controlled study of the efficacy and safety of desvenlaFAine succinate in the treatment of major depressive disorder. J Clin Psychiatry. 2007 May;68(5):677-88. PMID: 17503976.

 

Deecher DC, Beyer CE, Johnston G, et al. DesvenlaFAine succinate: A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006 Aug;318(2):657-65. PMID: 16675639.

" Not dangerous goods

LKT C5618 Coelenterazine, natural 1 mg 269.1 Light-emitting luciferin analog found in aquatic organisms. 2-(p-Hydroxybenzyl)-6-(p-hydroxyphenyl)-8-benzyl-imidazo[1,2-a]pyrazin-3-(7H)-one 55779-48-1 ≥98% 423.46 C26H21N3O3 C1=CC=C(C=C1)CC2=C3N=C(C(=O)N3C=C(N2)C4=CC=C(C=C4)O)CC5=CC=C(C=C5)O Ambient -20°C Soluble in ethanol or methanol. "Schill WB. Immunofluorescent localization of acrosin in spermatozoa by boar acrosin antibodies. Naturwissenschaften. 1975 Nov;62(11):540-1. PMID: 765844.

 

Shimomura O, Johnson FH. Chemical nature of bioluminescence systems in coelenterates. Proc Natl Acad Sci U S A. 1975 Apr;72(4):1546-9. PMID: 236561.

" Not dangerous goods.

LKT C5618 Coelenterazine, natural 5 mg 679.5 Light-emitting luciferin analog found in aquatic organisms. 2-(p-Hydroxybenzyl)-6-(p-hydroxyphenyl)-8-benzyl-imidazo[1,2-a]pyrazin-3-(7H)-one 55779-48-1 ≥98% 423.46 C26H21N3O3 C1=CC=C(C=C1)CC2=C3N=C(C(=O)N3C=C(N2)C4=CC=C(C=C4)O)CC5=CC=C(C=C5)O Ambient -20°C Soluble in ethanol or methanol. "Schill WB. Immunofluorescent localization of acrosin in spermatozoa by boar acrosin antibodies. Naturwissenschaften. 1975 Nov;62(11):540-1. PMID: 765844.

 

Shimomura O, Johnson FH. Chemical nature of bioluminescence systems in coelenterates. Proc Natl Acad Sci U S A. 1975 Apr;72(4):1546-9. PMID: 236561.

" Not dangerous goods.

LKT N5986 Novobiocin Sodium 1 g 65.3 Aminocoumarin; bacterial DNA gyrase inhibitor. 1476-53-5 ≥98% 634.61 C31H35N2NaO11 CC1=C(C=CC2=C1OC(=O)C(=C2O)NC(=O)C3=CC(=C(C=C3)[O-])CC=C(C)C)OC4C(C(C(C(O4)(C)C)OC)OC(=O)N)O.[Na+] Ambient Ambient "Gunaherath GM, Marron MT, Wijeratne EM, et al. Synthesis and biological evaluation of novobiocin analogues as potential heat shock protein 90 inhibitors. Bioorg Med Chem. 2013 Sep 1;21(17):5118-29. PMID: 23859777.

 

Wu D, Zhang R, Zhao R, et al. A novel function of novobiocin: disrupting the interaction of HIF 1α and p300/CBP through direct binding to the HIF1α C-terminal activation domain. PLoS One. 2013 May 6;8(5):e62014. PMID: 23671581.

 

Walsh TJ, Standiford HC, Reboli AC, et al. Randomized Double-Blinded Trial of Rifampin with Either Novobiocin or Trimethoprim-Sulfamethoxazole against Methicillin-Resistant Staphylococcus aureus Colonization: Prevention of Antimicrobial Resistance and Effect of Host Factors on Outcome. Antimicrobial agents and chemotherapy 1993 Jun;37(6):1334–42. PMID: 8328783.

 

Maxwell A. The interaction between coumarin drugs and DNA gyrase. Mol Microbiol 1993;9(4):681–6. PMID: 8231802.

" Not dangerous goods.

LKT N5986 Novobiocin Sodium 5 g 224.3 Aminocoumarin; bacterial DNA gyrase inhibitor. 1476-53-5 ≥98% 634.61 C31H35N2NaO11 CC1=C(C=CC2=C1OC(=O)C(=C2O)NC(=O)C3=CC(=C(C=C3)[O-])CC=C(C)C)OC4C(C(C(C(O4)(C)C)OC)OC(=O)N)O.[Na+] Ambient Ambient "Gunaherath GM, Marron MT, Wijeratne EM, et al. Synthesis and biological evaluation of novobiocin analogues as potential heat shock protein 90 inhibitors. Bioorg Med Chem. 2013 Sep 1;21(17):5118-29. PMID: 23859777.

 

Wu D, Zhang R, Zhao R, et al. A novel function of novobiocin: disrupting the interaction of HIF 1α and p300/CBP through direct binding to the HIF1α C-terminal activation domain. PLoS One. 2013 May 6;8(5):e62014. PMID: 23671581.

 

Walsh TJ, Standiford HC, Reboli AC, et al. Randomized Double-Blinded Trial of Rifampin with Either Novobiocin or Trimethoprim-Sulfamethoxazole against Methicillin-Resistant Staphylococcus aureus Colonization: Prevention of Antimicrobial Resistance and Effect of Host Factors on Outcome. Antimicrobial agents and chemotherapy 1993 Jun;37(6):1334–42. PMID: 8328783.

 

Maxwell A. The interaction between coumarin drugs and DNA gyrase. Mol Microbiol 1993;9(4):681–6. PMID: 8231802.

" Not dangerous goods.

LKT H9812 5-Hydroxytryptophol 10 mg 47.6 Serotonin/melatonin analog found in various plant and food sources, produced by Trypanosoma brucei. 2-(5-Hydroxy-3-indolyl)ethyl alcohol 154-02-9 ≥98% 177.2 C10H11NO2 C1=CC2=C(C=C1O)C(=CN2)CCO Ambient 4°C PBS to 0.3 mg/ml, ethanol to 30 mg/ml, DMSO to 30 mg/ml "Beck O, Helander A. 5-hydroxytryptophol as a marker for recent alcohol intake. Addiction. 2003 Dec;98 Suppl 2:63-72. PMID: 14984243.

 

Wang HX, Liu F, Ng TB. Examination of pineal indoles and 6-methoxy-2-benzoxazolinone for antioxidant and antimicrobial effects. Comp Biochem Physiol C Toxicol Pharmacol. 2001 Nov;130(3):379-88. PMID: 11701394.

 

Cornford EM, Bocash WD, Braun LD, et al. Journal of Clinical Investigation 1979;63(6):1241–8. PMID: 447842.

 

Feldstein A, Chang FH, Kucharski JM. Tryptophol, 5-hydroxytryptophol and 5-methoxytryptophol induced sleep in mice"". Life Sciences  1970;9 (6):323–9. PMID: 5444013.

" Not dangerous goods.

LKT H9812 5-Hydroxytryptophol 25 mg 101.9 Serotonin/melatonin analog found in various plant and food sources, produced by Trypanosoma brucei. 2-(5-Hydroxy-3-indolyl)ethyl alcohol 154-02-9 ≥98% 177.2 C10H11NO2 C1=CC2=C(C=C1O)C(=CN2)CCO Ambient 4°C PBS to 0.3 mg/ml, ethanol to 30 mg/ml, DMSO to 30 mg/ml "Beck O, Helander A. 5-hydroxytryptophol as a marker for recent alcohol intake. Addiction. 2003 Dec;98 Suppl 2:63-72. PMID: 14984243.

 

Wang HX, Liu F, Ng TB. Examination of pineal indoles and 6-methoxy-2-benzoxazolinone for antioxidant and antimicrobial effects. Comp Biochem Physiol C Toxicol Pharmacol. 2001 Nov;130(3):379-88. PMID: 11701394.

 

Cornford EM, Bocash WD, Braun LD, et al. Journal of Clinical Investigation 1979;63(6):1241–8. PMID: 447842.

 

Feldstein A, Chang FH, Kucharski JM. Tryptophol, 5-hydroxytryptophol and 5-methoxytryptophol induced sleep in mice"". Life Sciences  1970;9 (6):323–9. PMID: 5444013.

" Not dangerous goods.

LKT H9812 5-Hydroxytryptophol 100 mg 237.8 Serotonin/melatonin analog found in various plant and food sources, produced by Trypanosoma brucei. 2-(5-Hydroxy-3-indolyl)ethyl alcohol 154-02-9 ≥98% 177.2 C10H11NO2 C1=CC2=C(C=C1O)C(=CN2)CCO Ambient 4°C PBS to 0.3 mg/ml, ethanol to 30 mg/ml, DMSO to 30 mg/ml "Beck O, Helander A. 5-hydroxytryptophol as a marker for recent alcohol intake. Addiction. 2003 Dec;98 Suppl 2:63-72. PMID: 14984243.

 

Wang HX, Liu F, Ng TB. Examination of pineal indoles and 6-methoxy-2-benzoxazolinone for antioxidant and antimicrobial effects. Comp Biochem Physiol C Toxicol Pharmacol. 2001 Nov;130(3):379-88. PMID: 11701394.

 

Cornford EM, Bocash WD, Braun LD, et al. Journal of Clinical Investigation 1979;63(6):1241–8. PMID: 447842.

 

Feldstein A, Chang FH, Kucharski JM. Tryptophol, 5-hydroxytryptophol and 5-methoxytryptophol induced sleep in mice"". Life Sciences  1970;9 (6):323–9. PMID: 5444013.

" Not dangerous goods.

LKT L8011 D-Luciferin Sodium 5 mg 54.4 Heterocyclic light-emitting compound, natural ligand for luciferase, detects cell activity. 4,5-Dihydro-2-(6-hydroxy-2-benzothiazolyl)-4-thiazolecarboxylic acid sodium salt 103404-75-7 ≥99% 302.3 C11H7N2NaO3S2 C1C(NC(=C2N=C3C=CC(=O)C=C3S2)S1)C(=O)[O-].[Na+] Ambient -20°C Soluble in water. "Hastings JW. Chemistries and colors of bioluminescent reactions: a review. Gene 1996;173(1 Spec No):5–11. PMID: 8707056.

 

Green A, McElroy WD. Function of adenosine triphosphate in the activation of luciferin. Arch. Biochem. Biophys. 1956 Oct;64(2):257–71. PMID: 13363432.

" Not dangerous goods.

LKT L8011 D-Luciferin Sodium 25 mg 169.9 Heterocyclic light-emitting compound, natural ligand for luciferase, detects cell activity. 4,5-Dihydro-2-(6-hydroxy-2-benzothiazolyl)-4-thiazolecarboxylic acid sodium salt 103404-75-7 ≥99% 302.3 C11H7N2NaO3S2 C1C(NC(=C2N=C3C=CC(=O)C=C3S2)S1)C(=O)[O-].[Na+] Ambient -20°C Soluble in water. "Hastings JW. Chemistries and colors of bioluminescent reactions: a review. Gene 1996;173(1 Spec No):5–11. PMID: 8707056.

 

Green A, McElroy WD. Function of adenosine triphosphate in the activation of luciferin. Arch. Biochem. Biophys. 1956 Oct;64(2):257–71. PMID: 13363432.

" Not dangerous goods.

LKT L8010 D-Luciferin Potassium 5 mg 54.4 Heterocyclic light-emitting compound, natural ligand for luciferase, detects cell activity. 4,5-Dihydro-2-(6-hydroxy-2-benzothiazolyl)-4-thiazolecarboxylic acid potassium salt 115144-35-9 ≥98% 318.42 C11H7KN2O3S2 C1C(NC(=C2N=C3C=CC(=O)C=C3S2)S1)C(=O)[O-].[K+] ambient -20°C Soluble in water. "Hastings JW. Chemistries and colors of bioluminescent reactions: a review. Gene 1996;173(1 Spec No):5–11. PMID: 8707056.

 

Green A, McElroy WD. Function of adenosine triphosphate in the activation of luciferin. Arch. Biochem. Biophys. 1956 Oct;64(2):257–71. PMID: 13363432.

" Not dangerous goods.

LKT L8010 D-Luciferin Potassium 25 mg 169.9 Heterocyclic light-emitting compound, natural ligand for luciferase, detects cell activity. 4,5-Dihydro-2-(6-hydroxy-2-benzothiazolyl)-4-thiazolecarboxylic acid potassium salt 115144-35-9 ≥98% 318.42 C11H7KN2O3S2 C1C(NC(=C2N=C3C=CC(=O)C=C3S2)S1)C(=O)[O-].[K+] ambient -20°C Soluble in water. "Hastings JW. Chemistries and colors of bioluminescent reactions: a review. Gene 1996;173(1 Spec No):5–11. PMID: 8707056.

 

Green A, McElroy WD. Function of adenosine triphosphate in the activation of luciferin. Arch. Biochem. Biophys. 1956 Oct;64(2):257–71. PMID: 13363432.

" Not dangerous goods.

LKT L8009 D-Luciferin 1-(4,5-dimethoxy-2-nitrophenyl) Ethyl Ester 1 mg 47.6 Cell-membrane permeable heterocyclic light-emitting compound, natural ligand for luciferase, detects cell activity. DMNPE-caged Luciferin 223920-67-0 ≥95% 489.52 C21H19N3O7S2 CC(C1=CC(=C(C=C1[N+](=O)[O-])OC)OC)OC(=O)C2CSC(=C3N=C4C=CC(=O)C=C4S3)N2 Ambient -20°C Soluble in DMSO or DMF "Hastings JW. Chemistries and colors of bioluminescent reactions: a review. Gene 1996;173(1 Spec No):5–11. PMID: 8707056.

 

Green A, McElroy WD. Function of adenosine triphosphate in the activation of luciferin. Arch. Biochem. Biophys. 1956 Oct;64(2):257–71. PMID: 13363432.

" Not dangerous goods.

LKT L8009 D-Luciferin 1-(4,5-dimethoxy-2-nitrophenyl) Ethyl Ester 5 mg 163.2 Cell-membrane permeable heterocyclic light-emitting compound, natural ligand for luciferase, detects cell activity. DMNPE-caged Luciferin 223920-67-0 ≥95% 489.52 C21H19N3O7S2 CC(C1=CC(=C(C=C1[N+](=O)[O-])OC)OC)OC(=O)C2CSC(=C3N=C4C=CC(=O)C=C4S3)N2 Ambient -20°C Soluble in DMSO or DMF "Hastings JW. Chemistries and colors of bioluminescent reactions: a review. Gene 1996;173(1 Spec No):5–11. PMID: 8707056.

 

Green A, McElroy WD. Function of adenosine triphosphate in the activation of luciferin. Arch. Biochem. Biophys. 1956 Oct;64(2):257–71. PMID: 13363432.

" Not dangerous goods.

LKT L8009 D-Luciferin 1-(4,5-dimethoxy-2-nitrophenyl) Ethyl Ester 10 mg 251.5 Cell-membrane permeable heterocyclic light-emitting compound, natural ligand for luciferase, detects cell activity. DMNPE-caged Luciferin 223920-67-0 ≥95% 489.52 C21H19N3O7S2 CC(C1=CC(=C(C=C1[N+](=O)[O-])OC)OC)OC(=O)C2CSC(=C3N=C4C=CC(=O)C=C4S3)N2 Ambient -20°C Soluble in DMSO or DMF "Hastings JW. Chemistries and colors of bioluminescent reactions: a review. Gene 1996;173(1 Spec No):5–11. PMID: 8707056.

 

Green A, McElroy WD. Function of adenosine triphosphate in the activation of luciferin. Arch. Biochem. Biophys. 1956 Oct;64(2):257–71. PMID: 13363432.

" Not dangerous goods.

LKT L8008 D-Luciferin, firefly, Free Acid 5 mg 57.1 Heterocyclic light-emitting compound, natural ligand for luciferase, detects cell activity. (4S)-2-(6-hydroxy-1,3-benzothiazol-2-yl)-4,5-dihydrothiazole-4-carboxylic acid D(-)-Luciferin 2591-17-5 ≥98% 280.32 C11H8N2O3S2 C1C(NC(=C2N=C3C=CC(=O)C=C3S2)S1)C(=O)O Ambient -20°C Insoluble in water. Soluble in methanol. "Hastings JW. Chemistries and colors of bioluminescent reactions: a review. Gene 1996;173(1 Spec No):5–11. PMID: 8707056.

 

Green A, McElroy WD. Function of adenosine triphosphate in the activation of luciferin. Arch. Biochem. Biophys. 1956 Oct;64(2):257–71. PMID: 13363432.

" Not dangerous goods.

LKT L8008 D-Luciferin, firefly, Free Acid 25 mg 197.1 Heterocyclic light-emitting compound, natural ligand for luciferase, detects cell activity. (4S)-2-(6-hydroxy-1,3-benzothiazol-2-yl)-4,5-dihydrothiazole-4-carboxylic acid D(-)-Luciferin 2591-17-5 ≥98% 280.32 C11H8N2O3S2 C1C(NC(=C2N=C3C=CC(=O)C=C3S2)S1)C(=O)O Ambient -20°C Insoluble in water. Soluble in methanol. "Hastings JW. Chemistries and colors of bioluminescent reactions: a review. Gene 1996;173(1 Spec No):5–11. PMID: 8707056.

 

Green A, McElroy WD. Function of adenosine triphosphate in the activation of luciferin. Arch. Biochem. Biophys. 1956 Oct;64(2):257–71. PMID: 13363432.

" Not dangerous goods.

LKT D1757 L-Deoxyalliin 100 mg 54.4 Organosulfur found in garlic. S-Allyl-L-cysteine L-Cysteine, S-2-propenyl-; S-Allylcysteine 21593-77-1 ≥98% 161.22 C6H11NO2S C=CCSCC(C(=O)O)N Ambient 4°C Soluble in water.  "Spera MB, Quintão FA, Ferraresi DK, et al. Palladium(II) complex with S-allyl-L-cysteine: new solid-state NMR spectroscopic measurements, molecular modeling and antibacterial assays. Spectrochim Acta A Mol Biomol Spectrosc. 2011 Jan;78(1):313-8. PMID: 21050807.

 

Arnault I, Christidès JP, Mandon N, et al. High-performance ion-pair chromatography method for simultaneous analysis of alliin, deoxyalliin, allicin and dipeptide precursors in garlic products using multiple mass spectrometry and UV detection. J Chromatogr A. 2003 Mar 28;991(1):69-75. PMID: 12703902.

" Not dangerous goods.

LKT D1757 L-Deoxyalliin 250 mg 95.1 Organosulfur found in garlic. S-Allyl-L-cysteine L-Cysteine, S-2-propenyl-; S-Allylcysteine 21593-77-1 ≥98% 161.22 C6H11NO2S C=CCSCC(C(=O)O)N Ambient 4°C Soluble in water.  "Spera MB, Quintão FA, Ferraresi DK, et al. Palladium(II) complex with S-allyl-L-cysteine: new solid-state NMR spectroscopic measurements, molecular modeling and antibacterial assays. Spectrochim Acta A Mol Biomol Spectrosc. 2011 Jan;78(1):313-8. PMID: 21050807.

 

Arnault I, Christidès JP, Mandon N, et al. High-performance ion-pair chromatography method for simultaneous analysis of alliin, deoxyalliin, allicin and dipeptide precursors in garlic products using multiple mass spectrometry and UV detection. J Chromatogr A. 2003 Mar 28;991(1):69-75. PMID: 12703902.

" Not dangerous goods.

LKT E4444 Ellagic Acid 1 g 61.1 Phenol found in various fruits; HDAC modulator. 2,3,7,8-Tetrahydroxy-[1]benzopyrano[5,4,3-cde][1]benzopyran-5,10-dione Benzoaric acid; Lagistase. 476-66-4 ≥98% 302.2 C14H6O8 C1=C2C3=C(C(=C1O)O)OC(=O)C4=CC(=C(C(=C43)OC2=O)O)O Ambient Ambient Very slightly soluble in water. Soluble in 1 N NaOH (10mg/mL). "Zhou E, Fu Y, Wei Z, et al. Inhibition of allergic airway inflammation through the blockage of NF-κB activation by ellagic acid in an ovalbumin-induced mouse asthma model. Food Funct. 2014 Sep;5(9):2106-12. PMID: 24998475.

 

Kang I, Okla M, Chung S. Ellagic acid inhibits adipocyte differentiation through coactivator-associated arginine methyltransferase 1-mediated chromatin modification. J Nutr Biochem. 2014 Sep;25(9):946-53. PMID: 24929439.

 

Kowshik J, Giri H, Kiran Kishore TK, et al. Ellagic Acid Inhibits VEGF/VEGFR2, PI3K/Akt and MAPK Signaling Cascades in the Hamster Cheek Pouch Carcinogenesis Model. Anticancer Agents Med Chem. 2014 Jul 23. [Epub ahead of print]. PMID: 25060902.

 

Park SW, Kwon MJ, Yoo JY, et al. Antiviral activity and possible mode of action of ellagic acid identified in Lagerstroemia speciosa leaves toward human rhinoviruses. BMC Complement Altern Med. 2014 May 26;14:171. PMID: 24885569.

 

El-Shitany NA, El-Bastawissy EA, El-desoky K. Ellagic acid protects against carrageenan-induced acute inflammation through inhibition of nuclear factor kappa B, inducible cyclooxygenase and proinflammatory cytokines and enhancement of interleukin-10 via an antioxidant mechanism. Int Immunopharmacol. 2014 Apr;19(2):290-9. PMID: 24534771.

 

Njomnang Soh P, Witkowski B, Gales A, et al. Implication of glutathione in the in vitro antiplasmodial mechanism of action of ellagic acid. PLoS One. 2012;7(9):e45906. PMID: 23029306.

 

Beserra AM, Calegari PI, Souza Mdo C, et al. Gastroprotective and ulcer-healing mechanisms of ellagic acid in experimental rats. J Agric Food Chem. 2011 Jul 13;59(13):6957-65. PMID: 21644797

 

Feng Y, Yang SG, Du XT, et al. Ellagic acid promotes Abeta42 fibrillization and inhibits Abeta42-induced neurotoxicity. Biochem Biophys Res Commun. 2009 Dec 25;390(4):1250-4. PMID: 19878655.

 

Edderkaoui M, Odinokova I, Ohno I, et al. Ellagic acid induces apoptosis through inhibition of nuclear factor kappa B in pancreatic cancer cells. World J Gastroenterol. 2008 Jun 21;14(23):3672-80. PMID: 18595134.

 

Zhao M, Tang SN, Marsh JL, et al. Ellagic acid inhibits human pancreatic cancer growth in Balb c nude mice. Cancer Lett. 2013 Sep 1;337(2):210-217. PMID: 23684930.

" Xi Not dangerous goods.

LKT E4444 Ellagic Acid 5 g 122.3 Phenol found in various fruits; HDAC modulator. 2,3,7,8-Tetrahydroxy-[1]benzopyrano[5,4,3-cde][1]benzopyran-5,10-dione Benzoaric acid; Lagistase. 476-66-4 ≥98% 302.2 C14H6O8 C1=C2C3=C(C(=C1O)O)OC(=O)C4=CC(=C(C(=C43)OC2=O)O)O Ambient Ambient Very slightly soluble in water. Soluble in 1 N NaOH (10mg/mL). "Zhou E, Fu Y, Wei Z, et al. Inhibition of allergic airway inflammation through the blockage of NF-κB activation by ellagic acid in an ovalbumin-induced mouse asthma model. Food Funct. 2014 Sep;5(9):2106-12. PMID: 24998475.

 

Kang I, Okla M, Chung S. Ellagic acid inhibits adipocyte differentiation through coactivator-associated arginine methyltransferase 1-mediated chromatin modification. J Nutr Biochem. 2014 Sep;25(9):946-53. PMID: 24929439.

 

Kowshik J, Giri H, Kiran Kishore TK, et al. Ellagic Acid Inhibits VEGF/VEGFR2, PI3K/Akt and MAPK Signaling Cascades in the Hamster Cheek Pouch Carcinogenesis Model. Anticancer Agents Med Chem. 2014 Jul 23. [Epub ahead of print]. PMID: 25060902.

 

Park SW, Kwon MJ, Yoo JY, et al. Antiviral activity and possible mode of action of ellagic acid identified in Lagerstroemia speciosa leaves toward human rhinoviruses. BMC Complement Altern Med. 2014 May 26;14:171. PMID: 24885569.

 

El-Shitany NA, El-Bastawissy EA, El-desoky K. Ellagic acid protects against carrageenan-induced acute inflammation through inhibition of nuclear factor kappa B, inducible cyclooxygenase and proinflammatory cytokines and enhancement of interleukin-10 via an antioxidant mechanism. Int Immunopharmacol. 2014 Apr;19(2):290-9. PMID: 24534771.

 

Njomnang Soh P, Witkowski B, Gales A, et al. Implication of glutathione in the in vitro antiplasmodial mechanism of action of ellagic acid. PLoS One. 2012;7(9):e45906. PMID: 23029306.

 

Beserra AM, Calegari PI, Souza Mdo C, et al. Gastroprotective and ulcer-healing mechanisms of ellagic acid in experimental rats. J Agric Food Chem. 2011 Jul 13;59(13):6957-65. PMID: 21644797

 

Feng Y, Yang SG, Du XT, et al. Ellagic acid promotes Abeta42 fibrillization and inhibits Abeta42-induced neurotoxicity. Biochem Biophys Res Commun. 2009 Dec 25;390(4):1250-4. PMID: 19878655.

 

Edderkaoui M, Odinokova I, Ohno I, et al. Ellagic acid induces apoptosis through inhibition of nuclear factor kappa B in pancreatic cancer cells. World J Gastroenterol. 2008 Jun 21;14(23):3672-80. PMID: 18595134.

 

Zhao M, Tang SN, Marsh JL, et al. Ellagic acid inhibits human pancreatic cancer growth in Balb c nude mice. Cancer Lett. 2013 Sep 1;337(2):210-217. PMID: 23684930.

" Xi Not dangerous goods.

LKT E7657 Etoposide 25 mg 46.4 Podophyllotoxin derivative; topoisomerase II inhibitor. 9-[(4,6-O-Ethylidene-β-D-glucopyranosyl)oxy]-5,8,- 8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)- furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one EPEG; Lastet; Vepesid 33419-42-0 ≥98% 588.56 C29H32O13 CC1OCC2C(O1)C(C(C(O2)OC3C4COC(=O)C4C(C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O Ambient Ambient Slightly soluble in ethanol or chloroform. Practically insoluble in water. "Johnson TS, Terrell CE, Millen SH, et al. Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis. J Immunol. 2014 Jan 1;192(1):84-91. PMID: 24259502.

 

Mir Mohammadrezaei F, Mohseni kouchesfehani H, Montazeri H, et al. Signaling crosstalk of FHIT, CHK2 and p38 in etoposide induced growth inhibition in MCF-7 cells. Cell Signal. 2013 Jan;25(1):126-32. PMID: 23000346.

 

Yoo SH, Yoon YG, Lee JS, et al. Etoposide induces a mixed type of programmed cell death and overcomes the resistance conferred by Bcl-2 in Hep3B hepatoma cells. Int J Oncol. 2012 Oct;41(4):1443-54. PMID: 22895528.

 

Shin SY, Kim CG, Ko J, et al. Transcriptional and post-transcriptional regulation of the PKC delta gene by etoposide in L1210 murine leukemia cells: implication of PKC delta autoregulation. J Mol Biol. 2004 Jul 16;340(4):681-93. PMID: 15223313.

 

Mizumoto K, Rothman RJ, Farber JL. Programmed cell death (apoptosis) of mouse fibroblasts is induced by the topoisomerase II inhibitor etoposide. Mol Pharmacol. 1994 Nov;46(5):890-5. PMID: 7969076.

 

Nissen NI, Dombernowsky P, Hansen HH, et al. The epipodophyllotoxin derivatives VM-26 and VP-16-213, 1976-1979, a review. Recent Results Cancer Res. 1980;74:98-106. PMID: 7003663.

 

Marcon L, Zhang X, Hales BF, et al. Effects of chemotherapeutic agents for testicular cancer on rat spermatogonial stem/progenitor cells. J Androl. 2011 Jul-Aug;32(4):432-443. PMID: 21088230.

 

Li Z, Sun B, Clewell RA, et al. Dose-response modeling of etoposide-induced DNA damage response. Toxicol Sci. 2014 Feb;137(2):371-384. PMID: 24241721.

 

Zhang F, Koh GY, Hollingsworth J, et al. Reformulation of etoposide with solubility-enhancing rubusoside. Int J Pharm. 2012 Sep 15;434(1-2):453-459. PMID: 22698860." Xn, Carc., Xi Not dangerous goods.

LKT S3453 Sinigrin Monohydrate, synthetic 100 mg 92.5 ITC precursor found in cruciferous vegetables. 3952-98-5 ≥98% 415.49 C10H17KNO9S2 H2O C=CCC(=NOS(=O)(=O)[O-])SC1C(C(C(C(O1)CO)O)O)O.[K+] Ambient -20°C "Okulicz M. Multidirectional time-dependent effect of sinigrin and allyl isothiocyanate on metabolic parameters in rats. Plant Foods Hum Nutr. 2010 Sep;65(3):217-24. PMID: 20809411.

 

Washida K, Miyata M, Koyama T, et al. Suppressive effect of Yamato-mana (Brassica rapa L. Oleifera Group) constituent 3-butenyl glucosinolate (gluconapin) on postprandial hypertriglyceridemia in mice. Biosci Biotechnol Biochem. 2010;74(6):1286-9. PMID: 20530888.

 

Hwang ES, Lee HJ. Induction of quinone reductase by allylisothiocyanate (AITC) and the N-acetylcysteine conjugate of AITC in Hepa1c1c7 mouse hepatoma cells. Biofactors. 2006;26(1):7-15. PMID: 16614479

 

Hwang ES, Lee HJ. Allyl isothiocyanate and its N-acetylcysteine conjugate suppress metastasis via inhibition of invasion, migration, and matrix metalloproteinase-2/-9 activities in SK-Hep 1 human hepatoma cells. Exp Biol Med (Maywood). 2006 Apr;231(4):421-30. PMID: 16565438.

 

McWalter GK, Higgins LG, McLellan LI, et al. Transcription factor Nrf2 is essential for induction of NAD(P)H:quinone oxidoreductase 1, glutathione S-transferases, and glutamate cysteine ligase by broccoli seeds and isothiocyanates. J Nutr. 2004 Dec;134(12 Suppl):3499S-3506S. PMID: 15570060." Not dangerous goods.

LKT S3453 Sinigrin Monohydrate, synthetic 250 mg 169.9 ITC precursor found in cruciferous vegetables. 3952-98-5 ≥98% 415.49 C10H17KNO9S2 H2O C=CCC(=NOS(=O)(=O)[O-])SC1C(C(C(C(O1)CO)O)O)O.[K+] Ambient -20°C "Okulicz M. Multidirectional time-dependent effect of sinigrin and allyl isothiocyanate on metabolic parameters in rats. Plant Foods Hum Nutr. 2010 Sep;65(3):217-24. PMID: 20809411.

 

Washida K, Miyata M, Koyama T, et al. Suppressive effect of Yamato-mana (Brassica rapa L. Oleifera Group) constituent 3-butenyl glucosinolate (gluconapin) on postprandial hypertriglyceridemia in mice. Biosci Biotechnol Biochem. 2010;74(6):1286-9. PMID: 20530888.

 

Hwang ES, Lee HJ. Induction of quinone reductase by allylisothiocyanate (AITC) and the N-acetylcysteine conjugate of AITC in Hepa1c1c7 mouse hepatoma cells. Biofactors. 2006;26(1):7-15. PMID: 16614479

 

Hwang ES, Lee HJ. Allyl isothiocyanate and its N-acetylcysteine conjugate suppress metastasis via inhibition of invasion, migration, and matrix metalloproteinase-2/-9 activities in SK-Hep 1 human hepatoma cells. Exp Biol Med (Maywood). 2006 Apr;231(4):421-30. PMID: 16565438.

 

McWalter GK, Higgins LG, McLellan LI, et al. Transcription factor Nrf2 is essential for induction of NAD(P)H:quinone oxidoreductase 1, glutathione S-transferases, and glutamate cysteine ligase by broccoli seeds and isothiocyanates. J Nutr. 2004 Dec;134(12 Suppl):3499S-3506S. PMID: 15570060." Not dangerous goods.

LKT S3453 Sinigrin Monohydrate, synthetic 1 g 509.7 ITC precursor found in cruciferous vegetables. 3952-98-5 ≥98% 415.49 C10H17KNO9S2 H2O C=CCC(=NOS(=O)(=O)[O-])SC1C(C(C(C(O1)CO)O)O)O.[K+] Ambient -20°C "Okulicz M. Multidirectional time-dependent effect of sinigrin and allyl isothiocyanate on metabolic parameters in rats. Plant Foods Hum Nutr. 2010 Sep;65(3):217-24. PMID: 20809411.

 

Washida K, Miyata M, Koyama T, et al. Suppressive effect of Yamato-mana (Brassica rapa L. Oleifera Group) constituent 3-butenyl glucosinolate (gluconapin) on postprandial hypertriglyceridemia in mice. Biosci Biotechnol Biochem. 2010;74(6):1286-9. PMID: 20530888.

 

Hwang ES, Lee HJ. Induction of quinone reductase by allylisothiocyanate (AITC) and the N-acetylcysteine conjugate of AITC in Hepa1c1c7 mouse hepatoma cells. Biofactors. 2006;26(1):7-15. PMID: 16614479

 

Hwang ES, Lee HJ. Allyl isothiocyanate and its N-acetylcysteine conjugate suppress metastasis via inhibition of invasion, migration, and matrix metalloproteinase-2/-9 activities in SK-Hep 1 human hepatoma cells. Exp Biol Med (Maywood). 2006 Apr;231(4):421-30. PMID: 16565438.

 

McWalter GK, Higgins LG, McLellan LI, et al. Transcription factor Nrf2 is essential for induction of NAD(P)H:quinone oxidoreductase 1, glutathione S-transferases, and glutamate cysteine ligase by broccoli seeds and isothiocyanates. J Nutr. 2004 Dec;134(12 Suppl):3499S-3506S. PMID: 15570060." Not dangerous goods.

LKT W0273 R-(+)-Warfarin >99%ee 1 mg 81.6 Coumarin; VKORC1 inhibitor. (+)-Warfarin 5543-58-8 ≥98% 308.33 C19H16O4 CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O Ambient 4°C [a]D23 = +150° (c = 1.2, 0.5M NaOH) "Hall AM, Wilkins MR. Warfarin: a case history in pharmacogenetics. Heart. 2005 May;91(5):563-4. PMID: 15831631.

 

Tabrizi AR, Zehnbauer BA, Borecki IB, et al. The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin. J Am Coll Surg. 2002 Mar;194(3):267-73. PMID: 11893129.

 

Freedman MD. Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects. J Clin Pharmacol. 1992 Mar;32(3):196-209. PMID:1564123.

 

Wallin R, Martin LF. Vitamin K-dependent carboxylation and vitamin K metabolism in liver. Effects of warfarin. J Clin Invest. 1985 Nov;76(5):1879-84. PMID: 3932474.

 

Suttie JW. Mechanism of action of vitamin K: demonstration of a liver precursor of prothrombin. Science. 1973 Jan 12;179(4069):192-4. PMID: 4682251." "UN number: 2811     Class: 6.1     Packing Group: I

Proper shipping name: Toxic solid, organic, n.o.s. ((R)-(+)-Warfarin)"

LKT W0273 R-(+)-Warfarin >99%ee 5 mg 339.8 Coumarin; VKORC1 inhibitor. (+)-Warfarin 5543-58-8 ≥98% 308.33 C19H16O4 CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O Ambient 4°C [a]D23 = +150° (c = 1.2, 0.5M NaOH) "Hall AM, Wilkins MR. Warfarin: a case history in pharmacogenetics. Heart. 2005 May;91(5):563-4. PMID: 15831631.

 

Tabrizi AR, Zehnbauer BA, Borecki IB, et al. The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin. J Am Coll Surg. 2002 Mar;194(3):267-73. PMID: 11893129.

 

Freedman MD. Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects. J Clin Pharmacol. 1992 Mar;32(3):196-209. PMID:1564123.

 

Wallin R, Martin LF. Vitamin K-dependent carboxylation and vitamin K metabolism in liver. Effects of warfarin. J Clin Invest. 1985 Nov;76(5):1879-84. PMID: 3932474.

 

Suttie JW. Mechanism of action of vitamin K: demonstration of a liver precursor of prothrombin. Science. 1973 Jan 12;179(4069):192-4. PMID: 4682251." "UN number: 2811     Class: 6.1     Packing Group: I

Proper shipping name: Toxic solid, organic, n.o.s. ((R)-(+)-Warfarin)"

LKT W0273 R-(+)-Warfarin >99%ee 25 mg 1019.2 Coumarin; VKORC1 inhibitor. (+)-Warfarin 5543-58-8 ≥98% 308.33 C19H16O4 CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O Ambient 4°C [a]D23 = +150° (c = 1.2, 0.5M NaOH) "Hall AM, Wilkins MR. Warfarin: a case history in pharmacogenetics. Heart. 2005 May;91(5):563-4. PMID: 15831631.

 

Tabrizi AR, Zehnbauer BA, Borecki IB, et al. The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin. J Am Coll Surg. 2002 Mar;194(3):267-73. PMID: 11893129.

 

Freedman MD. Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects. J Clin Pharmacol. 1992 Mar;32(3):196-209. PMID:1564123.

 

Wallin R, Martin LF. Vitamin K-dependent carboxylation and vitamin K metabolism in liver. Effects of warfarin. J Clin Invest. 1985 Nov;76(5):1879-84. PMID: 3932474.

 

Suttie JW. Mechanism of action of vitamin K: demonstration of a liver precursor of prothrombin. Science. 1973 Jan 12;179(4069):192-4. PMID: 4682251." "UN number: 2811     Class: 6.1     Packing Group: I

Proper shipping name: Toxic solid, organic, n.o.s. ((R)-(+)-Warfarin)"

LKT W0272 S-(−)-Warfarin >99%ee 1 mg 101.9 Coumarin, more potent isomer; VKORC1 inhibitor. (-)-Warfarin 5543-57-7 ≥98% 308.33 C19H16O4 CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O Ambient 4°C [a]D23 = -148° (c = 1.2, 0.5M NaOH) "Hall AM, Wilkins MR. Warfarin: a case history in pharmacogenetics. Heart. 2005 May;91(5):563-4. PMID: 15831631.

 

Tabrizi AR, Zehnbauer BA, Borecki IB, et al. The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin. J Am Coll Surg. 2002 Mar;194(3):267-73. PMID: 11893129.

 

Freedman MD. Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects. J Clin Pharmacol. 1992 Mar;32(3):196-209. PMID:1564123.

 

Wallin R, Martin LF. Vitamin K-dependent carboxylation and vitamin K metabolism in liver. Effects of warfarin. J Clin Invest. 1985 Nov;76(5):1879-84. PMID: 3932474.

 

Suttie JW. Mechanism of action of vitamin K: demonstration of a liver precursor of prothrombin. Science. 1973 Jan 12;179(4069):192-4. PMID: 4682251." "UN number: 2811     Class: 6.1     Packing Group: I

Proper shipping name: Toxic solid, organic, n.o.s. ((S)-(-)-Warfarin)"

LKT W0272 S-(−)-Warfarin >99%ee 5 mg 407.7 Coumarin, more potent isomer; VKORC1 inhibitor. (-)-Warfarin 5543-57-7 ≥98% 308.33 C19H16O4 CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O Ambient 4°C [a]D23 = -148° (c = 1.2, 0.5M NaOH) "Hall AM, Wilkins MR. Warfarin: a case history in pharmacogenetics. Heart. 2005 May;91(5):563-4. PMID: 15831631.

 

Tabrizi AR, Zehnbauer BA, Borecki IB, et al. The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin. J Am Coll Surg. 2002 Mar;194(3):267-73. PMID: 11893129.

 

Freedman MD. Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects. J Clin Pharmacol. 1992 Mar;32(3):196-209. PMID:1564123.

 

Wallin R, Martin LF. Vitamin K-dependent carboxylation and vitamin K metabolism in liver. Effects of warfarin. J Clin Invest. 1985 Nov;76(5):1879-84. PMID: 3932474.

 

Suttie JW. Mechanism of action of vitamin K: demonstration of a liver precursor of prothrombin. Science. 1973 Jan 12;179(4069):192-4. PMID: 4682251." "UN number: 2811     Class: 6.1     Packing Group: I

Proper shipping name: Toxic solid, organic, n.o.s. ((S)-(-)-Warfarin)"

LKT W0272 S-(−)-Warfarin >99%ee 25 mg 1291 Coumarin, more potent isomer; VKORC1 inhibitor. (-)-Warfarin 5543-57-7 ≥98% 308.33 C19H16O4 CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O Ambient 4°C [a]D23 = -148° (c = 1.2, 0.5M NaOH) "Hall AM, Wilkins MR. Warfarin: a case history in pharmacogenetics. Heart. 2005 May;91(5):563-4. PMID: 15831631.

 

Tabrizi AR, Zehnbauer BA, Borecki IB, et al. The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin. J Am Coll Surg. 2002 Mar;194(3):267-73. PMID: 11893129.

 

Freedman MD. Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects. J Clin Pharmacol. 1992 Mar;32(3):196-209. PMID:1564123.

 

Wallin R, Martin LF. Vitamin K-dependent carboxylation and vitamin K metabolism in liver. Effects of warfarin. J Clin Invest. 1985 Nov;76(5):1879-84. PMID: 3932474.

 

Suttie JW. Mechanism of action of vitamin K: demonstration of a liver precursor of prothrombin. Science. 1973 Jan 12;179(4069):192-4. PMID: 4682251." "UN number: 2811     Class: 6.1     Packing Group: I

Proper shipping name: Toxic solid, organic, n.o.s. ((S)-(-)-Warfarin)"

LKT F4480 5-Fluorouracil 25 g 336.1 Pyrimidine analog; inhibits thymidylate synthase. 5-Fluoro-2,4(1H,3H)-pyrimidinedione Fluorouracil; 5-FU; 2,4-dioxo-5-fluoropyrimidine 51-21-8 ≥98% 130.08 C4H3FN2O2 C1=C(C(=O)NC(=O)N1)F Sensitive to light. Ambient Ambient Slightly soluble in water (12mg/mL). "Papanastasopoulos P, Stebbing J. Molecular basis of 5-fluorouracil-related toxicity: lessons from clinical practice. Anticancer Res. 2014 Apr;34(4):1531-5. PMID: 24692679.

 

Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003 May;3(5):330-8. PMID: 12724731.

" Xi, Xn, Repr. "UN number: 2811     Class:  6.1     Packing group:  III

Proper shipping name:  Toxic solids, organic, n.o.s. (Fluorouracil)

Reportable Quantity (RQ):  Marine pollutant:  No     Poison Inhalation Hazard:  No"

LKT S7600 Staurosporine 25 mg 407.7 Alkaloid produced by Streptomyces, precursor in the synthesis of K252c; PKC and mammalian RNA splicing inhibitor. AM-2282 62996-74-1 ≥98% 466.5 C28H26N4O3 CC12C(C(CC(O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)NC)OC Protect from light. Ambient -20°C Soluble in DMSO (50 mM), ethanol, or methanol (2 mg/mL). Insoluble in water. "Zhao C, Yin P, Mei C, et al. Down-regulation of DNA methyltransferase 3B in staurosporine-induced apoptosis and its mechanism in human hepatocarcinoma cell lines. Mol Cell Biochem. 2013 Apr;376(1-2):111-9. PMID: 23397112.

 

Bruges G, Betancourt M, March M, et al. Apoptotic-like activity of staurosporine in axenic cultures of Trypanosoma evansi. Rev Inst Med Trop Sao Paulo. 2012 Mar-Apr;54(2):103-8. PMID: 22499424.

 

Aukema KG, Chohan KK, Plourde GL, et al. Small molecule inhibitors of yeast pre-mRNA splicing. ACS Chem Biol. 2009 Sep 18;4(9):759-68. PMID: 19634919.

 

Tanramluk D, Schreyer A, Pitt WR, et al. On the origins of enzyme inhibitor selectivity and promiscuity: a case study of protein kinase binding to staurosporine. Chem Biol Drug Des. 2009 Jul;74(1):16-24. PMID: 19519740." Xn, T, Xi, Carc. Not dangerous goods.

LKT S7600 Staurosporine 100 mg 1155.2 Alkaloid produced by Streptomyces, precursor in the synthesis of K252c; PKC and mammalian RNA splicing inhibitor. AM-2282 62996-74-1 ≥98% 466.5 C28H26N4O3 CC12C(C(CC(O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)NC)OC Protect from light. Ambient -20°C Soluble in DMSO (50 mM), ethanol, or methanol (2 mg/mL). Insoluble in water. "Zhao C, Yin P, Mei C, et al. Down-regulation of DNA methyltransferase 3B in staurosporine-induced apoptosis and its mechanism in human hepatocarcinoma cell lines. Mol Cell Biochem. 2013 Apr;376(1-2):111-9. PMID: 23397112.

 

Bruges G, Betancourt M, March M, et al. Apoptotic-like activity of staurosporine in axenic cultures of Trypanosoma evansi. Rev Inst Med Trop Sao Paulo. 2012 Mar-Apr;54(2):103-8. PMID: 22499424.

 

Aukema KG, Chohan KK, Plourde GL, et al. Small molecule inhibitors of yeast pre-mRNA splicing. ACS Chem Biol. 2009 Sep 18;4(9):759-68. PMID: 19634919.

 

Tanramluk D, Schreyer A, Pitt WR, et al. On the origins of enzyme inhibitor selectivity and promiscuity: a case study of protein kinase binding to staurosporine. Chem Biol Drug Des. 2009 Jul;74(1):16-24. PMID: 19519740." Xn, T, Xi, Carc. Not dangerous goods.

LKT C5870 Corosolic Acid 10 mg 129 Pentacyclic triterpene found in the Banaba plant. 2α-Hydroxyursolic acid, Colosolic acid, Corsolic acid, Glucosol 4547-24-4 ≥98% 472.7 C30H48O4 CC1CCC2(CCC3(C(=CCC4C3(CCC5C4(CC(C(C5(C)C)O)O)C)C)C2C1C)C)C(=O)O Ambient 4°C "Nho KJ, Chun JM, Kim HK. Corosolic acid induces apoptotic cell death in human lung adenocarcinoma A549 cells in vitro. Food Chem Toxicol. 2013 Jun;56:8-17. PMID: 23454206.

 

Horlad H, Fujiwara Y, Takemura K, et al. Corosolic acid impairs tumor development and lung metastasis by inhibiting the immunosuppressive activity of myeloid-derived suppressor cells. Mol Nutr Food Res. 2013 Jun;57(6):1046-54. PMID: 23417831.

 

Miura T, Takagi S, Ishida T. Management of Diabetes and Its Complications with Banaba (Lagerstroemia speciosa L.) and Corosolic Acid. Evid Based Complement Alternat Med. 2012;2012:871495. PMID: 23082086.

 

Chen H, Yang J, Zhang Q, et al. Corosolic acid ameliorates atherosclerosis in apolipoprotein E-deficient mice by regulating the nuclear factor-κB signaling pathway and inhibiting monocyte chemoattractant protein-1 expression. Circ J. 2012;76(4):995-1003. PMID: 22293444.

 

Takagi S, Miura T, Ishihara E, et al. Effect of corosolic acid on dietary hypercholesterolemia and hepatic steatosis in KK-Ay diabetic mice. Biomed Res. 2010 Aug;31(4):213-8. PMID: 20834178." Not dangerous goods.

LKT C5870 Corosolic Acid 25 mg 265 Pentacyclic triterpene found in the Banaba plant. 2α-Hydroxyursolic acid, Colosolic acid, Corsolic acid, Glucosol 4547-24-4 ≥98% 472.7 C30H48O4 CC1CCC2(CCC3(C(=CCC4C3(CCC5C4(CC(C(C5(C)C)O)O)C)C)C2C1C)C)C(=O)O Ambient 4°C "Nho KJ, Chun JM, Kim HK. Corosolic acid induces apoptotic cell death in human lung adenocarcinoma A549 cells in vitro. Food Chem Toxicol. 2013 Jun;56:8-17. PMID: 23454206.

 

Horlad H, Fujiwara Y, Takemura K, et al. Corosolic acid impairs tumor development and lung metastasis by inhibiting the immunosuppressive activity of myeloid-derived suppressor cells. Mol Nutr Food Res. 2013 Jun;57(6):1046-54. PMID: 23417831.

 

Miura T, Takagi S, Ishida T. Management of Diabetes and Its Complications with Banaba (Lagerstroemia speciosa L.) and Corosolic Acid. Evid Based Complement Alternat Med. 2012;2012:871495. PMID: 23082086.

 

Chen H, Yang J, Zhang Q, et al. Corosolic acid ameliorates atherosclerosis in apolipoprotein E-deficient mice by regulating the nuclear factor-κB signaling pathway and inhibiting monocyte chemoattractant protein-1 expression. Circ J. 2012;76(4):995-1003. PMID: 22293444.

 

Takagi S, Miura T, Ishihara E, et al. Effect of corosolic acid on dietary hypercholesterolemia and hepatic steatosis in KK-Ay diabetic mice. Biomed Res. 2010 Aug;31(4):213-8. PMID: 20834178." Not dangerous goods.

LKT C5870 Corosolic Acid 100 mg 815.4 Pentacyclic triterpene found in the Banaba plant. 2α-Hydroxyursolic acid, Colosolic acid, Corsolic acid, Glucosol 4547-24-4 ≥98% 472.7 C30H48O4 CC1CCC2(CCC3(C(=CCC4C3(CCC5C4(CC(C(C5(C)C)O)O)C)C)C2C1C)C)C(=O)O Ambient 4°C "Nho KJ, Chun JM, Kim HK. Corosolic acid induces apoptotic cell death in human lung adenocarcinoma A549 cells in vitro. Food Chem Toxicol. 2013 Jun;56:8-17. PMID: 23454206.

 

Horlad H, Fujiwara Y, Takemura K, et al. Corosolic acid impairs tumor development and lung metastasis by inhibiting the immunosuppressive activity of myeloid-derived suppressor cells. Mol Nutr Food Res. 2013 Jun;57(6):1046-54. PMID: 23417831.

 

Miura T, Takagi S, Ishida T. Management of Diabetes and Its Complications with Banaba (Lagerstroemia speciosa L.) and Corosolic Acid. Evid Based Complement Alternat Med. 2012;2012:871495. PMID: 23082086.

 

Chen H, Yang J, Zhang Q, et al. Corosolic acid ameliorates atherosclerosis in apolipoprotein E-deficient mice by regulating the nuclear factor-κB signaling pathway and inhibiting monocyte chemoattractant protein-1 expression. Circ J. 2012;76(4):995-1003. PMID: 22293444.

 

Takagi S, Miura T, Ishihara E, et al. Effect of corosolic acid on dietary hypercholesterolemia and hepatic steatosis in KK-Ay diabetic mice. Biomed Res. 2010 Aug;31(4):213-8. PMID: 20834178." Not dangerous goods.

LKT L1761 Leptomycin B 10 µg 61.1 Polyketide; CRM1 inhibitor. "19-(3,6-dihydro-3-methyl-6-oxo-2H-pyran-2-yl)-17-ethyl-6-hydroxy-3,5,7,9,11,15-hexamethyl-8-oxo- 2,10,12,16,18-Nonadecapentaenoic acid

" LMB; Elactocin, CI-940, CL-1957A, NSC-364372, PD-114720. 87081-35-4 ≥98% 540.74 C33H48O6 CCC(=CC(C)CC=CC(=CC(C)C(=O)C(C)C(C(C)CC(=CC(=O)O)C)O)C)C=CC1C(C=CC(=O)O1)C WARNING:  Small quantities of LepB are reported to be unstable when dried down into a film.  Thus, under no circumstances should the solvent be removed from solutions of LepB, because rapid decomposition may result. Ambient -20°C "Soluble in ethanol or methanol.

 

" "Sun Q, Carrasco YP, Hu Y, et al. Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1. Proc Natl Acad Sci U S A. 2013 Jan 22;110(4):1303-8. PMID: 23297231.

 

Abkallo HM, Kawano H, Watanabe K, et al. A new cell-based reporter system for sensitive screening of nuclear export inhibitors. Drug Discov Ther. 2011 Dec;5(6):286-92. PMID: 22466439.

 

Lu C, Shao C, Cobos E, et al. Chemotherapeutic sensitization of leptomycin B resistant lung cancer cells by pretreatment with doxorubicin. PLoS One. 2012;7(3):e32895. PMID: 22412944.

 

Hamamoto T, Gunji S, Tsuji H, et al. Leptomycins A and B, new antifungal antibiotics. I. Taxonomy of the producing strain and their fermentation, purification and characterization. J Antibiot (Tokyo). 1983 Jun;36(6):639-45. PMID: 6874585.

" F, T, Xi "UN number: 1170     Class:  3     Packing group:  II

Proper shipping name:  Ethanol solution

Reportable Quantitiy (RQ):  7150 lbs.     Poison Inhalation Hazard:  No"

LKT L1761 Leptomycin B 50 µg 136 Polyketide; CRM1 inhibitor. "19-(3,6-dihydro-3-methyl-6-oxo-2H-pyran-2-yl)-17-ethyl-6-hydroxy-3,5,7,9,11,15-hexamethyl-8-oxo- 2,10,12,16,18-Nonadecapentaenoic acid

" LMB; Elactocin, CI-940, CL-1957A, NSC-364372, PD-114720. 87081-35-4 ≥98% 540.74 C33H48O6 CCC(=CC(C)CC=CC(=CC(C)C(=O)C(C)C(C(C)CC(=CC(=O)O)C)O)C)C=CC1C(C=CC(=O)O1)C WARNING:  Small quantities of LepB are reported to be unstable when dried down into a film.  Thus, under no circumstances should the solvent be removed from solutions of LepB, because rapid decomposition may result. Ambient -20°C "Soluble in ethanol or methanol.

 

" "Sun Q, Carrasco YP, Hu Y, et al. Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1. Proc Natl Acad Sci U S A. 2013 Jan 22;110(4):1303-8. PMID: 23297231.

 

Abkallo HM, Kawano H, Watanabe K, et al. A new cell-based reporter system for sensitive screening of nuclear export inhibitors. Drug Discov Ther. 2011 Dec;5(6):286-92. PMID: 22466439.

 

Lu C, Shao C, Cobos E, et al. Chemotherapeutic sensitization of leptomycin B resistant lung cancer cells by pretreatment with doxorubicin. PLoS One. 2012;7(3):e32895. PMID: 22412944.

 

Hamamoto T, Gunji S, Tsuji H, et al. Leptomycins A and B, new antifungal antibiotics. I. Taxonomy of the producing strain and their fermentation, purification and characterization. J Antibiot (Tokyo). 1983 Jun;36(6):639-45. PMID: 6874585.

" F, T, Xi "UN number: 1170     Class:  3     Packing group:  II

Proper shipping name:  Ethanol solution

Reportable Quantitiy (RQ):  7150 lbs.     Poison Inhalation Hazard:  No"

LKT C0150 Camptothecin 500 mg 243.4 Quinolone alkaloid precursor of irinotecan, originally found in Camptotheca; topoisomerase I inhibitor. (S)-4-Ethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino- [1,2-b]quinoline-3,14(4H,12H)-dione 7689-03-4 ≥98% 348.35 C20H16N2O4 CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=CC=CC=C5N=C4C3=C2)O Ambient -20°C Soluble in DMSO. "Rodríguez-Berna G, Mangas-Sanjuán V, Gonzalez-Alvarez M, et al. A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability. Eur J Med Chem. 2014 Jun 25;83C:366-373. PMID: 24980118.

 

Berniak K, Rybak P, Bernas T, et al. Relationship between DNA damage response, initiated by camptothecin or oxidative stress, and DNA replication, analyzed by quantitative 3D image analysis. Cytometry A. 2013 Jul 11. [Epub ahead of print]. PMID: 23846844.

 

Redinbo MR, Stewart L, Kuhn P, et al. Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science. 1998 Mar 6;279(5356):1504-13. PMID: 9488644.

" T "UN number: 1544     Class: 6.1     Packing group:  III

Proper shipping name:  Alkaloids, solid, n.o.s. ((S)-(+)-Camptothecin)

Marine pollutant:  No.     Poison Inhalation Hazard:  No"

LKT C0269 β-Carotene 25 g 136 Red-orange terpene pigment found in various plants and fruits, vitamin A prodrug. β,β-Carotene Carotaben; Provatene; Solatene 7235-40-7 ≥97% 536.87 C40H56 CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)C=CC2=C(CCCC2(C)C)C)C)C Ambient -20°C Insoluble in water. Sparingly soluble in ethanol. Soluble in benzene or chloroform. "Abdel-Mageed WM, Bayoumi SA, Salama AA, et al. Antioxidant lipoxygenase inhibitors from the leaf extracts of Simmondsia chinensis. Asian Pac J Trop Med. 2014 Sep;7S1:S521-6. PMID: 25312177.

 

Berti AP, Düsman E, Mariucci RG, et al. Antimutagenic and radioprotective activities of beta-carotene against the biological effects of iodine-131 radiopharmaceutical in Wistar rats. Genet Mol Res. 2014 Mar 31;13(1):2248-58. PMID: 24737473.

 

Gloria NF, Soares N, Brand C, et al. Lycopene and beta-carotene induce cell-cycle arrest and apoptosis in human breast cancer cell lines. Anticancer Res. 2014 Mar;34(3):1377-86. PMID: 24596385.

 

Silva LS, de Miranda AM, de Brito Magalhães CL, et al. Diet supplementation with beta-carotene improves the serum lipid profile in rats fed a cholesterol-enriched diet. J Physiol Biochem. 2013 Dec;69(4):811-20. PMID: 23645541.

 

Di Tomo P, Canali R, Ciavardelli D, et al. β-Carotene and lycopene affect endothelial response to TNF-α reducing nitro-oxidative stress and interaction with monocytes. Mol Nutr Food Res. 2012 Feb;56(2):217-27. PMID: 22162208.

 

Amengual J, Gouranton E, van Helden YG, et al. Beta-carotene reduces body adiposity of mice via BCMO1. PLoS One. 2011;6(6):e20644. PMID: 21673813.

" Xn, Xi Not dangerous goods.

LKT C0269 β-Carotene 50 g 231 Red-orange terpene pigment found in various plants and fruits, vitamin A prodrug. β,β-Carotene Carotaben; Provatene; Solatene 7235-40-7 ≥97% 536.87 C40H56 CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)C=CC2=C(CCCC2(C)C)C)C)C Ambient -20°C Insoluble in water. Sparingly soluble in ethanol. Soluble in benzene or chloroform. "Abdel-Mageed WM, Bayoumi SA, Salama AA, et al. Antioxidant lipoxygenase inhibitors from the leaf extracts of Simmondsia chinensis. Asian Pac J Trop Med. 2014 Sep;7S1:S521-6. PMID: 25312177.

 

Berti AP, Düsman E, Mariucci RG, et al. Antimutagenic and radioprotective activities of beta-carotene against the biological effects of iodine-131 radiopharmaceutical in Wistar rats. Genet Mol Res. 2014 Mar 31;13(1):2248-58. PMID: 24737473.

 

Gloria NF, Soares N, Brand C, et al. Lycopene and beta-carotene induce cell-cycle arrest and apoptosis in human breast cancer cell lines. Anticancer Res. 2014 Mar;34(3):1377-86. PMID: 24596385.

 

Silva LS, de Miranda AM, de Brito Magalhães CL, et al. Diet supplementation with beta-carotene improves the serum lipid profile in rats fed a cholesterol-enriched diet. J Physiol Biochem. 2013 Dec;69(4):811-20. PMID: 23645541.

 

Di Tomo P, Canali R, Ciavardelli D, et al. β-Carotene and lycopene affect endothelial response to TNF-α reducing nitro-oxidative stress and interaction with monocytes. Mol Nutr Food Res. 2012 Feb;56(2):217-27. PMID: 22162208.

 

Amengual J, Gouranton E, van Helden YG, et al. Beta-carotene reduces body adiposity of mice via BCMO1. PLoS One. 2011;6(6):e20644. PMID: 21673813.

" Xn, Xi Not dangerous goods.

LKT V3277 Vitamin E 5 g 27.2 Synthetic vitamin E, antioxidant. D,L-α-Tocopherol; (+-)-α-Tocopherol; Ephanyl 10191-41-0 ≥98% 430.7 C29H50O2 CC1=C(C(=C2CCC(OC2=C1C)(C)CCCC(C)CCCC(C)CCCC(C)C)C)O Stable to heat and alkalis. Protect from light. Ambient 4°C Soluble in ethanol, ether, chloroform, acetone or vegetable oils. "Reid VC, Mitchinson MJ. Toxicity of oxidised low density lipoprotein towards mouse peritoneal macrophages in vitro. Atherosclerosis. 1993 Jan 4;98(1):17-24. PMID: 8457247.

 

Williams RJ, Motteram JM, Sharp CH, et al. Dietary vitamin E and the attenuation of early lesion development in modified Watanabe rabbits. Atherosclerosis. 1992 Jun;94(2-3):153-9. PMID: 1632869.

" Xi Not dangerous goods.

LKT V3277 Vitamin E 25 g 38.1 Synthetic vitamin E, antioxidant. D,L-α-Tocopherol; (+-)-α-Tocopherol; Ephanyl 10191-41-0 ≥98% 430.7 C29H50O2 CC1=C(C(=C2CCC(OC2=C1C)(C)CCCC(C)CCCC(C)CCCC(C)C)C)O Stable to heat and alkalis. Protect from light. Ambient 4°C Soluble in ethanol, ether, chloroform, acetone or vegetable oils. "Reid VC, Mitchinson MJ. Toxicity of oxidised low density lipoprotein towards mouse peritoneal macrophages in vitro. Atherosclerosis. 1993 Jan 4;98(1):17-24. PMID: 8457247.

 

Williams RJ, Motteram JM, Sharp CH, et al. Dietary vitamin E and the attenuation of early lesion development in modified Watanabe rabbits. Atherosclerosis. 1992 Jun;94(2-3):153-9. PMID: 1632869.

" Xi Not dangerous goods.

LKT M1644 Meloxicam 25 mg 47.6 NSAID; COX-2 inhibitor. 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1, 1-dioxide Metacam; Mobec 71125-38-7 ≥98% 351.41 C14H13N3O4S2 CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O Ambient Ambient Insol in water.  Sol in DMF and DMSO. "Tasaki Y, Yamamoto J, Omura T, et al. Meloxicam ameliorates motor dysfunction and dopaminergic neurodegeneration by maintaining Akt-signaling in a mouse Parkinson's disease model. Neurosci Lett. 2012 Jul 11;521(1):15-9. PMID: 22617635.

 

Edfawy M, Hassan MH, Mansour A, et al. Meloxicam modulates oxidative stress status, inhibits prostaglandin E2, and abrogates apoptosis in carbon tetrachloride-induced rat hepatic injury. Int J Toxicol. 2012 Jun;31(3):276-86. PMID: 22556387.

 

Noble S, Balfour JA. Meloxicam. Drugs. 1996 Mar;51(3):424-32. PMID: 8882380.

 

Malreddy PR, Coetzee JF, Kukanich B, Gehring R. Pharmacokinetics and milk secretion of gabapentin and meloxicam co-administered orally in Holstein-Friesian cows. J Vet Pharmacol Ther. 2013 Feb;36(1):14-20. PMID: 22372845.

" Xn "UN number: 2811     Class:  6.1     Packing group:  III

Proper shipping name:  Toxic solids, organic, n.o.s. (Meloxicam)

Poison inhalation hazard:  No"

LKT N5768 Norfloxacin 1 g 27.2 Fluoroquinolone; topoisomerase IV and bacterial DNA gyrase inhibitor. "1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid

 

 

" Baccidal; Sebercim 70458-96-7 ≥98% 319.33 C16H18FN3O3 CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCNCC3)F)C(=O)O Ambient Ambient Soly at 25oC (mg/ml): water 0.28; methanol 0.98; ethanol 1.9. "Gouvea LR, Garcia LS, Lachter DR, et al.  Atypical fluoroquinolone gold(III) chelates as potential anticancer agents: relevance of DNA and protein interactions for their mechanism of action. Eur J Med Chem. 2012 Sep;55:67-73. PMID: 22835721.

 

Gómez-Hurtado I, Zapater P, Bellot P, et al. Interleukin-10-mediated heme oxygenase 1-induced underlying mechanism in inflammatory down-regulation by norfloxacin in cirrhosis. Hepatology. 2011 Mar;53(3):935-44. PMID: 21374664.

 

Padeĭskaia EN. Norfloxacin: more than 20 years of clinical use, the results and place among fluoroquinolones in modern chemotherapy for infections. Antibiot Khimioter. 2003;48(9):28-36. PMID: 15002177.

 

Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997 Sep;61(3):377-92. PMID: 9293187.

 

Ho YB, Zakaria MP, Latif PA, Saari N. Occurrence of veterinary antibiotics and progesterone in broiler manure and agricultural soil in Malaysia. Sci Total Environ. 2014 Aug 1;488-489:261-267. PMID: 24836135.

" None Not dangerous goods.

LKT N5768 Norfloxacin 5 g 61.1 Fluoroquinolone; topoisomerase IV and bacterial DNA gyrase inhibitor. "1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid

 

 

" Baccidal; Sebercim 70458-96-7 ≥98% 319.33 C16H18FN3O3 CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCNCC3)F)C(=O)O Ambient Ambient Soly at 25oC (mg/ml): water 0.28; methanol 0.98; ethanol 1.9. "Gouvea LR, Garcia LS, Lachter DR, et al.  Atypical fluoroquinolone gold(III) chelates as potential anticancer agents: relevance of DNA and protein interactions for their mechanism of action. Eur J Med Chem. 2012 Sep;55:67-73. PMID: 22835721.

 

Gómez-Hurtado I, Zapater P, Bellot P, et al. Interleukin-10-mediated heme oxygenase 1-induced underlying mechanism in inflammatory down-regulation by norfloxacin in cirrhosis. Hepatology. 2011 Mar;53(3):935-44. PMID: 21374664.

 

Padeĭskaia EN. Norfloxacin: more than 20 years of clinical use, the results and place among fluoroquinolones in modern chemotherapy for infections. Antibiot Khimioter. 2003;48(9):28-36. PMID: 15002177.

 

Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997 Sep;61(3):377-92. PMID: 9293187.

 

Ho YB, Zakaria MP, Latif PA, Saari N. Occurrence of veterinary antibiotics and progesterone in broiler manure and agricultural soil in Malaysia. Sci Total Environ. 2014 Aug 1;488-489:261-267. PMID: 24836135.

" None Not dangerous goods.

LKT H9715 Hydroxyurea 100 g 453 Fetal hemoglobin stimulator; ribonucleotide reductase inhibitor. Hydroxycarbamide; Droxia; Hydrea; Litalir 127-07-1 ≥98% 76.06 CH4N2O2 C(=O)(N)NO Ambient 4°C Soluble in water or hot alcohol. "Amaru Calzada A, Pedrini O, Finazzi G, et al. Givinostat and hydroxyurea synergize in vitro to induce apoptosis of cells from JAK2(V617F) myeloproliferative neoplasm patients. Exp Hematol. 2013 Mar;41(3):253-60.e2. PMID: 23111067.

 

Vankayala SL, Hargis JC, Woodcock HL. Unlocking the binding and reaction mechanism of hydroxyurea substrates as biological nitric oxide donors. J Chem Inf Model. 2012 May 25;52(5):1288-97. PMID: 22519847.

" Mut., Repr., T Not dangerous goods.

LKT I2056 Ifosfamide 250 mg 88.3 Nitrogen mustard, DNA alkylator. N, 3-Bis(2-chloroethyl)-tetrahydro-2H-1,3,2-oxaza- phosphorin-2-amine 2-oxide Holoxan; Ifex; Ifomide; Isoendoxan; Isophosphamide; Mitoxana 3778-73-2 ≥98% 261.09 C7H15Cl2N2O2P C1CN(P(=O)(OC1)NCCCl)CCCl Ambient Ambient Soluble in water. "Vincenzi B, Frezza AM, Santini D, et al. New therapies in soft tissue sarcoma. Expert Opin Emerg Drugs. 2010 Jun;15(2):237-48. PMID: 20465449.

 

Nissim I, Horyn O, Daikhin Y, et al. Ifosfamide-induced nephrotoxicity: mechanism and prevention. Cancer Res. 2006 Aug 1;66(15):7824-31. PMID: 16885387.

" T "UN number: 2811     Class: 6.1     Packing group:  III

Proper shipping name:  Toxic solids, organic, n.o.s. (Ifosfamide)

Poison Inhalation Hazard:  No"

LKT I2056 Ifosfamide 1 g 182 Nitrogen mustard, DNA alkylator. N, 3-Bis(2-chloroethyl)-tetrahydro-2H-1,3,2-oxaza- phosphorin-2-amine 2-oxide Holoxan; Ifex; Ifomide; Isoendoxan; Isophosphamide; Mitoxana 3778-73-2 ≥98% 261.09 C7H15Cl2N2O2P C1CN(P(=O)(OC1)NCCCl)CCCl Ambient Ambient Soluble in water. "Vincenzi B, Frezza AM, Santini D, et al. New therapies in soft tissue sarcoma. Expert Opin Emerg Drugs. 2010 Jun;15(2):237-48. PMID: 20465449.

 

Nissim I, Horyn O, Daikhin Y, et al. Ifosfamide-induced nephrotoxicity: mechanism and prevention. Cancer Res. 2006 Aug 1;66(15):7824-31. PMID: 16885387.

" T "UN number: 2811     Class: 6.1     Packing group:  III

Proper shipping name:  Toxic solids, organic, n.o.s. (Ifosfamide)

Poison Inhalation Hazard:  No"

LKT N3450 Nimesulide 1 g 20.4 NSAID; COX-2 inhibitor. N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide Aulin; Fansidol; Flogovital; Mesulid; Nide; Nidol; Nisulid 51803-78-2 ≥98% 308.31 C13H12N2O5S CS(=O)(=O)NC1=C(C=C(C=C1)[N+](=O)[O-])OC2=CC=CC=C2 Ambient Ambient Soluble in chloroform. "Jia-Jun T, Su-Mei L, Liang Y, et al. Nimesulide inhibited the growth of hypopharyngeal carcinoma cells via suppressing Survivin expression. Head Neck Oncol. 2012 Mar 27;4:7. PMID: 22453101.

 

Vellani V, Franchi S, Prandini M, et al. Nimesulide inhibits protein kinase C epsilon and substance P in sensory neurons - comparison with paracetamol. J Pain Res. 2011;4:177-87. PMID: 21811393.

 

Suleyman H, Cadirci E, Albayrak A, et al. Nimesulide is a selective COX-2 inhibitory, atypical non-steroidal anti-inflammatory drug. Curr Med Chem. 2008;15(3):278-83. PMID: 18333314.

" Xn "UN number: 2811     Class: 6.1     Packing Group: III

Proper shipping name: Toxic solid, organic, n.o.s. (Nimesulide)"

LKT P1754 Penciclovir 25 mg 47.6 Nucleoside (guanosine) analog; DNA chain terminator, viral DNA polymerase inhibitor. 2-Amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxy- methylbutyl]-6H-purin-6-one Denavir; Vectavir 39809-25-1 ≥98% 253.26 C10H15N5O3 C1=NC2=C(N1CCC(CO)CO)NC(=NC2=O)N Ambient Ambient Soluble in water. "Deval J. Antimicrobial strategies: inhibition of viral polymerases by 3'-hydroxyl nucleosides. Drugs. 2009;69(2):151-66. PMID: 19228073.

 

Villarreal EC. Current and potential therapies for the treatment of herpes-virus infections. Prog Drug Res. 2003;60:263-307. PMID: 12790345.

 

Balzarini J, Bohman C, Walker RT, et al. Comparative cytostatic activity of different antiherpetic drugs against herpes simplex virus thymidine kinase gene-transfected tumor cells. Mol Pharmacol. 1994 Jun;45(6):1253-8. PMID: 8022417.

" Xi Not dangerous goods.

LKT R3205 Ribavirin 25 mg 47.6 Purine nucleoside analog; DNA chain terminator. 1-β-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide Copegus; Ribamidil; RTCA; Varazid; Virazole 36791-04-5 ≥98% 244.21 C8H12N4O5 C1=NC(=NN1C2C(C(C(O2)CO)O)O)C(=O)N Ambient 4°C Soluble in water. "Pinilla-Macua I, Fernández-Calotti P, Pérez-Del-Pulgar S, et al. Ribavirin Uptake into Human Hepatocyte HHL5 Cells Is Enhanced by Interferon-α via up-Regulation of the Human Concentrative Nucleoside Transporter (hCNT2). Mol Pharm. 2014 Sep 2;11(9):3223-30. PMID: 24957263.

 

Parekh PJ, Shiffman ML. The role of interferon in the new era of hepatitis C treatments. Expert Rev Gastroenterol Hepatol. 2014 Aug;8(6):649-56. PMID: 24758387.

 

Wohl BM, Smith AA, Kryger MB, et al. Narrow therapeutic window of ribavirin as an inhibitor of nitric oxide synthesis is broadened by macromolecular prodrugs. Biomacromolecules. 2013 Nov 11;14(11):3916-26. PMID: 24156371.

" T Not dangerous goods.

LKT R3249 Rimantadine Hydrochloride 250 mg 61.1 Viral M2 proton channel blocker. α-Methyltricyclo[3.3.1.13,7]decane-1-methanamine Flumadine; Meradan; Roflual 1501-84-4 ≥98% 215.76 C12H21N HCl CC(C12CC3CC(C1)CC(C3)C2)N.Cl Ambient Ambient Soluble in water. "Ivanovic T, Rozendaal R, Floyd DL, et al. Kinetics of proton transport into influenza virions by the viral M2 channel. PLoS One. 2012;7(3):e31566. PMID: 22412838.

 

Leonov H, Astrahan P, Krugliak M, et al. How do aminoadamantanes block the influenza M2 channel, and how does resistance develop? J Am Chem Soc. 2011 Jun 29;133(25):9903-11. PMID: 21534619.

" Xn Not dangerous goods.

LKT R3249 Rimantadine Hydrochloride 1 g 136 Viral M2 proton channel blocker. α-Methyltricyclo[3.3.1.13,7]decane-1-methanamine Flumadine; Meradan; Roflual 1501-84-4 ≥98% 215.76 C12H21N HCl CC(C12CC3CC(C1)CC(C3)C2)N.Cl Ambient Ambient Soluble in water. "Ivanovic T, Rozendaal R, Floyd DL, et al. Kinetics of proton transport into influenza virions by the viral M2 channel. PLoS One. 2012;7(3):e31566. PMID: 22412838.

 

Leonov H, Astrahan P, Krugliak M, et al. How do aminoadamantanes block the influenza M2 channel, and how does resistance develop? J Am Chem Soc. 2011 Jun 29;133(25):9903-11. PMID: 21534619.

" Xn Not dangerous goods.

LKT T5761 Topotecan Hydrochloride 10 mg 73.4 Captothecin derivative; topoisomerase I inhibitor. (4S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9- dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]- quinoline-3,14(4H,12H)-dione hydrochloride Hycamtin; NSC-609669; SKF-104864A 119413-54-6 ≥98% 457.91 C23H25N3O5 HCl CCC1(C2=C(COC1=O)C(=O)N3CC4=C(C3=C2)N=C5C=CC(=C(C5=C4)CN(C)C)O)O.Cl Hygroscopic Ambient Ambient Soluble in methanol, water (92 mg/ml at 25 °C), DMSO (92 mg/ml at 25 °C), ethanol (<1 mg/ml at 25 °C), and 1: 1 solution of DMSO: PBS (pH 7.2, ~0.5 mg/ml). "Attia SM, Ahmad SF, Abd-Ellah MF, et al. Germ cell mutagenicity of topoisomerase I inhibitor topotecan detected in the male mouse-dominant lethal study. Food Chem Toxicol. 2013 Dec;62:470-4. PMID: 24036143.

 

Zhang M, Shan BE, Yuan NF, et al. Effect of topotecan on retinocytoma cell apoptosis and expression of Livin and PTEN. Chin Med J (Engl). 2013 Jan;126(2):340-4. PMID: 23324287.

 

Caltová K, Cervinka M. Antiproliferative effects of selected chemotherapeutics in human ovarian cancer cell line A2780. Acta Medica (Hradec Kralove). 2012;55(3):116-24. PMID: 23297519.

 

Sonabend AM, Stuart RM, Yun J, et al. Prolonged intracerebral convection-enhanced delivery of topotecan with a subcutaneously implantable infusion pump. Neuro Oncol. 2011 Aug;13(8):886-893. PMID: 21750007.

" Mut., T ,Xi Not dangerous goods.

LKT T5761 Topotecan Hydrochloride 50 mg 244.5 Captothecin derivative; topoisomerase I inhibitor. (4S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9- dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]- quinoline-3,14(4H,12H)-dione hydrochloride Hycamtin; NSC-609669; SKF-104864A 119413-54-6 ≥98% 457.91 C23H25N3O5 HCl CCC1(C2=C(COC1=O)C(=O)N3CC4=C(C3=C2)N=C5C=CC(=C(C5=C4)CN(C)C)O)O.Cl Hygroscopic Ambient Ambient Soluble in methanol, water (92 mg/ml at 25 °C), DMSO (92 mg/ml at 25 °C), ethanol (<1 mg/ml at 25 °C), and 1: 1 solution of DMSO: PBS (pH 7.2, ~0.5 mg/ml). "Attia SM, Ahmad SF, Abd-Ellah MF, et al. Germ cell mutagenicity of topoisomerase I inhibitor topotecan detected in the male mouse-dominant lethal study. Food Chem Toxicol. 2013 Dec;62:470-4. PMID: 24036143.

 

Zhang M, Shan BE, Yuan NF, et al. Effect of topotecan on retinocytoma cell apoptosis and expression of Livin and PTEN. Chin Med J (Engl). 2013 Jan;126(2):340-4. PMID: 23324287.

 

Caltová K, Cervinka M. Antiproliferative effects of selected chemotherapeutics in human ovarian cancer cell line A2780. Acta Medica (Hradec Kralove). 2012;55(3):116-24. PMID: 23297519.

 

Sonabend AM, Stuart RM, Yun J, et al. Prolonged intracerebral convection-enhanced delivery of topotecan with a subcutaneously implantable infusion pump. Neuro Oncol. 2011 Aug;13(8):886-893. PMID: 21750007.

" Mut., T ,Xi Not dangerous goods.

LKT T6902 Tranilast 10 mg 40.7 Mast cell stabilizer; TRPV2 antagonist, PDGFR inhibitor. 2-[[3-(3,4-Dimethoxyphenyl)-1-oxo-2-propenyl]- amino]benzoic acid Rizaben; N-5' 53902-12-8 ≥98% 327.34 C18H17NO5 COC1=C(C=C(C=C1)C=CC(=O)NC2=CC=CC=C2C(=O)O)OC In DMSO at +4 for 2 weeks at -80 for 6 months. Ambient Ambient DMSO to 100 mM, ethanol to 2 mg/mL, DMF to 35 mg/mL. "Luo J, Li Y, Yang Y, et al. Role and mechanism of tranilast preventing the progression of tubulointerstilial fibrosis in diabetic kidney diseases. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2013 Dec;38(12):1233-42. PMID: 24384948.

 

Zaher SS, Coe D, Chai JG, et al. Suppression of the allogeneic response by the anti-allergy drug N-(3,4-dimethoxycinnamonyl) anthranilic acid results from T-cell cycle arrest. Immunology. 2013 Feb;138(2):157-64. PMID: 23121382.

 

Subramaniam V, Chakrabarti R, Prud'homme GJ, et al. Tranilast inhibits cell proliferation and migration and promotes apoptosis in murine breast cancer. Anticancer Drugs. 2010 Apr;21(4):351-61. PMID: 20145538.

 

Li Y, Liu FY, Peng YM, et al. Mast cell, a promising therapeutic target in tubulointerstitial fibrosis. Med Hypotheses. 2007;69(1):99-103. PMID: 17257770.

 

Watanabe S, Matsuda A, Suzuki Y, et al. Inhibitory mechanism of tranilast in human coronary artery smooth muscle cells proliferation, due to blockade of PDGF-BB-receptors. Br J Pharmacol. 2000 May;130(2):307-14. PMID: 10807667.

 

Koyama S, Takagi H, Otani A, et al. Tranilast inhibits protein kinase C-dependent signalling pathway linked to angiogenic activities and gene expression of retinal microcapillary endothelial cells. Br J Pharmacol. 1999 May;127(2):537-45. PMID: 10385256.

" Xn Not dangerous goods.

LKT D3212 2′,3′-Dideoxycytidine 25 mg 40.7 Pyrimidine nucleoside (cytidine) analog; DNA chain terminator, RT inhibitor. Zalcitabine; ddCyd; Hivid 7481-89-2 ≥98% 211.22 C9H13N3O3 C1CC(OC1CO)N2C=CC(=NC2=O)N Ambient Ambient Moderately soluble in water. "Shelton MJ, O'Donnell AM, Morse GD. Zalcitabine. Ann Pharmacother. 1993 Apr;27(4):480-9. PMID: 8097417.

 

Balzarini J. Anti-retroviral activity and molecular-biochemical action mechanism of 2',3'-dideoxynucleoside analogs and 9-(2-phosphonylmethoxyethyl) purine derivatives. Verh K Acad Geneeskd Belg. 1991;53(1):61-98. PMID: 1647085.

" Xn Not dangerous goods.

LKT B4518 Bleomycin Sulfate 100 mg 1155.2 Mixture of glycopeptide bleomycin sulfate salts, induces DNA strand breaks. Blenoxane; Blexane 9041-93-4 ≥90% 1512.63 C55H84N17O21S3 H2SO4 CC1=C(N=C(N=C1N)C(CC(=O)N)NCC(C(=O)N)N)C(=O)NC(C(C2=CN=CN2)OC3C(C(C(C(O3)CO)O)O)OC4C(C(C(C(O4)CO)O)OC(=O)N)O)C(=O)NC(C)C(C(C)C(=O)NC(C(C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O.OS(=O)(=O)[O-] In DMSO at +4 for 2 weeks at -80 for 6 months. Ambient 4°C Soluble in water to 20 mg/mL. DMSO to 100 mg/mL. Methanol. "Ramírez-Fort MK, Au SC, Javed SA, et al. Management of cutaneous human papillomavirus infection: pharmacotherapies. Curr Probl Dermatol. 2014;45:175-85. PMID: 24643186.

 

Li P, Li DF, Guo ZT, et al. Therapeutic mechanism of bleomycin A5 on infancy hemangioma: an experimental study. Zhonghua Kou Qiang Yi Xue Za Zhi. 2013 Jan;48(1):18-22. PMID: 23534516.

 

Nguyen HT, Murray V. The DNA sequence specificity of bleomycin cleavage in telomeric sequences in human cells. J Biol Inorg Chem. 2012 Dec;17(8):1209-15. PMID: 22961398.

 

Yang Y, Sun M, Ma Q, et al. Bleomycin A5 sclerotherapy for cervicofacial lymphatic malformations. J Vasc Surg. 2011 Jan;53(1):150-5. PMID: 20843632.

 

Liu Y, Wu F, Zou G. Electrophoresis mobility shift assay and biosensor used in studying the interaction between bleomycin A5 and DNA. Anal Chim Acta. 2007 Sep 19;599(2):310-4. PMID: 17870295.

 

Vorobjev PE, Smith JB, Pyshnaya IA, et al. Site-specific cleavage of RNA and DNA by complementary DNA--bleomycin A5 conjugates. Bioconjug Chem. 2003 Nov-Dec;14(6):1307-13. PMID: 14624648.

 

Abraham AT, Lin JJ, Newton DL, et al. RNA cleavage and inhibition of protein synthesis by bleomycin. Chem Biol. 2003 Jan;10(1):45-52. PMID: 12573697.

 

Hecht SM. Bleomycin: new perspectives on the mechanism of action. J Nat Prod. 2000 Jan;63(1):158-68. PMID: 10650103.

 

Marcon L, Zhang X, Hales BF, et al. Effects of chemotherapeutic agents for testicular cancer on rat spermatogonial stem/progenitor cells. J Androl. 2011 Jul-Aug;32(4):432-443. PMID: 21088230." T Not dangerous goods.

LKT M1575 7-Methyl-6-mercaptopurine 10 mg 61.1 Thiopurine antimetabolite; PRPP amidotransferase inhibitor. 1,7-dihydro-7-methyl-6H-Purine-6-thione 7-Methyl-6-thiopurine; 7-Methylpurine-6-thiol 3324-79-6 ≥87% 166.21 C6H6N4S CN1C=NC2=C1C(=S)N=CN2 Ambient -20°C "Bradford K, Shih DQ. Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease. World J Gastroenterol. 2011 Oct 7;17(37):4166-73. PMID: 22072847.

 

Nielsen OH, Vainer B, Rask-Madsen J. Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Aliment Pharmacol Ther. 2001 Nov;15(11):1699-708. PMID: 11683683.

 

Lennard L, Welch JC, Lilleyman JS. Thiopurine drugs in the treatment of childhood leukaemia: the influence of inherited thiopurine methyltransferase activity on drug metabolism and cytotoxicity. Br J Clin Pharmacol. 1997 Nov;44(5):455-61. PMID: 9384462.

" Not dangerous goods.

LKT R5722 Rofecoxib 5 g 679.5 NSAID; COX-2 inhibitor. 4-[4-(Methylsulfonyl)-phenyl]-3-phenyl-2(5H)- furanone "Vioxx

" 162011-90-7 ≥98% 314.36 C17H14O4S CS(=O)(=O)C1=CC=C(C=C1)C2=C(C(=O)OC2)C3=CC=CC=C3 Ambient Ambient Slightly soluble in methanol and acetone. Insoluble in water. "D'Arca D, LeNoir J, Wildemore B, et al. Prevention of urinary bladder cancer in the FHIT knock-out mouse with Rofecoxib, a Cox-2 inhibitor. Urol Oncol. 2010 Mar-Apr;28(2):189-94. PMID: 19372053.

 

Akula KK, Dhir A, Kulkarni SK. Rofecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor increases pentylenetetrazol seizure threshold in mice: possible involvement of adenosinergic mechanism. Epilepsy Res. 2008 Jan;78(1):60-70. PMID: 18054463." Not dangerous goods.

LKT S3449 Simvastatin 10 mg 43.5 Statin; HMG-CoA reductase inhibitor, potential ATP-sensitive K+ channel activator, L-type Ca2+ channel blocker. 2,2-Dimethylbutanoic acid (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester Synvinolin; MK-733; Denan; Liponorm; Lodales; Simovil; Sinvacor; Sivastin; Zocor; Zocord 79902-63-9 ≥97% 418.57 C25H38O5 CCC(C)(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC3CC(CC(=O)O3)O)C Ambient Ambient Soluble in DMSO (540 mg/ml); ethanol (160 mg/ml); methanol (200 mg/ml). Insoluble in water. "Zhou J, Li W, Xie Q, et al. Effects of simvastatin on glucose metabolism in mouse MIN6 cells. J Diabetes Res. 2014;2014:376570. PMID: 24995341.

 

Banach M, Czuczwar SJ, Borowicz KK. Statins - are they anticonvulsant? Pharmacol Rep. 2014 Aug;66(4):521-8. PMID: 24948050.

 

Wang Q, Wei X, Gao H, et al. Simvastatin reverses the downregulation of M1/4 receptor binding in 6-hydroxydopamine-induced parkinsonian rats: the association with improvements in long-term memory. Neuroscience. 2014 May 16;267:57-66. PMID: 24613723.

 

Yang N, Cui Y, Tan J, et al. Local injection of a single dose of simvastatin augments osteoporotic bone mass in ovariectomized rats. J Bone Miner Metab. 2014 May;32(3):252-60. PMID: 23934055.

 

Ishikawa S, Hayashi H, Kinoshita K, et al. Statins inhibit tumor progression via an enhancer of zeste homolog 2-mediated epigenetic alteration in colorectal cancer. Int J Cancer. 2013 Dec 17. [Epub ahead of print]. PMID: 24346863.

 

Moraes LA, Vaiyapuri S, Sasikumar P, et al. Antithrombotic actions of statins involve PECAM-1 signaling. Blood. 2013 Oct 31;122(18):3188-96. PMID: 24030383.

 

Liu PY, Liu YW, Lin LJ, et al. Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation. 2009 Jan 6;119(1):131-8. PMID: 19075102.

" None Not dangerous goods.

LKT S3449 Simvastatin 25 mg 97.8 Statin; HMG-CoA reductase inhibitor, potential ATP-sensitive K+ channel activator, L-type Ca2+ channel blocker. 2,2-Dimethylbutanoic acid (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester Synvinolin; MK-733; Denan; Liponorm; Lodales; Simovil; Sinvacor; Sivastin; Zocor; Zocord 79902-63-9 ≥97% 418.57 C25H38O5 CCC(C)(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC3CC(CC(=O)O3)O)C Ambient Ambient Soluble in DMSO (540 mg/ml); ethanol (160 mg/ml); methanol (200 mg/ml). Insoluble in water. "Zhou J, Li W, Xie Q, et al. Effects of simvastatin on glucose metabolism in mouse MIN6 cells. J Diabetes Res. 2014;2014:376570. PMID: 24995341.

 

Banach M, Czuczwar SJ, Borowicz KK. Statins - are they anticonvulsant? Pharmacol Rep. 2014 Aug;66(4):521-8. PMID: 24948050.

 

Wang Q, Wei X, Gao H, et al. Simvastatin reverses the downregulation of M1/4 receptor binding in 6-hydroxydopamine-induced parkinsonian rats: the association with improvements in long-term memory. Neuroscience. 2014 May 16;267:57-66. PMID: 24613723.

 

Yang N, Cui Y, Tan J, et al. Local injection of a single dose of simvastatin augments osteoporotic bone mass in ovariectomized rats. J Bone Miner Metab. 2014 May;32(3):252-60. PMID: 23934055.

 

Ishikawa S, Hayashi H, Kinoshita K, et al. Statins inhibit tumor progression via an enhancer of zeste homolog 2-mediated epigenetic alteration in colorectal cancer. Int J Cancer. 2013 Dec 17. [Epub ahead of print]. PMID: 24346863.

 

Moraes LA, Vaiyapuri S, Sasikumar P, et al. Antithrombotic actions of statins involve PECAM-1 signaling. Blood. 2013 Oct 31;122(18):3188-96. PMID: 24030383.

 

Liu PY, Liu YW, Lin LJ, et al. Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation. 2009 Jan 6;119(1):131-8. PMID: 19075102.

" None Not dangerous goods.

LKT H9661 Hypocrellin A 1 mg 108.8 Prevents MHC II antigen presentation. Contains ~16% B Hypocrellin 77029-83-5 ≥77%, contains ~16% B 546.52 C30H26O10 CC(=O)C1C2=C(C(=C3C(=O)C=C(C4=C5C(=CC(=O)C6=C(C(=C(CC1(C)O)C(=C56)C2=C43)OC)O)OC)OC)O)OC Ambient 4°C Soluble in heptane. "Du W, Sun C, Liang Z, et al. Antibacterial activity of hypocrellin A against Staphylococcus aureus. World J Microbiol Biotechnol. 2012 Nov;28(11):3151-7. PMID: 22864599.

 

Park S, Im SA, Kim KH, et al. Immunomodulatory Effects of Hypocrellin A on MHC-restricted Antigen Processing. Immune Netw. 2011 Dec;11(6):412-5. PMID: 22346783.

 

Su Y, Sun J, Rao S, et al. Photodynamic antimicrobial activity of hypocrellin A. J Photochem Photobiol B. 2011 Apr 4;103(1):29-34. PMID: 21300554.

 

Xu Y, Zhang Z, Zhang H. Raman spectroscopic study of DNA after photosensitive damage caused by hypocrellins A and B. Sci China C Life Sci. 1998 Aug;41(4):360-6. PMID: 18726251.

 

" Not dangerous goods.

LKT H9661 Hypocrellin A 5 mg 217.4 Prevents MHC II antigen presentation. Contains ~16% B Hypocrellin 77029-83-5 ≥77%, contains ~16% B 546.52 C30H26O10 CC(=O)C1C2=C(C(=C3C(=O)C=C(C4=C5C(=CC(=O)C6=C(C(=C(CC1(C)O)C(=C56)C2=C43)OC)O)OC)OC)O)OC Ambient 4°C Soluble in heptane. "Du W, Sun C, Liang Z, et al. Antibacterial activity of hypocrellin A against Staphylococcus aureus. World J Microbiol Biotechnol. 2012 Nov;28(11):3151-7. PMID: 22864599.

 

Park S, Im SA, Kim KH, et al. Immunomodulatory Effects of Hypocrellin A on MHC-restricted Antigen Processing. Immune Netw. 2011 Dec;11(6):412-5. PMID: 22346783.

 

Su Y, Sun J, Rao S, et al. Photodynamic antimicrobial activity of hypocrellin A. J Photochem Photobiol B. 2011 Apr 4;103(1):29-34. PMID: 21300554.

 

Xu Y, Zhang Z, Zhang H. Raman spectroscopic study of DNA after photosensitive damage caused by hypocrellins A and B. Sci China C Life Sci. 1998 Aug;41(4):360-6. PMID: 18726251.

 

" Not dangerous goods.

LKT H9662 Hypocrellin B 1 mg 101.1 Induces DNA strand breakage. 123940-54-5 ≥90% 528.51 C30H24O9 CC1=C2C3=C4C(=C(C(=O)C(=O)C5=CC(=C6C(=CC(=C(C6=C54)C3=C(C(=C2C(=O)C)OC)O)O)OC)OC)OC)C1 Ambient 4°C Soluble in DMSO. "Jiang Y, Leung AW, Wang X, et al. Effect of photodynamic therapy with hypocrellin B on apoptosis, adhesion, and migration of cancer cells. Int J Radiat Biol. 2014 Jul;90(7):575-9. PMID: 24661233.

 

Jiang Y, Leung AW, Wang X, et al. Inactivation of Staphylococcus aureus by photodynamic action of hypocrellin B. Photodiagnosis Photodyn Ther. 2013 Dec;10(4):600-6. PMID: 24284117.

 

Babu A, Jeyasubramanian K, Gunasekaran P, et al. Gelatin nanocarrier enables efficient delivery and phototoxicity of hypocrellin B against a mice tumour model. J Biomed Nanotechnol. 2012 Feb;8(1):43-56. PMID: 22515093.

 

Xu Y, Zhang Z, Zhang H. Raman spectroscopic study of DNA after photosensitive damage caused by hypocrellins A and B. Sci China C Life Sci. 1998 Aug;41(4):360-6. PMID: 18726251.

 

" Not dangerous goods.

LKT H9662 Hypocrellin B 5 mg 202.2 Induces DNA strand breakage. 123940-54-5 ≥90% 528.51 C30H24O9 CC1=C2C3=C4C(=C(C(=O)C(=O)C5=CC(=C6C(=CC(=C(C6=C54)C3=C(C(=C2C(=O)C)OC)O)O)OC)OC)OC)C1 Ambient 4°C Soluble in DMSO. "Jiang Y, Leung AW, Wang X, et al. Effect of photodynamic therapy with hypocrellin B on apoptosis, adhesion, and migration of cancer cells. Int J Radiat Biol. 2014 Jul;90(7):575-9. PMID: 24661233.

 

Jiang Y, Leung AW, Wang X, et al. Inactivation of Staphylococcus aureus by photodynamic action of hypocrellin B. Photodiagnosis Photodyn Ther. 2013 Dec;10(4):600-6. PMID: 24284117.

 

Babu A, Jeyasubramanian K, Gunasekaran P, et al. Gelatin nanocarrier enables efficient delivery and phototoxicity of hypocrellin B against a mice tumour model. J Biomed Nanotechnol. 2012 Feb;8(1):43-56. PMID: 22515093.

 

Xu Y, Zhang Z, Zhang H. Raman spectroscopic study of DNA after photosensitive damage caused by hypocrellins A and B. Sci China C Life Sci. 1998 Aug;41(4):360-6. PMID: 18726251.

 

" Not dangerous goods.

LKT A5313 Andrographolide 100 mg 45.3 Labdane diterpene found in Andrographis; RLR (RIG1-like) antagonist. [1R-[1α[E(S*)],4ab,5α,6α,8aα]]-3-[2-[Decahydro-6- hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2- methylene-1-naphthalenyl]ethylidene]dihydro-4- hydroxy-2(3H)-furanone Andrographis 5508-58-7 ≥98% 350.45 C20H30O5 CC12CCC(C(C1CCC(=C)C2CC=C3C(COC3=O)O)(C)CO)O Ambient -20°C Soluble in methanol, acetone, chloroform or ether. Slightly soluble in water. "Lu CY, Yang YC, Li CC, et al. Andrographolide inhibits TNFα-induced ICAM-1 expression via suppression of NADPH oxidase activation and induction of HO-1 and GCLM expression through the PI3K/Akt/Nrf2 and PI3K/Akt/AP-1 pathways in human endothelial cells. Biochem Pharmacol. 2014 Sep 1;91(1):40-50. PMID: 24998495.

 

Yu B, Dai CQ, Jiang ZY, et al. Andrographolide as an anti-H1N1 drug and the mechanism related to retinoic acid-inducible gene-I-like receptors signaling pathway. Chin J Integr Med. 2014 Jul;20(7):540-5. PMID: 24972581.

 

Wang J, Tan XF, Nguyen VS, et al. A quantitative chemical proteomics approach to profile the specific cellular targets of andrographolide, a promising anticancer agent that suppresses tumor metastasis. Mol Cell Proteomics. 2014 Mar;13(3):876-86. PMID: 24445406.

 

Liu SH, Lin CH, Liang FP, et al. Andrographolide downregulates the v-Src and Bcr-Abl oncoproteins and induces Hsp90 cleavage in the ROS-dependent suppression of cancer malignancy. Biochem Pharmacol. 2014 Jan 15;87(2):229-42. PMID: 24161787.

 

Shen T, Yang WS, Yi YS, et al. AP-1/IRF-3 Targeted Anti-Inflammatory Activity of Andrographolide Isolated from Andrographis paniculata. Evid Based Complement Alternat Med. 2013;2013:210736. PMID: 23840248.

 

Zhang C, Gui L, Xu Y, et al. Preventive effects of andrographolide on the development of diabetes in autoimmune diabetic NOD mice by inducing immune tolerance. Int Immunopharmacol. 2013 Aug;16(4):451-6. PMID: 23707775.

" None Not dangerous goods.

LKT A5313 Andrographolide 250 mg 85.6 Labdane diterpene found in Andrographis; RLR (RIG1-like) antagonist. [1R-[1α[E(S*)],4ab,5α,6α,8aα]]-3-[2-[Decahydro-6- hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2- methylene-1-naphthalenyl]ethylidene]dihydro-4- hydroxy-2(3H)-furanone Andrographis 5508-58-7 ≥98% 350.45 C20H30O5 CC12CCC(C(C1CCC(=C)C2CC=C3C(COC3=O)O)(C)CO)O Ambient -20°C Soluble in methanol, acetone, chloroform or ether. Slightly soluble in water. "Lu CY, Yang YC, Li CC, et al. Andrographolide inhibits TNFα-induced ICAM-1 expression via suppression of NADPH oxidase activation and induction of HO-1 and GCLM expression through the PI3K/Akt/Nrf2 and PI3K/Akt/AP-1 pathways in human endothelial cells. Biochem Pharmacol. 2014 Sep 1;91(1):40-50. PMID: 24998495.

 

Yu B, Dai CQ, Jiang ZY, et al. Andrographolide as an anti-H1N1 drug and the mechanism related to retinoic acid-inducible gene-I-like receptors signaling pathway. Chin J Integr Med. 2014 Jul;20(7):540-5. PMID: 24972581.

 

Wang J, Tan XF, Nguyen VS, et al. A quantitative chemical proteomics approach to profile the specific cellular targets of andrographolide, a promising anticancer agent that suppresses tumor metastasis. Mol Cell Proteomics. 2014 Mar;13(3):876-86. PMID: 24445406.

 

Liu SH, Lin CH, Liang FP, et al. Andrographolide downregulates the v-Src and Bcr-Abl oncoproteins and induces Hsp90 cleavage in the ROS-dependent suppression of cancer malignancy. Biochem Pharmacol. 2014 Jan 15;87(2):229-42. PMID: 24161787.

 

Shen T, Yang WS, Yi YS, et al. AP-1/IRF-3 Targeted Anti-Inflammatory Activity of Andrographolide Isolated from Andrographis paniculata. Evid Based Complement Alternat Med. 2013;2013:210736. PMID: 23840248.

 

Zhang C, Gui L, Xu Y, et al. Preventive effects of andrographolide on the development of diabetes in autoimmune diabetic NOD mice by inducing immune tolerance. Int Immunopharmacol. 2013 Aug;16(4):451-6. PMID: 23707775.

" None Not dangerous goods.

LKT A5313 Andrographolide 1 g 276.8 Labdane diterpene found in Andrographis; RLR (RIG1-like) antagonist. [1R-[1α[E(S*)],4ab,5α,6α,8aα]]-3-[2-[Decahydro-6- hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2- methylene-1-naphthalenyl]ethylidene]dihydro-4- hydroxy-2(3H)-furanone Andrographis 5508-58-7 ≥98% 350.45 C20H30O5 CC12CCC(C(C1CCC(=C)C2CC=C3C(COC3=O)O)(C)CO)O Ambient -20°C Soluble in methanol, acetone, chloroform or ether. Slightly soluble in water. "Lu CY, Yang YC, Li CC, et al. Andrographolide inhibits TNFα-induced ICAM-1 expression via suppression of NADPH oxidase activation and induction of HO-1 and GCLM expression through the PI3K/Akt/Nrf2 and PI3K/Akt/AP-1 pathways in human endothelial cells. Biochem Pharmacol. 2014 Sep 1;91(1):40-50. PMID: 24998495.

 

Yu B, Dai CQ, Jiang ZY, et al. Andrographolide as an anti-H1N1 drug and the mechanism related to retinoic acid-inducible gene-I-like receptors signaling pathway. Chin J Integr Med. 2014 Jul;20(7):540-5. PMID: 24972581.

 

Wang J, Tan XF, Nguyen VS, et al. A quantitative chemical proteomics approach to profile the specific cellular targets of andrographolide, a promising anticancer agent that suppresses tumor metastasis. Mol Cell Proteomics. 2014 Mar;13(3):876-86. PMID: 24445406.

 

Liu SH, Lin CH, Liang FP, et al. Andrographolide downregulates the v-Src and Bcr-Abl oncoproteins and induces Hsp90 cleavage in the ROS-dependent suppression of cancer malignancy. Biochem Pharmacol. 2014 Jan 15;87(2):229-42. PMID: 24161787.

 

Shen T, Yang WS, Yi YS, et al. AP-1/IRF-3 Targeted Anti-Inflammatory Activity of Andrographolide Isolated from Andrographis paniculata. Evid Based Complement Alternat Med. 2013;2013:210736. PMID: 23840248.

 

Zhang C, Gui L, Xu Y, et al. Preventive effects of andrographolide on the development of diabetes in autoimmune diabetic NOD mice by inducing immune tolerance. Int Immunopharmacol. 2013 Aug;16(4):451-6. PMID: 23707775.

" None Not dangerous goods.

LKT I6932 Irinotecan 250 mg 543.6 Camptothecin analog; topoisomerase I inhibitor, potential AChE inhibitor. [1,4'-Bipiperidine]-1'-carboxylic acid (4S)-4,11- diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo- 1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester 97682-44-5 ≥98% 586.68 C33H38N4O6 CCC1=C2C=C(C=CC2=NC3=C1CN4C3=CC5=C(C4=O)COC(=O)C5(CC)O)OC(=O)N6CCC(CC6)N7CCCCC7 Ambient 4°C Insoluble in water.  Soluble in DMSO "Hu J, Kinn J, Zirakzadeh AA, et al. The effects of chemotherapeutic drugs on human monocyte-derived dendritic cell differentiation and antigen presentation. Clin Exp Immunol. 2013 Jun;172(3):490-9. PMID: 23600838.

 

Pan P, Li Y, Yu H, et al. Molecular principle of topotecan resistance by topoisomerase I mutations through molecular modeling approaches. J Chem Inf Model. 2013 Apr 22;53(4):997-1006. PMID: 23521602.

 

Chen AY, Chen PM, Chen YJ. DNA topoisomerase I drugs and radiotherapy for lung cancer. J Thorac Dis. 2012 Aug;4(4):390-7. PMID: 22934142.

 

Chintala S, Tóth K, Cao S, et al. Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1alpha. Cancer Chemother Pharmacol. 2010 Oct;66(5):899-911. PMID: 20066420.

 

Dodds HM, Rivory LP. The mechanism for the inhibition of acetylcholinesterases by irinotecan (CPT-11). Mol Pharmacol. 1999 Dec;56(6):1346-53. PMID: 10570064." Xn Not dangerous goods.

LKT C2800 Chalcone 500 g 418.6 Enone. 1,3-Diphenyl-2-propen-1-one Chalkone; trans-Benzylideneacetophenone 94-41-7 ≥97% 208.26 C15H12O C1=CC=C(C=C1)C=CC(=O)C2=CC=CC=C2 Ambient Ambient Insoluble in water.  Slightly soluble in ethanol. "Wu JZ, Cheng CC, Shen LL, et al. Synthetic Chalcones with Potent Antioxidant Ability on H2O2-Induced Apoptosis in PC12 Cells. Int J Mol Sci. 2014 Oct 14;15(10):18525-18539. PMID: 25318055.

 

Jantan I, Bukhari SN, Adekoya OA, et al. Studies of synthetic chalcone derivatives as potential inhibitors of secretory phospholipase A2, cyclooxygenases, lipoxygenase and pro-inflammatory cytokines. Drug Des Devel Ther. 2014 Sep 16;8:1405-18. PMID: 25258510.

 

Abdellatif KR, Elshemy HA, Salama SA, et al. Synthesis, characterization and biological evaluation of novel 4'-fluoro-2'-hydroxy-chalcone derivatives as antioxidant, anti-inflammatory and analgesic agents. J Enzyme Inhib Med Chem. 2014 Sep 8:1-8. PMID: 25198887.

 

Karthikeyan C, Narayana Moorthy NS, Ramasamy S, et al. Advances in Chalcones with Anticancer Activities. Recent Pat Anticancer Drug Discov. 2014 Aug 19. [Epub ahead of print]. PMID: 25138130.

 

Shivahare R, Korthikunta V, Chandasana H, et al. Synthesis, structure-activity relationships, and biological studies of chromenochalcones as potential antileishmanial agents. J Med Chem. 2014 Apr 24;57(8):3342-57. PMID: 24635539.

" Xn, Xi Not dangerous goods.

LKT D3262 Dipropyl Sulfide 25 g 146.2 Organosulfide found in Allium; cholesterol synthesis inhibitor. 4-Thiaheptane; Di-n-propyl sulfide; Dipropyl thioether; Propyl monosulfide; Propyl sulfide 111-47-7 ≥98% 118.24 C6H14S CCCSCCC Ambient Ambient Insoluble in water "Tsai CW, Liu KL, Lin CY, et al. Structure and function relationship study of allium organosulfur compounds on upregulating the pi class of glutathione S-transferase expression. J Agric Food Chem. 2011 Apr 13;59(7):3398-405. PMID: 21381664.

 

Arranz N, Haza AI, García A, et al. Protective effects of organosulfur compounds towards N-nitrosamine-induced DNA damage in the single-cell gel electrophoresis (SCGE)/HepG2 assay. Food Chem Toxicol. 2007 Sep;45(9):1662-9. PMID: 17434656.

 

Yeh YY, Liu L. Cholesterol-lowering effect of garlic extracts and organosulfur compounds: human and animal studies. J Nutr. 2001 Mar;131(3s):989S-93S. PMID: 11238803.

 

Srivastava SK, Hu X, Xia H, et al. Mechanism of differential efficacy of garlic organosulfides in preventing benzo(a)pyrene-induced cancer in mice. Cancer Lett. 1997 Sep 16;118(1):61-7. PMID: 9310261.

" Xi "UN number: 1993     Class:  3     Packing group:  III

Proper shipping name:  Flammable liquids, n.o.s. (Dipropyl sulfide)

Reportable Quantity (RQ):     Poison inhalation hazard:  No"

LKT F1669 Ferulic Acid 100 g 163.2 Hydroxycinnamic acid found in various plant sources, metabolite of verbascoside. 3-(4-Hydroxy-3-methoxyphenyl)-2-propenoic acid Caffeic acid 3-methyl ether; 4-Hydroxy-3-methoxy- cinnamic acid 1135-24-6 ≥98% 194.18 C10H10O4 COC1=C(C=CC(=C1)C=CC(=O)O)O Ambient Ambient Soluble in hot water, or ethyl acetate.DMSO:39mg/mL, Ethanol:39mg/mL "Quirantes-Piné R, Herranz-López M, Funes L, et al. Phenylpropanoids and their metabolites are the major compounds responsible for blood-cell protection against oxidative stress after administration of Lippia citriodora in rats. Phytomedicine. 2013 Sep 15;20(12):1112-8. PMID: 23827667.

 

Xu Y, Zhang L, Shao T, et al. Ferulic acid increases pain threshold and ameliorates depression-like behaviors in reserpine-treated mice: behavioral and neurobiological analyses. Metab Brain Dis. 2013 Dec;28(4):571-83. PMID: 23584961.

 

Picone P, Nuzzo D, Di Carlo M. Ferulic acid: a natural antioxidant against oxidative stress induced by oligomeric A-beta on sea urchin embryo. Biol Bull. 2013 Feb;224(1):18-28. PMID: 23493505.

 

Lin TY, Lu CW, Huang SK, et al. Ferulic acid suppresses glutamate release through inhibition of voltage-dependent calcium entry in rat cerebrocortical nerve terminals. J Med Food. 2013 Feb;16(2):112-9. PMID: 23342970.

 

Choi R, Kim BH, Naowaboot J, et al. Effects of ferulic acid on diabetic nephropathy in a rat model of type 2 diabetes. Exp Mol Med. 2011 Dec 31;43(12):676-83. PMID: 21975281.

" Xi Not dangerous goods.

LKT M1685 Mevastatin 250 mg 339.8 Statin; HMG-CoA reductase inhibitor. (2S)-2-Methylbutanoic acid (1S,7S,8S,8aR)- 1,2,3,7,8,8a-hexahydro-7-methyl-8-[2-[(2R,4R)- tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1- naphthalenyl ester Compactin; 6-demethylmevinolin; CS-500; ML-236B. 73573-88-3 ≥98% 390.51 C23H34O5 CCC(C)C(=O)OC1CCC=C2C1C(C(C=C2)C)CCC3CC(CC(=O)O3)O Ambient Ambient Soluble in DMSO, or ethanol. Insoluble in water. "Zhang S, Wang XL, Gan YH, et al. Activation of c-Jun N-terminal kinase is required for mevastatin-induced apoptosis of salivary adenoid cystic carcinoma cells. Anticancer Drugs. 2010 Aug;21(7):678-86. PMID: 20629200.

 

Thompson K, Rogers MJ. Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro. J Bone Miner Res. 2004 Feb;19(2):278-88. PMID: 14969398.

 

Endo A, Kuroda M, Tsujita Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J Antibiot (Tokyo). 1976 Dec;29(12):1346-8. PMID: 1010803.

" None Not dangerous goods.

LKT Q8016 Quercetin Dihydrate 500 g 427.1 Flavonoid found in fruits, vegetables, and grains; RT, MAO, calcineurin inhibitor. 4 H- 1-Benzopyran-4-one-2-(3,4-dihydroxyphenyl)- 3,5,7-trihydroxy-dihydrate CCRIS 3304 6151-25-3 ≥95% 338.26 C15H10O7 2H2O C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O.O.O Ambient 4°C Soluble in ethanol. Insoluble in water. "Pisonero-Vaquero S, García-Mediavilla MV, Jorquera F, et al. Modulation of PI3K-LXRα-dependent lipogenesis mediated by oxidative/nitrosative stress contributes to inhibition of HCV replication by quercetin. Lab Invest. 2014 Mar;94(3):262-74. PMID: 24492281.

 

Park HJ, Lee CM, Jung ID, et al. Quercetin regulates Th1/Th2 balance in a murine model of asthma. Int Immunopharmacol. 2009 Mar;9(3):261-7. PMID: 19061976.

 

Saaby L, Rasmussen HB, Jäger AK. MAO-A inhibitory activity of quercetin from Calluna vulgaris (L.) Hull. J Ethnopharmacol. 2009 Jan 12;121(1):178-81. PMID: 19013512.

 

Stewart LK, Soileau JL, Ribnicky D, et al. Quercetin transiently increases energy expenditure but persistently decreases circulating markers of inflammation in C57BL/6J mice fed a high-fat diet. Metabolism. 2008 Jul;57(7 Suppl 1):S39-46. PMID: 18555853.

 

Edwards RL, Lyon T, Litwin SE, et al. Quercetin reduces blood pressure in hypertensive subjects. J Nutr. 2007 Nov;137(11):2405-11. PMID: 17951477.

 

Spedding G, Ratty A, Middleton E Jr. Inhibition of reverse transcriptases by flavonoids. Antiviral Res. 1989 Sep;12(2):99-110. PMID: 2480745.

" T "UN number: 2811     Class:  6.1     Packing group:  III

Proper shipping name:  toxic solids, organic, n.o.s. (3,3’,4’,5,7-Pentahydroxyflavone dihydrate)

Marine pollutant:  No     Poison inhalation hazard:  No."

LKT D5692 Doxifluridine 250 mg 271.7 5-Fluorouracil prodrug, pyrimidine nucleoside analog; thymidylate synthase inhibitor. 5'-Deoxy-5-fluorouridine 5'-DFUR; Flutron; Furtulon 3094-09-5 ≥98% 246.19 C9H11FN2O5 CC1C(C(C(O1)N2C=C(C(=O)NC2=O)F)O)O Hygroscopic. Ambient Ambient "Zhao WH, Wang SF, Ding W, et al. Apoptosis induced by preoperative oral 5'-DFUR administration in gastric adenocarcinoma and its mechanism of action. World J Gastroenterol. 2006 Mar 7;12(9):1356-61. PMID: 16552801.

 

Saurat JH. Retinoids and psoriasis: novel issues in retinoid pharmacology and implications for psoriasis treatment. J Am Acad Dermatol. 1999 Sep;41(3 Pt 2):S2-6. PMID: 10459139.

" None Not dangerous goods.

LKT T2934 Thiamphenicol Palmitate 500 mg 40.7 Chloramphenicol derivative; protein translation inhibitor, peptidyl transferase inhibitor. 52628-58-7 ≥98% 594.63 C28H45Cl2NO6S CCCCCCCCCCCCCCCC(=O)OC(C1=CC=C(C=C1)S(=O)(=O)C)C(CO)NC(=O)C(Cl)Cl Ambient Ambient "Raymond J, Boutros N, Bergeret M. Role of thiamphenicol in the treatment of community-acquired lung infections. Med Trop (Mars). 2004;64(1):33-8. PMID: 15224555.

 

Marchese A, Debbia EA, Tonoli E, et al. In vitro activity of thiamphenicol against multiresistant Streptococcus pneumoniae, Haemophilus influenzae and Staphylococcus aureus in Italy. J Chemother. 2002 Dec;14(6):554-61. PMID: 12583545.

" Not dangerous goods.

LKT T2934 Thiamphenicol Palmitate 1 g 61.1 Chloramphenicol derivative; protein translation inhibitor, peptidyl transferase inhibitor. 52628-58-7 ≥98% 594.63 C28H45Cl2NO6S CCCCCCCCCCCCCCCC(=O)OC(C1=CC=C(C=C1)S(=O)(=O)C)C(CO)NC(=O)C(Cl)Cl Ambient Ambient "Raymond J, Boutros N, Bergeret M. Role of thiamphenicol in the treatment of community-acquired lung infections. Med Trop (Mars). 2004;64(1):33-8. PMID: 15224555.

 

Marchese A, Debbia EA, Tonoli E, et al. In vitro activity of thiamphenicol against multiresistant Streptococcus pneumoniae, Haemophilus influenzae and Staphylococcus aureus in Italy. J Chemother. 2002 Dec;14(6):554-61. PMID: 12583545.

" Not dangerous goods.

LKT M5746 Molsidomine 5 g 407.7 NO donor; annexin A2 inhibitor. N-(Ethoxycarbonyl)-3-(4-morpholinyl)sydnone imine Corvaton; Corvasal; Molsidolat; Morial; Motazominn 25717-80-0 ≥98% 242.23 C9H14N4O4 CCOC(=NC1=C[N+](=NO1)N2CCOCC2)[O-] Ambient Ambient Soluble in chloroform, methanol, ethanol, or ethyl acetate. Slightly soluble in water, acetone or benzene. "Harnek J, Zoucas E, de Sá VP, et al. Intimal hyperplasia in balloon dilated coronary arteries is reduced by local delivery of the NO donor, SIN-1 via a cGMP-dependent pathway. BMC Cardiovasc Disord. 2011 Jun 11;11:30. PMID: 21663688.

 

Won KJ, Lee P, Jung SH, et al. 3-morpholinosydnonimine participates in the attenuation of neointima formation via inhibition of annexin A2-mediated vascular smooth muscle cell migration. Proteomics. 2011 Jan;11(2):193-201. PMID: 21204247.

 

Cardoso MH, Morganti RP, Lilla S, et al. The role of superoxide anion in the inhibitory effect of SIN-1 in thrombin-activated human platelet adhesion. Eur J Pharmacol. 2010 Feb 10;627(1-3):229-34. PMID: 19895807.

" Xn Not dangerous goods.

LKT R3373 Risedronate Sodium Hydrate 25 mg 47.6 Bisphosphonate; inhibits transfer of farnesyl pyrophosphate. [1-Hydroxy-2-(3-pyridinyl)ethylidene]bisphosphonic acid monosodium salt Risedronic acid monosodium salt; Actonel; Optinate 115436-72-1 ≥98% 350.13 C7H10NO7P2Na 2.5H2O C1=CC(=CN=C1)CC(O)(P(=O)(O)O)P(=O)(O)[O-].[Na+] Ambient Ambient Soluble in water. Insoluble in organic solvents. "Lems WF, den Heijer M. Established and forthcoming drugs for the treatment of osteoporosis. Neth J Med. 2013 May;71(4):188-93. PMID: 23723112.

 

Jin J, Wang L, Wang XK, et al. Risedronate inhibits bone marrow mesenchymal stem cell adipogenesis and switches RANKL/OPG ratio to impair osteoclast differentiation. J Surg Res. 2013 Mar;180(1):e21-9. PMID: 22487394.

 

Matsumoto T, Nagase Y, Iwasawa M, et al. Distinguishing the proapoptotic and antiresorptive functions of risedronate in murine osteoclasts: role of the Akt pathway and the ERK/Bim axis. Arthritis Rheum. 2011 Dec;63(12):3908-17. PMID: 21898348.

 

Jordão FM, Saito AY, Miguel DC, et al. In vitro and in vivo antiplasmodial activities of risedronate and its interference with protein prenylation in Plasmodium falciparum. Antimicrob Agents Chemother. 2011 May;55(5):2026-31. PMID: 21357292.

" Xi Not dangerous goods.

LKT R3373 Risedronate Sodium Hydrate 500 mg 367 Bisphosphonate; inhibits transfer of farnesyl pyrophosphate. [1-Hydroxy-2-(3-pyridinyl)ethylidene]bisphosphonic acid monosodium salt Risedronic acid monosodium salt; Actonel; Optinate 115436-72-1 ≥98% 350.13 C7H10NO7P2Na 2.5H2O C1=CC(=CN=C1)CC(O)(P(=O)(O)O)P(=O)(O)[O-].[Na+] Ambient Ambient Soluble in water. Insoluble in organic solvents. "Lems WF, den Heijer M. Established and forthcoming drugs for the treatment of osteoporosis. Neth J Med. 2013 May;71(4):188-93. PMID: 23723112.

 

Jin J, Wang L, Wang XK, et al. Risedronate inhibits bone marrow mesenchymal stem cell adipogenesis and switches RANKL/OPG ratio to impair osteoclast differentiation. J Surg Res. 2013 Mar;180(1):e21-9. PMID: 22487394.

 

Matsumoto T, Nagase Y, Iwasawa M, et al. Distinguishing the proapoptotic and antiresorptive functions of risedronate in murine osteoclasts: role of the Akt pathway and the ERK/Bim axis. Arthritis Rheum. 2011 Dec;63(12):3908-17. PMID: 21898348.

 

Jordão FM, Saito AY, Miguel DC, et al. In vitro and in vivo antiplasmodial activities of risedronate and its interference with protein prenylation in Plasmodium falciparum. Antimicrob Agents Chemother. 2011 May;55(5):2026-31. PMID: 21357292.

" Xi Not dangerous goods.

LKT T2800 Thalidomide 25 mg 40.7 Immunomodulator; teratogen. (±)-2-(2,6-Dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione 1,3-Dioxo-2-(2,6-dioxopiperidin-3-yl)isoindoline; Actimid; Calmore; Distaval; Sedimide;Telagan 50-35-1 ≥98% 258.23 C13H10N2O4 C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O Ambient Ambient Insoluble in water and ethanol. Soluble in DMSO (56mg/mL). "Lien IC, Horng LY, Hsu PL, et al. Internal ribosome entry site of bFGF is the target of thalidomide for IMiDs development in multiple myeloma. Genes Cancer. 2014 Mar;5(3-4):127-41. PMID: 25053990.

 

Xu J, Zheng C, Huang Y, et al. Efficacy of thalidomide on trinitrobenzene sulfonate-induced colitis in young rats and its mechanism. Chin Med J (Engl). 2014;127(12):2368-75. PMID: 24931258.

 

Zhou S, Wang F, Hsieh TC, et al. Thalidomide-a notorious sedative to a wonder anticancer drug. Curr Med Chem. 2013;20(33):4102-8. PMID: 23931282.

" T "UN number: 2811     Class: 6.1     Packing Group: III

Proper shipping name: Toxic solid, organic, n.o.s. ((+/-)-Thalidomide)"

LKT C0265 Carnosic Acid 5 mg 67.9 Diterpene found in Rosmarinus. Salvin 3650-09-7 ≥98% 332.43 C20H28O4 CC(C)C1=C(C(=C2C(=C1)CCC3C2(CCCC3(C)C)C(=O)O)O)O Ambient -20°C Slightly soluble in water. soluble in DMSO. "Kim YJ, Kim JS, Seo YR, et al. Carnosic acid suppresses colon tumor formation in association with anti-adipogenic activity. Mol Nutr Food Res. 2014 Sep 9. [Epub ahead of print]. PMID: 25204550.

 

Gao Q, Liu H, Yao Y, et al. Carnosic acid induces autophagic cell death through inhibition of the Akt/mTOR pathway in human hepatoma cells. J Appl Toxicol. 2014 Sep 1. [Epub ahead of print]. PMID: 25178877.

 

Sahu BD, Putcha UK, Kuncha M, et al. Carnosic acid promotes myocardial antioxidant response and prevents isoproterenol-induced myocardial oxidative stress and apoptosis in mice. Mol Cell Biochem. 2014 Sep;394(1-2):163-76. PMID: 24903830.

 

Tsai CW, Liu KL, Lin YR, et al. The mechanisms of carnosic acid attenuates tumor necrosis factor-α-mediated inflammation and insulin resistance in 3T3-L1 adipocytes. Mol Nutr Food Res. 2014 Apr;58(4):654-64. PMID: 24668853.

 

Rasoolijazi H, Azad N, Joghataei MT, et al. The protective role of carnosic acid against beta-amyloid toxicity in rats. ScientificWorldJournal. 2013 Oct 24;2013:917082. PMID: 24363627.

" Not dangerous goods.

LKT S3353 Sinomenine Hydrochloride 1 g 40.7 Alkaloid found in Sinomenium; acid-sensing ion channel and L-type Ca2+ channel blocker. (9α,13α,14α)-7,8-Didehydro-4-hydroxy-3,7-di- methoxy-17-methylmorphinan-6-one hydrochloride 6080-33-7 ≥98% 365.86 C19H23NO4 HCl CN1CCC23CC(=O)C(=CC2C1CC4=C3C(=C(C=C4)OC)O)OC.Cl Ambient 4°C Soluble in chloroform, ethanol acetone or toluene. "Li X, Wang K, Ren Y, et al. MAPK signaling mediates sinomenine hydrochloride-induced human breast cancer cell death via both reactive oxygen species-dependent and -independent pathways: an in vitro and in vivo study. Cell Death Dis. 2014 Jul 31;5:e1356. PMID: 25077542.

 

Zhang MY, Li P, Wang DQ, et al. Analgesic effect of sinomenine on SSNI model rats and monoamine neurotransmitters in striatal extracellular fluid. Zhongguo Zhong Yao Za Zhi. 2013 Feb;38(4):597-604. PMID: 23713290.

 

Chen Z, Tao Z, Zhang N, et al. The role of sinomenine in treatment of allergic rhinitis mice model and its mechanism. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2013 Jan;27(2):81-4. PMID: 23650707.

 

Oh YC, Kang OH, Kim SB, et al. Anti-inflammatory effect of sinomenine by inhibition of pro-inflammatory mediators in PMA plus A23187-stimulated HMC-1 Cells. Eur Rev Med Pharmacol Sci. 2012 Sep;16(9):1184-91. PMID: 23047501.

 

Wu WN, Wu PF, Chen XL, et al.  Sinomenine protects against ischaemic brain injury: involvement of co-inhibition of acid-sensing ion channel 1a and L-type calcium channels. Br J Pharmacol. 2011 Nov;164(5):1445-59. PMID: 21585344.

" Xn, Xi Not dangerous goods.

LKT I7357 Isorhamnetin 25 mg 407.7 Flavonol found in Tagetes. 3,5,7-Trihydroxy-2-(4-hydroxy-3-methoxyphenyl)-4-benzopyrone 3-Methylquercetin; Quercetin- 3'-methyl ether 480-19-3 ≥98% 316.26 C16H12O7 COC1=C(C=CC(=C1)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O Ambient 4°C Soluble in acetone, methanol, ethylacetate, DMSO or water. "Seo K, Yang JH, Kim SC, et al. The antioxidant effects of isorhamnetin contribute to inhibit COX-2 expression in response to inflammation: a potential role of HO-1. Inflammation. 2014 Jun;37(3):712-22. PMID: 24337631.

 

Li C, Yang X, Chen C, et al. Isorhamnetin suppresses colon cancer cell growth through the PI3K Akt mTOR pathway. Mol Med Rep. 2014 Mar;9(3):935-40. PMID: 24398569.

 

Saud SM, Young MR, Jones-Hall YL, et al. Chemopreventive activity of plant flavonoid isorhamnetin in colorectal cancer is mediated by oncogenic Src and β-catenin. Cancer Res. 2013 Sep 1;73(17):5473-84. PMID: 23824743.

 

Kim JE, Lee DE, Lee KW, et al. Isorhamnetin suppresses skin cancer through direct inhibition of MEK1 and PI3-K. Cancer Prev Res (Phila). 2011 Apr;4(4):582-91. PMID: 21330379.

 

Lee J, Jung E, Lee J, et al. Isorhamnetin represses adipogenesis in 3T3-L1 cells. Obesity (Silver Spring). 2009 Feb;17(2):226-32. PMID: 18948972.

" Xn Not dangerous goods.

LKT P0218 Paeoniflorin 25 mg 149.5 Found in Paeonia; L-type Ca2+ channel blocker. Paeonia moutan; Paeony root 23180-57-6 ≥98% 480.46 C23H28O11 CC12CC3(C4CC1(C4(C(O2)O3)COC(=O)C5=CC=CC=C5)OC6C(C(C(C(O6)CO)O)O)O)O Hygroscopic. Ambient -20°C Soluble in water (10 mg/mL)  or ethanol. MeOH 1 mg/mL. "Zhang J, Dou W, Zhang E, et al. Paeoniflorin abrogates DSS-induced colitis via a TLR4-dependent pathway. Am J Physiol Gastrointest Liver Physiol. 2014 Jan 1;306(1):G27-36. PMID: 24232001.

 

Zhao Y, Zhou G, Wang J, et al. Paeoniflorin protects against ANIT-induced cholestasis by ameliorating oxidative stress in rats. Food Chem Toxicol. 2013 Aug;58:242-8. PMID: 23623840.

 

Qiu F, Zhong X, Mao Q, et al. The antidepressant-like effects of paeoniflorin in mouse models. Exp Ther Med. 2013 Apr;5(4):1113-1116. PMID: 23599734.

 

Wang H, Zhou H, Wang CX, et al. Paeoniflorin inhibits growth of human colorectal carcinoma HT 29 cells in vitro and in vivo. Food Chem Toxicol. 2012 May;50(5):1560-7. PMID: 22326807.

 

Zhang XJ, Li Z, Leung WM, et al. The analgesic effect of paeoniflorin on neonatal maternal separation-induced visceral hyperalgesia in rats. J Pain. 2008 Jun;9(6):497-505. PMID: 18387856.

 

Tsai TY, Wu SN, Liu YC, et al. Inhibitory action of L-type Ca2+ current by paeoniflorin, a major constituent of peony root, in NG108-15 neuronal cells. Eur J Pharmacol. 2005 Oct 31;523(1-3):16-24. PMID: 16243310.

" None Not dangerous goods.

LKT K0117 Kaempferol 25 mg 95.1 Flavonol found in various plant sources. 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-4H-1-benzo- pyran-4-one Nimbecetin; Populnetin; Rhamnolutein; Robigenin; Swartziol; Trifolitin 520-18-3 ≥98% 286.24 C15H10O6 C1=CC(=CC=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O Ambient -20°C Slightly soluble in water. Soluble in hot alcohol, ether or alkalies. "Tang XL, Liu JX, Dong W, et al. Protective Effect of Kaempferol on LPS plus ATP-Induced Inflammatory Response in Cardiac Fibroblasts. Inflammation. 2014 Sep 5. [Epub ahead of print]. PMID: 25189464.

 

Yang EJ, Kim GS, Jun M, et al. Kaempferol attenuates the glutamate-induced oxidative stress in mouse-derived hippocampal neuronal HT22 cells. Food Funct. 2014 Jul 25;5(7):1395-402. PMID: 24770605.

 

Dang Q, Song W, Xu D, et al. Kaempferol suppresses bladder cancer tumor growth by inhibiting cell proliferation and inducing apoptosis. Mol Carcinog. 2014 Apr 2. [Epub ahead of print]. PMID: 24700700.

 

Chen HJ, Lin CM, Lee CY, et al. Kaempferol suppresses cell metastasis via inhibition of the ERK-p38-JNK and AP-1 signaling pathways in U-2 OS human osteosarcoma cells. Oncol Rep. 2013 Aug;30(2):925-32. PMID: 23708932.

 

Park UH, Jeong JC, Jang JS, et al. Negative regulation of adipogenesis by kaempferol, a component of Rhizoma Polygonati falcatum in 3T3-L1 cells. Biol Pharm Bull. 2012;35(9):1525-33. PMID: 22975504.

 

Luo H, Rankin GO, Juliano N, et al. Kaempferol inhibits VEGF expression and in vitro angiogenesis through a novel ERK-NFκB-cMyc-p21 pathway. Food Chem. 2012 Jan 15;130(2):321-328. PMID: 21927533.

" T Not dangerous goods.

LKT C1668 Cerivastatin Sodium 5 mg 101.9 Statin; HMG-CoA reductase inhibitor. (3R,5S,6E)-7-[4-(4-Fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-6- heptenoic acid Baycol; Lipobay; Rivastatin 143201-11-0 ≥98% 481.53 C26H33FNNaO5 CC(C)C1=C(C(=C(C(=N1)C(C)C)C=CC(CC(CC(=O)[O-])O)O)C2=CC=C(C=C2)F)COC.[Na+] Ambient -20°C Soluble in water. "Takeshita Y, Takamura T, Hamaguchi E, et al. Tumor necrosis factor-alpha-induced production of plasminogen activator inhibitor 1 and its regulation by pioglitazone and cerivastatin in a nonmalignant human hepatocyte cell line. Metabolism. 2006 Nov;55(11):1464-72. PMID: 17046548.

 

Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005 Feb;19(1):117-25. PMID: 15660968.

 

Jamal SM, Eisenberg MJ, Christopoulos S. Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am Heart J. 2004 Jun;147(6):956-65. PMID: 15199341.

 

Viedt C, Shen W, Fei J, et al. HMG-CoA reductase inhibition reduces the proinflammatory activation of human vascular smooth muscle cells by the terminal complement factor C5b-9. Basic Res Cardiol. 2003 Nov;98(6):353-61. PMID: 14556080.

" Not dangerous goods.

LKT B1874 Bestatin Hydrochloride 25 mg 237.8 Dipeptide; aminopeptidase (N/CD13) inhibitor. N-[(2S,3R)-3-Amino-2-hydroxy-1-oxo-4-phenylbutyl]-L-leucine hydrochloride Ubenimex hydrochloride 65391-42-6 ≥98% 344.87 C16H24N2O4 HCl CC(C)CC(C(=O)O)NC(=O)C(C(CC1=CC=CC=C1)N)O.Cl Ambient -20°C Soluble in water (25mg.mL). "Hitzerd SM, Verbrugge SE, Ossenkoppele G, et al. Positioning of aminopeptidase inhibitors in next generation cancer therapy. Amino Acids. 2014 Apr;46(4):793-808. PMID: 24385243.

 

Qian X, He J, Zhao Y, et al. Inhibition of p38 MAPK Phosphorylation Is Critical for Bestatin to Enhance ATRA-Induced Cell Differentiation in Acute Promyelocytic Leukemia NB4 Cells. Am J Ther. 2013 Oct 17. [Epub ahead of print]. PMID: 24141198.

 

Jia MR, Wei T, Xu WF. The Analgesic Activity of Bestatin as a Potent APN Inhibitor. Front Neurosci. 2010 Jun 28;4:50. PMID: 20631848.

" Xn, Xi Not dangerous goods.

LKT D3356 Diosmetin 250 mg 88.3 O-methylated flavone found in vetch and various fruits. "

benzopyran-4-one " Cyanidenon-4'-methyl ether 1479; Luteolin-4'-methyl ether 520-34-3 ≥98% 300.26 C16H12O6 COC1=C(C=C(C=C1)C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O Ambient Ambient Sparingly soluble in water (<1 mg/ml). Soluble in acetonitrile, DMSO (60 mg/ml), and ethanol (17 mg/ml). "Liao W, Ning Z, Chen L, et al. Intracellular Antioxidant Detoxifying Effects of Diosmetin on 2,2-Azobis(2-amidinopropane) Dihydrochloride (AAPH)-Induced Oxidative Stress through Inhibition of Reactive Oxygen Species Generation. J Agric Food Chem. 2014 Aug 27;62(34):8648-54. PMID: 25075433.

 

Yu G, Wan R, Yin G, et al. Diosmetin ameliorates the severity of cerulein-induced acute pancreatitis in mice by inhibiting the activation of the nuclear factor-κB. Int J Clin Exp Pathol. 2014 Apr 15;7(5):2133-42. PMID: 24966921.

 

Androutsopoulos VP, Mahale S, Arroo RR, et al. Anticancer effects of the flavonoid diosmetin on cell cycle progression and proliferation of MDA-MB 468 breast cancer celLSue to CYP1 activation. Oncol Rep. 2009 Jun;21(6):1525-8. PMID: 19424633.

 

Hsu YL, Kuo PL. Diosmetin induces human osteoblastic differentiation through the protein kinase C/p38 and extracellular signal-regulated kinase 1/2 pathway. J Bone Miner Res. 2008 Jun;23(6):949-60. PMID: 18269307.

" Xn Not dangerous goods.

LKT "F5745

" Folic Acid 100 g 133.2 Non-endogenous essential vitamin (B9), found in leafy vegetables, required for synthesis and repair of DNA. N-[4-[[(2-Amino-1,4-dihydrox-4-oxo-6-pteridinyl)- methyl]amino]benzoyl]-L-glutamic acid PGA; Vitamin M; Folacin; Foliamin; Folipac; Folsan; Millafol 59-30-3 ≥96% 441.4 C19H19N7O6 C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)N=C(N3)N Ambient 4°C Soluble in hot dil HCl or H2SO4. Slightly soluble in methanol, acetic acid, phenol, or pyridine. Insoluble in acetone, chloroform, ether, water, or benzene. "Reynolds EH. The neurology of folic acid deficiency. Handb Clin Neurol. 2014;120:927-43. PMID: 24365361.

 

Czeizel AE, Dudás I, Vereczkey A, et al. Folate deficiency and folic acid supplementation: the prevention of neural-tube defects and congenital heart defects. Nutrients. 2013 Nov 21;5(11):4760-75. PMID: 24284617.

 

Ebisch IM, Thomas CM, Peters WH, et al. The importance of folate, zinc and antioxidants in the pathogenesis and prevention of subfertility. Hum Reprod Update. 2007 Mar-Apr;13(2):163-74. PMID: 17099205.

 

Coppen A, Bolander-Gouaille C. Treatment of depression: time to consider folic acid and vitamin B12. J Psychopharmacol. 2005 Jan;19(1):59-65. PMID: 15671130.

" None Not dangerous goods.

LKT D5709 Docetaxel 100 mg 1019.2 Semi-synthetic analog of taxol; microtubule depolymerization inhibitor. (αR,βS)-β-[[(1,1-Dimethylethoxy)carbonyl]amino]-α-hydroxybenzenepropanoic acid (2aR,4S,4aS,6R,9S,- 11S,12S,12aR,12bS)-12b-(acetyloxy)-12(benzoyloxy)- 2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11- trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol; Taxotere 114977-28-5 ≥98% 807.89 C43H53NO14 CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O In DMSO at +4 for 2 weeks at -80 for 6 months. Ambient -20°C Soluble in DMSO, ethanol, chloroform, dichloromethane, ethyl acetate, methanol. Insoluble in water. "Lyseng-Williamson KA, Fenton C. Docetaxel: a review of its use in metastatic breast cancer. Drugs. 2005;65(17):2513-31. PMID: 16296875.

 

Eisenhauer EA, Vermorken JB. The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs. 1998 Jan;55(1):5-30. PMID: 9463787.

" None Not dangerous goods.

LKT G3358 Ginkgolides 25 mg 47.6 Mixture of Ginkgolides A, B and C, found in Ginkgo. ≥98% Ambient -20°C Insoluble in water.  Soluble in DMSO. Not dangerous goods.

LKT O4917 Omeprazole 500 mg 67.9 H+/K+ ATPase inhibitor. 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole Antra; Gastrogard; Losec; Mepral; Omepral; Parizac' Prilosec; Zoltum 73590-58-6 ≥98% 345.42 C17H19N3O3S CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC Ambient 4°C Soluble in ethanol or methanol. Slightly soluble in acetone, isopropanol, or water. "Tonazzi A, Eberini I, Indiveri C. Molecular mechanism of inhibition of the mitochondrial carnitine/acylcarnitine transporter by omeprazole revealed by proteoliposome assay, mutagenesis and bioinformatics. PLoS One. 2013 Dec 9;8(12):e82286. PMID: 24349247.

 

Ward RM, Kearns GL. Proton pump inhibitors in pediatrics : mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics. Paediatr Drugs. 2013 Apr;15(2):119-31. PMID: 23512128.

 

Mefford IN, Mefford JT, Burris CA. Improved diabetes control and pancreatic function in a type 2 diabetic after omeprazole administration. Case Rep Endocrinol. 2012;2012:468609. PMID: 22937295.

" Xi Not dangerous goods.

LKT O9201 Oxaliplatin 500 mg 679.5 Pt-based DNA cross-linker. (SP-4-2)-[(1R,2R)-1.2-Cyclohexanediamine-κN,κN']- [ethanedioato(2-)-κO1,κO2]platinum Oxalatoplatin; Oxalatoplatinum 61825-94-3 ≥98% 397.29 C8H14N2O4Pt C1CCC(C(C1)N)N.C(=O)(C(=O)O)O.[Pt] Ambient -20°C Soluble in water (10 mM, 4 mg/mL), DMSO (50 mM or 20 mg /mL). "Chen X, Wu Y, Dong H, et al. Platinum-based agents for individualized cancer treatment. Curr Mol Med. 2013 Dec;13(10):1603-12. PMID: 24206132.

 

Gao J, Wang R, Yang Q, et al. Effect of Oxaliplatin on cell cycle of hepatocellular carcinoma cell line HepG2. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2013 Jul;42(4):437-42. PMID: 24022933.

 

Graham J, Mushin M, Kirkpatrick P. Oxaliplatin. Nat Rev Drug Discov. 2004 Jan;3(1):11-2. PMID: 14756144.

" Xi, Carc. Not dangerous goods.

LKT E6231 (−)-Epicatechin 25 mg 407.7 Flavanol originally found in Camilla (green tea). 2-(3,4-Dihydroxyphenyl)-3,4-dihydro-2H-1-benzo- pyran-3,5,7-triol Epicatechin; Epicatechol  490-46-0 ≥93% 290.27 C15H14O6 C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C=C3)O)O)O Ambient -20°C Soluble in water or alcohol. "Yamazaki KG, Andreyev AY, Ortiz-Vilchis P, et al. Intravenous (-)-epicatechin reduces myocardial ischemic injury by protecting mitochondrial function. Int J Cardiol. 2014 Aug 1;175(2):297-306. PMID: 24908200.

 

Zeng YQ, Wang YJ, Zhou XF. Effects of (-)Epicatechin on the Pathology of APP/PS1 Transgenic Mice. Front Neurol. 2014 May 9;5:69. PMID: 24847308.

 

Morrison M, van der Heijden R, Heeringa P, et al. Epicatechin attenuates atherosclerosis and exerts anti-inflammatory effects on diet-induced human-CRP and NFκB in vivo. Atherosclerosis. 2014 Mar;233(1):149-56. PMID: 24529136.

 

Butt MS, Ahmad RS, Sultan MT, et al. Green tea and anticancer perspectives: Updates from last decade. Crit Rev Food Sci Nutr. 2013 Sep 20. [Epub ahead of print]. PMID: 24915354.

" Xi Not dangerous goods.

LKT E6232 (−)-Epicatechin gallate 25 mg 339.8 Flavanol originally found in Camilla (green tea); CB1 agonist. 3,4,5-Trihydroxybenzoic acid, (2R,3R)-3,4- dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2-H-1-benzopyran-3-yl ester ECG 1257-08-5 ≥98% 442.37 C22H18O10 C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C=C3)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O Ambient -20°C Soluble in water or alcohol. "Nakanishi T, Mukai K, Hosokawa Y, et al. Catechins inhibit vascular endothelial growth factor production and cyclooxygenase-2 expression in human dental pulp cells. Int Endod J. 2014 May 21. [Epub ahead of print]. PMID: 24847951.

 

Ly BT, Chi HT, Yamagishi M, et al. Inhibition of FLT3 expression by green tea catechins in FLT3 mutated-AML cells. PLoS One. 2013 Jun 20;8(6):e66378. PMID: 23840454.

 

Korte G, Dreiseitel A, Schreier P, et al. Tea catechins' affinity for human cannabinoid receptors. Phytomedicine. 2010 Jan;17(1):19-22. PMID: 19897346.

" None Not dangerous goods.

LKT E5358 Enoxacin 5 g 233.7 Fluoroquinolone; vacuolar H+ ATPase, topoisomerase IV, bacterial DNA gyrase inhibitor. 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridine-3-carboxylic acid Abenox; Bactidan; Comprecin; Flumark; Penetrex 74011-58-8 ≥98% 320.32 C15H17FN4O3 CCN1C=C(C(=O)C2=CC(=C(N=C21)N3CCNCC3)F)C(=O)O Ambient Ambient Insoluble in water. "Liu X, Qu X, Wu C, et al. The effect of enoxacin on osteoclastogenesis and reduction of titanium particle-induced osteolysis via suppression of JNK signaling pathway. Biomaterials. 2014 Jul;35(22):5721-30. PMID: 24767789.

 

Toro EJ, Zuo J, Ostrov DA, et al. Enoxacin directly inhibits osteoclastogenesis without inducing apoptosis. J Biol Chem. 2012 May 18;287(21):17894-904. PMID: 22474295.

 

Zuma AA, Cavalcanti DP, Maia MC, et al. Effect of topoisomerase inhibitors and DNA-binding drugs on the cell proliferation and ultrastructure of Trypanosoma cruzi. Int J Antimicrob Agents. 2011 May;37(5):449-56. PMID: 21292448.

 

Koseki N, Deguchi J, Yamashita A, et al. Establishment fo a novel experimental protocol for drug-induced seizure liability screening based on a locomotor activity assay in zebrafish. J Toxicol Sci. 2014 Aug;39(4):579-600. PMID: 25056783.

" Xi Not dangerous goods.

LKT M1680 5-Methoxyindole 25 g 314.6 Core structure of melatonin; potential PPARγ and 5-HT3 agonist. 5-Methoxy-1H-indole Femedol 1006-94-6 ≥98% 147.17 C9H9NO COC1=CC2=C(C=C1)NC=C2 Ambient Ambient Insoluble in water. "Czimmerer Z, Varga T, Poliska S, et al. Identification of novel markers of alternative activation and potential endogenous PPARγ ligand production mechanisms in human IL-4 stimulated differentiating macrophages. Immunobiology. 2012 Dec;217(12):1301-14. PMID: 22954708.

 

Koike T, Hoashi Y, Takai T, et al. 1,6-Dihydro-2H-indeno[5,4-b]furan derivatives: design, synthesis, and pharmacological characterization of a novel class of highly potent MT₂-selective agonists. J Med Chem. 2011 May 12;54(9):3436-44. PMID: 21473625.

" Not dangerous goods.

LKT R5772 Rosiglitazone Maleate 100 mg 88.3 Thiazolidinedione; PPARγ agonist. 5-[[4-[2-(Methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione BRL-49653c; Avandia 155141-29-0 ≥98% 473.51 C18H19N3O3S C4H4O4 CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3.C(=CC(=O)O)C(=O)O Ambient Ambient Readily soluble in ethanol and in buffered aqueous solutions with a pH of 2.3. "Rui M, Huang Z, Liu Y, et al. Rosiglitazone suppresses angiogenesis in multiple myeloma via downregulation of hypoxia inducible factor 1α and insulin like growth factor 1 mRNA expression. Mol Med Rep. 2014 Jul 22. [Epub ahead of print]. PMID: 25050627.

 

Mingfeng D, Xiaodong M, Yue L, et al. Effects of PPAR-γ Agonist Treatment on LPS-Induced Mastitis in Rats. Inflammation. 2014 May 18. [Epub ahead of print]. PMID: 24839089.

 

Liu Y, Tian XY, Huang Y, et al. Rosiglitazone Attenuated Endothelin-1-Induced Vasoconstriction of Pulmonary Arteries in the Rat Model of Pulmonary Arterial Hypertension via Differential Regulation of ET-1 Receptors. PPAR Res. 2014;2014:374075. PMID: 24701204.

 

He H, Tao H, Xiong H, et al. Rosiglitazone causes cardiotoxicity via peroxisome proliferator-activated receptor γ-independent mitochondrial oxidative stress in mouse hearts. Toxicol Sci. 2014 Apr;138(2):468-81. PMID: 24449420.

 

Hou X, Zhang Y, Shen YH, et al. PPAR-γ activation by rosiglitazone suppresses angiotensin II-mediated proliferation and phenotypictransition in cardiac fibroblasts via inhibition of activation of activator protein 1. Eur J Pharmacol. 2013 Sep 5;715(1-3):196-203. PMID: 23791613.

 

Sharma AN, Elased KM, Lucot JB. Rosiglitazone treatment reversed depression- but not psychosis-like behavior of db/db diabetic mice. J Psychopharmacol. 2012 May;26(5):724-732. PMID: 22331176.

" Xn "UN number: 3077     Class: 9     Packing Group: III

Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (Rosiglitazone maleate)"

LKT S6000 Sparfloxacin 5 g 169.9 Fluoroquinolone; topoisomerase IV and bacterial DNA gyrase inhibitor. rel-5-Amino-1-cyclopropyl-7-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-6,8-difluoro-1,4-dihydro-4-oxo-3- quinolinecarboxylic acid Zagam; Spara 110871-86-8 ≥98% 392.4 C19H22F2N4O3 CC1CN(CC(N1)C)C2=C(C3=C(C(=C2F)N)C(=O)C(=CN3C4CC4)C(=O)O)F Ambient Ambient Soluble in alcohol and chloroform.  Water(0.11 g/100 ml) "Gouvea LR, Garcia LS, Lachter DR, et al. Atypical fluoroquinolone gold(III) chelates as potential anticancer agents: relevance of DNA and protein interactions for their mechanism of action. Eur J Med Chem. 2012 Sep;55:67-73. PMID: 22835721.

 

Harding I, Simpson I. Fluoroquinolones: is there a different mechanism of action and resistance against Streptococcus pneumoniae? J Chemother. 2000 Oct;12 Suppl 4:7-15. PMID: 11131958.

 

Schentag JJ. Sparfloxacin: a review. Clin Ther. 2000 Apr;22(4):372-87; PMID: 10823360.

" Xi Not dangerous goods.

LKT C0152 9-Aminocamptothecin 1 mg 47.6 Camptothecin derivative; topoisomerase I inhibitor. 9-Amino-20-camptothecin; 9-AC 91421-43-1 ≥98% 363.37 C20H17N3O4 CCC1(C2=C(COC1=O)C(=O)N3CC4=C(C3=C2)N=C5C=CC=C(C5=C4)N)O Ambient -20°C Soluble in DMSO. "Rodríguez-Berna G, Mangas-Sanjuán V, Gonzalez-Alvarez M, et al. A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability. Eur J Med Chem. 2014 Jun 25;83C:366-373. PMID: 24980118.

 

Berniak K, Rybak P, Bernas T, et al. Relationship between DNA damage response, initiated by camptothecin or oxidative stress, and DNA replication, analyzed by quantitative 3D image analysis. Cytometry A. 2013 Jul 11. [Epub ahead of print]. PMID: 23846844.

 

Redinbo MR, Stewart L, Kuhn P, et al. Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science. 1998 Mar 6;279(5356):1504-13. PMID: 9488644.

" Not dangerous goods.

LKT C9660 Cypermethrin 1 g 339.8 Synthetic type II pyrethroid insecticide; protein phosphatase inhibitor. 3-(2,2-Dichloroethenyl)-2,2-dimethylcyclopropane- carboxylic acid cyano(3-phenoxyphenyl)methyl ester Ammo; Arrivo; Basathrin; Cymbush; Demon; Ripcord 52315-07-8 ≥98% 416.3 C22H19Cl2NO3 CC1(C(C1C(=O)OC(C#N)C2=CC(=CC=C2)OC3=CC=CC=C3)C=C(Cl)Cl)C Ambient Ambient Soluble in methanol, acetone, xylene or methylene dichloride. Insoluble in water.  "Maurya SK, Mishra J, Tripathi VK, et al. Cypermethrin induces astrocyte damage: role of aberrant Ca(2+), ROS, JNK, P38, matrix metalloproteinase 2 and migration related reelin protein. Pestic Biochem Physiol. 2014 May;111:51-9. PMID: 24861934.

 

Gammon DW. Correlations between in vitro and in vivo mechanisms of pyrethroid insecticide action. Fundam Appl Toxicol. 1985 Feb;5(1):9-23. PMID: 2985459.

" Xn, N "UN number: 2811 Class: 6.1     Packing Group: III

Proper shipping name: Toxic solid, organic, n.o.s. (Cypermethrin)"

LKT F5769 Formestane 1 g 149.5 Steroid; aromatase inhibitor. 4-Hydroxyandrost-4-ene-3,17-dione 4-OHA; Lentaron 566-48-3 ≥98% 302.41 C19H26O3 CC12CCC(=O)C(=C1CCC3C2CCC4(C3CCC4=O)C)O Ambient Ambient Soluble in methanol. "Miller WR. Aromatase inhibitors: mechanism of action and role in the treatment of breast cancer. Semin Oncol. 2003 Aug;30(4 Suppl 14):3-11. PMID: 14513432.

 

Dowsett M. Aromatase inhibition: basic concepts, and the pharmacodynamics of formestane. Ann Oncol. 1994;5 Suppl 7:S3-5. PMID: 7873460." T Not dangerous goods.

LKT F5769 Formestane 5 g 380.5 Steroid; aromatase inhibitor. 4-Hydroxyandrost-4-ene-3,17-dione 4-OHA; Lentaron 566-48-3 ≥98% 302.41 C19H26O3 CC12CCC(=O)C(=C1CCC3C2CCC4(C3CCC4=O)C)O Ambient Ambient Soluble in methanol. "Miller WR. Aromatase inhibitors: mechanism of action and role in the treatment of breast cancer. Semin Oncol. 2003 Aug;30(4 Suppl 14):3-11. PMID: 14513432.

 

Dowsett M. Aromatase inhibition: basic concepts, and the pharmacodynamics of formestane. Ann Oncol. 1994;5 Suppl 7:S3-5. PMID: 7873460." T Not dangerous goods.

LKT I1400 Idarubicin Hydrochloride 10 mg 217.4 Anthracycline, DNA intercalator; topoisomerase II inhibitor. (7S,9S)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-α-L- lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11- trihydroxy-5,12-naphthacenedione hydrochloride Idamycin; Zavedos 57852-57-0 ≥98% 533.96 C26H27NO9 HCl CC1C(C(CC(O1)OC2CC(CC3=C(C4=C(C(=C23)O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O.Cl Ambient -20°C Soluble in water and methanol. "Eda Satana Kara H. Redox mechanism of anticancer drug idarubicin and in-situ evaluation of interaction with DNA using an electrochemical biosensor. Bioelectrochemistry. 2014 Oct;99:17-23. PMID: 24967755.

 

Pang B, Qiao X, Janssen L, et al. Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin. Nat Commun. 2013;4:1908. PMID: 23715267.

 

Crivellari D, Lombardi D, Spazzapan S, et al. New oral drugs in older patients: a review of idarubicin in elderly patients. Crit Rev Oncol Hematol. 2004 Feb;49(2):153-63. PMID: 15012975.

" T+ "UN number: 2811     Class: 6.1     Packing Group: II

Proper shipping name: Toxic solid, organic, n.o.s. (Idarubicin Hydrochloride)"

LKT R5773 Rosiglitazone 100 mg 61.1 Thiazolidinedione; PPARγ agonist. 5-[[4-[2-(Methyl-2-pyridinylamino)ethoxy]phenyl]- methyl]-2,4-thiazolidinedione BRL-49653 122320-73-4 ≥98% 357.43 C18H19N3O3S CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3 Ambient Ambient Soluble in ethanol and in buffered aqueous solutions (pH of 2.3). "Rui M, Huang Z, Liu Y, et al. Rosiglitazone suppresses angiogenesis in multiple myeloma via downregulation of hypoxia inducible factor 1α and insulin like growth factor 1 mRNA expression. Mol Med Rep. 2014 Jul 22. [Epub ahead of print]. PMID: 25050627.

 

Mingfeng D, Xiaodong M, Yue L, et al. Effects of PPAR-γ Agonist Treatment on LPS-Induced Mastitis in Rats. Inflammation. 2014 May 18. [Epub ahead of print]. PMID: 24839089.

 

Liu Y, Tian XY, Huang Y, et al. Rosiglitazone Attenuated Endothelin-1-Induced Vasoconstriction of Pulmonary Arteries in the Rat Model of Pulmonary Arterial Hypertension via Differential Regulation of ET-1 Receptors. PPAR Res. 2014;2014:374075. PMID: 24701204.

 

He H, Tao H, Xiong H, et al. Rosiglitazone causes cardiotoxicity via peroxisome proliferator-activated receptor γ-independent mitochondrial oxidative stress in mouse hearts. Toxicol Sci. 2014 Apr;138(2):468-81. PMID: 24449420.

 

Hou X, Zhang Y, Shen YH, et al. PPAR-γ activation by rosiglitazone suppresses angiotensin II-mediated proliferation and phenotypictransition in cardiac fibroblasts via inhibition of activation of activator protein 1. Eur J Pharmacol. 2013 Sep 5;715(1-3):196-203. PMID: 23791613.

" None Not dangerous goods.

LKT N5769 Norfloxacin Nicotinate 1 g 33.9 Fluoroquinolone; topoisomerase IV and bacterial DNA gyrase inhibitor. 118803-81-9 ≥98% 442.44 C16H18FN3O3C6H5NO2 CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCNCC3)F)C(=O)O.C1=CC(=CN=C1)C(=O)O Ambient Ambient Soluble in water. "Gouvea LR, Garcia LS, Lachter DR, et al.  Atypical fluoroquinolone gold(III) chelates as potential anticancer agents: relevance of DNA and protein interactions for their mechanism of action. Eur J Med Chem. 2012 Sep;55:67-73. PMID: 22835721.

 

Gómez-Hurtado I, Zapater P, Bellot P, et al. Interleukin-10-mediated heme oxygenase 1-induced underlying mechanism in inflammatory down-regulation by norfloxacin in cirrhosis. Hepatology. 2011 Mar;53(3):935-44. PMID: 21374664.

 

Padeĭskaia EN. Norfloxacin: more than 20 years of clinical use, the results and place among fluoroquinolones in modern chemotherapy for infections. Antibiot Khimioter. 2003;48(9):28-36. PMID: 15002177.

 

Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997 Sep;61(3):377-92. PMID: 9293187.

" Not dangerous goods.

LKT P0398 Pazufloxacin Methanesulfonate 100 mg 122.3 Fluoroquinolone; topoisomerase IV and bacterial DNA gyrase inhibitor. (3S)-10-(1-Aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6- carboxylic acid Pazufloxacin mesylate 163680-77-1 ≥98% 414.41 C16H15FN2O4 CH3SO3H CC1COC2=C3N1C=C(C(=O)C3=CC(=C2C4(CC4)N)F)C(=O)O.CS(=O)(=O)O Ambient Ambient Soluble in water. "Higa F, Akamine M, Haranaga S, et al. In vitro activity of pazufloxacin, tosufloxacin and other quinolones against Legionella species. J Antimicrob Chemother. 2005 Dec;56(6):1053-7. PMID: 16260445.

 

Takei M, Fukuda H, Kishii R, et al. Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob Agents Chemother. 2001 Dec;45(12):3544-7. PMID: 11709337.

 

Mikamo H, Sato Y, Hayasaki Y, et al. In vitro activities of pazufloxacin, a novel injectable quinolone, against bacteria causing infections in obstetric and gynecological patients. Chemotherapy. 1999 May-Jun;45(3):154-7. PMID: 10224336.

" Xi, C, F Not dangerous goods.

LKT P0297 Paroxetine Hydrochloride Hemihydrate 25 mg 67.9 FIASMA, SERT and NET inhibitor, mAChR antagonist. (3S-trans)-3-[(1,3-Benzodioxol-5-yloxy)methyl]-4-(4- fluorophenyl)piperidine hydrochloride hemihydrate Paroxetine hydrochloride hemihydrate; Paxil: Aropax; Deroxat; Seroxat 110429-35-1 ≥98% 374.84 C19H20FNO3 HCl 1/2H2O C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4 Ambient Ambient Soluble in water (5.4 mg/mL), DMSO(73 mg/mL), and ethanol (35mg/mL) "Liu RP, Zou M, Wang JY, et al. Paroxetine ameliorates lipopolysaccharide-induced microglia activation via differential regulation of MAPK signaling. J Neuroinflammation. 2014 Mar 12;11:47. PMID: 24618100.

 

Aboukhatwa M, Luo Y. Antidepressants modulate intracellular amyloid peptide species in N2a neuroblastoma cells. J Alzheimers Dis. 2011;24(2):221-34. PMID: 21263193.

 

Young TJ, Oliver GP, Pryde D, et al. Antifungal activity of selective serotonin reuptake inhibitors attributed to non-specific cytotoxicity. J Antimicrob Chemother. 2003 Apr;51(4):1045-7. PMID: 12654745.

 

Munoz-Bellido JL, Munoz-Criado S, Garcìa-Rodrìguez JA. Antimicrobial activity of psychotropic drugs: selective serotonin reuptake inhibitors. Int J Antimicrob Agents. 2000 Apr;14(3):177-80. PMID: 10773485.

" Xn Not dangerous goods.

LKT F4557 Floxuridine 100 mg 88.3 5-Fluorouracil derivative, fluorinated pyrimidine nuceloside analog; thymidylate synthase inhibitor. 2'-Deoxy-5-fluorouridine NSC-27640; FUDR 50-91-9 ≥98% 246.19 C9H11FN2O5 C1C(C(OC1N2C=C(C(=O)NC2=O)F)CO)O Ambient Ambient Soluble in water. "Fischer MA, Smith JL, Shum D, et al. Flaviviruses are sensitive to inhibition of thymidine synthesis pathways. J Virol. 2013 Sep;87(17):9411-9. PMID: 23824813.

 

Muñoz-Pinedo C, Robledo G, López-Rivas A. Thymidylate synthase inhibition triggers glucose-dependent apoptosis in p53-negative leukemic cells. FEBS Lett. 2004 Jul 16;570(1-3):205-10. PMID: 15251465.

 

Tobias SC, Borch RF. Synthesis and biological studies of novel nucleoside phosphoramidate prodrugs. J Med Chem. 2001 Dec 6;44(25):4475-80. PMID: 11728193.

" Xn "UN number: 2811 Class: 6.1     Packing Group: III

Proper shipping name: Toxic solid, organic, n.o.s. (Floxuridine)"

LKT A1017 Aceclofenac 1 g 47.6 Diclofenac analog, NSAID; COX-2 inhibitor. "2-[(2,6-Dichlorophenyl)amino]benzeneacetic acid 

carboxymethyl ester 

" Airtal; Falcol; Gerbin; Preservex 89796-99-6 ≥98% 354.18 C16H13Cl2NO4 C1=CC=C(C(=C1)CC(=O)OCC(=O)O)NC2=C(C=CC=C2Cl)Cl Ambient Ambient Soluble in ethanol and acetone, insoluble in water "Chopade AR, Sayyad FJ, Naikwade NS. Pharmacological characterization of carrageenan induced heat muscle hyperalgesia in rats using non-selective, preferential and selective COX-2 inhibitors. Pharmacol Rep. 2014 Jun;66(3):353-62. PMID: 24905509.

 

González-Alvaro I, Carmona L, Díaz-González F, et al. Aceclofenac, a new nonsteroidal antiinflammatory drug, decreases the expression and function of some adhesion molecules on human neutrophils. J Rheumatol. 1996 Apr;23(4):723-9. PMID: 8730134.

" Xn "UN number: 2811     Class:  6.1     Packing group:  III

Proper shipping name:  Toxic solids, organic, n.o.s. (ACECLOFENAC)

Reportable Quantity (RQ):     Marine pollutant:  No     Poison inhalation hazard:  No."

LKT A4578 Altretamine 100 mg 61.1 DNA alkylator. N,N,N',N',N'',N''-Hexamethyl-1,3,5-triazine-2,4,6-triamine HMM; Hexalen; Hexamethylmelamine 645-05-6 ≥98% 210.28 C9H18N6 CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C Ambient 4°C Practically insoluble in water. Soluble in DMSO. "Chan JK, Loizzi V, Manetta A, et al. Oral altretamine used as salvage therapy in recurrent ovarian cancer. Gynecol Oncol. 2004 Jan;92(1):368-71. PMID: 14751188.

 

Coley HM, Brooks N, Phillips DH, et al. The role of the N-(hydroxymethyl)melamines as antitumour agents: mechanism of action studies. Biochem Pharmacol. 1995 May 11;49(9):1203-12. PMID: 7763301.

 

Hansen LA, Hughes TE. Altretamine. DICP. 1991 Feb;25(2):146-52. PMID: 1905441.

" Xn Not dangerous goods.

LKT A5035 5-Aminosalicylic Acid 5 g 27.2 Salicylic acid derivative; PPARγ agonist, potential COX-1/2 inhibitor. 5-amino-2-hydroxybenzoic acid 5-ASA; Mesalamine; Asacol; Salofalk; 5-amino-2- hydroxybenzoic acid 89-57-6 ≥98% 153.14 C7H7NO3 C1=CC(=C(C=C1N)C(=O)O)O Ambient Ambient "Poh J, Knowles S. Safety of 5-Aminosalicylic Acid Derivatives in Patients with Sensitivity to Acetylsalicylic Acid and Nonsteroidal Anti-inflammatory Drugs. Can J Hosp Pharm. 2014 Jan;67(1):35-8. PMID: 24634525.

 

Managlia E, Katzman RB, Brown JB, et al. Antioxidant properties of mesalamine in colitis inhibit phosphoinositide 3-kinase signaling in progenitor cells. Inflamm Bowel Dis. 2013 Sep;19(10):2051-60. PMID: 23867870.

 

Baan B, Dihal AA, Hoff E, et al. 5-Aminosalicylic acid inhibits cell cycle progression in a phospholipase D dependent manner in colorectal cancer. Gut. 2012 Dec;61(12):1708-15. PMID: 22187071.

" Xi Not dangerous goods.

LKT A5326 Aniracetam 25 mg 47.6 AMPA positive allosteric modulator, D2, 5-HT2A, nAChR agonist. 1-(4-Methoxybenzoyl)-2-pyrrolidinone "Ro-13-5057; Draganon; Sarpul

 

" 72432-10-1 ≥98% 219.24 C12H13NO3 COC1=CC=C(C=C1)C(=O)N2CCCC2=O Ambient Ambient "Soluble in chloroform and ethyl acetate. Slightly soluble in ethanol. Insoluble in water.

" "Wang YF, Li CC, Cai JX. Aniracetam attenuates H2O2-induced deficiency of neuron viability, mitochondria potential and hippocampal long-term potentiation of mice in vitro. Neurosci Bull. 2006 Sep;22(5):274-80. PMID: 17690727.

 

Jin R, Clark S, Weeks AM, et al. Mechanism of positive allosteric modulators acting on AMPA receptors. J Neurosci. 2005 Sep 28;25(39):9027-36. PMID: 16192394.

 

Nakamura K. Aniracetam: its novel therapeutic potential in cerebral dysfunctional disorders based on recent pharmacological discoveries. CNS Drug Rev. 2002 Spring;8(1):70-89. PMID: 12070527.

 

Nakamura K, Kurasawa M. Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43. PMID: 11412837.

 

Ito I, Tanabe S, Kohda A, et al. Allosteric potentiation of quisqualate receptors by a nootropic drug aniracetam. J Physiol. 1990 May;424:533-43. PMID: 1975272.

" Not dangerous goods.

LKT B0150 Bambuterol Hydrochloride 100 mg 54.4 β2-adrenergic agonist, BChE inhibitor. Dimethylcarbamic acid 5-[2-[(1,1-dimethylethyl)- amino]-1-hydroxyethyl]-1,3-phenylene ester hydrochloride KWD-2183; Bambec 81732-46-9 ≥98% 403.91 C18H29N3O5 HCl CC(C)(C)NCC(C1=CC(=CC(=C1)OC(=O)N(C)C)OC(=O)N(C)C)O.Cl Ambient 4°C Soluble in water (33mg/mL). "Mohr F, Zimmermann M, Klein J. Mice heterozygous for AChE are more sensitive to AChE inhibitors but do not respond to BuChE inhibition. Neuropharmacology. 2013 Apr;67:37-45. PMID: 23147415.

 

Bosak A, Gazić I, Vinković V, et al. Stereoselective inhibition of human, mouse, and horse cholinesterases by bambuterol enantiomers. Chem Biol Interact. 2008 Sep 25;175(1-3):192-5. PMID: 18582854.

 

Waldeck B. Beta-adrenoceptor agonists and asthma--100 years of development. Eur J Pharmacol. 2002 Jun 7;445(1-2):1-12. PMID: 12065188.

" None Not dangerous goods.

LKT B6957 Bromhexine Hydrochloride 25 g 40.7 Synthetic derivative of vasicine, mucolytic. 2-Amino-3,5-dibromo-N-cyclohexyl-N-methyl- benzenemethanamine hydrochloride Auxit; Bisolvon; Ophtosol; Quentan 611-75-6 ≥98% 412.6 C14H20Br2N2 HCl CN(CC1=CC(=CC(=C1N)Br)Br)C2CCCCC2.Cl Ambient Ambient Slightly soluble in chloroform. Sparingly soluble in ethanol or methanol. "Winsel K, Grollmuss H, Unger U, et al. Modulation of alveolar macrophage activity by ambroxol, bromhexine and exogenous arachidonic acid. Z Erkr Atmungsorgane. 1985;165(2):149-62. PMID: 3002048.

 

Takeda H, Abe Y, Misawa M, et al. The role of vagal reflex in mechanism of secretagogic action of bromhexine. Jpn J Pharmacol. 1984 Aug;35(4):445-50. PMID: 6503040.

" Not dangerous goods.

LKT C3210 Ciglitazone 25 mg 543.6 Thiazolidinedione; PPARγ agonist. (+/-)-5-[4-(1-Methylcyclohexylmethoxy)benzyl]thiazolidine-2,4-dione 74772-77-3 ≥98% 333.45 C18H23NO3S CC1(CCCCC1)COC2=CC=C(C=C2)CC3C(=O)NC(=O)S3 Ambient Ambient Soluble in DMSO or ethanol. "Shah DK, Menon KM, Cabrera LM, et al. Thiazolidinediones decrease vascular endothelial growth factor (VEGF) production by human luteinized granulosa cells in vitro. Fertil Steril. 2010 Apr;93(6):2042-7. PMID: 19342033.

 

Cheon CW, Kim DH, Kim DH, et al. Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20. PMID: 19140230.

 

Pershadsingh HA, Szollosi J, Benson S, et al. Effects of ciglitazone on blood pressure and intracellular calcium metabolism. Hypertension. 1993 Jun;21(6 Pt 2):1020-3. PMID: 8505086.

" Not dangerous goods.

LKT E6432 (−)-Epinephrine 100 g 679.5 Active isomer of epinephrine, endogenous hormone neurotransmitter, involved in sympathetic nervous system signaling; α/β-adrenergic agonist. Bronkaid Mist; Eppy; Glauposine; Simplene; Suprarenaline 51-43-4 ≥98% 183.2 C9H13NO3 CNCC(C1=CC(=C(C=C1)O)O)O Crystals brown when exposed to light and air. Ambient 4°C Slightly soluble in water and alcohol. Soluble in aqueous solutions of mineral acids, NaOH, and KOH. Insoluble in ether, chloroform or acetone. "Seravalle G, Dimitriadis K, Dell'Oro R, et al. How to assess sympathetic nervous system activity in clinical practice. Curr Clin Pharmacol. 2013 Aug;8(3):182-8. PMID: 23173963.

 

Busse PJ, Buckland MS. Non-histaminergic angioedema: focus on bradykinin-mediated angioedema. Clin Exp Allergy. 2013 Apr;43(4):385-94. PMID: 23517034.

 

Warren JB, Pixley FJ, Dollery CT. Importance of beta 2-adrenoceptor stimulation in the suppression of intradermal antigen challenge by adrenaline. Br J Clin Pharmacol. 1989 Feb;27(2):173-7. PMID: 2565729.

 

Warren J. The adrenal medulla and the airway. Br J Dis Chest. 1986 Jan;80(1):1-6. PMID: 3004549.

 

Berecek KH, Brody MJ. Evidence for a neurotransmitter role for epinephrine derived from the adrenal medulla. Am J Physiol. 1982 Apr;242(4):H593-601. PMID: 6278965

" T "UN number: 2811     Class:  6.1     Packing group:  II

Proper shipping name:  Toxic solids, organic, n.o.s. (Epinephrine)

Reportable quantity (RQ):  1000 lbs.     Poison inhalation hazard:  No."

LKT O1078 Octreotide Acetate 25 mg 611.5 Somatostatin analog, peptide; somatostatin agonist. D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D- tryptophyl-L-lysyl-L-threonyl-N-[2-hydroxy-1- (hydroxymethyl)propyl]-L-cysteinamide cyclic (2->7)-disulfide acetate (salt) Sandostatin  79517-01-4 ≥98% 1139.36 C49H66N10O10S2 2C2H4O2 CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O Ambient -20°C Soluble in methanol. "Wang S, Bao Z, Liang QM, et al. Octreotide stimulates somatostatin receptor-induced apoptosis of SW480 colon cancer cells by activation of glycogen synthase kinase-3β, A Wnt/β-catenin pathway modulator. Hepatogastroenterology. 2013 Oct;60(127):1639-46. PMID: 24634935.

 

Wang J, Wang L, Song G, et al. The mechanism through which octreotide inhibits hepatic stellate cell activity. Mol Med Rep. 2013 May;7(5):1559-64. PMID: 23525276.

 

Tug T, Kara H, Karaoglu A, et al. The effect of octreotide, an analog of somatostatin, on bleomycin-induced interstitial pulmonary fibrosis in rats. Drug Chem Toxicol. 2013 Apr;36(2):181-6. PMID: 22946449.

 

Zhang Y, Huang W, Li F, et al.  Octreotide for the treatment of systemic lupus erythematosus: clinical effects and an in vitro study on its therapeutic mechanism. Lupus. 2011 Oct;20(11):1172-81. PMID: 21979989.

" Not dangerous goods.

LKT N3520 Nifursol 5 g 33.9 Nitrofuran, livestock antibiotic. 3,5-Dinitrosalicylic acid (5-nitrofurfurylidene)hydrazide Histomon; Salfuride; Sulfuride 16915-70-1 ≥98% 365.21 C12H7N5O9 C1=C(OC(=C1)[N+](=O)[O-])C=NNC(=O)C2=CC(=CC(=C2O)[N+](=O)[O-])[N+](=O)[O-] Ambient Ambient "Verdon E, Couedor P, Sanders P. Multi-residue monitoring for the simultaneous determination of five nitrofurans (furazolidone, furaltadone, nitrofurazone, nitrofurantoine, nifursol) in poultry muscle tissue through the detection of their five major metabolites (AOZ, AMOZ, SEM, AHD, DNSAH) by liquid chromatography coupled to electrospray tandem mass spectrometry--in-house validation in line with Commission Decision 657/2002/EC. Anal Chim Acta. 2007 Mar 14;586(1-2):336-47. PMID: 17386733.

 

Callait MP, Granier C, Chauve C, et al. In vitro activity of therapeutic drugs against Histomonas meleagridis (Smith, 1895). Poult Sci. 2002 Aug;81(8):1122-7. PMID: 12211302.

" Not dangerous goods.

LKT S1609 Securinine 100 mg 787.5 Alkaloid found in Securinega; potential GABA-A antagonist. Securinan-11-one 5610-40-2 ≥98% 217.26 C13H15NO2 C1CCN2C(C1)C34CC2C=CC3=CC(=O)O4 Ambient -20°C Soluble in ethanol 16 mg/mL, DMSO 50 mg/mL.  Insoluble in water. "Han S, Zhang G, Li M, et al. L-securinine induces apoptosis in the human promyelocytic leukemia cell line HL-60 and influences the expression of genes involved in the PI3K/AKT/mTOR signaling pathway. Oncol Rep. 2014 May;31(5):2245-51. PMID: 24676995.

 

Li M, Han S, Zhang G, et al. Antiproliferative activity and apoptosis-inducing mechanism of L-securinine on human breast cancer MCF-7 cells. Pharmazie. 2014 Mar;69(3):217-23. PMID: 24716413.

 

Shipman M, Lubick K, Fouchard D, et al. Proteomic and systems biology analysis of monocytes exposed to securinine, a GABA(A) receptor antagonist and immune adjuvant. PLoS One. 2012;7(9):e41278. PMID: 23028424.

 

Singh AK, Pandey MB, Singh S, et al. Antifungal Activity of Securinine against Some Plant Pathogenic Fungi. Mycobiology. 2008 Jun;36(2):99-101. PMID: 23990741.

 

Lin X, Jun-Tian Z. Neuroprotection by D-securinine against neurotoxicity induced by beta-amyloid (25-35). Neurol Res. 2004 Oct;26(7):792-6. PMID: 15494124.

 

Rana S, Gupta K, Gomez J, et al. Securinine induces p73-dependent apoptosis preferentially in p53-deficient colon cancer cells. FASEB. 2010 Jun;24(6):2126-2134. PMID: 20133503.

" Xn Not dangerous goods.

LKT S5746 Solanesol 10 mg 47.6 All-trans nonaprenol isoprenoid, found in Solanaceae family plants, used as biomarker for combustible tobacco use or exposure. "(2E,6E,10E,14E,18E,22E,26E,30E)-3,7,11,15,19,23,27,31,35-Nonamethyl-2,6,10,14,18,22,26,30,34-hexa- triacontanonaen-1-ol

" Nonaisoprenol 13190-97-1 ≥92% 631.07 C45H74O CC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCO)C)C)C)C)C)C)C)C)C Ambient -20°C Soluble in organic solvents. Insoluble in water. "Purkis SW, Troude V, Hill CA. Effect of puffing intensity on cigarette smoke yields. Regul Toxicol Pharmacol. 2013 Jun;66(1):72-82. PMID: 23523712.

 

Tomida A, Suzuki H. Synergistic effect in culture of bleomycin-group antibiotics and N-solanesyl-N,N'-bis(3,4-dimethoxybenzyl)ethylenediamine, a synthetic isoprenoid. Jpn J Cancer Res. 1990 Nov;81(11):1184-90. PMID: 1702416.

 

Suzuki H, Tomida A, Nishimura T. Cytocidal activity of a synthetic isoprenoid, N-solanesyl-N,N'-bis(3,4-dimethoxybenzyl)ethylenediamine, and its potentiation of antitumor drugs against multidrug-resistant and sensitive cells in vitro. Jpn J Cancer Res. 1990 Mar;81(3):298-303. PMID: 2161816.

" Not dangerous goods.

LKT S6235 Spironolactone 250 mg 47.6 Mineralocorticoid, aldosterone, AR antagonist, ENaC channel blocker, potential voltage-gated Ca2+ channel blocker. (7α,17α)-7-(Acetylthio)-17-hydroxy-3-oxopregn-4- ene-21-carboxylic acid γ-lactone Spirolactone; Spiroctan; Aldactone 52-01-7 ≥97% 416.57 C24H32O4S CC(=O)SC1CC2=CC(=O)CCC2(C3C1C4CCC5(C4(CC3)C)CCC(=O)O5)C Ambient Ambient Soluble in organic solvents. Practically insoluble in water. "Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Oct 15;62(16):e147-239. PMID: 23747642.

 

Mann SJ, Parikh NS. A simplified mechanistic algorithm for treating resistant hypertension: efficacy in a retrospective study. J Clin Hypertens (Greenwich). 2012 Apr;14(4):191-7. PMID: 22458739.

 

Nappi JM, Sieg A. Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure. Vasc Health Risk Manag. 2011;7:353-63. PMID: 21731887.

" Repr., Carc. Not dangerous goods.

LKT T1672 Terbinafine Hydrochloride 250 mg 47.6 Allylamine; squalene oxidase and KSR1 inhibitor. N-[(2E)-6,6-Dimethyl-2-hepten-4-ynyl]-N-methyl-1- naphthalenemethanamine hydrochloride Lamisil 78628-80-5 ≥98% 327.9 C21H25N HCl CC(C)(C)C#CC=CCN(C)CC1=CC=CC2=CC=CC=C21.Cl Ambient 4°C Soluble in methanol, methylene chloride or ethanol. "Li B, Lu L, Zhong M, et al. Terbinafine inhibits KSR1 and suppresses Raf-MEK-ERK signaling in oral squamous cell carcinoma cells. Neoplasma. 2013;60(4):406-12. PMID: 23581412.

 

Nowosielski M, Hoffmann M, Wyrwicz LS, et al. Detailed mechanism of squalene epoxidase inhibition by terbinafine. J Chem Inf Model. 2011 Feb 28;51(2):455-62. PMID: 21229992.

 

Revankar SG, Nailor MD, Sobel JD. Use of terbinafine in rare and refractory mycoses. Future Microbiol. 2008 Feb;3(1):9-17. PMID: 18230029.

" Xi, N Not dangerous goods.

LKT A5334 Anisodamine 5 g 271.8 Tropane alkaloid found in Solanaceae plants; α1-adrenergic and mAChR antagonist. "α-(hydroxymethyl)benzeneacetic acid-6-hydroxy- 8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester

" 6-Hydroxy hyoscyamine 55869-99-3 ≥98% 305.37 C17H23NO4 CN1C2CC(CC1C(C2)O)OC(=O)C(CO)C3=CC=CC=C3 Ambient Ambient "Wang W, Chen QF, Li QB, et al. Efficiency of anisodamine for organophosphorus-poisoned patients when atropinization cannot be achieved with high doses of atropine. Environ Toxicol Pharmacol. 2014 Mar;37(2):477-81. PMID: 24561530.

 

Guoshou Z, Chengye Z, Zhihui L, et al. Effects of high dose of anisodamine on the respiratory function of patients with traumatic acute lung injury. Cell Biochem Biophys. 2013 Jun;66(2):365-9. PMID: 23504631.

 

Geng W, Fu XH, Gu XS, et al. Preventive effects of anisodamine against contrast-induced nephropathy in type 2 diabetics with renal insufficiency undergoing coronary angiography or angioplasty. Chin Med J (Engl). 2012 Oct;125(19):3368-72. PMID: 23044290.

 

Zhang ZX, Wang P, Zhang QS, et al. Effects of anisodamine on the expressions of vascular endothelial growth factor and intercellular adhesion molecule 1 in experimental infusion phlebitis. Chin Med J (Engl). 2012 Jan;125(2):300-5. PMID: 22340563.

 

Zhang WW, Song MK, Cui YY, et al. Differential neuropsychopharmacological influences of naturally occurring tropane alkaloids anisodamine versus scopolamine. Neurosci Lett. 2008 Oct 10;443(3):241-5. PMID: 18672024.

 

Varma DR, Yue TL. Adrenoceptor blocking properties of atropine-like agents anisodamine and anisodine on brain and cardiovascular tissues of rats. Br J Pharmacol. 1986 Mar;87(3):587-94. PMID: 2879586.

" Not dangerous goods.

LKT C0267 Carnosol 25 mg 611.5 Diterpene compound originally found in Rosmarinus; PGE2 synthase inhibitor. "2H-9,4a-(Epoxymethano)phenanthren-12-one,1,3,4,9,110a-hexahydro-5,6-dihydroxy-1,1-dimethyl-7-(1- methylethyl)-, (4aR-(4aalpha,9alpha,10abeta))- 

" CCRIS 7122 5957-80-2 ≥98% 330.42 C20H26O4 CC(C)C1=C(C(=C2C(=C1)C3CC4C2(CCCC4(C)C)C(=O)O3)O)O Protect from light. Blue Ice -20°C Soluble in DMSO, DMF or ethanol. Sparingly soluble in aqueaous buffers. "Vergara D, Simeone P, Bettini S, et al. Antitumor activity of the dietary diterpene carnosol against a panel of human cancer cell lines. Food Funct. 2014 Jun 28;5(6):1261-9. PMID: 24733049.

 

Park KW, Kundu J, Chae IG, et al. Carnosol induces apoptosis through generation of ROS and inactivation of STAT3 signaling in human colon cancer HCT116 cells. Int J Oncol. 2014 Apr;44(4):1309-15. PMID: 24481553.

 

López-Jiménez A, García-Caballero M, Medina MÁ, et al. Anti-angiogenic properties of carnosol and carnosic acid, two major dietary compounds from rosemary. Eur J Nutr. 2013 Feb;52(1):85-95. PMID: 22173778.

 

Machado DG, Cunha MP, Neis VB, et al. Antidepressant-like effects of fractions, essential oil, carnosol and betulinic acid isolated from Rosmarinus officinalis L. Food Chem. 2013 Jan 15;136(2):999-1005. PMID: 23122155.

 

Bauer J, Kuehnl S, Rollinger JM, et al. Carnosol and carnosic acids from Salvia officinalis inhibit microsomal prostaglandin E2 synthase-1. J Pharmacol Exp Ther. 2012 Jul;342(1):169-76. PMID: 22511203.

 

Mengoni ES, Vichera G, Rigano LA, et al. Suppression of COX-2, IL-1β and TNF-α expression and leukocyte infiltration in inflamed skin by bioactive compounds from Rosmarinus officinalis L. Fitoterapia. 2011 Apr;82(3):414-21. PMID: 21129455.

 

Johnson JJ, Syed DN, Suh Y, et al. Disruption of androgen and estrogen receptor activity in prostate cancer by a novel dietary diterpene carnosol: implications for chemoprevention. Cancer Prev Res (Phila). 2010 Sep;3(9):1112-23. PMID: 20736335.

" U/A Not dangerous goods.

LKT C4757 Clozapine 250 mg 136 M4 mAChR agonist, 5-HT1A partial agonist, M1/2/3/5 mAChR, D2 antagonist, Kv1.1 K+ channel blocker. "8-chloro-11-(4-methyl-1-piperazinyl)-5H-Dibenzo(b,e)(1,4)diazepine

" Clozaril,  Leponex 5786-21-0 ≥97% 326.82 C18H19ClN4 CN1CCN(CC1)C2=C3C=CC=CC3=NC4=C(N2)C=C(C=C4)Cl Ambient Ambient Soluble in DMSO or dilute aqueous acid. "Hill AP, Perrin MJ, Heide J, et al. Kinetics of drug interaction with the Kv11.1 potassium channel. Mol Pharmacol. 2014 May;85(5):769-76. PMID: 24586056.

 

Tanahashi S, Yamamura S, Nakagawa M, et al. Clozapine, but not haloperidol, enhances glial D-serine and L-glutamate release in rat frontal cortex and primary cultured astrocytes. Br J Pharmacol. 2012 Mar;165(5):1543-55. PMID: 21880034.

 

Wu Y, Blichowski M, Daskalakis ZJ, et al. Evidence that clozapine directly interacts on the GABAB receptor. Neuroreport. 2011 Sep 14;22(13):637-41. PMID: 21753741.

 

Nord M, Farde L. Antipsychotic occupancy of dopamine receptors in schizophrenia. CNS Neurosci Ther. 2011 Apr;17(2):97-103. PMID: 21143431.

 

Alvir JM, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med. 1993 Jul 15;329(3):162-7. PMID: 8515788.

" Xn "UN number: 2811     Class:  6.1     Packing group:  III

Proper shipping name:  Toxic solids, organic, n.o.s. (Clozapine)

Reportable Quantity (RQ)"

LKT C9610 D-Cycloserine 250 mg 47.6 NMDA partial agonist, D-Ala-D-Ala ligase inhibitor. D-4-Amino-3-isoxazolidinone Closina; Farmiserina; Micoserina; Oxamycin; Seromycin. 68-41-7 ≥98% 102.09 C3H6N2O2 C1C(C(=O)NO1)N Ambient 4°C Soluble in water. Slightly soluble in methanol or propylene glycol. "Dang YH, Ma XC, Zhang JC, et al. Targeting of NMDA Receptors in the Treatment of Major Depression. Curr Pharm Des. 2014 Jan 10. [Epub ahead of print]. PMID: 24410564.

 

Prosser GA, de Carvalho LP. Metabolomics Reveal d-Alanine:d-Alanine Ligase As the Target of d-Cycloserine in Mycobacterium tuberculosis.  ACS Med Chem Lett. 2013 Dec 12;4(12):1233-1237. PMID: 24478820.

 

Portero-Tresserra M, Martí-Nicolovius M, Guillazo-Blanch G, et al. D-cycloserine in the basolateral amygdala prevents extinction and enhances reconsolidation of odor-reward associative learning in rats. Neurobiol Learn Mem. 2013 Feb;100:1-11. PMID: 23200640.

" Not dangerous goods.

LKT D3301 Diaveridine 250 mg 40.7 Coccidiostat; dihydrofolate reductase inhibitor. 5-[(3,4-Dimethoxyphenyl)methyl]-2,4-pyrimidine- diamine Diaveridin 5355-16-8 ≥98% 260.29 C13H16N4O2 COC1=C(C=C(C=C1)CC2=CN=C(N=C2N)N)OC Ambient Ambient Soluble in HCl or chloroform (1:600). "Ono T, Sekiya T, Takahashi Y, et al. The genotoxicity of diaveridine and trimethoprim. Environ Toxicol Pharmacol. 1997 Sep;3(4):297-306. PMID: 21781790.

 

Cirioni O, Giacometti A, Scalise G. In-vitro activity of atovaquone, sulphamethoxazole and dapsone alone and combined with inhibitors of dihydrofolate reductase and macrolides against Pneumocystis carinii. J Antimicrob Chemother. 1997 Jan;39(1):45-51. PMID: 9044027.

 

Walzer PD, Kim CK, Foy JM, et al. Inhibitors of folic acid synthesis in the treatment of experimental Pneumocystis carinii pneumonia. Antimicrob Agents Chemother. 1988 Jan;32(1):96-103. PMID: 3258144.

" Xi Not dangerous goods.

LKT D3219 Diflubenzuron 1 g 47.6 Benzoylurea, insect growth regulator; chitin synthesis inhibitor. "N-(((4-chlorophenyl)amino)carbonyl)- 2,6-difluoro- benzamide

" Difluron; Dimilin; Duphacid; Micromite. 35367-38-5 ≥95% 310.68 C14H9ClF2N2O2 C1=CC(=C(C(=C1)F)C(=O)NC(=O)NC2=CC=C(C=C2)Cl)F Ambient 4°C Soluble in acetone (0.65 gm/100ml at 20oC), DMSO or methanol. "Merzendorfer H, Kim HS, Chaudhari SS, et al. Genomic and proteomic studies on the effects of the insect growth regulator diflubenzuron in the model beetle species Tribolium castaneum. Insect Biochem Mol Biol. 2012 Apr;42(4):264-76. PMID: 22212827.

 

Zhang J, Zhu KY. Characterization of a chitin synthase cDNA and its increased mRNA level associated with decreased chitin synthesis in Anopheles quadrimaculatus exposed to diflubenzuron. Insect Biochem Mol Biol. 2006 Sep;36(9):712-25. PMID: 16935220.

 

Fetterer RH, Urban JF Jr, Miller RW. Effects of the chitin synthesis inhibitor diflubenzuron on development of Ascaris suum and Haemonchus contortus. Vet Parasitol. 1989 Jul 15;32(2-3):181-92. PMID: 2505433.

" N Not dangerous goods.

LKT H0142 Haloperidol 1 g 40.7 Butyrophenone; σ2 agonist, α1-adrenergic, D2, 5-HT2A, σ1 antagonist. "1-Butanone, 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-

1-(4-fluorophenyl)- 

" Haldol; Halosten; Linton; Keselan; Aloperidin; Brotopon; Dozic. 52-86-8 ≥95% 375.86 C21H23ClFNO2 C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F Ambient Ambient Soluble in chloroform, ethanol (16 mg/mL),methanol, acetone or benzene.  Insoluble in water. "Cobos EJ, del Pozo E, Baeyens JM. Irreversible blockade of sigma-1 receptors by haloperidol and its metabolites in guinea pig brain and SH-SY5Y human neuroblastoma cells. J Neurochem. 2007 Aug;102(3):812-25. PMID: 17419803.

 

Colabufo NA, Berardi F, Contino M, et al. Antiproliferative and cytotoxic effects of some sigma2 agonists and sigma1 antagonists in tumour cell lines. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):106-13. PMID: 15322732.

 

Seeman P, Tallerico T. Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol Psychiatry. 1998 Mar;3(2):123-34. PMID: 9577836.

 

Schotte A, Janssen PF, Megens AA, et al. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Brain Res. 1993 Dec 24;631(2):191-202. PMID: 7510574.

" Repr., T, Xi "UN number: 2811     Class:  6.1     Packing group:  III

Proper shipping name:  Toxic solids, organic, n.o.s.  (Haloperidol)

Reportable quantity (RQ):     Marine pollutant:  No     Poison inhalation hazard:  No"

LKT H9717 Hydroxyzine Dihydrochloride 1 g 40.7 FIASMA, histamine H1 inverse agonist, 5-HT2A, D1/2, α1-adrenergic antagonist. "Ethanol, 2-(2-(4-((4-chlorophenyl)phenylmethyl)-1-

piperazinyl)ethoxy)-, dihydrochloride" Alamon; Atarax; Aterax; Durrax; Orgatrax; Quiess; Vistaril Parental. 2192-20-3 ≥98% 447.83 C21H27ClN2O2 2HCl C1CN(CCN1CCOCCO)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl.Cl.Cl Ambient Ambient Soluble in water (<700mg/mL), ethanol (220 mg/mL), chloroform (60mg/mL) or acetone (2mg/mL). "Llorca PM, Spadone C, Sol O, et al. Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3-month double-blind study. J Clin Psychiatry. 2002 Nov;63(11):1020-7. PMID: 12444816.

 

Minogiannis P, El-Mansoury M, Betances JA, et al. Hydroxyzine inhibits neurogenic bladder mast cell activation. Int J Immunopharmacol. 1998 Oct;20(10):553-63. PMID: 9839659.

 

Haraguchi K, Ito K, Kotaki H, et al. Prediction of drug-induced catalepsy based on dopamine D1, D2, and muscarinic acetylcholine receptor occupancies. Drug Metab Dispos. 1997 Jun;25(6):675-84. PMID: 9193868.

 

Snowman AM, Snyder SH. Cetirizine: actions on neurotransmitter receptors. J Allergy Clin Immunol. 1990 Dec;86(6 Pt 2):1025-8. PMID: 1979798.

" Xn, Not dangerous goods.

LKT M7530 [Nle4, D-Phe7]-α-Melanocyte Stimulating Hormone 25 mg 672.2 Semi-synthetic peptide, melanocortin analog; MCR agonist. NDP-MSH, Melanotan I; afamelanotide ≥98% 1646.9 C78H111N21O19 Ambient -20°C "Lonati C, Carlin A, Leonardi P, et al. Modulatory effects of NDP-MSH in the regenerating liver after partial hepatectomy in rats. Peptides. 2013 Dec;50:145-52. PMID: 24446557.

 

Figueiredo J, Ferreira AE, Silva RL, et al. NDP-MSH inhibits neutrophil migration through nicotinic and adrenergic receptors in experimental peritonitis. Naunyn Schmiedebergs Arch Pharmacol. 2013 Apr;386(4):311-8. PMID: 23338711.

 

Gatti S, Lonati C, Acerbi F, et al. Protective action of NDP-MSH in experimental subarachnoid hemorrhage. Exp Neurol. 2012 Mar;234(1):230-8. PMID: 22230666.

" Not dangerous goods.

LKT M1770 Meropenem Sodium Carbonate 1 g 570.8 Carbapenem β-lactam; penicillin binding protein inhibitor. (4R,5S,6S)-3-[[(3S,5S)5-[(Dimethylamino)carbonyl]-3-pyrrolidinyl]thio]-6-((1R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3,2,0]hept-2-ene-2-carboxyloc acid Merrem 96036-03-2 ≥81% 383.46 C17H25N3O5S CC1C2C(C(=O)N2C(=C1SC3CC(NC3)C(=O)N(C)C)C(=O)O)C(C)O Stable at room temperature. Ambient 4°C Soluble in water "Guzek A, Tomaszewski D, Rybicki Z, et al. Comparison of in vitro efficacy of ertapenem, imipenem and meropenem in the infections caused by the Enterobacteriaceae strains family. Anaesthesiol Intensive Ther. 2013 Apr-Jun;45(2):67-72. PMID: 23877897.

 

Li WJ, Li DF, Hu YL, et al. Crystal structure of L,D-transpeptidase LdtMt2 in complex with meropenem reveals the mechanism of carbapenem against Mycobacterium tuberculosis. Cell Res. 2013 May;23(5):728-31. PMID: 23588382.

 

Louie A, VanScoy BD, Brown DL, et al. Impact of spores on the comparative efficacies of five antibiotics for treatment of Bacillus anthracis in an in vitro hollow fiber pharmacodynamic model. Antimicrob Agents Chemother. 2012 Mar;56(3):1229-39. PMID: 22155821.

 

Isozumi R, Yoshimatsu K, Yamashiro T, et al. bla(NDM-1)-positive Klebsiella pneumoniae from environment, Vietnam. Emerg Infect Dis. 2012 Aug;18(8):1383-1385. PMID: 22840532.

" Xi Not dangerous goods.

LKT R3374 Risedronic Acid 25 mg 40.7 Bisphosphonate; inhibits transfer of farnesyl pyrophosphate. [1-Hydroxy-2-(3-pyridinyl)ethylidene]bisphosphonic acid Risedronate 105462-24-6 ≥97% 283.11 C7H11NO7P2 C1=CC(=CN=C1)CC(O)(P(=O)(O)O)P(=O)(O)O Ambient Ambient "Jin J, Wang L, Wang XK, et al. Risedronate inhibits bone marrow mesenchymal stem cell adipogenesis and switches RANKL/OPG ratio to impair osteoclast differentiation. J Surg Res. 2013 Mar;180(1):e21-9. PMID: 22487394.

 

Jordão FM, Saito AY, Miguel DC, et al. In vitro and in vivo antiplasmodial activities of risedronate and its interference with protein prenylation in Plasmodium falciparum. Antimicrob Agents Chemother. 2011 May;55(5):2026-31. PMID: 21357292.

 

Carvalho AP, Bezerra MM, Girão VC, et al. Anti-inflammatory and anti-nociceptive activity of risedronate in experimental pain models in rats and mice. Clin Exp Pharmacol Physiol. 2006 Jul;33(7):601-6. PMID: 16789926.

" Not dangerous goods.

LKT R3374 Risedronic Acid 250 mg 251.5 Bisphosphonate; inhibits transfer of farnesyl pyrophosphate. [1-Hydroxy-2-(3-pyridinyl)ethylidene]bisphosphonic acid Risedronate 105462-24-6 ≥97% 283.11 C7H11NO7P2 C1=CC(=CN=C1)CC(O)(P(=O)(O)O)P(=O)(O)O Ambient Ambient "Jin J, Wang L, Wang XK, et al. Risedronate inhibits bone marrow mesenchymal stem cell adipogenesis and switches RANKL/OPG ratio to impair osteoclast differentiation. J Surg Res. 2013 Mar;180(1):e21-9. PMID: 22487394.

 

Jordão FM, Saito AY, Miguel DC, et al. In vitro and in vivo antiplasmodial activities of risedronate and its interference with protein prenylation in Plasmodium falciparum. Antimicrob Agents Chemother. 2011 May;55(5):2026-31. PMID: 21357292.

 

Carvalho AP, Bezerra MM, Girão VC, et al. Anti-inflammatory and anti-nociceptive activity of risedronate in experimental pain models in rats and mice. Clin Exp Pharmacol Physiol. 2006 Jul;33(7):601-6. PMID: 16789926.

" Not dangerous goods.

LKT T0008 Tacrolimus 100 mg 611.5 Calcineurin inhibitor. "3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R, 26aS)5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-(2-(4-hydroxy-3-methoxycyclohexyl)-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-5,19-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone

" FK-506; Fujimycin; Prograf; Protopic; CCRIS 7124. 104987-11-3 ≥98% 804.02 C44H69NO12 CC1CC(C2C(CC(C(O2)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C(CC(=O)C(C=C(C1)C)CC=C)O)C)C(=CC4CCC(C(C4)OC)O)C)O)C)OC)OC In DMSO at +4 for 2 weeks at -80 for 6 months. Ambient Ambient Soluble in DMSO (20 mg/ml), ethanol (30 mg/ml), acetone, ethyl acetate, diethyl ether or chloroform. "Carr WW. Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations. Paediatr Drugs. 2013 Aug;15(4):303-10. PMID: 23549982.

 

Manojlovic Z, Blackmon J, Stefanovic B. Tacrolimus (FK506) prevents early stages of ethanol induced hepatic fibrosis by targeting LARP6 dependent mechanism of collagen synthesis. PLoS One. 2013 Jun 3;8(6):e65897. PMID: 23755290.

 

Grigoriu S, Bond R, Cossio P, et al. The molecular mechanism of substrate engagement and immunosuppressant inhibition of calcineurin. PLoS Biol. 2013;11(2):e1001492. PMID: 23468591.

 

Shin JH, Park HR, Kim SW, et al. The effect of topical FK506 (tacrolimus) in a mouse model of allergic rhinitis. Am J Rhinol Allergy. 2012 Mar-Apr;26(2):e71-5. PMID: 22487280.

 

Izumi S, Nozaki Y, Komori T, et al. Substrate-dependent inhibition of organic anion transporting polypeptide 1B1: comparative analysis with prototypical probe substrates estradiol-17beta-glucuronide, estrone-3-sulfate, and sulfobromophthalein. Drug Metab Dispos. 2013 Oct;41(10):1859-1866. PMID: 23920221.

" Xi, T "UN number: 2811     Class: 6.1     Packing group: III

Proper shipping name: Toxic solid, organic, n.o.s. (Tacrolimus)

Marine pollutant: no     Poison inhalation hazard: no"

LKT T1298 TDZD-8 100 mg 611.5 GSK-3β inhibitor. 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione 327036-89-5 ≥98% 222.26 C10H10N2O2S CN1C(=O)N(C(=O)S1)CC2=CC=CC=C2 Protect from light. Packaged under inert gas. Ambient -20°C Soluble in DMSO (18mg/mL). "Jellestad L, Fink T, Pradarutti S, et al. Inhibition of glycogen synthase kinase (GSK)-3-β improves liver microcirculation and hepatocellular function after hemorrhagic shock. Eur J Pharmacol. 2014 Feb 5;724:175-84. PMID: 24389157.

 

Kwon YJ, Yoon CH, Lee SW, et al. Inhibition of glycogen synthase kinase-3β suppresses inflammatory responses in rheumatoid arthritis fibroblast-like synoviocytes and collagen-induced arthritis. Joint Bone Spine. 2013 Oct 28. [Epub ahead of print]. PMID: 24176738.

 

Willi R, Harmeier A, Giovanoli S, et al. Altered GSK3β signaling in an infection-based mouse model of developmental neuropsychiatric disease. Neuropharmacology. 2013 Oct;73:56-65. PMID: 23707483.

" Not dangerous goods.

LKT T1298 TDZD-8 250 mg 883.3 GSK-3β inhibitor. 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione 327036-89-5 ≥98% 222.26 C10H10N2O2S CN1C(=O)N(C(=O)S1)CC2=CC=CC=C2 Protect from light. Packaged under inert gas. Ambient -20°C Soluble in DMSO (18mg/mL). "Jellestad L, Fink T, Pradarutti S, et al. Inhibition of glycogen synthase kinase (GSK)-3-β improves liver microcirculation and hepatocellular function after hemorrhagic shock. Eur J Pharmacol. 2014 Feb 5;724:175-84. PMID: 24389157.

 

Kwon YJ, Yoon CH, Lee SW, et al. Inhibition of glycogen synthase kinase-3β suppresses inflammatory responses in rheumatoid arthritis fibroblast-like synoviocytes and collagen-induced arthritis. Joint Bone Spine. 2013 Oct 28. [Epub ahead of print]. PMID: 24176738.

 

Willi R, Harmeier A, Giovanoli S, et al. Altered GSK3β signaling in an infection-based mouse model of developmental neuropsychiatric disease. Neuropharmacology. 2013 Oct;73:56-65. PMID: 23707483.

" Not dangerous goods.

LKT G1745 Gemcitabine Hydrochloride 250 mg 475.7 Nucleoside (deoxycytidine) analog; ribonucleotide reductase inhibitor, DNA synthesis inhibitor. 2'-deoxy-2',2'-difluorocytidine monohydrochloride ((beta)-isomer) Gemzar 122111-03-9 ≥98% 299.66 C9H12ClF2N3O4 C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F.Cl In DMSO at +4 for 2 weeks at -80 for 6 months. Ambient Ambient Soluble in water. Slightly soluble in methanol, acetone, DMSO. "Chen SH, Li DL, Yang F, et al. Gemcitabine-induced pancreatic cancer cell death is associated with MST1/Cyclophilin D mitochondrial complexation. Biochimie. 2014 Apr 13. Epub ahead of print]. PMID: 24732633.

 

Su CH, Chu WC, Lan KH, et al. Gemcitabine causes telomere attrition by stabilizing TRF2. Eur J Cancer. 2012 Dec;48(18):3465-74. PMID: 22704123.

 

Greggs WM 3rd, Clouser CL, Patterson SE, et al. Discovery of drugs that possess activity against feline leukemia virus. J Gen Virol. 2012 Apr;93(Pt 4):900-5. PMID: 22258856.

 

Cerqueira NM, Fernandes PA, Ramos MJ. Understanding ribonucleotide reductase inactivation by gemcitabine. Chemistry. 2007;13(30):8507-15. PMID: 17636467.

 

Blackwood E, Epler J, Yen I, et al. Combination drug scheduling defines a “window of opportunity” for chemopotentiation of gemcitabine by an orally bioavailable, selective ChK1 inhibitor, GNE-900. Mol Cancer Ther. 2013 Oct;12(10):1968-1980. PMID: 23873850.

 

 

 

 

Reconstituted gemcitabine as the hydrochloride salt in the original vials is chemically stable at room temperature for 35 days but may develop crystals when stored at 4 degrees C. The crystaLSo not redissolve upon warming. Gemcitabine prepared as intravenous admixtures of 0.1 and 10 mg/mL as the hydrochloride salt in 5% dextrose injection and 0.9% sodium chloride injection in PVC bags and as a solution of 38 mg/mL in 0.9% sodium chloride injection packaged in plastic syringes is physically and chemically stable for at least 35 days at 4 degrees C and 23 degrees C. Gemcitabine as the hydrochloride salt is stable for at least 7 days at concentrations of 0.1, 10, and 38 mg/mL in 5% dextrose injection and 0.9% sodium chloride injection stored at 32 degrees C during simulated ambulatory infusion." Xn, T, T+, C, Xi, Muta. Cat. 2, Repr. Cat. Not dangerous goods.

LKT D0375 Dasatinib Monohydrate 10 mg 88.3 Abl, PDGFR, EphR, Src, k-Kit, FYN, LCK, HCK inhibitor. N-(2-chlro-6-methylphenyl)-2-[[6-[4[(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazole carboxamide monohydrate 863127-77-9 ≥98% 506.02 C22H26ClN7O2S H2O CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=NC(=NC(=C3)N4CCN(CC4)CCO)C.O Ambient Ambient Sparingly soluble in water (5.06 mg/ml), and ethanol. Soluble in DMSO (200 mg/ml). "Xie N, Zhong L, Liu L, et al. Autophagy contributes to dasatinib-induced myeloid differentiation of human acute myeloid leukemia cells. Biochem Pharmacol. 2014 May 1;89(1):74-85. PMID: 24607273.

 

de Wispelaere M, LaCroix AJ, Yang PL. The small molecules AZD0530 and dasatinib inhibit dengue virus RNA replication via Fyn kinase. J Virol. 2013 Jul;87(13):7367-81. PMID: 23616652.

 

Montero JC, Seoane S, Ocaña A, et al. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin Cancer Res. 2011 Sep 1;17(17):5546-52. PMID: 21670084.

 

Das J, Chen P, Norris D, et al. 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J Med Chem. 2006 Nov 16;49(23):6819-32. PMID: 17154512.

" Not dangerous goods.

LKT N0163 2-(1,8-Naphthyridin-2-yl)phenol 100 mg 61.1 Naphthalene; indirect STAT1 agonist. 65182-56-1 ≥98% 222.24 C14H10N2O C1=CC(=C2C=CC3=C(N2)N=CC=C3)C(=O)C=C1 Ambient -20°C Lynch RA, Etchin J, Battle TE, et al. A small-molecule enhancer of signal transducer and activator of transcription 1 transcriptional activity accentuates the antiproliferative effects of IFN-gamma in human cancer cells. Cancer Res. 2007 Feb 1;67(3):1254-61. PMID: 17283162. Not dangerous goods.

LKT L0076 Latrunculin A 500 µg 762.8 76343-93-6 421.55 C22H31NO5S CC1CCC2CC(CC(O2)(C3CSC(=O)N3)O)OC(=O)C=C(CCC=CC=C1)C Ambient 4°C "Helal MA, Khalifa S, Ahmed S. Differential binding of latrunculins to G-actin: a molecular dynamics study. J Chem Inf Model. 2013 Sep 23;53(9):2369-75. PMID: 23988111.

 

Bartolini F, Ramalingam N, Gundersen GG. Actin-capping protein promotes microtubule stability by antagonizing the actin activity of mDia1. Mol Biol Cell. 2012 Oct;23(20):4032-40. PMID: 22918941.

 

Rennebaum S, Caflisch A. Inhibition of interdomain motion in g-actin by the natural product latrunculin: a molecular dynamics study. Proteins. 2012 Aug;80(8):1998-2008. PMID: 22488806.

 

Khanfar MA, Youssef DT, El Sayed KA. Semisynthetic latrunculin derivatives as inhibitors of metastatic breast cancer: biological evaluations, preliminary structure-activity relationship and molecular modeling studies. ChemMedChem. 2010 Feb 1;5(2):274-85. PMID: 20043312.

 

Sayed KA, Khanfar MA, Shallal HM, et al. Latrunculin A and its C-17-O-carbamates inhibit prostate tumor cell invasion and HIF-1 activation in breast tumor cells. J Nat Prod. 2008 Mar;71(3):396-402. PMID: 18298079.

" Xn Not dangerous goods.

LKT M9710 Mycophenolic Acid 500 mg 305.9 Phthalide; PPARγ agonist, IMPDH inhibitor, microtubule polymerization inhibitor. 24280-93-1 ≥98% 320.34 C17H20O6 CC1=C(C(=C(C2=C1COC2=O)O)CC=C(C)CCC(=O)O)OC Ambient Ambient DMSO, Ethanol, Methanol, DCM. Insoluble in water "Rinaldelli E, Panattoni A, Luvisi A, et al. Effect of mycophenolic acid on trans-plasma membrane electron transport and electric potential in virus-infected plant tissue. Plant Physiol Biochem. 2012 Nov;60:137-40. PMID: 22935477.

 

Eickenberg S, Mickholz E, Jung E, et al. Mycophenolic acid counteracts B cell proliferation and plasmablast formation in patients with systemic lupus erythematosus. Arthritis Res Ther. 2012;14(3):R110. PMID: 22571761.

 

Zheng ZH, Yang Y, Lu XH, et al. Mycophenolic acid induces adipocyte-like differentiation and reversal of malignancy of breast cancer cells partly through PPARγ. Eur J Pharmacol. 2011 May 1;658(1):1-8. PMID: 21349264.

 

Huh KH, Ahn HJ, Park J, et al. Mycophenolic acid inhibits oleic acid-induced mesangial cell activation through both cellular reactive oxygen species and inosine monophosphate dehydrogenase 2 pathways. Pediatr Nephrol. 2009 Apr;24(4):737-45. PMID: 19093139.

 

Chaigne-Delalande B, Guidicelli G, Couzi L, et al. The immunosuppressor mycophenolic acid kills activated lymphocytes by inducing a nonclassical actin-dependent necrotic signal. J Immunol. 2008 Dec 1;181(11):7630-8. PMID: 19017951.

" T, N Not dangerous goods.

LKT U6959 Urotensin II, human 2.5 mg 612.4 Endogenous peptide, involved in stress signaling; UT agonist. ≥95% 1388.6 C64H85N13O18S2 Ambient -20°C "Peng H, Zhang M, Cai X, et al. Association between Human Urotensin II and Essential Hypertension-A 1:1 Matched Case-Control Study. PLoS One. 2013 Dec 10;8(12):e81764. PMID: 24339964.

 

Wang HX, Wu XR, Yang H, et al. Urotensin II inhibits skeletal muscle glucose transport signaling pathways via the NADPH oxidase pathway. PLoS One. 2013 Oct 8;8(10):e76796. PMID: 24116164.

 

Park SL, Lee BK, Kim YA, et al. Inhibitory Effect of an Urotensin II Receptor Antagonist on Proinflammatory Activation Induced by Urotensin II in Human Vascular Endothelial Cells. Biomol Ther (Seoul). 2013 Jul 30;21(4):277-83. PMID: 24244812.

" Not dangerous goods.

LKT F4782 Fludarabine Phosphate 100 mg 434.9 Nucleoside (adenosine) analog; DNA chain terminator, ribonucleotide reductase, DNA ligase, DNA primase inhibitor, A1 adenosine antagonist. F-ara-A 75607-67-9 ≥98% 365.21 C10H13FN5O7P C1=NC2=C(N1C3C(C(C(O3)COP(=O)(O)O)O)O)N=C(N=C2N)F Ambient Ambient Slightly soluble in water (6 mg/mL). Soluble in DMSO (70 mg/mL) "Robak P and Robak T. Older and new purine nucleoside analogs for patients with acute leukemias. Cancer Treat Rev. 2013 Dec;39(8):851-61. PMID: 23566572.

 

Jensen K, Johnson LA, Jacobson PA, et al. Cytotoxic purine nucleoside analogues bind to A1, A2A, and A3 adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol. 2012 May;385(5):519-25. PMID: 22249336.

 

Nishioka C, Ikezoe T, Togitani K, et al. Fludarabine induces growth arrest and apoptosis of cytokine- or alloantigen-stimulated peripheral blood mononuclear cells, and decreases production of Th1 cytokines via inhibition of nuclear factor kappaB. Bone Marrow Transplant. 2008 Feb;41(3):303-9. PMID: 17994120.

 

Gandhi V, Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet. 2002;41(2):93-103. PMID: 11888330.

 

Yamauchi T, Nowak BJ, Keating MJ, et al. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res. 2001 Nov;7(11):3580-9. PMID: 11705880.

 

Catapano CV, Perrino FW, Fernandes DJ. Primer RNA chain termination induced by 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-triphosphate. A mechanism of DNA synthesis inhibition. J Biol Chem. 1993 Apr 5;268(10):7179-85. PMID: 7681821.

" Not dangerous goods.

LKT M2076 Metformin Hydrochloride 5 g 28.1 AMPK activator. 1,1-Dimethylbiguanide Hydrochloride Dimethylbiguanide hydrochloride; Imidodicaronimidic diamide; N,N-dimethyl-, monohydrochloride; N,N-Dimethylbiguanide hydrochloride 1115-70-4 ≥98% 165.62 C4H11N5 HCl CN(C)C(=N)N=C(N)N.Cl In DMSO at +4 for 2 weeks at -80 for 6 months. Ambient Ambient 100 mM water, 50 mM DMSO "Fan C, Wang Y, Liu Z, et al. Metformin exerts anticancer effects through the inhibition of the Sonic hedgehog signaling pathway in breast cancer. Int J Mol Med. 2015 May 21. [Epub ahead of print]. PMID: 25999130.

 

Miyoshi H, Kato K, Iwama H, et al. Effect of the anti-diabetic drug metformin in hepatocellular carcinoma in vitro and in vivo. Int J Oncol. 2013 Dec 30. [Epub ahead of print]. PMID: 24378856.

 

Piwkowska A, Rogacka D, Jankowski M, et al. Metformin reduces NAD(P)H oxidase activity in mouse cultured podocytes through purinergic dependent mechanism by increasing extracellular ATP concentration. Acta Biochim Pol. 2013;60(4):607-12. PMID: 24432311.

 

Akinyeke T, Matsumura S, Wang X, et al. Metformin targets c-MYC oncogene to prevent prostate cancer. Carcinogenesis. 2013 Dec;34(12):2823-32. PMID: 24130167.

 

Zhang Y, Guan M, Zheng Z, et al. Effects of metformin on CD133+ colorectal cancer cells in diabetic patients. PLoS One. 2013 Nov 21;8(11):e81264. PMID: 24278407.

 

Shin S, Hyun B, Lee A, et al. Metformin Suppresses MHC-Restricted Antigen Presentation by Inhibiting Co-Stimulatory Factors and MHC Molecules in APCs. Biomol Ther (Seoul). 2013 Jan;21(1):35-41. PMID: 24009856.

 

Chu CA, Wiernsperger N, Muscato N, et al. The acute effect of metformin on glucose production in the conscious dog is primarily attributable to inhibition of glycogenolysis. Metabolism. 2000 Dec;49(12):1619-26. PMID: 11145127.

 

Lin HZ, Yang SQ, Chuckaree C, et al. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med. 2000 Sep;6(9):998-1003. PMID: 10973319.

 

Minassian C, Tarpin S, Mithieux G. Role of glucose-6 phosphatase, glucokinase, and glucose-6 phosphate in liver insulin resistance and its correction by metformin. Biochem Pharmacol. 1998 Apr 15;55(8):1213-9. PMID: 9719475.

 

Stumvoll M, Nurjhan N, Perriello G, et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med. 1995 Aug 31;333(9):550-4. PMID: 7623903.

 

Nakamichi N, Shima H, Asano S, et al.  Involvement of carnitine/organic cation transporter OCTN1/SLC22A4 in gastrointestinal absorption of metformin. J Pharm Sci. 2013 Sep;102(9):3407-3417. PMID: 23666872.

" Xn, Xi Not dangerous goods.

LKT R5611 Rocuronium Bromide 250 mg 394.9 Non-depolarizing NMJ blocker; nAChR and M2/3 mAChR antagonist. 119302-91-9 ≥98% 609.68 C32H53BrN2O4 CC(=O)OC1C(CC2C1(CCC3C2CCC4C3(CC(C(C4)O)N5CCOCC5)C)C)[N+]6(CCCC6)CC=C.[Br-] Ambient Ambient Water "Pape A, Kertscho H, Stein P, et al. Neuromuscular blockade with rocuronium bromide increases the tolerance of acute normovolemic anemia in anesthetized pigs. Eur Surg Res. 2012;48(1):16-25. PMID: 22189343.

 

Bowman WC. Neuromuscular block. Br J Pharmacol. 2006 Jan;147 Suppl 1:S277-86. PMID: 16402115.

 

Hou VY, Hirshman CA, Emala CW. Neuromuscular relaxants as antagonists for M2 and M3 muscarinic receptors. Anesthesiology. 1998 Mar;88(3):744-50. PMID: 9523819.

" Not dangerous goods.

LKT E6846 Erlotinib Hydrochloride 500 mg 502.8 EGFR inhibitor. 183319-69-9 ≥98% 429.9 C22H23N3O4 HCl COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC.Cl Ambient Ambient DMSO (16 mg/mL) H2O "Li YY, Lam SK, Mak JC, et al. Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer. Lung Cancer. 2013 Sep;81(3):354-61. PMID: 23769318.

 

Miyabayashi K, Ijichi H, Mohri D, et al. Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals. Cancer Res. 2013 Apr 1;73(7):2221-34. PMID: 23378339.

 

Weickhardt AJ, Price TJ, Chong G, et al. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer. J Clin Oncol. 2012 May 1;30(13):1505-12. PMID: 22412142.

 

Zerbe LK, Dwyer-Nield LD, Fritz JM, et al. Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice. Cancer Chemother Pharmacol. 2008 Sep;62(4):605-20. PMID: 18030469.

 

Ling YH, Li T, Yuan Z, et al. Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 up-regulation and nuclear translocation in association with cell growth inhibition and G1/S phase arrest in human non-small-cell lung cancer cell lines. Mol Pharmacol. 2007 Aug;72(2):248-58. PMID: 17456787.

" Xn, Carc. Cat. 3, Repr. Cat. 3, N "UN number: 2811     Class: 6.1     Packing Group: III

Proper shipping name: Toxic solid, organic, n.o.s. (Erlotinib hydrochloride)"

LKT R8179 Rutaecarpine, synthetic 25 mg 61.1 Found in Evodia rutaecarpa; potential cAMP, 3β-HSD, 11β-hydroxylase inhibitor. 8,13-Dihydroindolo[2',3':3,4]pyrido[2,1-b]quinazolin- 5(7H)-one Rutecarpine 84-26-4 ≥98% 287.32 C18H13N3O C1CN2C(=NC3=CC=CC=C3C2=O)C4=C1C5=CC=CC=C5N4 Ambient 4°C Soluble in alcohol, benzene, chloroform and ether. Practically insoluble in water. "Xu Y, Liu Q, Xu Y, et al. Rutaecarpine suppresses atherosclerosis in ApoE-/- mice through up-regulating ABCA1 and SR-BI within RCT. J Lipid Res. 2014 Jun 7. [Epub ahead of print]. PMID: 24908654.

 

Chen YC, Zeng XY, He Y, et al. Rutaecarpine analogues reduce lipid accumulation in adipocytes via inhibiting adipogenesis/lipogenesis with AMPK activation and UPR suppression. ACS Chem Biol. 2013 Oct 18;8(10):2301-11. PMID: 23962138.

 

Bao MH, Dai W, Li YJ, et al. Rutaecarpine prevents hypoxia-reoxygenation-induced myocardial cell apoptosis via inhibition of NADPH oxidases. Can J Physiol Pharmacol. 2011 Mar;89(3):177-86. PMID: 21423291.

 

Kim SJ, Lee SJ, Lee S, et al. Rutecarpine ameliorates bodyweight gain through the inhibition of orexigenic neuropeptides NPY and AgRP in mice. Biochem Biophys Res Commun. 2009 Nov 20;389(3):437-42. PMID: 19732749.

 

Yu PL, Chao HL, Wang SW, et al. Effects of evodiamine and rutaecarpine on the secretion of corticosterone by zona fasciculata-reticularis cells in male rats. J Cell Biochem. 2009 Oct 1;108(2):469-75. PMID: 19639602.

 

Sheu JR, Hung WC, Lee YM, et al. Mechanism of inhibition of platelet aggregation by rutaecarpine, an alkaloid isolated from Evodia rutaecarpa. Eur J Pharmacol. 1996 Dec 30;318(2-3):469-75. PMID: 9016940.

" T Not dangerous goods.

LKT C0367 S-(−)-Carbidopa Monohydrate 1 g 129 Hydrazine; L-amino acid decarboxylase inhibitor. 38821-49-7 ≥98% 244.24 C10H14N2O4 H2O CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN.O Ambient Ambient "Katow H, Suyemitsu T, Ooka S, et al. Development of a dopaminergic system in sea urchin embryos and larvae. J Exp Biol. 2010 Aug 15;213(Pt 16):2808-19. PMID: 20675551.

 

Thomas SA, Marck BT, Palmiter RD, et al. Restoration of norepinephrine and reversal of phenotypes in mice lacking dopamine beta-hydroxylase. J Neurochem. 1998 Jun;70(6):2468-76. PMID: 9603211.

" Not dangerous goods.

LKT C0367 S-(−)-Carbidopa Monohydrate 5 g 183.4 Hydrazine; L-amino acid decarboxylase inhibitor. 38821-49-7 ≥98% 244.24 C10H14N2O4 H2O CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN.O Ambient Ambient "Katow H, Suyemitsu T, Ooka S, et al. Development of a dopaminergic system in sea urchin embryos and larvae. J Exp Biol. 2010 Aug 15;213(Pt 16):2808-19. PMID: 20675551.

 

Thomas SA, Marck BT, Palmiter RD, et al. Restoration of norepinephrine and reversal of phenotypes in mice lacking dopamine beta-hydroxylase. J Neurochem. 1998 Jun;70(6):2468-76. PMID: 9603211.

" Not dangerous goods.

LKT B1879 Betamethasone Valerate 25 mg 61.1 Synthetic steroid hormone; glucocorticoid agonist. 2152-44-5 ≥98% 476.58 C27H37FO6 CCCCC(=O)OC1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)C(=O)CO Ambient Ambient Insoluble in water.  Ethanol (62 mg/mL). Soluble in acetone, DMSO. "Naldi L, Yawalkar N, Kaszuba A, et al. Efficacy and safety of the Betamethasone valerate 0.1% plaster in mild-to-moderate chronic plaque psoriasis: a randomized, parallel-group, active-controlled, phase III study. Am J Clin Dermatol. 2011 Jun 1;12(3):191-201. PMID: 21284407.

 

Meindl S, Vaculik C, Meingassner JG, et al. Differential effects of corticosteroids and pimecrolimus on the developing skin immune system in humans and mice. J Invest Dermatol. 2009 Sep;129(9):2184-92. PMID: 19295616.

 

Leivo T, Arjomaa P, Oivula J, et al. Differential modulation of transforming growth factor-beta by betamethasone-17- valerate and isotretinoin: corticosteroid decreases and isotretinoin increases the level of transforming growth factor-beta in suction blister fluid. Skin Pharmacol Appl Skin Physiol. 2000 May-Aug;13(3-4):150-6. PMID: 10859533.

 

Marks R, Sawyer M. Glucocorticoid-induced vasoconstriction in human skin. An inhibitory role on phospholipase A2 activity. Arch Dermatol. 1986 Aug;122(8):881-3. PMID: 2874773.

" None Not dangerous goods.

LKT R0248 Ramatroban 5 mg 101.9 CRTH2 inhibitor, TxA2 antagonist. 116649-85-5 ≥98% 416.47 C21H21FN2O4S C1CC2=C(CC1NS(=O)(=O)C3=CC=C(C=C3)F)C4=CC=CC=C4N2CCC(=O)O Ambient Ambient "Suzuki Y, Inoue T, Yamamoto A, et al. Prophylactic effects of the histamine H1 receptor antagonist epinastine and the dual thromboxane A2 receptor and chemoattractant receptor-homologous molecule expressed on Th2 cells antagonist ramatroban on allergic rhinitis model in mice. Biol Pharm Bull. 2011;34(4):507-10. PMID: 21467637.

 

Akiyama K, Karaki M, Kobayshi R, et al. IL-16 variability and modulation by antiallergic drugs in a murine experimental allergic rhinitis model. Int Arch Allergy Immunol. 2009;149(4):315-22. PMID: 19295235.

 

Sugimoto H, Shichijo M, Okano M, et al. CRTH2-specific binding characteristics of [3H]ramatroban and its effects on PGD2-, 15-deoxy-Delta12, 14-PGJ2- and indomethacin-induced agonist responses. Eur J Pharmacol. 2005 Nov 7;524(1-3):30-7. PMID: 16256979.

 

Shiraishi Y, Asano K, Nakajima T, et al. Prostaglandin D2-induced eosinophilic airway inflammation is mediated by CRTH2 receptor. J Pharmacol Exp Ther. 2005 Mar;312(3):954-60. PMID: 15528449.

 

Ishizuka T, Matsui T, Okamoto Y, et al. Ramatroban (BAY u 3405): a novel dual antagonist of TXA2 receptor and CRTh2, a newly identified prostaglandin D2 receptor. Cardiovasc Drug Rev. 2004 Summer;22(2):71-90. PMID: 15179446.

" Xi Not dangerous goods.

LKT P3210 Picoplatin 1 mg 115.5 Pt-based DNA cross-linker. azane; 2-methylpyridine; platinum(2+); dichloride 181630-15-9 ≥98% 376.15 C6H10N Pt Cl2 NH3 CC1=CC=CC=N1.N.[Cl-].[Cl-].[Pt+2] Ambient -20°C "Matos CS, de Carvalho AL, Lopes RP, et al. New strategies against prostate cancer--Pt(II)-based chemotherapy. Curr Med Chem. 2012;19(27):4678-87. PMID: 22856665.

 

Eckardt JR, Bentsion DL, Lipatov ON, et al. Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer. J Clin Oncol. 2009 Apr 20;27(12):2046-51. PMID: 19289620.

 

Kanzawa F, Akiyama Y, Saijo N, et al. In vitro effects of combinations of cis-amminedichloro (2-methylpyridine) platinum (II) (ZD0473) with other novel anticancer drugs on the growth of SBC-3, a human small cell lung cancer cell line. Lung Cancer. 2003 Jun;40(3):325-32. PMID: 12781432.

 

Munk VP, Diakos CI, Ellis LT, et al. Investigations into the interactions between DNA and conformationally constrained pyridylamineplatinum(II) analogues of AMD473. Inorg Chem. 2003 Jun 2;42(11):3582-90. PMID: 12767196.

" T Not dangerous goods.

LKT N3323 Nifuratel 1 g 33.9 Nitrofuran derivative. 5-[(methylthio)methyl]-3--1,3-oxazolidin-2-one 4936-47-4 ≥98% 285.28 C10H11N3O5S CSCC1CN(C(=O)O1)N=CC2=CC=C(O2)[N+](=O)[O-] Ambient Ambient "Togni G, Battini V, Bulgheroni A, et al. In vitro activity of nifuratel on vaginal bacteria: could it be a good candidate for the treatment of bacterial vaginosis? Antimicrob Agents Chemother. 2011 May;55(5):2490-2. PMID: 21321147.

 

Hamilton-Miller JM, Brumfitt W. Comparative in vitro activity of five nitrofurans. Chemotherapy. 1978;24(3):161-5. PMID: 657876.

" Not dangerous goods.

LKT E5568 Enramycin A 1 mg 74.8 Polypeptide; peptidoglycan inhibitor. 34438-27-2 ≥95% C107H138Cl2N26O31 CC1C(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O) Ambient 4°C 0.1% Formic acid in H2O "Pedroso AA, Menten JF, Lambais MR, et al. Intestinal bacterial community and growth performance of chickens fed diets containing antibiotics. Poult Sci. 2006 Apr;85(4):747-52. PMID: 16615359.

 

Ohya T, Sato S. Effects of dietary antibiotics on intestinal microflora in broiler chickens. Natl Inst Anim Health Q (Tokyo). 1983 Summer;23(2):49-60. PMID: 6680771.

 

Kariyama R. Increase of cardiolipin content in Staphylococcus aureus by the use of antibiotics affecting the cell wall. J Antibiot (Tokyo). 1982 Dec;35(12):1700-4. PMID: 7166534.

 

Kawakami M, Nagai Y, Fujii T, et al. Anti-microbial activities of enduracidin (enramycin) in vitro and in vivo. J Antibiot (Tokyo). 1971 Sep;24(9):583-6. PMID: 5132246.

" Not dangerous goods.

LKT M1566 (+)-S-Methyl-L-cysteine-S-oxide 5 mg 67.9 Alliin analog found in cruciferous vegetables. S-Methylcysteine sulfoxide; Methyiin, pyrolyzate 6853-87-8 ≥98% 151.19 C4H9NO3S "CS(=O)CC(C(=O)O)N

" Ambient 4°C [a]D23= +115° (c=1 in water) "Kook S, Kim GH, Choi K. The antidiabetic effect of onion and garlic in experimental diabetic rats: meta-analysis. J Med Food. 2009 Jun;12(3):552-60. PMID: 19627203.

 

Kumari K, Augusti KT. Lipid lowering effect of S-methyl cysteine sulfoxide from Allium cepa Linn in high cholesterol diet fed rats. J Ethnopharmacol. 2007 Feb 12;109(3):367-71. PMID: 16987625.

 

Kumari K, Augusti KT. Antidiabetic and antioxidant effects of S-methyl cysteine sulfoxide isolated from onions (Allium cepa Linn) as compared to standard drugs in alloxan diabetic rats. Indian J Exp Biol. 2002 Sep;40(9):1005-9. PMID: 12587728.

 

Komatsu W, Miura Y, Yagasaki K. Suppression of hypercholesterolemia in hepatoma-bearing rats by cabbage extract and its component, S-methyl-L-cysteine sulfoxide. Lipids. 1998 May;33(5):499-503. PMID: 9625597.

" Not dangerous goods.

LKT M1566 (+)-S-Methyl-L-cysteine-S-oxide 25 mg 203.8 Alliin analog found in cruciferous vegetables. S-Methylcysteine sulfoxide; Methyiin, pyrolyzate 6853-87-8 ≥98% 151.19 C4H9NO3S "CS(=O)CC(C(=O)O)N

" Ambient 4°C [a]D23= +115° (c=1 in water) "Kook S, Kim GH, Choi K. The antidiabetic effect of onion and garlic in experimental diabetic rats: meta-analysis. J Med Food. 2009 Jun;12(3):552-60. PMID: 19627203.

 

Kumari K, Augusti KT. Lipid lowering effect of S-methyl cysteine sulfoxide from Allium cepa Linn in high cholesterol diet fed rats. J Ethnopharmacol. 2007 Feb 12;109(3):367-71. PMID: 16987625.

 

Kumari K, Augusti KT. Antidiabetic and antioxidant effects of S-methyl cysteine sulfoxide isolated from onions (Allium cepa Linn) as compared to standard drugs in alloxan diabetic rats. Indian J Exp Biol. 2002 Sep;40(9):1005-9. PMID: 12587728.

 

Komatsu W, Miura Y, Yagasaki K. Suppression of hypercholesterolemia in hepatoma-bearing rats by cabbage extract and its component, S-methyl-L-cysteine sulfoxide. Lipids. 1998 May;33(5):499-503. PMID: 9625597.

" Not dangerous goods.

LKT M1566 (+)-S-Methyl-L-cysteine-S-oxide 100 mg 577.6 Alliin analog found in cruciferous vegetables. S-Methylcysteine sulfoxide; Methyiin, pyrolyzate 6853-87-8 ≥98% 151.19 C4H9NO3S "CS(=O)CC(C(=O)O)N

" Ambient 4°C [a]D23= +115° (c=1 in water) "Kook S, Kim GH, Choi K. The antidiabetic effect of onion and garlic in experimental diabetic rats: meta-analysis. J Med Food. 2009 Jun;12(3):552-60. PMID: 19627203.

 

Kumari K, Augusti KT. Lipid lowering effect of S-methyl cysteine sulfoxide from Allium cepa Linn in high cholesterol diet fed rats. J Ethnopharmacol. 2007 Feb 12;109(3):367-71. PMID: 16987625.

 

Kumari K, Augusti KT. Antidiabetic and antioxidant effects of S-methyl cysteine sulfoxide isolated from onions (Allium cepa Linn) as compared to standard drugs in alloxan diabetic rats. Indian J Exp Biol. 2002 Sep;40(9):1005-9. PMID: 12587728.

 

Komatsu W, Miura Y, Yagasaki K. Suppression of hypercholesterolemia in hepatoma-bearing rats by cabbage extract and its component, S-methyl-L-cysteine sulfoxide. Lipids. 1998 May;33(5):499-503. PMID: 9625597.

" Not dangerous goods.

LKT B6917 Brevetoxin 2 5 mg 6455.2 Polyether neurotoxin found in Karenia brevis; Nav1.4/1.5 Na+ channel activator. PbTx-2 79580-28-2 ≥95% 895.2 C50H70O14 CC1CC2C(CC3(C(O2)CC4C(O3)C(=CC(=O)O4)C)C)OC5C1OC6CC7C(CC8C(O7)(CC=CC9C(O8)CC1C(O9)CC2C(O1)(C(CC(O2)CC(=C)C=O)O)C)C)(OC6(CC5)C)C Ambient -20°C "Zaias J, Fleming LE, Baden DG, et al. Repeated exposure to aerosolized brevetoxin-3 induces prolonged airway hyperresponsiveness and lung inflammation in sheep. Inhal Toxicol. 2011 Mar;23(4):205-11. PMID: 21456953.

 

Liberona JL, Cárdenas JC, Reyes R, et al. Sodium-dependent action potentials induced by brevetoxin-3 trigger both IP3 increase and intracellular Ca2+ release in rat skeletal myotubes. Cell Calcium. 2008 Sep;44(3):289-97. PMID: 18276006.

 

Radwan FF, Ramsdell JS. Brevetoxin forms covalent DNA adducts in rat lung following intratracheal exposure. Environ Health Perspect. 2008 Jul;116(7):930-6. PMID: 18629316.

 

Cao Z, George J, Baden DG, et al. Brevetoxin-induced phosphorylation of Pyk2 and Src in murine neocortical neurons involves distinct signaling pathways. Brain Res. 2007 Dec 12;1184:17-27. PMID: 17963734.

 

Bottein Dechraoui MY, Ramsdell JS. Type B brevetoxins show tissue selectivity for voltage-gated sodium channels: comparison of brain, skeletal muscle and cardiac sodium channels. Toxicon. 2003 Jun;41(7):919-27. PMID: 12782093.

 

Berman FW, Murray TF. Brevetoxins cause acute excitotoxicity in primary cultures of rat cerebellar granule neurons. J Pharmacol Exp Ther. 1999 Jul;290(1):439-44. PMID: 10381810.

" "UN Number: 3462     Class: 6.1     Packing Group: II

Proper Shipping Name:  Toxins, extracted from living sources, solid, n.o.s. (Brevetoxin 2) "

LKT G1651 Geniposidic Acid 5 mg 122.3 Iridoid glucoside found in Eucommia, Castilleja, Plantago, Gardeniae. 27741-01-1 ≥98% 374.34 C16H22O10 C1C=C(C2C1C(=COC2OC3C(C(C(C(O3)CO)O)O)O)C(=O)O)CO Ambient Ambient "Hirata T, Kobayashi T, Wada A, et al. Anti-obesity compounds in green leaves of Eucommia ulmoides. Bioorg Med Chem Lett. 2011 Mar 15;21(6):1786-91. PMID: 21324693.

 

Tzakou O, Mylonas P, Vagias C, et al. Iridoid glucosides with insecticidal activity from Galium melanantherum. Z Naturforsch C. 2007 Jul-Aug;62(7-8):597-602. PMID: 17913079.

 

Mi FL, Huang CT, Chiu YL, et al. Aglycone geniposidic acid, a naturally occurring crosslinking agent, and its application for the fixation of collagenous tissues. J Biomed Mater Res A. 2007 Dec 1;83(3):667-73. PMID: 17530623.

 

Ha H, Ho J, Shin S, et al. Effects of Eucommiae Cortex on osteoblast-like cell proliferation and osteoclast inhibition. Arch Pharm Res. 2003 Nov;26(11):929-36. PMID: 14661859.

 

Li Y, Sato T, Metori K, et al. The promoting effects of geniposidic acid and aucubin in Eucommia ulmoides Oliver leaves on collagen synthesis. Biol Pharm Bull. 1998 Dec;21(12):1306-10. PMID: 9881644.

 

Hsu HY, Yang JJ, Lin SY, et al. Comparisons of geniposidic acid and geniposide on antitumor and radioprotection after sublethal irradiation. Cancer Lett. 1997 Feb 26;113(1-2):31-7. PMID: 9065798.

" Not dangerous goods.

LKT G1651 Geniposidic Acid 25 mg 367 Iridoid glucoside found in Eucommia, Castilleja, Plantago, Gardeniae. 27741-01-1 ≥98% 374.34 C16H22O10 C1C=C(C2C1C(=COC2OC3C(C(C(C(O3)CO)O)O)O)C(=O)O)CO Ambient Ambient "Hirata T, Kobayashi T, Wada A, et al. Anti-obesity compounds in green leaves of Eucommia ulmoides. Bioorg Med Chem Lett. 2011 Mar 15;21(6):1786-91. PMID: 21324693.

 

Tzakou O, Mylonas P, Vagias C, et al. Iridoid glucosides with insecticidal activity from Galium melanantherum. Z Naturforsch C. 2007 Jul-Aug;62(7-8):597-602. PMID: 17913079.

 

Mi FL, Huang CT, Chiu YL, et al. Aglycone geniposidic acid, a naturally occurring crosslinking agent, and its application for the fixation of collagenous tissues. J Biomed Mater Res A. 2007 Dec 1;83(3):667-73. PMID: 17530623.

 

Ha H, Ho J, Shin S, et al. Effects of Eucommiae Cortex on osteoblast-like cell proliferation and osteoclast inhibition. Arch Pharm Res. 2003 Nov;26(11):929-36. PMID: 14661859.

 

Li Y, Sato T, Metori K, et al. The promoting effects of geniposidic acid and aucubin in Eucommia ulmoides Oliver leaves on collagen synthesis. Biol Pharm Bull. 1998 Dec;21(12):1306-10. PMID: 9881644.

 

Hsu HY, Yang JJ, Lin SY, et al. Comparisons of geniposidic acid and geniposide on antitumor and radioprotection after sublethal irradiation. Cancer Lett. 1997 Feb 26;113(1-2):31-7. PMID: 9065798.

" Not dangerous goods.

LKT P6865 Propranolol Hydrochloride 1 g 33.9 β1/2-adrenergic antagonist. 318-98-9 ≥98% 295.8 C16H21NO2 HCl CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O.Cl Ambient Ambient "Ji Y, Li K, Xiao X, et al. Effects of propranolol on the proliferation and apoptosis of hemangioma-derived endothelial cells. J Pediatr Surg. 2012 Dec;47(12):2216-23. PMID: 23217879.

 

Izadpanah A, Izadpanah A, Kanevsky J, et al. Propranolol versus corticosteroids in the treatment of infantile hemangioma: a systematic review and meta-analysis. Plast Reconstr Surg. 2013 Mar;131(3):601-13. PMID: 23142941.

 

Romana-Souza B, Santos JS, Monte-Alto-Costa A. beta-1 and beta-2, but not alpha-1 and alpha-2, adrenoceptor blockade delays rat cutaneous wound healing. Wound Repair Regen. 2009 Mar-Apr;17(2):230-9. PMID: 19320892.

 

Casucci G, Villani V, Frediani F. Central mechanism of action of antimigraine prophylactic drugs. Neurol Sci. 2008 May;29 Suppl 1:S123-6. PMID: 18545912.

 

Pereira CT, Jeschke MG, Herndon DN. Beta-blockade in burns. Novartis Found Symp. 2007;280:238-48. PMID: 17380798.

 

Garvey HL, Ram N. Comparative antihypertensive effects and tissue distribution of beta adrenergic blocking drugs. J Pharmacol Exp Ther. 1975 Jul;194(1):220-33. PMID: 1151751.

" Not dangerous goods.

LKT P6865 Propranolol Hydrochloride 5 g 115.5 β1/2-adrenergic antagonist. 318-98-9 ≥98% 295.8 C16H21NO2 HCl CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O.Cl Ambient Ambient "Ji Y, Li K, Xiao X, et al. Effects of propranolol on the proliferation and apoptosis of hemangioma-derived endothelial cells. J Pediatr Surg. 2012 Dec;47(12):2216-23. PMID: 23217879.

 

Izadpanah A, Izadpanah A, Kanevsky J, et al. Propranolol versus corticosteroids in the treatment of infantile hemangioma: a systematic review and meta-analysis. Plast Reconstr Surg. 2013 Mar;131(3):601-13. PMID: 23142941.

 

Romana-Souza B, Santos JS, Monte-Alto-Costa A. beta-1 and beta-2, but not alpha-1 and alpha-2, adrenoceptor blockade delays rat cutaneous wound healing. Wound Repair Regen. 2009 Mar-Apr;17(2):230-9. PMID: 19320892.

 

Casucci G, Villani V, Frediani F. Central mechanism of action of antimigraine prophylactic drugs. Neurol Sci. 2008 May;29 Suppl 1:S123-6. PMID: 18545912.

 

Pereira CT, Jeschke MG, Herndon DN. Beta-blockade in burns. Novartis Found Symp. 2007;280:238-48. PMID: 17380798.

 

Garvey HL, Ram N. Comparative antihypertensive effects and tissue distribution of beta adrenergic blocking drugs. J Pharmacol Exp Ther. 1975 Jul;194(1):220-33. PMID: 1151751.

" Not dangerous goods.

LKT P6865 Propranolol Hydrochloride 25 g 441.6 β1/2-adrenergic antagonist. 318-98-9 ≥98% 295.8 C16H21NO2 HCl CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O.Cl Ambient Ambient "Ji Y, Li K, Xiao X, et al. Effects of propranolol on the proliferation and apoptosis of hemangioma-derived endothelial cells. J Pediatr Surg. 2012 Dec;47(12):2216-23. PMID: 23217879.

 

Izadpanah A, Izadpanah A, Kanevsky J, et al. Propranolol versus corticosteroids in the treatment of infantile hemangioma: a systematic review and meta-analysis. Plast Reconstr Surg. 2013 Mar;131(3):601-13. PMID: 23142941.

 

Romana-Souza B, Santos JS, Monte-Alto-Costa A. beta-1 and beta-2, but not alpha-1 and alpha-2, adrenoceptor blockade delays rat cutaneous wound healing. Wound Repair Regen. 2009 Mar-Apr;17(2):230-9. PMID: 19320892.

 

Casucci G, Villani V, Frediani F. Central mechanism of action of antimigraine prophylactic drugs. Neurol Sci. 2008 May;29 Suppl 1:S123-6. PMID: 18545912.

 

Pereira CT, Jeschke MG, Herndon DN. Beta-blockade in burns. Novartis Found Symp. 2007;280:238-48. PMID: 17380798.

 

Garvey HL, Ram N. Comparative antihypertensive effects and tissue distribution of beta adrenergic blocking drugs. J Pharmacol Exp Ther. 1975 Jul;194(1):220-33. PMID: 1151751.

" Not dangerous goods.

LKT P6865 Propranolol Hydrochloride 100 g 1019.2 β1/2-adrenergic antagonist. 318-98-9 ≥98% 295.8 C16H21NO2 HCl CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O.Cl Ambient Ambient "Ji Y, Li K, Xiao X, et al. Effects of propranolol on the proliferation and apoptosis of hemangioma-derived endothelial cells. J Pediatr Surg. 2012 Dec;47(12):2216-23. PMID: 23217879.

 

Izadpanah A, Izadpanah A, Kanevsky J, et al. Propranolol versus corticosteroids in the treatment of infantile hemangioma: a systematic review and meta-analysis. Plast Reconstr Surg. 2013 Mar;131(3):601-13. PMID: 23142941.

 

Romana-Souza B, Santos JS, Monte-Alto-Costa A. beta-1 and beta-2, but not alpha-1 and alpha-2, adrenoceptor blockade delays rat cutaneous wound healing. Wound Repair Regen. 2009 Mar-Apr;17(2):230-9. PMID: 19320892.

 

Casucci G, Villani V, Frediani F. Central mechanism of action of antimigraine prophylactic drugs. Neurol Sci. 2008 May;29 Suppl 1:S123-6. PMID: 18545912.

 

Pereira CT, Jeschke MG, Herndon DN. Beta-blockade in burns. Novartis Found Symp. 2007;280:238-48. PMID: 17380798.

 

Garvey HL, Ram N. Comparative antihypertensive effects and tissue distribution of beta adrenergic blocking drugs. J Pharmacol Exp Ther. 1975 Jul;194(1):220-33. PMID: 1151751.

" Not dangerous goods.

LKT S1846 Selumetinib 1 mg 61.1 MEK1/2 inhibitor. AZD6244, ARRY 142886 606143-52-6 ≥98% 457.68 C17H15BrClFN4O3 CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)Cl)C(=O)NOCCO Ambient Ambient "Paolo M, Assunta S, Antonio R, et al. Selumetinib in Advanced Non Small Cell Lung Cancer (NSCLC) Harbouring KRAS Mutation: Endless Clinical Challenge to KRAS-mutant NSCLC. Rev Recent Clin Trials. 2013 Jun;8(2):93-100. PMID: 24063423.

 

Muchir A, Kim YJ, Reilly SA, et al. Inhibition of extracellular signal-regulated kinase 1/2 signaling has beneficial effects on skeletal muscle in a mouse model of Emery-Dreifuss muscular dystrophy caused by lamin A/C gene mutation. Skelet Muscle. 2013 Jul 1;3(1):17. PMID: 23815988.

 

Shindo T, Kim TK, Benjamin CL, et al. MEK inhibitors selectively suppress alloreactivity and graft-versus-host disease in a memory stage-dependent manner. Blood. 2013 Jun 6;121(23):4617-26. PMID: 23575444.

 

Sabnis GJ, Kazi A, Golubeva O, et al. Effect of selumetinib on the growth of anastrozole-resistant tumors. Breast Cancer Res Treat. 2013 Apr;138(3):699-708. PMID: 23508762.

 

Huynh H, Soo KC, Chow PK, et al. Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma. Mol Cancer Ther. 2007 Jan;6(1):138-46. PMID: 17237274.

" Not dangerous goods.

LKT S1846 Selumetinib 10 mg 203.8 MEK1/2 inhibitor. AZD6244, ARRY 142886 606143-52-6 ≥98% 457.68 C17H15BrClFN4O3 CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)Cl)C(=O)NOCCO Ambient Ambient "Paolo M, Assunta S, Antonio R, et al. Selumetinib in Advanced Non Small Cell Lung Cancer (NSCLC) Harbouring KRAS Mutation: Endless Clinical Challenge to KRAS-mutant NSCLC. Rev Recent Clin Trials. 2013 Jun;8(2):93-100. PMID: 24063423.

 

Muchir A, Kim YJ, Reilly SA, et al. Inhibition of extracellular signal-regulated kinase 1/2 signaling has beneficial effects on skeletal muscle in a mouse model of Emery-Dreifuss muscular dystrophy caused by lamin A/C gene mutation. Skelet Muscle. 2013 Jul 1;3(1):17. PMID: 23815988.

 

Shindo T, Kim TK, Benjamin CL, et al. MEK inhibitors selectively suppress alloreactivity and graft-versus-host disease in a memory stage-dependent manner. Blood. 2013 Jun 6;121(23):4617-26. PMID: 23575444.

 

Sabnis GJ, Kazi A, Golubeva O, et al. Effect of selumetinib on the growth of anastrozole-resistant tumors. Breast Cancer Res Treat. 2013 Apr;138(3):699-708. PMID: 23508762.

 

Huynh H, Soo KC, Chow PK, et al. Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma. Mol Cancer Ther. 2007 Jan;6(1):138-46. PMID: 17237274.

" Not dangerous goods.

LKT S1846 Selumetinib 50 mg 611.5 MEK1/2 inhibitor. AZD6244, ARRY 142886 606143-52-6 ≥98% 457.68 C17H15BrClFN4O3 CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)Cl)C(=O)NOCCO Ambient Ambient "Paolo M, Assunta S, Antonio R, et al. Selumetinib in Advanced Non Small Cell Lung Cancer (NSCLC) Harbouring KRAS Mutation: Endless Clinical Challenge to KRAS-mutant NSCLC. Rev Recent Clin Trials. 2013 Jun;8(2):93-100. PMID: 24063423.

 

Muchir A, Kim YJ, Reilly SA, et al. Inhibition of extracellular signal-regulated kinase 1/2 signaling has beneficial effects on skeletal muscle in a mouse model of Emery-Dreifuss muscular dystrophy caused by lamin A/C gene mutation. Skelet Muscle. 2013 Jul 1;3(1):17. PMID: 23815988.

 

Shindo T, Kim TK, Benjamin CL, et al. MEK inhibitors selectively suppress alloreactivity and graft-versus-host disease in a memory stage-dependent manner. Blood. 2013 Jun 6;121(23):4617-26. PMID: 23575444.

 

Sabnis GJ, Kazi A, Golubeva O, et al. Effect of selumetinib on the growth of anastrozole-resistant tumors. Breast Cancer Res Treat. 2013 Apr;138(3):699-708. PMID: 23508762.

 

Huynh H, Soo KC, Chow PK, et al. Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma. Mol Cancer Ther. 2007 Jan;6(1):138-46. PMID: 17237274.

" Not dangerous goods.

LKT AS101 Chamomile Flavonoid Standards Kit 1 kit 1174.2 Ambient -20°C

LKT AS102 Aristolochic Acids Standards Kit 1 kit 2550.8 Ambient -20°C

LKT AS103 Skullcap Standards Kit 1 kit 1391.7 Ambient -20°C

LKT AS104 Camptothecins Standards Kit 1 kit 1685.1 Ambient -20°C

LKT AS105 Buckthorn Standards Kit 1 kit 1216.3 Ambient -20°C

LKT AS106 Magnolia Standards Kit 1 kit 1179.7 Ambient -20°C

LKT AS107 Caffeic Acid Esters Standards Kit 1 kit 1229.9 Ambient -20°C

LKT AS108 Kudzu Flavonoid Standards Kit 1 kit 1546.7 Ambient -20°C

LKT AS109 Soy Isoflavone Standards Kit 1 kit 1662.2 Ambient -20°C

LKT AS110 Red Clover Standards Kit 1 kit 1488.1 Ambient -20°C

LKT AS111 Berry Flavonoid Standards Kit 1 kit 1307.4 Ambient -20°C

LKT AS112 Grape Skin Standards Kit 1 kit 1190.5 Ambient -20°C

LKT AS113 Evodia Standards Kit 1 kit 1200 Ambient -20°C

LKT AS114 Citrus Flavonoids Standards Kit 1 kit 1195.8 Ambient -20°C

LKT AS115 Celery Standards Kit 1 kit 1206.9 Ambient -20°C

LKT M5793 Moxifloxacin Free Base 100 mg 136 Fluoroquinolone; topoisomerase IV, topoisomerase II, and bacterial DNA gyrase inhibitor. 151096-09-2 ≥98% 401.43 C21H24FN3O4 COC1=C2C(=CC(=C1N3CC4CCCNC4C3)F)C(=O)C(=CN2C5CC5)C(=O)O Ambient 4°C "Wohlkonig A, Chan PF, Fosberry AP, et al. Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance. Nat Struct Mol Biol. 2010 Sep;17(9):1152-3. PMID: 20802486.

 

Reuveni D, Halperin D, Shalit I, et al. Moxifloxacin enhances etoposide-induced cytotoxic, apoptotic and anti-topoisomerase II effects in a human colon carcinoma cell line. Int J Oncol. 2010 Aug;37(2):463-71. PMID: 20596674.

 

Reuveni D, Halperin D, Fabian I, et al. Moxifloxacin increases anti-tumor and anti-angiogenic activity of irinotecan in human xenograft tumors. Biochem Pharmacol. 2010 Apr 15;79(8):1100-7. PMID: 20025849.

 

Laponogov I, Sohi MK, Veselkov DA, et al. Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases. Nat Struct Mol Biol. 2009 Jun;16(6):667-9. PMID: 19448616.

 

Stroman DW, Dajcs JJ, Cupp GA, et al. In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinolone. Surv Ophthalmol. 2005 Nov;50 Suppl 1:S16-31. PMID: 16257308.

 

Aldred KJ, McPherson SA, Wang P, et al. Drug interactions with Bacillus anthracis topoisomerase IV: biochemical basis for quinolone action and resistance. Biochemistry. 2012 Jan 10;51(1):370-381. PMID: 22126453." Not dangerous goods.

LKT M5793 Moxifloxacin Free Base 500 mg 475.7 Fluoroquinolone; topoisomerase IV, topoisomerase II, and bacterial DNA gyrase inhibitor. 151096-09-2 ≥98% 401.43 C21H24FN3O4 COC1=C2C(=CC(=C1N3CC4CCCNC4C3)F)C(=O)C(=CN2C5CC5)C(=O)O Ambient 4°C "Wohlkonig A, Chan PF, Fosberry AP, et al. Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance. Nat Struct Mol Biol. 2010 Sep;17(9):1152-3. PMID: 20802486.

 

Reuveni D, Halperin D, Shalit I, et al. Moxifloxacin enhances etoposide-induced cytotoxic, apoptotic and anti-topoisomerase II effects in a human colon carcinoma cell line. Int J Oncol. 2010 Aug;37(2):463-71. PMID: 20596674.

 

Reuveni D, Halperin D, Fabian I, et al. Moxifloxacin increases anti-tumor and anti-angiogenic activity of irinotecan in human xenograft tumors. Biochem Pharmacol. 2010 Apr 15;79(8):1100-7. PMID: 20025849.

 

Laponogov I, Sohi MK, Veselkov DA, et al. Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases. Nat Struct Mol Biol. 2009 Jun;16(6):667-9. PMID: 19448616.

 

Stroman DW, Dajcs JJ, Cupp GA, et al. In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinolone. Surv Ophthalmol. 2005 Nov;50 Suppl 1:S16-31. PMID: 16257308.

 

Aldred KJ, McPherson SA, Wang P, et al. Drug interactions with Bacillus anthracis topoisomerase IV: biochemical basis for quinolone action and resistance. Biochemistry. 2012 Jan 10;51(1):370-381. PMID: 22126453." Not dangerous goods.

LKT M5793 Moxifloxacin Free Base 1 g 611.5 Fluoroquinolone; topoisomerase IV, topoisomerase II, and bacterial DNA gyrase inhibitor. 151096-09-2 ≥98% 401.43 C21H24FN3O4 COC1=C2C(=CC(=C1N3CC4CCCNC4C3)F)C(=O)C(=CN2C5CC5)C(=O)O Ambient 4°C "Wohlkonig A, Chan PF, Fosberry AP, et al. Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance. Nat Struct Mol Biol. 2010 Sep;17(9):1152-3. PMID: 20802486.

 

Reuveni D, Halperin D, Shalit I, et al. Moxifloxacin enhances etoposide-induced cytotoxic, apoptotic and anti-topoisomerase II effects in a human colon carcinoma cell line. Int J Oncol. 2010 Aug;37(2):463-71. PMID: 20596674.

 

Reuveni D, Halperin D, Fabian I, et al. Moxifloxacin increases anti-tumor and anti-angiogenic activity of irinotecan in human xenograft tumors. Biochem Pharmacol. 2010 Apr 15;79(8):1100-7. PMID: 20025849.

 

Laponogov I, Sohi MK, Veselkov DA, et al. Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases. Nat Struct Mol Biol. 2009 Jun;16(6):667-9. PMID: 19448616.

 

Stroman DW, Dajcs JJ, Cupp GA, et al. In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinolone. Surv Ophthalmol. 2005 Nov;50 Suppl 1:S16-31. PMID: 16257308.

 

Aldred KJ, McPherson SA, Wang P, et al. Drug interactions with Bacillus anthracis topoisomerase IV: biochemical basis for quinolone action and resistance. Biochemistry. 2012 Jan 10;51(1):370-381. PMID: 22126453." Not dangerous goods.

LKT W0274 S-(−)-Warfarin Sodium >99%ee 1 mg 101.9 Coumarin, more potent isomer; VKORC1 inhibitor. ≥98% 330.31 C19H15NaO4 CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)[O-].[Na+] Ambient 4°C [a]D23 = -95° (c = 3.2, ethanol) "Hall AM, Wilkins MR. Warfarin: a case history in pharmacogenetics. Heart. 2005 May;91(5):563-4. PMID: 15831631.

 

Tabrizi AR, Zehnbauer BA, Borecki IB, et al. The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin. J Am Coll Surg. 2002 Mar;194(3):267-73. PMID: 11893129.

 

Freedman MD. Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects. J Clin Pharmacol. 1992 Mar;32(3):196-209. PMID:1564123.

 

Wallin R, Martin LF. Vitamin K-dependent carboxylation and vitamin K metabolism in liver. Effects of warfarin. J Clin Invest. 1985 Nov;76(5):1879-84. PMID: 3932474.

 

Suttie JW. Mechanism of action of vitamin K: demonstration of a liver precursor of prothrombin. Science. 1973 Jan 12;179(4069):192-4. PMID: 4682251.

" "UN number: 2811     Class: 6.1     Packing Group: I

Proper shipping name: Toxic solid, organic, n.o.s. ((S)-(-)-Warfarin sodium)"

LKT W0274 S-(−)-Warfarin Sodium >99%ee 5 mg 407.7 Coumarin, more potent isomer; VKORC1 inhibitor. ≥98% 330.31 C19H15NaO4 CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)[O-].[Na+] Ambient 4°C [a]D23 = -95° (c = 3.2, ethanol) "Hall AM, Wilkins MR. Warfarin: a case history in pharmacogenetics. Heart. 2005 May;91(5):563-4. PMID: 15831631.

 

Tabrizi AR, Zehnbauer BA, Borecki IB, et al. The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin. J Am Coll Surg. 2002 Mar;194(3):267-73. PMID: 11893129.

 

Freedman MD. Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects. J Clin Pharmacol. 1992 Mar;32(3):196-209. PMID:1564123.

 

Wallin R, Martin LF. Vitamin K-dependent carboxylation and vitamin K metabolism in liver. Effects of warfarin. J Clin Invest. 1985 Nov;76(5):1879-84. PMID: 3932474.

 

Suttie JW. Mechanism of action of vitamin K: demonstration of a liver precursor of prothrombin. Science. 1973 Jan 12;179(4069):192-4. PMID: 4682251.

" "UN number: 2811     Class: 6.1     Packing Group: I

Proper shipping name: Toxic solid, organic, n.o.s. ((S)-(-)-Warfarin sodium)"

LKT W0274 S-(−)-Warfarin Sodium >99%ee 25 mg 1291 Coumarin, more potent isomer; VKORC1 inhibitor. ≥98% 330.31 C19H15NaO4 CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)[O-].[Na+] Ambient 4°C [a]D23 = -95° (c = 3.2, ethanol) "Hall AM, Wilkins MR. Warfarin: a case history in pharmacogenetics. Heart. 2005 May;91(5):563-4. PMID: 15831631.

 

Tabrizi AR, Zehnbauer BA, Borecki IB, et al. The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin. J Am Coll Surg. 2002 Mar;194(3):267-73. PMID: 11893129.

 

Freedman MD. Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects. J Clin Pharmacol. 1992 Mar;32(3):196-209. PMID:1564123.

 

Wallin R, Martin LF. Vitamin K-dependent carboxylation and vitamin K metabolism in liver. Effects of warfarin. J Clin Invest. 1985 Nov;76(5):1879-84. PMID: 3932474.

 

Suttie JW. Mechanism of action of vitamin K: demonstration of a liver precursor of prothrombin. Science. 1973 Jan 12;179(4069):192-4. PMID: 4682251.

" "UN number: 2811     Class: 6.1     Packing Group: I

Proper shipping name: Toxic solid, organic, n.o.s. ((S)-(-)-Warfarin sodium)"

LKT W0275 R-(+)-Warfarin Sodium >99%ee 1 mg 81.6 Coumarin; VKORC1 inhibitor. ≥98% 330.31 C19H15NaO4 CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)[O-].[Na+] Ambient 4°C [a]D23 = +125° (c = 3.2, ethanol) Water "Hall AM, Wilkins MR. Warfarin: a case history in pharmacogenetics. Heart. 2005 May;91(5):563-4. PMID: 15831631.

 

Tabrizi AR, Zehnbauer BA, Borecki IB, et al. The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin. J Am Coll Surg. 2002 Mar;194(3):267-73. PMID: 11893129.

 

Freedman MD. Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects. J Clin Pharmacol. 1992 Mar;32(3):196-209. PMID:1564123.

 

Wallin R, Martin LF. Vitamin K-dependent carboxylation and vitamin K metabolism in liver. Effects of warfarin. J Clin Invest. 1985 Nov;76(5):1879-84. PMID: 3932474.

 

Suttie JW. Mechanism of action of vitamin K: demonstration of a liver precursor of prothrombin. Science. 1973 Jan 12;179(4069):192-4. PMID: 4682251.

" "UN number: 2811     Class: 6.1     Packing Group: I

Proper shipping name: Toxic solid, organic, n.o.s. ((R)-(+)-Warfarin sodium)"

LKT W0275 R-(+)-Warfarin Sodium >99%ee 5 mg 339.8 Coumarin; VKORC1 inhibitor. ≥98% 330.31 C19H15NaO4 CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)[O-].[Na+] Ambient 4°C [a]D23 = +125° (c = 3.2, ethanol) Water "Hall AM, Wilkins MR. Warfarin: a case history in pharmacogenetics. Heart. 2005 May;91(5):563-4. PMID: 15831631.

 

Tabrizi AR, Zehnbauer BA, Borecki IB, et al. The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin. J Am Coll Surg. 2002 Mar;194(3):267-73. PMID: 11893129.

 

Freedman MD. Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects. J Clin Pharmacol. 1992 Mar;32(3):196-209. PMID:1564123.

 

Wallin R, Martin LF. Vitamin K-dependent carboxylation and vitamin K metabolism in liver. Effects of warfarin. J Clin Invest. 1985 Nov;76(5):1879-84. PMID: 3932474.

 

Suttie JW. Mechanism of action of vitamin K: demonstration of a liver precursor of prothrombin. Science. 1973 Jan 12;179(4069):192-4. PMID: 4682251.

" "UN number: 2811     Class: 6.1     Packing Group: I

Proper shipping name: Toxic solid, organic, n.o.s. ((R)-(+)-Warfarin sodium)"

LKT W0275 R-(+)-Warfarin Sodium >99%ee 25 mg 1019.2 Coumarin; VKORC1 inhibitor. ≥98% 330.31 C19H15NaO4 CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)[O-].[Na+] Ambient 4°C [a]D23 = +125° (c = 3.2, ethanol) Water "Hall AM, Wilkins MR. Warfarin: a case history in pharmacogenetics. Heart. 2005 May;91(5):563-4. PMID: 15831631.

 

Tabrizi AR, Zehnbauer BA, Borecki IB, et al. The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin. J Am Coll Surg. 2002 Mar;194(3):267-73. PMID: 11893129.

 

Freedman MD. Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects. J Clin Pharmacol. 1992 Mar;32(3):196-209. PMID:1564123.

 

Wallin R, Martin LF. Vitamin K-dependent carboxylation and vitamin K metabolism in liver. Effects of warfarin. J Clin Invest. 1985 Nov;76(5):1879-84. PMID: 3932474.

 

Suttie JW. Mechanism of action of vitamin K: demonstration of a liver precursor of prothrombin. Science. 1973 Jan 12;179(4069):192-4. PMID: 4682251.

" "UN number: 2811     Class: 6.1     Packing Group: I

Proper shipping name: Toxic solid, organic, n.o.s. ((R)-(+)-Warfarin sodium)"

LKT P4780 Plumbagin 100 mg 36.4 Naphthoquinone found in Plumbago. 481-42-5 ≥98% 188.18 C11H8O3 CC1=CC(=O)C2=C(C1=O)C=CC=C2O Ambient Ambient "Sagar S, Esau L, Moosa B, et al. Cytotoxicity and Apoptosis Induced by a Plumbagin Derivative in Estrogen Positive MCF-7 Breast Cancer Cells. Anticancer Agents Med Chem. 2013 Oct 21. [Epub ahead of print]. PMID: 24164046.

 

Yong R, Chen XM, Shen S, et al. Plumbagin ameliorates diabetic nephropathy via interruption of pathways that include NOX4 signalling. PLoS One. 2013 Aug 26;8(8):e73428. PMID: 23991195.

 

Qiu JX, He YQ, Wang Y, et al. Plumbagin induces the apoptosis of human tongue carcinoma cells through the mitochondria-mediated pathway. Med Sci Monit Basic Res. 2013 Aug 28;19:228-36. PMID: 23982457.

 

Bhattacharya A, Jindal B, Singh P, et al. Plumbagin inhibits cytokinesis in Bacillus subtilis by inhibiting FtsZ assembly--a mechanistic study of its antibacterial activity. FEBS J. 2013 Sep;280(18):4585-99. PMID: 23841620.

 

Pile JE, Navalta JW, Davis CD, et al. Interventional effects of plumbagin on experimental ulcerative colitis in mice. J Nat Prod. 2013 Jun 28;76(6):1001-6. PMID: 23742275.

 

Xu TP, Shen H, Liu LX, et al. Plumbagin from Plumbago Zeylanica L induces apoptosis in human non-small cell lung cancer cell lines through NF-κB inactivation. Asian Pac J Cancer Prev. 2013;14(4):2325-31. PMID: 23725135.

" "UN number: 2923     Class: 8     Packing Group: II

Proper shipping name: Corrosive solid, toxic, n.o.s. (Plumbagin)"

LKT P4780 Plumbagin 250 mg 46.1 Naphthoquinone found in Plumbago. 481-42-5 ≥98% 188.18 C11H8O3 CC1=CC(=O)C2=C(C1=O)C=CC=C2O Ambient Ambient "Sagar S, Esau L, Moosa B, et al. Cytotoxicity and Apoptosis Induced by a Plumbagin Derivative in Estrogen Positive MCF-7 Breast Cancer Cells. Anticancer Agents Med Chem. 2013 Oct 21. [Epub ahead of print]. PMID: 24164046.

 

Yong R, Chen XM, Shen S, et al. Plumbagin ameliorates diabetic nephropathy via interruption of pathways that include NOX4 signalling. PLoS One. 2013 Aug 26;8(8):e73428. PMID: 23991195.

 

Qiu JX, He YQ, Wang Y, et al. Plumbagin induces the apoptosis of human tongue carcinoma cells through the mitochondria-mediated pathway. Med Sci Monit Basic Res. 2013 Aug 28;19:228-36. PMID: 23982457.

 

Bhattacharya A, Jindal B, Singh P, et al. Plumbagin inhibits cytokinesis in Bacillus subtilis by inhibiting FtsZ assembly--a mechanistic study of its antibacterial activity. FEBS J. 2013 Sep;280(18):4585-99. PMID: 23841620.

 

Pile JE, Navalta JW, Davis CD, et al. Interventional effects of plumbagin on experimental ulcerative colitis in mice. J Nat Prod. 2013 Jun 28;76(6):1001-6. PMID: 23742275.

 

Xu TP, Shen H, Liu LX, et al. Plumbagin from Plumbago Zeylanica L induces apoptosis in human non-small cell lung cancer cell lines through NF-κB inactivation. Asian Pac J Cancer Prev. 2013;14(4):2325-31. PMID: 23725135.

" "UN number: 2923     Class: 8     Packing Group: II

Proper shipping name: Corrosive solid, toxic, n.o.s. (Plumbagin)"

LKT P4780 Plumbagin 1 g 118.9 Naphthoquinone found in Plumbago. 481-42-5 ≥98% 188.18 C11H8O3 CC1=CC(=O)C2=C(C1=O)C=CC=C2O Ambient Ambient "Sagar S, Esau L, Moosa B, et al. Cytotoxicity and Apoptosis Induced by a Plumbagin Derivative in Estrogen Positive MCF-7 Breast Cancer Cells. Anticancer Agents Med Chem. 2013 Oct 21. [Epub ahead of print]. PMID: 24164046.

 

Yong R, Chen XM, Shen S, et al. Plumbagin ameliorates diabetic nephropathy via interruption of pathways that include NOX4 signalling. PLoS One. 2013 Aug 26;8(8):e73428. PMID: 23991195.

 

Qiu JX, He YQ, Wang Y, et al. Plumbagin induces the apoptosis of human tongue carcinoma cells through the mitochondria-mediated pathway. Med Sci Monit Basic Res. 2013 Aug 28;19:228-36. PMID: 23982457.

 

Bhattacharya A, Jindal B, Singh P, et al. Plumbagin inhibits cytokinesis in Bacillus subtilis by inhibiting FtsZ assembly--a mechanistic study of its antibacterial activity. FEBS J. 2013 Sep;280(18):4585-99. PMID: 23841620.

 

Pile JE, Navalta JW, Davis CD, et al. Interventional effects of plumbagin on experimental ulcerative colitis in mice. J Nat Prod. 2013 Jun 28;76(6):1001-6. PMID: 23742275.

 

Xu TP, Shen H, Liu LX, et al. Plumbagin from Plumbago Zeylanica L induces apoptosis in human non-small cell lung cancer cell lines through NF-κB inactivation. Asian Pac J Cancer Prev. 2013;14(4):2325-31. PMID: 23725135.

" "UN number: 2923     Class: 8     Packing Group: II

Proper shipping name: Corrosive solid, toxic, n.o.s. (Plumbagin)"

LKT T0253 Tangeretin 5 mg 149.5 Polymethoxy flavonoid found in citrus fruits. Tangeritin, 4',5,6,7,8-Pentamethoxyflavone 481-53-8 ≥98% 372.37 C20H20O7 COC1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C(=C(C(=C3OC)OC)OC)OC Ambient Ambient "Jang SE, Ryu KR, Park SH, et al. Nobiletin and tangeretin ameliorate scratching behavior in mice by inhibiting the action of histamine and the activation of NF-κB, AP-1 and p38. Int Immunopharmacol. 2013 Aug 9;17(3):502-507. PMID: 23938254.

 

Tominari T, Hirata M, Matsumoto C, et al. Polymethoxy flavonoids, nobiletin and tangeretin, prevent lipopolysaccharide-induced inflammatory bone loss in an experimental model for periodontitis. J Pharmacol Sci. 2012;119(4):390-4. PMID: 22850615.

 

Kim MS, Hur HJ, Kwon DY, et al. Tangeretin stimulates glucose uptake via regulation of AMPK signaling pathways in C2C12 myotubes and improves glucose tolerance in high-fat diet-induced obese mice. Mol Cell Endocrinol. 2012 Jul 6;358(1):127-34. PMID: 22476082.

 

Morley KL, Ferguson PJ, Koropatnick J. Tangeretin and nobiletin induce G1 cell cycle arrest but not apoptosis in human breast and colon cancer cells. Cancer Lett. 2007 Jun 18;251(1):168-78. PMID: 17197076." "UN number: 2811     Class: 6.1     Packing Group: II

Proper shipping name: Toxic solid, organic, n.o.s. (Tangeretin)"

LKT T0253 Tangeretin 10 mg 279.1 Polymethoxy flavonoid found in citrus fruits. Tangeritin, 4',5,6,7,8-Pentamethoxyflavone 481-53-8 ≥98% 372.37 C20H20O7 COC1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C(=C(C(=C3OC)OC)OC)OC Ambient Ambient "Jang SE, Ryu KR, Park SH, et al. Nobiletin and tangeretin ameliorate scratching behavior in mice by inhibiting the action of histamine and the activation of NF-κB, AP-1 and p38. Int Immunopharmacol. 2013 Aug 9;17(3):502-507. PMID: 23938254.

 

Tominari T, Hirata M, Matsumoto C, et al. Polymethoxy flavonoids, nobiletin and tangeretin, prevent lipopolysaccharide-induced inflammatory bone loss in an experimental model for periodontitis. J Pharmacol Sci. 2012;119(4):390-4. PMID: 22850615.

 

Kim MS, Hur HJ, Kwon DY, et al. Tangeretin stimulates glucose uptake via regulation of AMPK signaling pathways in C2C12 myotubes and improves glucose tolerance in high-fat diet-induced obese mice. Mol Cell Endocrinol. 2012 Jul 6;358(1):127-34. PMID: 22476082.

 

Morley KL, Ferguson PJ, Koropatnick J. Tangeretin and nobiletin induce G1 cell cycle arrest but not apoptosis in human breast and colon cancer cells. Cancer Lett. 2007 Jun 18;251(1):168-78. PMID: 17197076." "UN number: 2811     Class: 6.1     Packing Group: II

Proper shipping name: Toxic solid, organic, n.o.s. (Tangeretin)"

LKT X0254 Xanthohumol 5 mg 237.8 Prenylated flavonoid found in Humulus lupulus. (E)-1-[2,4-dihydroxy-6-methoxy-3-(3-methylbut-2-enyl)phenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one 6754-58-1 ≥98% 354.4 C21H22O5 CC(=CCC1=C(C=C(C(=C1O)C(=O)C=CC2=CC=C(C=C2)O)OC)O)C ambient 4°C "Kunnimalaiyaan S, Sokolowski KM, Balamurugan M, et al. Xanthohumol inhibits notch signaling and induces apoptosis in hepatocellular carcinoma. PLoS One. 2015 May 26;10(5):e0127464. PMID: 26011160.

 

Suh KS, Rhee SY, Kim YS, et al. Xanthohumol modulates the expression of osteoclast-specific genes during osteoclastogenesis in RAW264.7 cells. Food Chem Toxicol. 2013 Aug 27. [Epub ahead of print] PMID: 23994090.

 

Doddapattar P, Radović B, Patankar JV, et al. Xanthohumol ameliorates atherosclerotic plaque formation, hypercholesterolemia, and hepatic steatosis in ApoE-deficient mice. Mol Nutr Food Res. 2013 May 3. [Epub ahead of print] PMID: 23650230.

 

Viola K, Kopf S, Rarova L, et al. Xanthohumol attenuates tumour cell-mediated breaching of the lymphendothelial barrier and prevents intravasation and metastasis. Arch Toxicol. 2013 Jul;87(7):1301-12. PMID: 23503627.

 

Yen TL, Hsu CK, Lu WJ, et al. Neuroprotective effects of xanthohumol, a prenylated flavonoid from hops (Humulus lupulus), in ischemic stroke of rats. J Agric Food Chem. 2012 Feb 29;60(8):1937-44. PMID: 22300539.

 

Monteiro R, Calhau C, Silva AO, et al. Xanthohumol inhibits inflammatory factor production and angiogenesis in breast cancer xenografts. J Cell Biochem. 2008 Aug 1;104(5):1699-707. PMID: 18348194.

 

Yang JY, Della-Fera MA, Rayalam S, et al. Effect of xanthohumol and isoxanthohumol on 3T3-L1 cell apoptosis and adipogenesis. Apoptosis. 2007 Nov;12(11):1953-63. PMID: 17874298." "UN number: 3077     Class: 9     Packing Group: III

Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (Xanthohumol)"

LKT X0254 Xanthohumol 10 mg 434.9 Prenylated flavonoid found in Humulus lupulus. (E)-1-[2,4-dihydroxy-6-methoxy-3-(3-methylbut-2-enyl)phenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one 6754-58-1 ≥98% 354.4 C21H22O5 CC(=CCC1=C(C=C(C(=C1O)C(=O)C=CC2=CC=C(C=C2)O)OC)O)C ambient 4°C "Kunnimalaiyaan S, Sokolowski KM, Balamurugan M, et al. Xanthohumol inhibits notch signaling and induces apoptosis in hepatocellular carcinoma. PLoS One. 2015 May 26;10(5):e0127464. PMID: 26011160.

 

Suh KS, Rhee SY, Kim YS, et al. Xanthohumol modulates the expression of osteoclast-specific genes during osteoclastogenesis in RAW264.7 cells. Food Chem Toxicol. 2013 Aug 27. [Epub ahead of print] PMID: 23994090.

 

Doddapattar P, Radović B, Patankar JV, et al. Xanthohumol ameliorates atherosclerotic plaque formation, hypercholesterolemia, and hepatic steatosis in ApoE-deficient mice. Mol Nutr Food Res. 2013 May 3. [Epub ahead of print] PMID: 23650230.

 

Viola K, Kopf S, Rarova L, et al. Xanthohumol attenuates tumour cell-mediated breaching of the lymphendothelial barrier and prevents intravasation and metastasis. Arch Toxicol. 2013 Jul;87(7):1301-12. PMID: 23503627.

 

Yen TL, Hsu CK, Lu WJ, et al. Neuroprotective effects of xanthohumol, a prenylated flavonoid from hops (Humulus lupulus), in ischemic stroke of rats. J Agric Food Chem. 2012 Feb 29;60(8):1937-44. PMID: 22300539.

 

Monteiro R, Calhau C, Silva AO, et al. Xanthohumol inhibits inflammatory factor production and angiogenesis in breast cancer xenografts. J Cell Biochem. 2008 Aug 1;104(5):1699-707. PMID: 18348194.

 

Yang JY, Della-Fera MA, Rayalam S, et al. Effect of xanthohumol and isoxanthohumol on 3T3-L1 cell apoptosis and adipogenesis. Apoptosis. 2007 Nov;12(11):1953-63. PMID: 17874298." "UN number: 3077     Class: 9     Packing Group: III

Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (Xanthohumol)"

LKT X0254 Xanthohumol 25 mg 849.3 Prenylated flavonoid found in Humulus lupulus. (E)-1-[2,4-dihydroxy-6-methoxy-3-(3-methylbut-2-enyl)phenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one 6754-58-1 ≥98% 354.4 C21H22O5 CC(=CCC1=C(C=C(C(=C1O)C(=O)C=CC2=CC=C(C=C2)O)OC)O)C ambient 4°C "Kunnimalaiyaan S, Sokolowski KM, Balamurugan M, et al. Xanthohumol inhibits notch signaling and induces apoptosis in hepatocellular carcinoma. PLoS One. 2015 May 26;10(5):e0127464. PMID: 26011160.

 

Suh KS, Rhee SY, Kim YS, et al. Xanthohumol modulates the expression of osteoclast-specific genes during osteoclastogenesis in RAW264.7 cells. Food Chem Toxicol. 2013 Aug 27. [Epub ahead of print] PMID: 23994090.

 

Doddapattar P, Radović B, Patankar JV, et al. Xanthohumol ameliorates atherosclerotic plaque formation, hypercholesterolemia, and hepatic steatosis in ApoE-deficient mice. Mol Nutr Food Res. 2013 May 3. [Epub ahead of print] PMID: 23650230.

 

Viola K, Kopf S, Rarova L, et al. Xanthohumol attenuates tumour cell-mediated breaching of the lymphendothelial barrier and prevents intravasation and metastasis. Arch Toxicol. 2013 Jul;87(7):1301-12. PMID: 23503627.

 

Yen TL, Hsu CK, Lu WJ, et al. Neuroprotective effects of xanthohumol, a prenylated flavonoid from hops (Humulus lupulus), in ischemic stroke of rats. J Agric Food Chem. 2012 Feb 29;60(8):1937-44. PMID: 22300539.

 

Monteiro R, Calhau C, Silva AO, et al. Xanthohumol inhibits inflammatory factor production and angiogenesis in breast cancer xenografts. J Cell Biochem. 2008 Aug 1;104(5):1699-707. PMID: 18348194.

 

Yang JY, Della-Fera MA, Rayalam S, et al. Effect of xanthohumol and isoxanthohumol on 3T3-L1 cell apoptosis and adipogenesis. Apoptosis. 2007 Nov;12(11):1953-63. PMID: 17874298." "UN number: 3077     Class: 9     Packing Group: III

Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (Xanthohumol)"

LKT L3456 γ-Linolenic Acid (6c, 9c, 12c) 10 mg 65.3 Omega-6 fatty acid found in vegetable oils; PPAR agonist. gamma-Linolenic acid,  cis,cis,cis-6,9,12-Octadecatrienoic acid; GLA 506-26-3 ≥98% 278.43 C18H30O2 CCCCCC=CCC=CCC=CCCCCC(=O)O Ambient -20°C "Lai MC, Teng TH, Yang C. The Natural PPAR Agonist Linoleic Acid Stimulated Insulin Release in Rat Pancreas. J Vet Med Sci. 2013 Jul 5. [Epub ahead of print] PMID: 23832628.

 

Kim DH, Yoo TH, Lee SH, et al. Gamma linolenic acid exerts anti-inflammatory and anti-fibrotic effects in diabetic nephropathy. Yonsei Med J. 2012 Nov 1;53(6):1165-75. PMID: 23074118.

 

Das UN. Tumoricidal and anti-angiogenic actions of gamma-linolenic acid and its derivatives. Curr Pharm Biotechnol. 2006 Dec;7(6):457-66. PMID: 17168663.

 

Kong X, Ge H, Hou L, et al. Induction of apoptosis in K562/ADM cells by gamma-linolenic acid involves lipid peroxidation and activation of caspase-3. Chem Biol Interact. 2006 Aug 25;162(2):140-8. PMID: 16857180.

 

Jung KC, Park CH, Hwang YH, et al. Fatty acids, inhibitors for the DNA binding of c-Myc/Max dimer, suppress proliferation and induce apoptosis of differentiated HL-60 human leukemia cell. Leukemia. 2006 Jan;20(1):122-7. PMID: 16281068.

 

Andreassi M, Forleo P, Di Lorio A, et al. Efficacy of gamma-linolenic acid in the treatment of patients with atopic dermatitis. J Int Med Res. 1997 Sep-Oct;25(5):266-74. PMID: 9364289.

" Not dangerous goods.

LKT L3456 γ-Linolenic Acid (6c, 9c, 12c) 25 mg 115.5 Omega-6 fatty acid found in vegetable oils; PPAR agonist. gamma-Linolenic acid,  cis,cis,cis-6,9,12-Octadecatrienoic acid; GLA 506-26-3 ≥98% 278.43 C18H30O2 CCCCCC=CCC=CCC=CCCCCC(=O)O Ambient -20°C "Lai MC, Teng TH, Yang C. The Natural PPAR Agonist Linoleic Acid Stimulated Insulin Release in Rat Pancreas. J Vet Med Sci. 2013 Jul 5. [Epub ahead of print] PMID: 23832628.

 

Kim DH, Yoo TH, Lee SH, et al. Gamma linolenic acid exerts anti-inflammatory and anti-fibrotic effects in diabetic nephropathy. Yonsei Med J. 2012 Nov 1;53(6):1165-75. PMID: 23074118.

 

Das UN. Tumoricidal and anti-angiogenic actions of gamma-linolenic acid and its derivatives. Curr Pharm Biotechnol. 2006 Dec;7(6):457-66. PMID: 17168663.

 

Kong X, Ge H, Hou L, et al. Induction of apoptosis in K562/ADM cells by gamma-linolenic acid involves lipid peroxidation and activation of caspase-3. Chem Biol Interact. 2006 Aug 25;162(2):140-8. PMID: 16857180.

 

Jung KC, Park CH, Hwang YH, et al. Fatty acids, inhibitors for the DNA binding of c-Myc/Max dimer, suppress proliferation and induce apoptosis of differentiated HL-60 human leukemia cell. Leukemia. 2006 Jan;20(1):122-7. PMID: 16281068.

 

Andreassi M, Forleo P, Di Lorio A, et al. Efficacy of gamma-linolenic acid in the treatment of patients with atopic dermatitis. J Int Med Res. 1997 Sep-Oct;25(5):266-74. PMID: 9364289.

" Not dangerous goods.

LKT L3456 γ-Linolenic Acid (6c, 9c, 12c) 100 mg 339.8 Omega-6 fatty acid found in vegetable oils; PPAR agonist. gamma-Linolenic acid,  cis,cis,cis-6,9,12-Octadecatrienoic acid; GLA 506-26-3 ≥98% 278.43 C18H30O2 CCCCCC=CCC=CCC=CCCCCC(=O)O Ambient -20°C "Lai MC, Teng TH, Yang C. The Natural PPAR Agonist Linoleic Acid Stimulated Insulin Release in Rat Pancreas. J Vet Med Sci. 2013 Jul 5. [Epub ahead of print] PMID: 23832628.

 

Kim DH, Yoo TH, Lee SH, et al. Gamma linolenic acid exerts anti-inflammatory and anti-fibrotic effects in diabetic nephropathy. Yonsei Med J. 2012 Nov 1;53(6):1165-75. PMID: 23074118.

 

Das UN. Tumoricidal and anti-angiogenic actions of gamma-linolenic acid and its derivatives. Curr Pharm Biotechnol. 2006 Dec;7(6):457-66. PMID: 17168663.

 

Kong X, Ge H, Hou L, et al. Induction of apoptosis in K562/ADM cells by gamma-linolenic acid involves lipid peroxidation and activation of caspase-3. Chem Biol Interact. 2006 Aug 25;162(2):140-8. PMID: 16857180.

 

Jung KC, Park CH, Hwang YH, et al. Fatty acids, inhibitors for the DNA binding of c-Myc/Max dimer, suppress proliferation and induce apoptosis of differentiated HL-60 human leukemia cell. Leukemia. 2006 Jan;20(1):122-7. PMID: 16281068.

 

Andreassi M, Forleo P, Di Lorio A, et al. Efficacy of gamma-linolenic acid in the treatment of patients with atopic dermatitis. J Int Med Res. 1997 Sep-Oct;25(5):266-74. PMID: 9364289.

" Not dangerous goods.

LKT B1973 Besifloxacin Hydrochloride 25 mg 88.3 Fluoroquinolone; topoisomerase IV and bacterial DNA gyrase inhibitor. 7-[(3R) -3-aminoazepam- 1-yl]- 8-chloro- 1-cyclopropyl- 6-fluoro- 4-oxo- 1,4- dihydroquinoline- 3-carboxylic acid hydrochloride 405165-61-9 ≥98% 430.31 C19H22ClFN3O3 HCl C1CCN(CC(C1)N)C2=C(C=C3C(=C2Cl)N(C=C(C3=O)C(=O)O)C4CC4)F.Cl Ambient -20°C Sparingly soluble in water (1 mg/mL), DMSO (<1 mg/mL) "Miller D, Chang JS, Flynn HW, et al. Comparative in vitro susceptibility of besifloxacin and seven comparators against ciprofloxacin- and methicillin-susceptible/nonsusceptible staphylococci. J Ocul Pharmacol Ther. 2013 Apr;29(3):339-44. PMID: 23289847.

 

Lan W, Petznick A, Heryati S, et al. Nuclear Factor-κB: central regulator in ocular surface inflammation and diseases. Ocul Surf. 2012 Jul;10(3):137-48. PMID: 22814642.

 

Cambau E, Matrat S, Pan XS, et al. Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli. J Antimicrob Chemother. 2009 Mar;63(3):443-50. PMID: 19147516.

 

Zhang JZ, Ward KW. Besifloxacin, a novel fluoroquinolone antimicrobial agent, exhibits potent inhibition of pro-inflammatory cytokines in human THP-1 monocytes. J Antimicrob Chemother. 2008 Jan;61(1):111-6. PMID: 17965029.

" Not dangerous goods.

LKT B1973 Besifloxacin Hydrochloride 100 mg 169.9 Fluoroquinolone; topoisomerase IV and bacterial DNA gyrase inhibitor. 7-[(3R) -3-aminoazepam- 1-yl]- 8-chloro- 1-cyclopropyl- 6-fluoro- 4-oxo- 1,4- dihydroquinoline- 3-carboxylic acid hydrochloride 405165-61-9 ≥98% 430.31 C19H22ClFN3O3 HCl C1CCN(CC(C1)N)C2=C(C=C3C(=C2Cl)N(C=C(C3=O)C(=O)O)C4CC4)F.Cl Ambient -20°C Sparingly soluble in water (1 mg/mL), DMSO (<1 mg/mL) "Miller D, Chang JS, Flynn HW, et al. Comparative in vitro susceptibility of besifloxacin and seven comparators against ciprofloxacin- and methicillin-susceptible/nonsusceptible staphylococci. J Ocul Pharmacol Ther. 2013 Apr;29(3):339-44. PMID: 23289847.

 

Lan W, Petznick A, Heryati S, et al. Nuclear Factor-κB: central regulator in ocular surface inflammation and diseases. Ocul Surf. 2012 Jul;10(3):137-48. PMID: 22814642.

 

Cambau E, Matrat S, Pan XS, et al. Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli. J Antimicrob Chemother. 2009 Mar;63(3):443-50. PMID: 19147516.

 

Zhang JZ, Ward KW. Besifloxacin, a novel fluoroquinolone antimicrobial agent, exhibits potent inhibition of pro-inflammatory cytokines in human THP-1 monocytes. J Antimicrob Chemother. 2008 Jan;61(1):111-6. PMID: 17965029.

" Not dangerous goods.

LKT B1973 Besifloxacin Hydrochloride 250 mg 271.7 Fluoroquinolone; topoisomerase IV and bacterial DNA gyrase inhibitor. 7-[(3R) -3-aminoazepam- 1-yl]- 8-chloro- 1-cyclopropyl- 6-fluoro- 4-oxo- 1,4- dihydroquinoline- 3-carboxylic acid hydrochloride 405165-61-9 ≥98% 430.31 C19H22ClFN3O3 HCl C1CCN(CC(C1)N)C2=C(C=C3C(=C2Cl)N(C=C(C3=O)C(=O)O)C4CC4)F.Cl Ambient -20°C Sparingly soluble in water (1 mg/mL), DMSO (<1 mg/mL) "Miller D, Chang JS, Flynn HW, et al. Comparative in vitro susceptibility of besifloxacin and seven comparators against ciprofloxacin- and methicillin-susceptible/nonsusceptible staphylococci. J Ocul Pharmacol Ther. 2013 Apr;29(3):339-44. PMID: 23289847.

 

Lan W, Petznick A, Heryati S, et al. Nuclear Factor-κB: central regulator in ocular surface inflammation and diseases. Ocul Surf. 2012 Jul;10(3):137-48. PMID: 22814642.

 

Cambau E, Matrat S, Pan XS, et al. Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli. J Antimicrob Chemother. 2009 Mar;63(3):443-50. PMID: 19147516.

 

Zhang JZ, Ward KW. Besifloxacin, a novel fluoroquinolone antimicrobial agent, exhibits potent inhibition of pro-inflammatory cytokines in human THP-1 monocytes. J Antimicrob Chemother. 2008 Jan;61(1):111-6. PMID: 17965029.

" Not dangerous goods.

LKT A0916 Acepromazine Maleate 25 mg 88.3 Phenothiazine derivative; D1/2 and 5-HT1A/2A antagonist. 3598-37-6 ≥98% 442.53 C19H22N2OS C4H4O4 CC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN(C)C Ambient Ambient Water (>10 mg/mL) "Monteiro ER, Teixeira Neto FJ, et al. Effects of acepromazine on the cardiovascular actions of dopamine in anesthetized dogs. Vet Anaesth Analg. 2007 Sep;34(5):312-21. PMID: 17686118.

 

Harrigan T, Bureau YR, Persinger MA, et al. Prevention of sudden cardiac death by the atypical neuroleptic acepromazine following status epilepticus in rats. Life Sci. 1994;54(24):PL457-62. PMID: 8196501.

 

Wirth W, Goesswald R, Vater W. On the pharmacology of acylated phenothiazine derivatives. Arch Int Pharmacodyn Ther. 1959 Dec 1;123:78-114. PMID: 13845370." Not dangerous goods.

LKT A0916 Acepromazine Maleate 100 mg 169.9 Phenothiazine derivative; D1/2 and 5-HT1A/2A antagonist. 3598-37-6 ≥98% 442.53 C19H22N2OS C4H4O4 CC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN(C)C Ambient Ambient Water (>10 mg/mL) "Monteiro ER, Teixeira Neto FJ, et al. Effects of acepromazine on the cardiovascular actions of dopamine in anesthetized dogs. Vet Anaesth Analg. 2007 Sep;34(5):312-21. PMID: 17686118.

 

Harrigan T, Bureau YR, Persinger MA, et al. Prevention of sudden cardiac death by the atypical neuroleptic acepromazine following status epilepticus in rats. Life Sci. 1994;54(24):PL457-62. PMID: 8196501.

 

Wirth W, Goesswald R, Vater W. On the pharmacology of acylated phenothiazine derivatives. Arch Int Pharmacodyn Ther. 1959 Dec 1;123:78-114. PMID: 13845370." Not dangerous goods.

LKT A0916 Acepromazine Maleate 250 mg 271.7 Phenothiazine derivative; D1/2 and 5-HT1A/2A antagonist. 3598-37-6 ≥98% 442.53 C19H22N2OS C4H4O4 CC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN(C)C Ambient Ambient Water (>10 mg/mL) "Monteiro ER, Teixeira Neto FJ, et al. Effects of acepromazine on the cardiovascular actions of dopamine in anesthetized dogs. Vet Anaesth Analg. 2007 Sep;34(5):312-21. PMID: 17686118.

 

Harrigan T, Bureau YR, Persinger MA, et al. Prevention of sudden cardiac death by the atypical neuroleptic acepromazine following status epilepticus in rats. Life Sci. 1994;54(24):PL457-62. PMID: 8196501.

 

Wirth W, Goesswald R, Vater W. On the pharmacology of acylated phenothiazine derivatives. Arch Int Pharmacodyn Ther. 1959 Dec 1;123:78-114. PMID: 13845370." Not dangerous goods.

LKT D5611 Docosahexaenoic Acid (all cis-4,7,10,13,16,19) Methyl Ester 25 mg 61.1 Essential fatty acid found in fish oil, involved in prostaglandin synthesis. all cis-4,7,10,13,16,19-Docosahxaenoic acid methyl ester; DHA methyl ester ≥99% 342.51 C23H34O2 Ambient -20°C "Tapiero H, Ba GN, Couvreur P, et al. Polyunsaturated fatty acids (PUFA) and eicosanoids in human health and pathologies. Biomed Pharmacother. 2002 Jul;56(5):215-22. PMID: 12199620.

 

Hu PC, Chen BH. Effects of riboflavin and fatty acid methyl esters on cholesterol oxidation during illumination. J Agric Food Chem. 2002 Jun 5;50(12):3572-8. PMID: 12033831.

 

Liu W, Wang HJ, Wang LP, et al. Formation of high-molecular-weight protein adducts by methyl docosahexaenoate peroxidation products. Biochim Biophys Acta. 2007 Feb;1774(2):258-66. PMID: 17207667.

" Not dangerous goods.

LKT D5611 Docosahexaenoic Acid (all cis-4,7,10,13,16,19) Methyl Ester 100 mg 190.3 Essential fatty acid found in fish oil, involved in prostaglandin synthesis. all cis-4,7,10,13,16,19-Docosahxaenoic acid methyl ester; DHA methyl ester ≥99% 342.51 C23H34O2 Ambient -20°C "Tapiero H, Ba GN, Couvreur P, et al. Polyunsaturated fatty acids (PUFA) and eicosanoids in human health and pathologies. Biomed Pharmacother. 2002 Jul;56(5):215-22. PMID: 12199620.

 

Hu PC, Chen BH. Effects of riboflavin and fatty acid methyl esters on cholesterol oxidation during illumination. J Agric Food Chem. 2002 Jun 5;50(12):3572-8. PMID: 12033831.

 

Liu W, Wang HJ, Wang LP, et al. Formation of high-molecular-weight protein adducts by methyl docosahexaenoate peroxidation products. Biochim Biophys Acta. 2007 Feb;1774(2):258-66. PMID: 17207667.

" Not dangerous goods.

LKT D5610 Docosahexaenoic Acid (all cis-4,7,10,13,16,19) 25 mg 61.1 Essential fatty acid found in fish oil, involved in prostaglandin synthesis. all cis-4,7,10,13,16,19-Docosahxaenoic acid; DHA ≥99% 328.49 C22H32O2 Ambient -20°C "Tapiero H, Ba GN, Couvreur P, et al. Polyunsaturated fatty acids (PUFA) and eicosanoids in human health and pathologies. Biomed Pharmacother. 2002 Jul;56(5):215-22. PMID: 12199620.

 

Hu PC, Chen BH. Effects of riboflavin and fatty acid methyl esters on cholesterol oxidation during illumination. J Agric Food Chem. 2002 Jun 5;50(12):3572-8. PMID: 12033831.

 

Liu W, Wang HJ, Wang LP, et al. Formation of high-molecular-weight protein adducts by methyl docosahexaenoate peroxidation products. Biochim Biophys Acta. 2007 Feb;1774(2):258-66. PMID: 17207667.

" Not dangerous goods.

LKT D5610 Docosahexaenoic Acid (all cis-4,7,10,13,16,19) 100 mg 190.3 Essential fatty acid found in fish oil, involved in prostaglandin synthesis. all cis-4,7,10,13,16,19-Docosahxaenoic acid; DHA ≥99% 328.49 C22H32O2 Ambient -20°C "Tapiero H, Ba GN, Couvreur P, et al. Polyunsaturated fatty acids (PUFA) and eicosanoids in human health and pathologies. Biomed Pharmacother. 2002 Jul;56(5):215-22. PMID: 12199620.

 

Hu PC, Chen BH. Effects of riboflavin and fatty acid methyl esters on cholesterol oxidation during illumination. J Agric Food Chem. 2002 Jun 5;50(12):3572-8. PMID: 12033831.

 

Liu W, Wang HJ, Wang LP, et al. Formation of high-molecular-weight protein adducts by methyl docosahexaenoate peroxidation products. Biochim Biophys Acta. 2007 Feb;1774(2):258-66. PMID: 17207667.

" Not dangerous goods.

LKT P3198 Phytanic Acid 5 mg 169.9 Fatty acid metabolite of chlorophyll; RXR and PPAR agonist, potential GPR40 agonist. 3,7,11,15-Tetramethylhexadecanoic acid 14721-66-5 ≥97% 312.53 C20H40O2 CC(C)CCCC(C)CCCC(C)CCCC(C)CC(=O)O Ambient -20°C "Che BN, Oksbjerg N, Hellgren LI, et al. Phytanic acid stimulates glucose uptake in a model of skeletal muscles, the primary porcine myotubes. Lipids Health Dis. 2013 Feb 11;12:14. PMID: 23398851.

 

Busanello EN, Amaral AU, Tonin AM, et al. Disruption of mitochondrial homeostasis by phytanic acid in cerebellum of young rats. Cerebellum. 2013 Jun;12(3):362-9. PMID: 23081695.

 

Kruska N, Reiser G. Phytanic acid and pristanic acid, branched-chain fatty acids associated with Refsum disease and other inherited peroxisomal disorders, mediate intracellular Ca2+ signaling through activation of free fatty acid receptor GPR40. Neurobiol Dis. 2011 Aug;43(2):465-72. PMID: 21570468.

 

Schönfeld P, Kahlert S, Reiser G. A study of the cytotoxicity of branched-chain phytanic acid with mitochondria and rat brain astrocytes. Exp Gerontol. 2006 Jul;41(7):688-96. PMID: 16616447." Not dangerous goods.

LKT P3198 Phytanic Acid 25 mg 543.6 Fatty acid metabolite of chlorophyll; RXR and PPAR agonist, potential GPR40 agonist. 3,7,11,15-Tetramethylhexadecanoic acid 14721-66-5 ≥97% 312.53 C20H40O2 CC(C)CCCC(C)CCCC(C)CCCC(C)CC(=O)O Ambient -20°C "Che BN, Oksbjerg N, Hellgren LI, et al. Phytanic acid stimulates glucose uptake in a model of skeletal muscles, the primary porcine myotubes. Lipids Health Dis. 2013 Feb 11;12:14. PMID: 23398851.

 

Busanello EN, Amaral AU, Tonin AM, et al. Disruption of mitochondrial homeostasis by phytanic acid in cerebellum of young rats. Cerebellum. 2013 Jun;12(3):362-9. PMID: 23081695.

 

Kruska N, Reiser G. Phytanic acid and pristanic acid, branched-chain fatty acids associated with Refsum disease and other inherited peroxisomal disorders, mediate intracellular Ca2+ signaling through activation of free fatty acid receptor GPR40. Neurobiol Dis. 2011 Aug;43(2):465-72. PMID: 21570468.

 

Schönfeld P, Kahlert S, Reiser G. A study of the cytotoxicity of branched-chain phytanic acid with mitochondria and rat brain astrocytes. Exp Gerontol. 2006 Jul;41(7):688-96. PMID: 16616447." Not dangerous goods.

LKT G0248 Gambogic Acid 5 mg 95.1 Xanthone found in Garcinia hanburyi. 2752-65-0 ≥98% 628.75 C38H44O8 CC(=CCCC1(C=CC2=C(O1)C(=C3C(=C2O)C(=O)C4=CC5CC6C4(O3)C(C5=O)(OC6(C)C)CC=C(C)C(=O)O)CC=C(C)C)C)C ambient -20°C -656.76° Insoluble in water, soluble in DMSO (25 mg/mL), and ethanol (25 mg/mL). "He XY, Liu XJ, Chen X, et al. Gambogic acid induces EGFR degradation and Akt/mTORC1 inhibition through AMPK dependent-LRIG1 upregulation in cultured U87 glioma cells. Biochem Biophys Res Commun. 2013 Jun 7;435(3):397-402. PMID: 23665322.

 

Gu H, Rao S, Zhao J, et al. Gambogic acid reduced bcl-2 expression via p53 in human breast MCF-7 cancer cells. J Cancer Res Clin Oncol. 2009 Dec;135(12):1777-82. PMID: 19582475.

 

Nie F, Zhang X, Qi Q, et al. Reactive oxygen species accumulation contributes to gambogic acid-induced apoptosis in human hepatoma SMMC-7721 cells. Toxicology. 2009 Jun 16;260(1-3):60-7. PMID: 19464570.

 

Pandey MK, Sung B, Ahn KS, et al. Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-kappaB signaling pathway. Blood. 2007 Nov 15;110(10):3517-25. PMID: 17673602.

 

Wu ZQ, Guo QL, You QD, et al. Gambogic acid inhibits proliferation of human lung carcinoma SPC-A1 cells in vivo and in vitro and represses telomerase activity and telomerase reverse transcriptase mRNA expression in the cells. Biol Pharm Bull. 2004 Nov;27(11):1769-74. PMID: 15516720.

" "UN number: 2811     Class: 6.1     Packing Group: III

Proper shipping name: Toxic solid, organic, n.o.s. (Gambogic acid)"

LKT G0248 Gambogic Acid 25 mg 373.7 Xanthone found in Garcinia hanburyi. 2752-65-0 ≥98% 628.75 C38H44O8 CC(=CCCC1(C=CC2=C(O1)C(=C3C(=C2O)C(=O)C4=CC5CC6C4(O3)C(C5=O)(OC6(C)C)CC=C(C)C(=O)O)CC=C(C)C)C)C ambient -20°C -656.76° Insoluble in water, soluble in DMSO (25 mg/mL), and ethanol (25 mg/mL). "He XY, Liu XJ, Chen X, et al. Gambogic acid induces EGFR degradation and Akt/mTORC1 inhibition through AMPK dependent-LRIG1 upregulation in cultured U87 glioma cells. Biochem Biophys Res Commun. 2013 Jun 7;435(3):397-402. PMID: 23665322.

 

Gu H, Rao S, Zhao J, et al. Gambogic acid reduced bcl-2 expression via p53 in human breast MCF-7 cancer cells. J Cancer Res Clin Oncol. 2009 Dec;135(12):1777-82. PMID: 19582475.

 

Nie F, Zhang X, Qi Q, et al. Reactive oxygen species accumulation contributes to gambogic acid-induced apoptosis in human hepatoma SMMC-7721 cells. Toxicology. 2009 Jun 16;260(1-3):60-7. PMID: 19464570.

 

Pandey MK, Sung B, Ahn KS, et al. Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-kappaB signaling pathway. Blood. 2007 Nov 15;110(10):3517-25. PMID: 17673602.

 

Wu ZQ, Guo QL, You QD, et al. Gambogic acid inhibits proliferation of human lung carcinoma SPC-A1 cells in vivo and in vitro and represses telomerase activity and telomerase reverse transcriptase mRNA expression in the cells. Biol Pharm Bull. 2004 Nov;27(11):1769-74. PMID: 15516720.

" "UN number: 2811     Class: 6.1     Packing Group: III

Proper shipping name: Toxic solid, organic, n.o.s. (Gambogic acid)"

LKT G0248 Gambogic Acid 100 mg 1121.2 Xanthone found in Garcinia hanburyi. 2752-65-0 ≥98% 628.75 C38H44O8 CC(=CCCC1(C=CC2=C(O1)C(=C3C(=C2O)C(=O)C4=CC5CC6C4(O3)C(C5=O)(OC6(C)C)CC=C(C)C(=O)O)CC=C(C)C)C)C ambient -20°C -656.76° Insoluble in water, soluble in DMSO (25 mg/mL), and ethanol (25 mg/mL). "He XY, Liu XJ, Chen X, et al. Gambogic acid induces EGFR degradation and Akt/mTORC1 inhibition through AMPK dependent-LRIG1 upregulation in cultured U87 glioma cells. Biochem Biophys Res Commun. 2013 Jun 7;435(3):397-402. PMID: 23665322.

 

Gu H, Rao S, Zhao J, et al. Gambogic acid reduced bcl-2 expression via p53 in human breast MCF-7 cancer cells. J Cancer Res Clin Oncol. 2009 Dec;135(12):1777-82. PMID: 19582475.

 

Nie F, Zhang X, Qi Q, et al. Reactive oxygen species accumulation contributes to gambogic acid-induced apoptosis in human hepatoma SMMC-7721 cells. Toxicology. 2009 Jun 16;260(1-3):60-7. PMID: 19464570.

 

Pandey MK, Sung B, Ahn KS, et al. Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-kappaB signaling pathway. Blood. 2007 Nov 15;110(10):3517-25. PMID: 17673602.

 

Wu ZQ, Guo QL, You QD, et al. Gambogic acid inhibits proliferation of human lung carcinoma SPC-A1 cells in vivo and in vitro and represses telomerase activity and telomerase reverse transcriptase mRNA expression in the cells. Biol Pharm Bull. 2004 Nov;27(11):1769-74. PMID: 15516720.

" "UN number: 2811     Class: 6.1     Packing Group: III

Proper shipping name: Toxic solid, organic, n.o.s. (Gambogic acid)"

LKT D1731 15,16-Dehydrocafestol 10 mg 339.8 Diterpene found in roasted coffee. Dehydrocafestol ≥98% 298.42 C20H26O2 Ambient -20°C [a]23 D=-76° (c=1.7, EtOH) "Arauz J, Moreno MG, Cortés-Reynosa P, et al. Coffee attenuates fibrosis by decreasing the expression of TGF-β and CTGF in a murine model of liver damage. J Appl Toxicol. 2013 Sep;33(9):970-9. PMID: 22899499.

 

Lee KA, Chae JI, Shim JH. Natural diterpenes from coffee, cafestol and kahweol induce apoptosis through regulation of specificity protein 1 expression in human malignant pleural mesothelioma. J Biomed Sci. 2012 Jun 26;19:60. PMID: 22734486.

" Not dangerous goods.

LKT D1731 15,16-Dehydrocafestol 25 mg 679.5 Diterpene found in roasted coffee. Dehydrocafestol ≥98% 298.42 C20H26O2 Ambient -20°C [a]23 D=-76° (c=1.7, EtOH) "Arauz J, Moreno MG, Cortés-Reynosa P, et al. Coffee attenuates fibrosis by decreasing the expression of TGF-β and CTGF in a murine model of liver damage. J Appl Toxicol. 2013 Sep;33(9):970-9. PMID: 22899499.

 

Lee KA, Chae JI, Shim JH. Natural diterpenes from coffee, cafestol and kahweol induce apoptosis through regulation of specificity protein 1 expression in human malignant pleural mesothelioma. J Biomed Sci. 2012 Jun 26;19:60. PMID: 22734486.

" Not dangerous goods.

LKT D1731 15,16-Dehydrocafestol 5 mg 224.3 Diterpene found in roasted coffee. Dehydrocafestol ≥98% 298.42 C20H26O2 Ambient -20°C [a]23 D=-76° (c=1.7, EtOH) "Arauz J, Moreno MG, Cortés-Reynosa P, et al. Coffee attenuates fibrosis by decreasing the expression of TGF-β and CTGF in a murine model of liver damage. J Appl Toxicol. 2013 Sep;33(9):970-9. PMID: 22899499.

 

Lee KA, Chae JI, Shim JH. Natural diterpenes from coffee, cafestol and kahweol induce apoptosis through regulation of specificity protein 1 expression in human malignant pleural mesothelioma. J Biomed Sci. 2012 Jun 26;19:60. PMID: 22734486.

" Not dangerous goods.

LKT E4418 β-Elemene 25 mg 61.1 Sesquiterpene found in various plant sources. 1S,2S,4R)-1-Methyl-2,4-di(prop-1-en-2-yl)-1-vinylcyclohexane 515-13-9 ≥98% 204.35 C15H24 CC(=C)C1CCC(C(C1)C(=C)C)(C)C=C Ambient 4°C "Yan B, Zhou Y, Feng S, et al. β -Elemene-Attenuated Tumor Angiogenesis by Targeting Notch-1 in Gastric Cancer Stem-Like Cells. Evid Based Complement Alternat Med. 2013;2013:268468. PMID: 23710217.

 

Zhang X, Li Y, Zhang Y, et al. Beta-elemene blocks epithelial-mesenchymal transition in human breast cancer cell line MCF-7 through Smad3-mediated down-regulation of nuclear transcription factors. PLoS One. 2013;8(3):e58719. PMID: 23516540.

 

Dai ZJ, Tang W, Lu WF, et al. Antiproliferative and apoptotic effects of β-elemene on human hepatoma HepG2 cells. Cancer Cell Int. 2013 Mar 14;13(1):27. PMID: 23496852.

 

Zhang R, Tian A, Zhang H, et al. Amelioration of experimental autoimmune encephalomyelitis by β-elemene treatment is associated with Th17 and Treg cell balance. J Mol Neurosci. 2011 May;44(1):31-40. PMID: 21246417.

 

Li Q, Wang G, Huang F, et al. Antineoplastic effect of beta-elemene on prostate cancer cells and other types of solid tumour cells. J Pharm Pharmacol. 2010 Aug;62(8):1018-27. PMID: 20663036.

" Not dangerous goods.

LKT E4418 β-Elemene 100 mg 136 Sesquiterpene found in various plant sources. 1S,2S,4R)-1-Methyl-2,4-di(prop-1-en-2-yl)-1-vinylcyclohexane 515-13-9 ≥98% 204.35 C15H24 CC(=C)C1CCC(C(C1)C(=C)C)(C)C=C Ambient 4°C "Yan B, Zhou Y, Feng S, et al. β -Elemene-Attenuated Tumor Angiogenesis by Targeting Notch-1 in Gastric Cancer Stem-Like Cells. Evid Based Complement Alternat Med. 2013;2013:268468. PMID: 23710217.

 

Zhang X, Li Y, Zhang Y, et al. Beta-elemene blocks epithelial-mesenchymal transition in human breast cancer cell line MCF-7 through Smad3-mediated down-regulation of nuclear transcription factors. PLoS One. 2013;8(3):e58719. PMID: 23516540.

 

Dai ZJ, Tang W, Lu WF, et al. Antiproliferative and apoptotic effects of β-elemene on human hepatoma HepG2 cells. Cancer Cell Int. 2013 Mar 14;13(1):27. PMID: 23496852.

 

Zhang R, Tian A, Zhang H, et al. Amelioration of experimental autoimmune encephalomyelitis by β-elemene treatment is associated with Th17 and Treg cell balance. J Mol Neurosci. 2011 May;44(1):31-40. PMID: 21246417.

 

Li Q, Wang G, Huang F, et al. Antineoplastic effect of beta-elemene on prostate cancer cells and other types of solid tumour cells. J Pharm Pharmacol. 2010 Aug;62(8):1018-27. PMID: 20663036.

" Not dangerous goods.

LKT E4418 β-Elemene 500 mg 475.7 Sesquiterpene found in various plant sources. 1S,2S,4R)-1-Methyl-2,4-di(prop-1-en-2-yl)-1-vinylcyclohexane 515-13-9 ≥98% 204.35 C15H24 CC(=C)C1CCC(C(C1)C(=C)C)(C)C=C Ambient 4°C "Yan B, Zhou Y, Feng S, et al. β -Elemene-Attenuated Tumor Angiogenesis by Targeting Notch-1 in Gastric Cancer Stem-Like Cells. Evid Based Complement Alternat Med. 2013;2013:268468. PMID: 23710217.

 

Zhang X, Li Y, Zhang Y, et al. Beta-elemene blocks epithelial-mesenchymal transition in human breast cancer cell line MCF-7 through Smad3-mediated down-regulation of nuclear transcription factors. PLoS One. 2013;8(3):e58719. PMID: 23516540.

 

Dai ZJ, Tang W, Lu WF, et al. Antiproliferative and apoptotic effects of β-elemene on human hepatoma HepG2 cells. Cancer Cell Int. 2013 Mar 14;13(1):27. PMID: 23496852.

 

Zhang R, Tian A, Zhang H, et al. Amelioration of experimental autoimmune encephalomyelitis by β-elemene treatment is associated with Th17 and Treg cell balance. J Mol Neurosci. 2011 May;44(1):31-40. PMID: 21246417.

 

Li Q, Wang G, Huang F, et al. Antineoplastic effect of beta-elemene on prostate cancer cells and other types of solid tumour cells. J Pharm Pharmacol. 2010 Aug;62(8):1018-27. PMID: 20663036.

" Not dangerous goods.

LKT N8460 NVP-BHG712 1 mg 92.5 EphB4 inhibitor. 4-methyl-3-(1-methyl-6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino)-N-(3-(trifluoromethyl)phenyl)benzamide - 940310-85-0 ≥98% 503.48 C26H20F3N7O CC1=C(C=C(C=C1)C(=O)NC2=CC=CC(=C2)C(F)(F)F)NC3=NC(=NC4=C3C=NN4C)C5=CN=CC=C5 Ambient -20°C DMSO 101 mg/mL "Wnuk M, Hlushchuk R, Janot M, et al. Podocyte EphB4 signaling helps recovery from glomerular injury. Kidney Int. 2012 Jun;81(12):1212-25. PMID: 22398409.

 

Martiny-Baron G, Holzer P, Billy E, et al. The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis. Angiogenesis. 2010 Sep;13(3):259-67. PMID: 20803239.

" Not dangerous goods.

LKT N8460 NVP-BHG712 5 mg 339.8 EphB4 inhibitor. 4-methyl-3-(1-methyl-6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino)-N-(3-(trifluoromethyl)phenyl)benzamide - 940310-85-0 ≥98% 503.48 C26H20F3N7O CC1=C(C=C(C=C1)C(=O)NC2=CC=CC(=C2)C(F)(F)F)NC3=NC(=NC4=C3C=NN4C)C5=CN=CC=C5 Ambient -20°C DMSO 101 mg/mL "Wnuk M, Hlushchuk R, Janot M, et al. Podocyte EphB4 signaling helps recovery from glomerular injury. Kidney Int. 2012 Jun;81(12):1212-25. PMID: 22398409.

 

Martiny-Baron G, Holzer P, Billy E, et al. The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis. Angiogenesis. 2010 Sep;13(3):259-67. PMID: 20803239.

" Not dangerous goods.

LKT M1564 S-Methyl-L-cysteine 1 g 33.9 Antioxidant found in Brassicaceae family plants. (R)-2-Amino-3-(methylmercapto)propionic acid; SMLC 1187-84-4 ≥99% 135.18 C4H9NO2S CSCC(C(=O)O)N Ambient 4°C [a]23 D -29° (c=.1, H2O) Soluble in 0.1 N NaOH (1% w/v) or water (50 mg/mL). "Ishiwata S, Ogata S, Umino A, et al. Increasing effects of S-methyl-L-cysteine on the extracellular D-serine concentrations in the rat medial frontal cortex. Amino Acids. 2013 May;44(5):1391-5. PMID: 23417484. 

 

Yoshinari O, Shiojima Y, Igarashi K. Anti-obesity effects of onion extract in Zucker diabetic fatty rats. Nutrients. 2012 Oct 22;4(10):1518-26. PMID: 23201769.

 

Wassef R, Haenold R, Hansel A, et al. Methionine sulfoxide reductase A and a dietary supplement S-methyl-L-cysteine prevent Parkinson's-like symptoms. J Neurosci. 2007 Nov 21;27(47):12808-16. PMID: 18032652.

" Not dangerous goods.

LKT M1564 S-Methyl-L-cysteine 5 g 74.8 Antioxidant found in Brassicaceae family plants. (R)-2-Amino-3-(methylmercapto)propionic acid; SMLC 1187-84-4 ≥99% 135.18 C4H9NO2S CSCC(C(=O)O)N Ambient 4°C [a]23 D -29° (c=.1, H2O) Soluble in 0.1 N NaOH (1% w/v) or water (50 mg/mL). "Ishiwata S, Ogata S, Umino A, et al. Increasing effects of S-methyl-L-cysteine on the extracellular D-serine concentrations in the rat medial frontal cortex. Amino Acids. 2013 May;44(5):1391-5. PMID: 23417484. 

 

Yoshinari O, Shiojima Y, Igarashi K. Anti-obesity effects of onion extract in Zucker diabetic fatty rats. Nutrients. 2012 Oct 22;4(10):1518-26. PMID: 23201769.

 

Wassef R, Haenold R, Hansel A, et al. Methionine sulfoxide reductase A and a dietary supplement S-methyl-L-cysteine prevent Parkinson's-like symptoms. J Neurosci. 2007 Nov 21;27(47):12808-16. PMID: 18032652.

" Not dangerous goods.

LKT M1564 S-Methyl-L-cysteine 25 g 298.9 Antioxidant found in Brassicaceae family plants. (R)-2-Amino-3-(methylmercapto)propionic acid; SMLC 1187-84-4 ≥99% 135.18 C4H9NO2S CSCC(C(=O)O)N Ambient 4°C [a]23 D -29° (c=.1, H2O) Soluble in 0.1 N NaOH (1% w/v) or water (50 mg/mL). "Ishiwata S, Ogata S, Umino A, et al. Increasing effects of S-methyl-L-cysteine on the extracellular D-serine concentrations in the rat medial frontal cortex. Amino Acids. 2013 May;44(5):1391-5. PMID: 23417484. 

 

Yoshinari O, Shiojima Y, Igarashi K. Anti-obesity effects of onion extract in Zucker diabetic fatty rats. Nutrients. 2012 Oct 22;4(10):1518-26. PMID: 23201769.

 

Wassef R, Haenold R, Hansel A, et al. Methionine sulfoxide reductase A and a dietary supplement S-methyl-L-cysteine prevent Parkinson's-like symptoms. J Neurosci. 2007 Nov 21;27(47):12808-16. PMID: 18032652.

" Not dangerous goods.

LKT G8850 GW-5074 1 mg 47.6 c-Raf inhibitor. 2H-Indol-2-one, 3-[(3,5-dibromo-4-hydroxyphenyl)methylene]-1,3-dihydro-5-iodo- 220904-83-6 ≥98% 520.94 C15H8Br2INO2 C1=CC2=C(C=C1I)C(=CC3=CC(=C(C(=C3)Br)O)Br)C(=O)N2 Ambient -20°C DMSO 104 mg/mL "Suenkel B, Fischer F, Steegborn C. Inhibition of the human deacylase Sirtuin 5 by the indole GW5074. Bioorg Med Chem Lett. 2013 Jan 1;23(1):143-6. PMID: 23195732.

Li J, Fan Y, Zhang YN, et al. The Raf-1 inhibitor W5074 and the ERK1/2 pathway inhibitor U0126 ameliorate PC12 cells apoptosis induced by 6-hydroxydopamine. Pharmazie. 2012 Aug;67(8):718-24. PMID: 22957439.

" N/A Not dangerous goods.

LKT G8850 GW-5074 5 mg 142.7 c-Raf inhibitor. 2H-Indol-2-one, 3-[(3,5-dibromo-4-hydroxyphenyl)methylene]-1,3-dihydro-5-iodo- 220904-83-6 ≥98% 520.94 C15H8Br2INO2 C1=CC2=C(C=C1I)C(=CC3=CC(=C(C(=C3)Br)O)Br)C(=O)N2 Ambient -20°C DMSO 104 mg/mL "Suenkel B, Fischer F, Steegborn C. Inhibition of the human deacylase Sirtuin 5 by the indole GW5074. Bioorg Med Chem Lett. 2013 Jan 1;23(1):143-6. PMID: 23195732.

Li J, Fan Y, Zhang YN, et al. The Raf-1 inhibitor W5074 and the ERK1/2 pathway inhibitor U0126 ameliorate PC12 cells apoptosis induced by 6-hydroxydopamine. Pharmazie. 2012 Aug;67(8):718-24. PMID: 22957439.

" N/A Not dangerous goods.

LKT Z4833 ZM-336372 5 mg 81.6 c-Raf activator, tyrosine kinase inhibitor. Benzamide, 3-(dimethylamino)-N-[3-[(4-hydroxybenzoyl)amino]-4-methylphenyl]- 208260-29-1 ≥98% 389.45 C23H23N3O3 CC1=C(C=C(C=C1)NC(=O)C2=CC(=CC=C2)N(C)C)NC(=O)C3=CC=C(C=C3)O Ambient -20°C DMSO 78mg/ml "Deming D, Geiger P, Chen H, et al. ZM336372 induces apoptosis associated with phosphorylation of GSK-3beta in pancreatic adenocarcinoma cell lines. J Surg Res. 2010 Jun 1;161(1):28-32. PMID: 20031160.

 

Deming D, Geiger P, Chen H, et al. ZM336372, a Raf-1 activator, causes suppression of proliferation in a human hepatocellular carcinoma cell line. J Gastrointest Surg. 2008 May;12(5):852-7. PMID: 18299943.

 

Kappes A, Vaccaro A, Kunnimalaiyaan M, et al. ZM336372, a Raf-1 activator, inhibits growth of pheochromocytoma cells. J Surg Res. 2006 Jun 1;133(1):42-5. PMID: 16603190.

" Not dangerous goods.

LKT Z4833 ZM-336372 25 mg 333 c-Raf activator, tyrosine kinase inhibitor. Benzamide, 3-(dimethylamino)-N-[3-[(4-hydroxybenzoyl)amino]-4-methylphenyl]- 208260-29-1 ≥98% 389.45 C23H23N3O3 CC1=C(C=C(C=C1)NC(=O)C2=CC(=CC=C2)N(C)C)NC(=O)C3=CC=C(C=C3)O Ambient -20°C DMSO 78mg/ml "Deming D, Geiger P, Chen H, et al. ZM336372 induces apoptosis associated with phosphorylation of GSK-3beta in pancreatic adenocarcinoma cell lines. J Surg Res. 2010 Jun 1;161(1):28-32. PMID: 20031160.

 

Deming D, Geiger P, Chen H, et al. ZM336372, a Raf-1 activator, causes suppression of proliferation in a human hepatocellular carcinoma cell line. J Gastrointest Surg. 2008 May;12(5):852-7. PMID: 18299943.

 

Kappes A, Vaccaro A, Kunnimalaiyaan M, et al. ZM336372, a Raf-1 activator, inhibits growth of pheochromocytoma cells. J Surg Res. 2006 Jun 1;133(1):42-5. PMID: 16603190.

" Not dangerous goods.

LKT S0459 SB-590885 1 mg 47.6 B-Raf inhibitor. (E)-5-(2-(4-(2-(dimethylamino)ethoxy)phenyl)-4-(pyridin-4-yl)-1H-imidazol-5-yl)-2,3-dihydroinden-1-one oxime 405554-55-4 ≥97% 453.54 C27H27N5O2 CN(C)CCOC1=CC=C(C=C1)C2=NC(=C3C=CC4=C(CCC4=C3)N=O)C(=C5C=CNC=C5)N2 Ambient -20°C DMSO 5 mg/mL "Ahnstedt H, Säveland H, Nilsson O, et al. Human cerebrovascular contractile receptors are upregulated via a B-Raf/MEK/ERK-sensitive signaling pathway. BMC Neurosci. 2011 Jan 11;12:5. PMID: 21223556.

 

King AJ, Patrick DR, Batorsky RS, et al. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res. 2006 Dec 1;66(23):11100-5. PMID: 17145850.

" Not dangerous goods.

LKT S0459 SB-590885 5 mg 142.7 B-Raf inhibitor. (E)-5-(2-(4-(2-(dimethylamino)ethoxy)phenyl)-4-(pyridin-4-yl)-1H-imidazol-5-yl)-2,3-dihydroinden-1-one oxime 405554-55-4 ≥97% 453.54 C27H27N5O2 CN(C)CCOC1=CC=C(C=C1)C2=NC(=C3C=CC4=C(CCC4=C3)N=O)C(=C5C=CNC=C5)N2 Ambient -20°C DMSO 5 mg/mL "Ahnstedt H, Säveland H, Nilsson O, et al. Human cerebrovascular contractile receptors are upregulated via a B-Raf/MEK/ERK-sensitive signaling pathway. BMC Neurosci. 2011 Jan 11;12:5. PMID: 21223556.

 

King AJ, Patrick DR, Batorsky RS, et al. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res. 2006 Dec 1;66(23):11100-5. PMID: 17145850.

" Not dangerous goods.

LKT C1660 CEP-32496 1 mg 136 V600E B-Raf inhibitor. Urea, N-[3-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N-[5-(2,2,2-trifluoro-1,1-dimethylethyl)-3-isoxazolyl]- 1188910-76-0 ≥98% 517.46 C24H22F3N5O5 CC(C)(C1=CON=C1NC(=O)NC2=CC(=CC=C2)OC3=NC=NC4=CC(=C(C=C43)OC)OC)C(F)(F)F Ambient -20°C DMSO 9 mg/mL "James J, Ruggeri B, Armstrong RC, et al. CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity. Mol Cancer Ther. 2012 Apr;11(4):930-41. PMID: 22319199.

 

Rowbottom MW, Faraoni R, Chao Q, et al. Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E. J Med Chem. 2012 Feb 9;55(3):1082-105. PMID: 22168626.

" Not dangerous goods.

LKT C1660 CEP-32496 5 mg 502.8 V600E B-Raf inhibitor. Urea, N-[3-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N-[5-(2,2,2-trifluoro-1,1-dimethylethyl)-3-isoxazolyl]- 1188910-76-0 ≥98% 517.46 C24H22F3N5O5 CC(C)(C1=CON=C1NC(=O)NC2=CC(=CC=C2)OC3=NC=NC4=CC(=C(C=C43)OC)OC)C(F)(F)F Ambient -20°C DMSO 9 mg/mL "James J, Ruggeri B, Armstrong RC, et al. CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity. Mol Cancer Ther. 2012 Apr;11(4):930-41. PMID: 22319199.

 

Rowbottom MW, Faraoni R, Chao Q, et al. Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E. J Med Chem. 2012 Feb 9;55(3):1082-105. PMID: 22168626.

" Not dangerous goods.

LKT G1208 GDC-0879 1 mg 67.9 V600E B-Raf inhibitor. (E)-5-(1-(2-hydroxyethyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2,3-dihydroinden-1-one oxime 905281-76-7 ≥96% 334.37 C19H18N4O2 C1CC(=NO)C2=C1C=C(C=C2)C3=CN(N=C3C4=CC=NC=C4)CCO Ambient -20°C DMSO 67 mg/mL "Hoeflich KP, Herter S, Tien J, et al. Antitumor efficacy of the novel RAF inhibitor DC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Cancer Res. 2009 Apr 1;69(7):3042-51. PMID: 19276360.

 

Wong H, Belvin M, Herter S, et al. Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase kinase 1 inhibition, and efficacy. J Pharmacol Exp Ther. 2009 Apr;329(1):360-7. PMID: 19147858.

" Not dangerous goods.

LKT G1208 GDC-0879 5 mg 251.5 V600E B-Raf inhibitor. (E)-5-(1-(2-hydroxyethyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2,3-dihydroinden-1-one oxime 905281-76-7 ≥96% 334.37 C19H18N4O2 C1CC(=NO)C2=C1C=C(C=C2)C3=CN(N=C3C4=CC=NC=C4)CCO Ambient -20°C DMSO 67 mg/mL "Hoeflich KP, Herter S, Tien J, et al. Antitumor efficacy of the novel RAF inhibitor DC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Cancer Res. 2009 Apr 1;69(7):3042-51. PMID: 19276360.

 

Wong H, Belvin M, Herter S, et al. Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase kinase 1 inhibition, and efficacy. J Pharmacol Exp Ther. 2009 Apr;329(1):360-7. PMID: 19147858.

" Not dangerous goods.

LKT A9662 AZ-628 1 mg 67.9 B-Raf and c-Raf inhibitor. 3-(2-cyanopropan-2-yl)-N-(4-methyl-3-(3-methyl-4-oxo-3,4-dihydroquinazolin-6-ylamino)phenyl)benzamide 878739-06-1 ≥96% 451.52 C27H25N5O2 CC1=C(C=C(C=C1)NC(=O)C2=CC(=CC=C2)C(C)(C)C#N)NC3=CC4=C(C=C3)N=CN(C4=O)C Ambient -20°C DMSO 90 mg/mL "Whittaker SR, Theurillat JP, Van Allen E, et al. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov. 2013 Mar;3(3):350-62. PMID: 23288408.

 

Montagut C, Sharma SV, Shioda T, et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 2008 Jun 15;68(12):4853-61. PMID: 18559533.

" "UN number: 2811     Class:  6.1     Packing group:  III

Proper shipping name:  Toxic solids, organic, n.o.s. (AZ628)  Reportable Quantity (RQ)  Poison inhalation hazard:  No"

LKT A9662 AZ-628 5 mg 251.5 B-Raf and c-Raf inhibitor. 3-(2-cyanopropan-2-yl)-N-(4-methyl-3-(3-methyl-4-oxo-3,4-dihydroquinazolin-6-ylamino)phenyl)benzamide 878739-06-1 ≥96% 451.52 C27H25N5O2 CC1=C(C=C(C=C1)NC(=O)C2=CC(=CC=C2)C(C)(C)C#N)NC3=CC4=C(C=C3)N=CN(C4=O)C Ambient -20°C DMSO 90 mg/mL "Whittaker SR, Theurillat JP, Van Allen E, et al. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov. 2013 Mar;3(3):350-62. PMID: 23288408.

 

Montagut C, Sharma SV, Shioda T, et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 2008 Jun 15;68(12):4853-61. PMID: 18559533.

" "UN number: 2811     Class:  6.1     Packing group:  III

Proper shipping name:  Toxic solids, organic, n.o.s. (AZ628)  Reportable Quantity (RQ)  Poison inhalation hazard:  No"

LKT R0020 RAF265 1 mg 116.9 B-Raf, VEGFR2, c-Raf, PDGFR, CSF-1R, RET, c-Kit, Src, STE20 inhibitor. 1-methyl-5-(2-(5-(trifluoromethyl)-1H-imidazol-2-yl)pyridin-4-yloxy)-N-(4-(trifluoromethyl)phenyl)-1H-benzo[d]imidazol-2-amine 927880-90-8 ≥98% 518.4 C24H16F6N6O CN1C2=C(C=C(C=C2)OC3=CC(=NC=C3)C4=NC=C(N4)C(F)(F)F)N=C1NC5=CC=C(C=C5)C(F)(F)F Ambient -20°C DMSO 100 mg/mL "Garcia-Gomez A, Ocio EM, Pandiella A, et al. RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications. Invest New Drugs. 2013 Feb;31(1):200-5. d PMID: 22773056.

 

Huang T, Karsy M, Zhuge J, et al. B-Raf and the inhibitors: from bench to bedside. J Hematol Oncol. 2013 Apr 25;6:30. PMID: 23617957.

 

Su Y, Vilgelm AE, Kelley MC, et al. RAF265 inhibits the growth of advanced human melanoma tumors. Clin Cancer Res. 2012 Apr 15;18(8):2184-98. Erratum in: Clin Cancer Res. 2012 Aug 15;18(16):4475. PMID: 22351689.

" Not dangerous goods.

LKT R0020 RAF265 5 mg 434.9 B-Raf, VEGFR2, c-Raf, PDGFR, CSF-1R, RET, c-Kit, Src, STE20 inhibitor. 1-methyl-5-(2-(5-(trifluoromethyl)-1H-imidazol-2-yl)pyridin-4-yloxy)-N-(4-(trifluoromethyl)phenyl)-1H-benzo[d]imidazol-2-amine 927880-90-8 ≥98% 518.4 C24H16F6N6O CN1C2=C(C=C(C=C2)OC3=CC(=NC=C3)C4=NC=C(N4)C(F)(F)F)N=C1NC5=CC=C(C=C5)C(F)(F)F Ambient -20°C DMSO 100 mg/mL "Garcia-Gomez A, Ocio EM, Pandiella A, et al. RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications. Invest New Drugs. 2013 Feb;31(1):200-5. d PMID: 22773056.

 

Huang T, Karsy M, Zhuge J, et al. B-Raf and the inhibitors: from bench to bedside. J Hematol Oncol. 2013 Apr 25;6:30. PMID: 23617957.

 

Su Y, Vilgelm AE, Kelley MC, et al. RAF265 inhibits the growth of advanced human melanoma tumors. Clin Cancer Res. 2012 Apr 15;18(8):2184-98. Erratum in: Clin Cancer Res. 2012 Aug 15;18(16):4475. PMID: 22351689.

" Not dangerous goods.

LKT V1668 Vemurafenib 10 mg 95.1 B-Raf inhibitor. N-(3-(5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl)propane-1-sulfonamide PLX-4032; RG7204; RO5185426 1029872-54-5 ≥98% 489.92 C23H18ClF2N3O3S CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=NC=C(C=C23)C4=CC=C(C=C4)Cl)F Ambient -20°C "Anforth R, Blumetti TC, Clements A, et al. Systemic Retinoids for the Chemoprevention of Cutaneous Squamous Cell Carcinoma and Verrucal Keratosis in a Cohort of Patients on BRAF inhibitors. Br J Dermatol. 2013 Jul 20. PMID: 23870055. 

 

Beck D, Niessner H, Smalley KS, et al. Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells. Sci Signal. 2013 Jan 29;6(260):ra7. PMID: 23362240.

 

Huang T, Karsy M, Zhuge J, et al. B-Raf and the inhibitors: from bench to bedside. J Hematol Oncol. 2013 Apr 25;6:30. PMID: 23617957.

" Not dangerous goods.

LKT V1668 Vemurafenib 25 mg 190.3 B-Raf inhibitor. N-(3-(5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl)propane-1-sulfonamide PLX-4032; RG7204; RO5185426 1029872-54-5 ≥98% 489.92 C23H18ClF2N3O3S CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=NC=C(C=C23)C4=CC=C(C=C4)Cl)F Ambient -20°C "Anforth R, Blumetti TC, Clements A, et al. Systemic Retinoids for the Chemoprevention of Cutaneous Squamous Cell Carcinoma and Verrucal Keratosis in a Cohort of Patients on BRAF inhibitors. Br J Dermatol. 2013 Jul 20. PMID: 23870055. 

 

Beck D, Niessner H, Smalley KS, et al. Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells. Sci Signal. 2013 Jan 29;6(260):ra7. PMID: 23362240.

 

Huang T, Karsy M, Zhuge J, et al. B-Raf and the inhibitors: from bench to bedside. J Hematol Oncol. 2013 Apr 25;6:30. PMID: 23617957.

" Not dangerous goods.

LKT M4452 MLN2480 1 mg 81.6 Raf inhibitor. 1096708-71-2 ≥98% 506.3 C17H12Cl2F3N7O2S CC(C1=NC=C(S1)C(=O)NC2=NC=C(C(=C2)C(F)(F)F)Cl)NC(=O)C3=C(C(=NC=N3)N)Cl Ambient -20°C 

LKT M4452 MLN2480 5 mg 271.7 Raf inhibitor. 1096708-71-2 ≥98% 506.3 C17H12Cl2F3N7O2S CC(C1=NC=C(S1)C(=O)NC2=NC=C(C(=C2)C(F)(F)F)Cl)NC(=O)C3=C(C(=NC=N3)N)Cl Ambient -20°C 

LKT D0005 Dabrafenib Mesylate 5 mg 67.9 B-Raf and c-Raf inhibitor. 1195768-06-9 ≥98% 615.67 C23H20F3N5O2S2 CH3SO3H CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F.CS(=O)(=O)O Ambient -20°C "Ballantyne AD, Garnock-Jones KP. Dabrafenib: First Global Approval. Drugs. 2013 Jul 24. [Epub ahead of print] PMID: 23881668. 

 

Huang T, Karsy M, Zhuge J, et al. B-Raf and the inhibitors: from bench to bedside. J Hematol Oncol. 2013 Apr 25;6:30. PMID: 23617957.

 

Klinac D, Gray ES, Millward M, et al. Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Front Oncol. 2013;3:54. PMID: 23515890.

 

Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012 Jul 28;380(9839):358-65. PMID: 22735384." Not dangerous goods.

LKT D0005 Dabrafenib Mesylate 25 mg 319.4 B-Raf and c-Raf inhibitor. 1195768-06-9 ≥98% 615.67 C23H20F3N5O2S2 CH3SO3H CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F.CS(=O)(=O)O Ambient -20°C "Ballantyne AD, Garnock-Jones KP. Dabrafenib: First Global Approval. Drugs. 2013 Jul 24. [Epub ahead of print] PMID: 23881668. 

 

Huang T, Karsy M, Zhuge J, et al. B-Raf and the inhibitors: from bench to bedside. J Hematol Oncol. 2013 Apr 25;6:30. PMID: 23617957.

 

Klinac D, Gray ES, Millward M, et al. Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Front Oncol. 2013;3:54. PMID: 23515890.

 

Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012 Jul 28;380(9839):358-65. PMID: 22735384." Not dangerous goods.

LKT P4492 PLX4720 5 mg 88.3 V600E B-Raf inhibitor. 918505-84-7 ≥98% 413.83 C17H14ClF2N3O3S CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=NC=C(C=C23)Cl)F Ambient -20°C "Liu C, Peng W, Xu C, et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res. 2013 Jan 15;19(2):393-403. PMID: 23204132.

 

Bottos A, Martini M, Di Nicolantonio F, et al. Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia. Proc Natl Acad Sci U S A. 2012 Feb 7;109(6):E353-9. PMID: 22203991.

 

Wilmott JS, Long GV, Howle JR, et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res. 2012 Mar 1;18(5):1386-94. PMID: 22156613.

 

Boni A, Cogdill AP, Dang P, et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 2010 Jul 1;70(13):5213-9. PMID: 20551059.

" Not dangerous goods.

LKT P4492 PLX4720 25 mg 441.6 V600E B-Raf inhibitor. 918505-84-7 ≥98% 413.83 C17H14ClF2N3O3S CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=NC=C(C=C23)Cl)F Ambient -20°C "Liu C, Peng W, Xu C, et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res. 2013 Jan 15;19(2):393-403. PMID: 23204132.

 

Bottos A, Martini M, Di Nicolantonio F, et al. Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia. Proc Natl Acad Sci U S A. 2012 Feb 7;109(6):E353-9. PMID: 22203991.

 

Wilmott JS, Long GV, Howle JR, et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res. 2012 Mar 1;18(5):1386-94. PMID: 22156613.

 

Boni A, Cogdill AP, Dang P, et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 2010 Jul 1;70(13):5213-9. PMID: 20551059.

" Not dangerous goods.

LKT R1876 all-trans-Retinol 25 mg 43.5 Diterpene component of vitamin A, differentiation inducer; RAR and RXR agonist. 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclchexen-1-yl)-2,- 4,6,8-nonatetraen-1-ol Alphasterol; Retinol; Avitol; Vitamin A 68-26-8 ≥95% 286.45 C20H30O CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CCO)C)C Blue Ice -20°C Soluble in alcohol, methanol, chloroform, ether, fats or oils. "Friedman MD, Jeevan DS, Tobias M, et al. Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid. Oncol Rep. 2013 Oct;30(4):1645-50. PMID: 23877261.

 

Farhangi MA, Keshavarz SA, Eshraghian M, et al. Vitamin a supplementation and serum Th1- and th2-associated cytokine response in women. J Am Coll Nutr. 2013 Aug;32(4):280-5. PMID: 24024773.

 

Sharma RB, Wang Q, Khillan JS. Amplification of tumor inducing putative cancer stem cells (CSCs) by vitamin A/retinol from mammary tumors. Biochem Biophys Res Commun. 2013 Jul 12;436(4):625-31. PMID: 23764401.

 

Zhan XX, Liu Y, Yang JF, et al. All-trans-retinoic acid ameliorates experimental allergic encephalomyelitis by affecting dendritic cell and monocyte development. Immunology. 2013 Apr;138(4):333-45. PMID: 23181351.

 

Duester G. Retinoic acid synthesis and signaling during early organogenesis. Cell. 2008 Sep 19;134(6):921-31. PMID: 18805086.

" Xn Not dangerous goods.

LKT B1977 Betulin 500 mg 61.1 Pentacyclic triterpene found in various plant sources. Lup-20(29)-ene-3β,28-diol 473-98-3 ≥98% 442.72 C30H50O2 CC(=C)C1CCC2(C1C3CCC4C5(CCC(C(C5CCC4(C3(CC2)C)C)(C)C)O)C)CO Ambient "Wan Y, Jiang S, Lian LH, et al. Betulinic acid and betulin ameliorate acute ethanol-induced fatty liver via TLR4 and STAT3 in vivo and in vitro. Int Immunopharmacol. 2013 Jun 28;17(2):184-190. [Epub ahead of print] PMID: 23816536. 

 

Jonnalagadda SC, Corsello MA, Sleet CE. Betulin-Betulinic Acid Natural Product Based Analogs as Anti-Cancer Agents. Anticancer Agents Med Chem. 2013 Jun 11. [Epub ahead of print] PubMed PMID: 23848199. 

 

Szuster-Ciesielska A, Plewka K, Kandefer-Szerszeń M. Betulin, betulinic acid and butein are inhibitors of acetaldehyde-induced activation of liver stellate cells. Pharmacol Rep. 2011;63(5):1109-23. PMID: 22180353. 

" Not dangerous goods.

LKT B1977 Betulin 1 g 122.3 Pentacyclic triterpene found in various plant sources. Lup-20(29)-ene-3β,28-diol 473-98-3 ≥98% 442.72 C30H50O2 CC(=C)C1CCC2(C1C3CCC4C5(CCC(C(C5CCC4(C3(CC2)C)C)(C)C)O)C)CO Ambient "Wan Y, Jiang S, Lian LH, et al. Betulinic acid and betulin ameliorate acute ethanol-induced fatty liver via TLR4 and STAT3 in vivo and in vitro. Int Immunopharmacol. 2013 Jun 28;17(2):184-190. [Epub ahead of print] PMID: 23816536. 

 

Jonnalagadda SC, Corsello MA, Sleet CE. Betulin-Betulinic Acid Natural Product Based Analogs as Anti-Cancer Agents. Anticancer Agents Med Chem. 2013 Jun 11. [Epub ahead of print] PubMed PMID: 23848199. 

 

Szuster-Ciesielska A, Plewka K, Kandefer-Szerszeń M. Betulin, betulinic acid and butein are inhibitors of acetaldehyde-induced activation of liver stellate cells. Pharmacol Rep. 2011;63(5):1109-23. PMID: 22180353. 

" Not dangerous goods.

LKT B1977 Betulin 5 g 529.9 Pentacyclic triterpene found in various plant sources. Lup-20(29)-ene-3β,28-diol 473-98-3 ≥98% 442.72 C30H50O2 CC(=C)C1CCC2(C1C3CCC4C5(CCC(C(C5CCC4(C3(CC2)C)C)(C)C)O)C)CO Ambient "Wan Y, Jiang S, Lian LH, et al. Betulinic acid and betulin ameliorate acute ethanol-induced fatty liver via TLR4 and STAT3 in vivo and in vitro. Int Immunopharmacol. 2013 Jun 28;17(2):184-190. [Epub ahead of print] PMID: 23816536. 

 

Jonnalagadda SC, Corsello MA, Sleet CE. Betulin-Betulinic Acid Natural Product Based Analogs as Anti-Cancer Agents. Anticancer Agents Med Chem. 2013 Jun 11. [Epub ahead of print] PubMed PMID: 23848199. 

 

Szuster-Ciesielska A, Plewka K, Kandefer-Szerszeń M. Betulin, betulinic acid and butein are inhibitors of acetaldehyde-induced activation of liver stellate cells. Pharmacol Rep. 2011;63(5):1109-23. PMID: 22180353. 

" Not dangerous goods.

LKT E6236 Epigallocatechin Gallate Octaacetate 10 mg 51.7 EGCG/green tea catechin derivative. Peracetylated Epigallocatechin gallate, Octaacetyl Epigallocatechin gallate 148707-39-5 ≥98% 794.67 C38H34O19 Ambient 4°C "Chiou YS, Sang S, Cheng KH, et al. Peracetylated (-)-epigallocatechin-3-gallate (AcEGCG) potently prevents skin carcinogenesis by suppressing the PKD1-dependent signaling pathway in CD34+ skin stem cells and skin tumors. Carcinogenesis. 2013 Jun;34(6):1315-22. PMID: 23385063.

 

 

Chiou YS, Ma NJ, Sang S, et al. Peracetylated (-)-epigallocatechin-3-gallate (AcEGCG) potently suppresses dextran sulfate sodium-induced colitis and colon tumorigenesis in mice. J Agric Food Chem. 2012 Apr 4;60(13):3441-51. PMID: 22409325. 

 

Lambert JD, Sang S, Hong J, et al. Peracetylation as a means of enhancing in vitro bioactivity and bioavailability of epigallocatechin-3-gallate. Drug Metab Dispos. 2006 Dec;34(12):2111-6. PMID: 16997910.

" Not dangerous goods.

LKT E6236 Epigallocatechin Gallate Octaacetate 25 mg 81.6 EGCG/green tea catechin derivative. Peracetylated Epigallocatechin gallate, Octaacetyl Epigallocatechin gallate 148707-39-5 ≥98% 794.67 C38H34O19 Ambient 4°C "Chiou YS, Sang S, Cheng KH, et al. Peracetylated (-)-epigallocatechin-3-gallate (AcEGCG) potently prevents skin carcinogenesis by suppressing the PKD1-dependent signaling pathway in CD34+ skin stem cells and skin tumors. Carcinogenesis. 2013 Jun;34(6):1315-22. PMID: 23385063.

 

 

Chiou YS, Ma NJ, Sang S, et al. Peracetylated (-)-epigallocatechin-3-gallate (AcEGCG) potently suppresses dextran sulfate sodium-induced colitis and colon tumorigenesis in mice. J Agric Food Chem. 2012 Apr 4;60(13):3441-51. PMID: 22409325. 

 

Lambert JD, Sang S, Hong J, et al. Peracetylation as a means of enhancing in vitro bioactivity and bioavailability of epigallocatechin-3-gallate. Drug Metab Dispos. 2006 Dec;34(12):2111-6. PMID: 16997910.

" Not dangerous goods.

LKT E6236 Epigallocatechin Gallate Octaacetate 100 mg 244.5 EGCG/green tea catechin derivative. Peracetylated Epigallocatechin gallate, Octaacetyl Epigallocatechin gallate 148707-39-5 ≥98% 794.67 C38H34O19 Ambient 4°C "Chiou YS, Sang S, Cheng KH, et al. Peracetylated (-)-epigallocatechin-3-gallate (AcEGCG) potently prevents skin carcinogenesis by suppressing the PKD1-dependent signaling pathway in CD34+ skin stem cells and skin tumors. Carcinogenesis. 2013 Jun;34(6):1315-22. PMID: 23385063.

 

 

Chiou YS, Ma NJ, Sang S, et al. Peracetylated (-)-epigallocatechin-3-gallate (AcEGCG) potently suppresses dextran sulfate sodium-induced colitis and colon tumorigenesis in mice. J Agric Food Chem. 2012 Apr 4;60(13):3441-51. PMID: 22409325. 

 

Lambert JD, Sang S, Hong J, et al. Peracetylation as a means of enhancing in vitro bioactivity and bioavailability of epigallocatechin-3-gallate. Drug Metab Dispos. 2006 Dec;34(12):2111-6. PMID: 16997910.

" Not dangerous goods.

LKT I7759 Isoxanthohumol 1 mg 81.6 Prenylflavinoid, derivative of xanthohumol found in Humulus lupulus. 7-hydroxy-2-(4-hydroxyphenyl)-5-methoxy-8-(3-methylbut-2-enyl)-2,3-dihydrochromen-4-one 70872-29-6 ≥98% 354.39 C21H22O5 CC(=CCC1=C(C=C(C2=C1OC(CC2=O)C3=CC=C(C=C3)O)OC)O)C ambient 4°C "Negrão R, Duarte D, Costa R, et al. Isoxanthohumol modulates angiogenesis and inflammation via vascular endothelial growth factor receptor, tumor necrosis factor alpha and nuclear factor kappa B pathways. Biofactors. 2013 Aug 1. [Epub ahead of print] PMID: 23904052.

 

Negrão R, Costa R, Duarte D, et al. Angiogenesis and inflammation signaling are targets of beer polyphenols on vascular cells. J Cell Biochem. 2010 Dec 1;111(5):1270-9. PMID: 20803553.

 

Possemiers S, Rabot S, Espín JC, et al. Eubacterium limosum activates isoxanthohumol from hops (Humulus lupulus L.) into the potent phytoestrogen 8-prenylnaringenin in vitro and in rat intestine. J Nutr. 2008 Jul;138(7):1310-6. PMID: 18567753.

 

Yang JY, Della-Fera MA, Rayalam S, et al. Effect of xanthohumol and isoxanthohumol on 3T3-L1 cell apoptosis and adipogenesis. Apoptosis. 2007 Nov;12(11):1953-63. PMID: 17874298.

 

Possemiers S, Bolca S, Grootaert C,  et al. The prenylflavonoid isoxanthohumol from hops (Humulus lupulus L.) is activated into the potent phytoestrogen 8-prenylnaringenin in vitro and in the human intestine. J Nutr. 2006 Jul;136(7):1862-7. PMID: 16772450.

" Not dangerous goods.

LKT I7759 Isoxanthohumol 5 mg 373.7 Prenylflavinoid, derivative of xanthohumol found in Humulus lupulus. 7-hydroxy-2-(4-hydroxyphenyl)-5-methoxy-8-(3-methylbut-2-enyl)-2,3-dihydrochromen-4-one 70872-29-6 ≥98% 354.39 C21H22O5 CC(=CCC1=C(C=C(C2=C1OC(CC2=O)C3=CC=C(C=C3)O)OC)O)C ambient 4°C "Negrão R, Duarte D, Costa R, et al. Isoxanthohumol modulates angiogenesis and inflammation via vascular endothelial growth factor receptor, tumor necrosis factor alpha and nuclear factor kappa B pathways. Biofactors. 2013 Aug 1. [Epub ahead of print] PMID: 23904052.

 

Negrão R, Costa R, Duarte D, et al. Angiogenesis and inflammation signaling are targets of beer polyphenols on vascular cells. J Cell Biochem. 2010 Dec 1;111(5):1270-9. PMID: 20803553.

 

Possemiers S, Rabot S, Espín JC, et al. Eubacterium limosum activates isoxanthohumol from hops (Humulus lupulus L.) into the potent phytoestrogen 8-prenylnaringenin in vitro and in rat intestine. J Nutr. 2008 Jul;138(7):1310-6. PMID: 18567753.

 

Yang JY, Della-Fera MA, Rayalam S, et al. Effect of xanthohumol and isoxanthohumol on 3T3-L1 cell apoptosis and adipogenesis. Apoptosis. 2007 Nov;12(11):1953-63. PMID: 17874298.

 

Possemiers S, Bolca S, Grootaert C,  et al. The prenylflavonoid isoxanthohumol from hops (Humulus lupulus L.) is activated into the potent phytoestrogen 8-prenylnaringenin in vitro and in the human intestine. J Nutr. 2006 Jul;136(7):1862-7. PMID: 16772450.

" Not dangerous goods.

LKT I7759 Isoxanthohumol 10 mg 611.5 Prenylflavinoid, derivative of xanthohumol found in Humulus lupulus. 7-hydroxy-2-(4-hydroxyphenyl)-5-methoxy-8-(3-methylbut-2-enyl)-2,3-dihydrochromen-4-one 70872-29-6 ≥98% 354.39 C21H22O5 CC(=CCC1=C(C=C(C2=C1OC(CC2=O)C3=CC=C(C=C3)O)OC)O)C ambient 4°C "Negrão R, Duarte D, Costa R, et al. Isoxanthohumol modulates angiogenesis and inflammation via vascular endothelial growth factor receptor, tumor necrosis factor alpha and nuclear factor kappa B pathways. Biofactors. 2013 Aug 1. [Epub ahead of print] PMID: 23904052.

 

Negrão R, Costa R, Duarte D, et al. Angiogenesis and inflammation signaling are targets of beer polyphenols on vascular cells. J Cell Biochem. 2010 Dec 1;111(5):1270-9. PMID: 20803553.

 

Possemiers S, Rabot S, Espín JC, et al. Eubacterium limosum activates isoxanthohumol from hops (Humulus lupulus L.) into the potent phytoestrogen 8-prenylnaringenin in vitro and in rat intestine. J Nutr. 2008 Jul;138(7):1310-6. PMID: 18567753.

 

Yang JY, Della-Fera MA, Rayalam S, et al. Effect of xanthohumol and isoxanthohumol on 3T3-L1 cell apoptosis and adipogenesis. Apoptosis. 2007 Nov;12(11):1953-63. PMID: 17874298.

 

Possemiers S, Bolca S, Grootaert C,  et al. The prenylflavonoid isoxanthohumol from hops (Humulus lupulus L.) is activated into the potent phytoestrogen 8-prenylnaringenin in vitro and in the human intestine. J Nutr. 2006 Jul;136(7):1862-7. PMID: 16772450.

" Not dangerous goods.

LKT O6932 Oridonin 5 mg 61.1 Diterpenoid found in Rabdosia rubescens; potential HSP70 activator. 7a,20-Epoxy-1a,6b,7,14-tetrahydroxy-Kaur-16-en-15-one Isodonol, Rubescensin A (high purity) 28957-04-2 ≥98% 364.43 C20H28O6 CC1(CCC(C23C1C(C(C45C2CCC(C4O)C(=C)C5=O)(OC3)O)O)O)C Ambient 4°C "Chen Z, Wang Z, Chen J, et al. Resonance light scattering technique as a new tool to determine the binding mode of anticancer drug oridonin to DNA. Eur J Med Chem. 2013 Aug;66:380-7. PMID: 23827178.

 

Dal Piaz F, Cotugno R, Lepore L, et al. Chemical proteomics reveals HSP70 1A as a target for the anticancer diterpene oridonin in Jurkat cells. J Proteomics. 2013 Apr 26;82:14-26. PMID: 23416714.

 

Yin B, Sheng H, Lin J, et al. The cell death of C6 astrocytoma cells induced by oridonin and its mechanism. Int J Clin Exp Pathol. 2012;5(6):562-8. PMID: 22949939.

 

Li X, Li X, Wang J, et al. Oridonin up-regulates expression of P21 and induces autophagy and apoptosis in human prostate cancer cells. Int J Biol Sci. 2012;8(6):901-12. PMID: 22745580.

" Not dangerous goods.

LKT O6932 Oridonin 25 mg 203.8 Diterpenoid found in Rabdosia rubescens; potential HSP70 activator. 7a,20-Epoxy-1a,6b,7,14-tetrahydroxy-Kaur-16-en-15-one Isodonol, Rubescensin A (high purity) 28957-04-2 ≥98% 364.43 C20H28O6 CC1(CCC(C23C1C(C(C45C2CCC(C4O)C(=C)C5=O)(OC3)O)O)O)C Ambient 4°C "Chen Z, Wang Z, Chen J, et al. Resonance light scattering technique as a new tool to determine the binding mode of anticancer drug oridonin to DNA. Eur J Med Chem. 2013 Aug;66:380-7. PMID: 23827178.

 

Dal Piaz F, Cotugno R, Lepore L, et al. Chemical proteomics reveals HSP70 1A as a target for the anticancer diterpene oridonin in Jurkat cells. J Proteomics. 2013 Apr 26;82:14-26. PMID: 23416714.

 

Yin B, Sheng H, Lin J, et al. The cell death of C6 astrocytoma cells induced by oridonin and its mechanism. Int J Clin Exp Pathol. 2012;5(6):562-8. PMID: 22949939.

 

Li X, Li X, Wang J, et al. Oridonin up-regulates expression of P21 and induces autophagy and apoptosis in human prostate cancer cells. Int J Biol Sci. 2012;8(6):901-12. PMID: 22745580.

" Not dangerous goods.

LKT O6932 Oridonin 100 mg 638.7 Diterpenoid found in Rabdosia rubescens; potential HSP70 activator. 7a,20-Epoxy-1a,6b,7,14-tetrahydroxy-Kaur-16-en-15-one Isodonol, Rubescensin A (high purity) 28957-04-2 ≥98% 364.43 C20H28O6 CC1(CCC(C23C1C(C(C45C2CCC(C4O)C(=C)C5=O)(OC3)O)O)O)C Ambient 4°C "Chen Z, Wang Z, Chen J, et al. Resonance light scattering technique as a new tool to determine the binding mode of anticancer drug oridonin to DNA. Eur J Med Chem. 2013 Aug;66:380-7. PMID: 23827178.

 

Dal Piaz F, Cotugno R, Lepore L, et al. Chemical proteomics reveals HSP70 1A as a target for the anticancer diterpene oridonin in Jurkat cells. J Proteomics. 2013 Apr 26;82:14-26. PMID: 23416714.

 

Yin B, Sheng H, Lin J, et al. The cell death of C6 astrocytoma cells induced by oridonin and its mechanism. Int J Clin Exp Pathol. 2012;5(6):562-8. PMID: 22949939.

 

Li X, Li X, Wang J, et al. Oridonin up-regulates expression of P21 and induces autophagy and apoptosis in human prostate cancer cells. Int J Biol Sci. 2012;8(6):901-12. PMID: 22745580.

" Not dangerous goods.

LKT T3200 Ticagrelor 5 mg 61.1 Nucleoside (adenosine) analog; P2Y12 antagonist. (1S,2S,3R,5S)-3-[7-[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino]-5-(propylthio)- 3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol AZD-6140 274693-27-5 ≥98% 522.57 C23H28F2N6O4S CCCSC1=NC2=C(C(=N1)NC3CC3C4=CC(=C(C=C4)F)F)N=NN2C5CC(C(C5O)O)OCCO Ambient Ambient "Rahman M, Gustafsson D, Wang Y, et al. Ticagrelor reduces neutrophil recruitment and lung damage in abdominal sepsis. Platelets. 2013 Jul 15. [Epub ahead of print] PMID: 23855479.

 

Wittfeldt A, Emanuelsson H, Brandrup-Wognsen G, et al. Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans. J Am Coll Cardiol. 2013 Feb 19;61(7):723-7. PMID: 23312702.

 

Birkeland K, Parra D, Rosenstein R. Antiplatelet therapy in acute coronary syndromes: focus on ticagrelor. J Blood Med. 2010;1:197-219. PMID: 22282698.

" Not dangerous goods.

LKT T3200 Ticagrelor 25 mg 224.3 Nucleoside (adenosine) analog; P2Y12 antagonist. (1S,2S,3R,5S)-3-[7-[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino]-5-(propylthio)- 3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol AZD-6140 274693-27-5 ≥98% 522.57 C23H28F2N6O4S CCCSC1=NC2=C(C(=N1)NC3CC3C4=CC(=C(C=C4)F)F)N=NN2C5CC(C(C5O)O)OCCO Ambient Ambient "Rahman M, Gustafsson D, Wang Y, et al. Ticagrelor reduces neutrophil recruitment and lung damage in abdominal sepsis. Platelets. 2013 Jul 15. [Epub ahead of print] PMID: 23855479.

 

Wittfeldt A, Emanuelsson H, Brandrup-Wognsen G, et al. Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans. J Am Coll Cardiol. 2013 Feb 19;61(7):723-7. PMID: 23312702.

 

Birkeland K, Parra D, Rosenstein R. Antiplatelet therapy in acute coronary syndromes: focus on ticagrelor. J Blood Med. 2010;1:197-219. PMID: 22282698.

" Not dangerous goods.

LKT T3200 Ticagrelor 100 mg 577.6 Nucleoside (adenosine) analog; P2Y12 antagonist. (1S,2S,3R,5S)-3-[7-[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino]-5-(propylthio)- 3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol AZD-6140 274693-27-5 ≥98% 522.57 C23H28F2N6O4S CCCSC1=NC2=C(C(=N1)NC3CC3C4=CC(=C(C=C4)F)F)N=NN2C5CC(C(C5O)O)OCCO Ambient Ambient "Rahman M, Gustafsson D, Wang Y, et al. Ticagrelor reduces neutrophil recruitment and lung damage in abdominal sepsis. Platelets. 2013 Jul 15. [Epub ahead of print] PMID: 23855479.

 

Wittfeldt A, Emanuelsson H, Brandrup-Wognsen G, et al. Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans. J Am Coll Cardiol. 2013 Feb 19;61(7):723-7. PMID: 23312702.

 

Birkeland K, Parra D, Rosenstein R. Antiplatelet therapy in acute coronary syndromes: focus on ticagrelor. J Blood Med. 2010;1:197-219. PMID: 22282698.

" Not dangerous goods.

LKT D0004 Dabrafenib 5 mg 67.9 B-Raf and c-Raf inhibitor. 1195765-45-7 ≥98% 519.56 C23H20F3N5O2S2 CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F Ambient -20°C "Ballantyne AD, Garnock-Jones KP. Dabrafenib: First Global Approval. Drugs. 2013 Jul 24. [Epub ahead of print] PMID: 23881668. 

 

Huang T, Karsy M, Zhuge J, et al. B-Raf and the inhibitors: from bench to bedside. J Hematol Oncol. 2013 Apr 25;6:30. PMID: 23617957.

 

Klinac D, Gray ES, Millward M, et al. Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Front Oncol. 2013;3:54. PMID: 23515890.

 

Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012 Jul 28;380(9839):358-65. PMID: 22735384." Not dangerous goods.

LKT D0004 Dabrafenib 25 mg 319.4 B-Raf and c-Raf inhibitor. 1195765-45-7 ≥98% 519.56 C23H20F3N5O2S2 CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F Ambient -20°C "Ballantyne AD, Garnock-Jones KP. Dabrafenib: First Global Approval. Drugs. 2013 Jul 24. [Epub ahead of print] PMID: 23881668. 

 

Huang T, Karsy M, Zhuge J, et al. B-Raf and the inhibitors: from bench to bedside. J Hematol Oncol. 2013 Apr 25;6:30. PMID: 23617957.

 

Klinac D, Gray ES, Millward M, et al. Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Front Oncol. 2013;3:54. PMID: 23515890.

 

Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012 Jul 28;380(9839):358-65. PMID: 22735384." Not dangerous goods.

LKT A6971 ARRY-162 5 mg 88.3 MEK1/2 and ERK inhibitor. MEK162 606143-89-9 ≥99% 441.23 C17H15BrF2N4O3 CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO Ambient -20°C Soluble in DMSO

LKT A6971 ARRY-162 25 mg 203.8 MEK1/2 and ERK inhibitor. MEK162 606143-89-9 ≥99% 441.23 C17H15BrF2N4O3 CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO Ambient -20°C Soluble in DMSO

LKT A6971 ARRY-162 100 mg 611.5 MEK1/2 and ERK inhibitor. MEK162 606143-89-9 ≥99% 441.23 C17H15BrF2N4O3 CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO Ambient -20°C Soluble in DMSO Not dangerous goods.

LKT A7400 ASP3026 1 mg 88.3 ALK inhibitor. ASP-3026, ASP 3026 1097917-15-1 ≥99% 580.74 C29H40N8O3S CC(C)S(=O)(=O)C1=CC=CC=C1NC2=NC=NC(=N2)NC3=C(C=C(C=C3)N4CCC(CC4)N5CCN(CC5)C)OC Ambient -20°C "

 

 

" Not dangerous goods.

LKT A7400 ASP3026 5 mg 224.3 ALK inhibitor. ASP-3026, ASP 3026 1097917-15-1 ≥99% 580.74 C29H40N8O3S CC(C)S(=O)(=O)C1=CC=CC=C1NC2=NC=NC(=N2)NC3=C(C=C(C=C3)N4CCC(CC4)N5CCN(CC5)C)OC Ambient -20°C "

 

" Not dangerous goods.

LKT A7400 ASP3026 25 mg 516.4 ALK inhibitor. ASP-3026, ASP 3026 1097917-15-1 ≥99% 580.74 C29H40N8O3S CC(C)S(=O)(=O)C1=CC=CC=C1NC2=NC=NC(=N2)NC3=C(C=C(C=C3)N4CCC(CC4)N5CCN(CC5)C)OC Ambient -20°C "

 

4001504

" Not dangerous goods.

LKT A9600 AZD-3463 1 mg 101.9 ALK and IGF-1R inhibitor. AZD-3463 1356962-20-3 ≥99% 448.95 C24H25ClN6O COC1=C(C=CC(=C1)N2CCC(CC2)N)NC3=NC=C(C(=N3)C4=CNC5=CC=CC=C54)Cl Ambient -20°C In DMSO, water with 1 eq. of acid Abstract: Yang B. Discovery of AZD3463 as a novel ALK/IGFR dual inhibitor and its ability in overcoming acquired resistance to crizotinib. Protein Kinases in Drug Discovery Conference. 2013. Not dangerous goods.

LKT A9600 AZD-3463 5 mg 244.5 ALK and IGF-1R inhibitor. AZD-3463 1356962-20-3 ≥99% 448.95 C24H25ClN6O COC1=C(C=CC(=C1)N2CCC(CC2)N)NC3=NC=C(C(=N3)C4=CNC5=CC=CC=C54)Cl Ambient -20°C In DMSO, water with 1 eq. of acid Abstract: Yang B. Discovery of AZD3463 as a novel ALK/IGFR dual inhibitor and its ability in overcoming acquired resistance to crizotinib. Protein Kinases in Drug Discovery Conference. 2013. Not dangerous goods.

LKT A9600 AZD-3463 25 mg 570.8 ALK and IGF-1R inhibitor. AZD-3463 1356962-20-3 ≥99% 448.95 C24H25ClN6O COC1=C(C=CC(=C1)N2CCC(CC2)N)NC3=NC=C(C(=N3)C4=CNC5=CC=CC=C54)Cl Ambient -20°C In DMSO, water with 1 eq. of acid Abstract: Yang B. Discovery of AZD3463 as a novel ALK/IGFR dual inhibitor and its ability in overcoming acquired resistance to crizotinib. Protein Kinases in Drug Discovery Conference. 2013. Not dangerous goods.

LKT A9601 AZD-5363 1 mg 122.3 AKT inhibitor, potential ROCK, p70S6K, PKA, MKK1, MSK1, MSK2, PKC, PKG, PRKX, RSK2/3 inhibitor. AZD-5363 1143532-39-1 ≥99%, ≥99%ee 428.92 C21H25ClN6O2 C1CN(CCC1(C(=O)NC(CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4 Ambient -20°C In DMSO, water with 2 eq. of acid "Addie M, Ballard P, Buttar D, et al. Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases. J Med Chem. 2013 Mar 14;56(5):2059-73. PMID: 23394218. 

 

Lamoureux F, Thomas C, Crafter C, et al. Blocked autophagy using lysosomotropic agents sensitizes resistant prostate tumor cells to the novel Akt inhibitor AZD5363. Clin Cancer Res. 2013 Feb 15;19(4):833-44. PMID: 23258740.

 

Davies BR, Greenwood H, Dudley P, et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther. 2012 Apr;11(4):873-87. PMID: 22294718.

" Not dangerous goods.

LKT A9601 AZD-5363 5 mg 298.9 AKT inhibitor, potential ROCK, p70S6K, PKA, MKK1, MSK1, MSK2, PKC, PKG, PRKX, RSK2/3 inhibitor. AZD-5363 1143532-39-1 ≥99%, ≥99%ee 428.92 C21H25ClN6O2 C1CN(CCC1(C(=O)NC(CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4 Ambient -20°C In DMSO, water with 2 eq. of acid "Addie M, Ballard P, Buttar D, et al. Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases. J Med Chem. 2013 Mar 14;56(5):2059-73. PMID: 23394218. 

 

Lamoureux F, Thomas C, Crafter C, et al. Blocked autophagy using lysosomotropic agents sensitizes resistant prostate tumor cells to the novel Akt inhibitor AZD5363. Clin Cancer Res. 2013 Feb 15;19(4):833-44. PMID: 23258740.

 

Davies BR, Greenwood H, Dudley P, et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther. 2012 Apr;11(4):873-87. PMID: 22294718.

" Not dangerous goods.

LKT A9601 AZD-5363 25 mg 652.3 AKT inhibitor, potential ROCK, p70S6K, PKA, MKK1, MSK1, MSK2, PKC, PKG, PRKX, RSK2/3 inhibitor. AZD-5363 1143532-39-1 ≥99%, ≥99%ee 428.92 C21H25ClN6O2 C1CN(CCC1(C(=O)NC(CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4 Ambient -20°C In DMSO, water with 2 eq. of acid "Addie M, Ballard P, Buttar D, et al. Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases. J Med Chem. 2013 Mar 14;56(5):2059-73. PMID: 23394218. 

 

Lamoureux F, Thomas C, Crafter C, et al. Blocked autophagy using lysosomotropic agents sensitizes resistant prostate tumor cells to the novel Akt inhibitor AZD5363. Clin Cancer Res. 2013 Feb 15;19(4):833-44. PMID: 23258740.

 

Davies BR, Greenwood H, Dudley P, et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther. 2012 Apr;11(4):873-87. PMID: 22294718.

" Not dangerous goods.

LKT B5000 BMS-911543 1 mg 251.5 JAK2 inhibitor. BMS911543 1271022-90-2 ≥99% 432.52 C23H28N8O CCN1C(=CC2=C3C(=C(N=C21)NC4=NN(C(=C4)C)C)N=CN3C)C(=O)N(C5CC5)C6CC6 Ambient -20°C Soluble in DMSO "Purandare AV, McDevitt TM, Wan H, et al. Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2. Leukemia. 2012 Feb;26(2):280-8. PMID: 22015772.

 

Tibes R, Bogenberger JM, Geyer HL, et al. JAK2 inhibitors in the treatment of myeloproliferative neoplasms. Expert Opin Investig Drugs. 2012 Dec;21(12):1755-74. PMID: 22991927.

" Not dangerous goods.

LKT B5000 BMS-911543 5 mg 611.5 JAK2 inhibitor. BMS911543 1271022-90-2 ≥99% 432.52 C23H28N8O CCN1C(=CC2=C3C(=C(N=C21)NC4=NN(C(=C4)C)C)N=CN3C)C(=O)N(C5CC5)C6CC6 Ambient -20°C Soluble in DMSO "Purandare AV, McDevitt TM, Wan H, et al. Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2. Leukemia. 2012 Feb;26(2):280-8. PMID: 22015772.

 

Tibes R, Bogenberger JM, Geyer HL, et al. JAK2 inhibitors in the treatment of myeloproliferative neoplasms. Expert Opin Investig Drugs. 2012 Dec;21(12):1755-74. PMID: 22991927.

" Not dangerous goods.

LKT B9700 BYL719 1 mg 122.3 p110α PI3K inhibitor. BYL-719 1217486-61-7 ≥99%, ≥99%ee 441.47 C19H22F3N5O2S CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F Ambient -20°C In DMSO "Bonelli MA, Cavazzoni A, Saccani F, et al. Inhibition of PI3K pathway reduces invasiveness and epithelial-to-mesenchymal transition in squamous lung cancer cell lines harboring PIK3CA gene alterations. Mol Cancer Ther. 2015 May 26. [Epub ahead of print]. PMID: 26013318.

 

Elkabets M, Vora S, Juric D, et al. mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA-Mutant Breast Cancer. Sci Transl Med. 2013 Jul 31;5(196):196ra99. PMID: 23903756.

 

Abstract: Juric. BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study. American Association for Cancer Research. 2012.

" Not dangerous goods.

LKT B9700 BYL719 5 mg 298.9 p110α PI3K inhibitor. BYL-719 1217486-61-7 ≥99%, ≥99%ee 441.47 C19H22F3N5O2S CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F Ambient -20°C In DMSO "Bonelli MA, Cavazzoni A, Saccani F, et al. Inhibition of PI3K pathway reduces invasiveness and epithelial-to-mesenchymal transition in squamous lung cancer cell lines harboring PIK3CA gene alterations. Mol Cancer Ther. 2015 May 26. [Epub ahead of print]. PMID: 26013318.

 

Elkabets M, Vora S, Juric D, et al. mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA-Mutant Breast Cancer. Sci Transl Med. 2013 Jul 31;5(196):196ra99. PMID: 23903756.

 

Abstract: Juric. BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study. American Association for Cancer Research. 2012.

" Not dangerous goods.

LKT B9700 BYL719 25 mg 652.3 p110α PI3K inhibitor. BYL-719 1217486-61-7 ≥99%, ≥99%ee 441.47 C19H22F3N5O2S CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F Ambient -20°C In DMSO "Bonelli MA, Cavazzoni A, Saccani F, et al. Inhibition of PI3K pathway reduces invasiveness and epithelial-to-mesenchymal transition in squamous lung cancer cell lines harboring PIK3CA gene alterations. Mol Cancer Ther. 2015 May 26. [Epub ahead of print]. PMID: 26013318.

 

Elkabets M, Vora S, Juric D, et al. mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA-Mutant Breast Cancer. Sci Transl Med. 2013 Jul 31;5(196):196ra99. PMID: 23903756.

 

Abstract: Juric. BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study. American Association for Cancer Research. 2012.

" Not dangerous goods.

LKT C0271 Carfilzomib 1 mg 101.9 Epoxomicin analog; proteasome inhibitor. PR-171 868540-17-4 ≥98% 719.91 C40H57N5O7 CC(C)CC(C(=O)C1(CO1)C)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC(C)C)NC(=O)C(CCC3=CC=CC=C3)NC(=O)CN4CCOCC4 Ambient -20°C ~15 mg/ml in DMSO "Gu JJ, Hernandez-Ilizaliturri FJ, Kaufman GP, et al. The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma. Br J Haematol. 2013 Jul 4. Epub ahead of print] PMID: 23826755. 

 

Lee HC, Shah JJ, Orlowski RZ. Novel approaches to treatment of double-refractory multiple myeloma. Am Soc Clin Oncol Educ Book. 2013;2013:302-6. doi: E10.1200/EdBook_AM.2013.33.e302. PMID: 23714530.

 

Nooka A, Gleason C, Casbourne D, et al. Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib. Biologics. 2013;7:13-32. PMID: 23386784

" Not dangerous goods.

LKT C0271 Carfilzomib 5 mg 244.5 Epoxomicin analog; proteasome inhibitor. PR-171 868540-17-4 ≥98% 719.91 C40H57N5O7 CC(C)CC(C(=O)C1(CO1)C)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC(C)C)NC(=O)C(CCC3=CC=CC=C3)NC(=O)CN4CCOCC4 Ambient -20°C ~15 mg/ml in DMSO "Gu JJ, Hernandez-Ilizaliturri FJ, Kaufman GP, et al. The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma. Br J Haematol. 2013 Jul 4. Epub ahead of print] PMID: 23826755. 

 

Lee HC, Shah JJ, Orlowski RZ. Novel approaches to treatment of double-refractory multiple myeloma. Am Soc Clin Oncol Educ Book. 2013;2013:302-6. doi: E10.1200/EdBook_AM.2013.33.e302. PMID: 23714530.

 

Nooka A, Gleason C, Casbourne D, et al. Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib. Biologics. 2013;7:13-32. PMID: 23386784

" Not dangerous goods.

LKT C0271 Carfilzomib 25 mg 570.8 Epoxomicin analog; proteasome inhibitor. PR-171 868540-17-4 ≥98% 719.91 C40H57N5O7 CC(C)CC(C(=O)C1(CO1)C)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC(C)C)NC(=O)C(CCC3=CC=CC=C3)NC(=O)CN4CCOCC4 Ambient -20°C ~15 mg/ml in DMSO "Gu JJ, Hernandez-Ilizaliturri FJ, Kaufman GP, et al. The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma. Br J Haematol. 2013 Jul 4. Epub ahead of print] PMID: 23826755. 

 

Lee HC, Shah JJ, Orlowski RZ. Novel approaches to treatment of double-refractory multiple myeloma. Am Soc Clin Oncol Educ Book. 2013;2013:302-6. doi: E10.1200/EdBook_AM.2013.33.e302. PMID: 23714530.

 

Nooka A, Gleason C, Casbourne D, et al. Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib. Biologics. 2013;7:13-32. PMID: 23386784

" Not dangerous goods.

LKT D0006 Dacomitinib Monohydrate 1 mg 101.9 EGFR inhibitor. PF-00299804 1042385-75-0 ≥99% 487.95 C24H27ClFN5O3 COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)NC(=O)C=CCN4CCCCC4.O Ambient -20°C In DMSO "Kalous O, Conklin D, Desai AJ, et al. Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib. Mol Cancer Ther. 2012 Sep;11(9):1978-87. PMID: 22761403.

 

Gonzales AJ, Hook KE, Althaus IW, et al. Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol Cancer Ther. 2008 Jul;7(7):1880-9. PMID: 18606718.

" Not dangerous goods.

LKT D0006 Dacomitinib Monohydrate 5 mg 244.5 EGFR inhibitor. PF-00299804 1042385-75-0 ≥99% 487.95 C24H27ClFN5O3 COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)NC(=O)C=CCN4CCCCC4.O Ambient -20°C In DMSO "Kalous O, Conklin D, Desai AJ, et al. Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib. Mol Cancer Ther. 2012 Sep;11(9):1978-87. PMID: 22761403.

 

Gonzales AJ, Hook KE, Althaus IW, et al. Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol Cancer Ther. 2008 Jul;7(7):1880-9. PMID: 18606718.

" Not dangerous goods.

LKT D0006 Dacomitinib Monohydrate 25 mg 570.8 EGFR inhibitor. PF-00299804 1042385-75-0 ≥99% 487.95 C24H27ClFN5O3 COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)NC(=O)C=CCN4CCCCC4.O Ambient -20°C In DMSO "Kalous O, Conklin D, Desai AJ, et al. Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib. Mol Cancer Ther. 2012 Sep;11(9):1978-87. PMID: 22761403.

 

Gonzales AJ, Hook KE, Althaus IW, et al. Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol Cancer Ther. 2008 Jul;7(7):1880-9. PMID: 18606718.

" Not dangerous goods.

LKT E6396 EPZ005687 1 mg 92.5 EZH2 HMT inhibitor. 1396772-26-1 ≥99% 539.67 C32H37N5O3 CC1=CC(=C(C(=O)N1)CNC(=O)C2=C3C=NN(C3=CC(=C2)C4=CC=C(C=C4)CN5CCOCC5)C6CCCC6)C Ambient -20°C DMSO Knutson SK, Wigle TJ, Warholic NM, et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol. 2012 Nov;8(11):890-6. PMID: 23023262. Not dangerous goods.

LKT E6396 EPZ005687 5 mg 237.8 EZH2 HMT inhibitor. 1396772-26-1 ≥99% 539.67 C32H37N5O3 CC1=CC(=C(C(=O)N1)CNC(=O)C2=C3C=NN(C3=CC(=C2)C4=CC=C(C=C4)CN5CCOCC5)C6CCCC6)C Ambient -20°C DMSO Knutson SK, Wigle TJ, Warholic NM, et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol. 2012 Nov;8(11):890-6. PMID: 23023262. Not dangerous goods.

LKT E6396 EPZ005687 25 mg 570.8 EZH2 HMT inhibitor. 1396772-26-1 ≥99% 539.67 C32H37N5O3 CC1=CC(=C(C(=O)N1)CNC(=O)C2=C3C=NN(C3=CC(=C2)C4=CC=C(C=C4)CN5CCOCC5)C6CCCC6)C Ambient -20°C DMSO Knutson SK, Wigle TJ, Warholic NM, et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol. 2012 Nov;8(11):890-6. PMID: 23023262. Not dangerous goods.

LKT E6397 EPZ6438 1 mg 108.8 E7438 1403254-99-8 ≥99% 572.74 C34H44N4O4 CCN(C1CCOCC1)C2=CC(=CC(=C2C)C(=O)NCC3=C(C=C(NC3=O)C)C)C4=CC=C(C=C4)CN5CCOCC5 Ambient -20°C In DMSO Knutson SK, Warholic NM, Wigle TJ, et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci U S A. 2013 May 7;110(19):7922-7. PMID: 23620515. Not dangerous goods.

LKT E6397 EPZ6438 5 mg 271.7 E7438 1403254-99-8 ≥99% 572.74 C34H44N4O4 CCN(C1CCOCC1)C2=CC(=CC(=C2C)C(=O)NCC3=C(C=C(NC3=O)C)C)C4=CC=C(C=C4)CN5CCOCC5 Ambient -20°C In DMSO Knutson SK, Warholic NM, Wigle TJ, et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci U S A. 2013 May 7;110(19):7922-7. PMID: 23620515. Not dangerous goods.

LKT E6397 EPZ6438 25 mg 611.5 E7438 1403254-99-8 ≥99% 572.74 C34H44N4O4 CCN(C1CCOCC1)C2=CC(=CC(=C2C)C(=O)NCC3=C(C=C(NC3=O)C)C)C4=CC=C(C=C4)CN5CCOCC5 Ambient -20°C In DMSO Knutson SK, Warholic NM, Wigle TJ, et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci U S A. 2013 May 7;110(19):7922-7. PMID: 23620515. Not dangerous goods.

LKT G1200 GDC-0068 1 mg 224.3 Akt inhibitor. RG7440, Ipatasertib 1001264-89-6 ≥99% 458 C24H32ClN5O2 CC1CC(C2=C1C(=NC=N2)N3CCN(CC3)C(=O)C(CNC(C)C)C4=CC=C(C=C4)Cl)O Ambient -20°C Soluble in DMSO "Davies BR, Greenwood H, Dudley P, et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther. 2012 Apr;11(4):873-87. PMID: 22294718.

 

Markman B, Dienstmann R, Tabernero J. Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs. Oncotarget. 2010 Nov;1(7):530-43. Review. PubMed PMID: 21317449.

" Not dangerous goods.

LKT G1200 GDC-0068 5 mg 570.8 Akt inhibitor. RG7440, Ipatasertib 1001264-89-6 ≥99% 458 C24H32ClN5O2 CC1CC(C2=C1C(=NC=N2)N3CCN(CC3)C(=O)C(CNC(C)C)C4=CC=C(C=C4)Cl)O Ambient -20°C Soluble in DMSO "Davies BR, Greenwood H, Dudley P, et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther. 2012 Apr;11(4):873-87. PMID: 22294718.

 

Markman B, Dienstmann R, Tabernero J. Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs. Oncotarget. 2010 Nov;1(7):530-43. Review. PubMed PMID: 21317449.

" Not dangerous goods.

LKT G7340 GSK-126 1 mg 203.8 EZH2 HMT inhibitor. 1346574-57-9 ≥99%, ≥99%ee 526.67 C31H38N6O2 CCC(C)N1C=C(C2=C(C=C(C=C21)C3=CN=C(C=C3)N4CCNCC4)C(=O)NCC5=C(C=C(NC5=O)C)C)C Ambient -20°C Soluble in DMSO "Tian X, Zhang S, Liu HM, et al. Histone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and prevention. Curr Cancer Drug Targets. 2013 Jun 10;13(5):558-79. PMID: 23713993.

 

McCabe MT, Ott HM, Ganji G, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 2012 Dec 6;492(7427):108-12. PMID: 23051747.

" Not dangerous goods.

LKT G7340 GSK-126 5 mg 543.6 EZH2 HMT inhibitor. 1346574-57-9 ≥99%, ≥99%ee 526.67 C31H38N6O2 CCC(C)N1C=C(C2=C(C=C(C=C21)C3=CN=C(C=C3)N4CCNCC4)C(=O)NCC5=C(C=C(NC5=O)C)C)C Ambient -20°C Soluble in DMSO "Tian X, Zhang S, Liu HM, et al. Histone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and prevention. Curr Cancer Drug Targets. 2013 Jun 10;13(5):558-79. PMID: 23713993.

 

McCabe MT, Ott HM, Ganji G, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 2012 Dec 6;492(7427):108-12. PMID: 23051747.

" Not dangerous goods.

LKT G7342 GSK-2126458 1 mg 136 p110α PI3K and mTOR inhibitor. GSK458 1086062-66-9 ≥99% 505.5 C25H17F2N5O3S COC1=C(C=C(C=N1)C2=CC3=C(C=CN=C3C=C2)C4=CN=NC=C4)NS(=O)(=O)C5=C(C=C(C=C5)F)F Ambient -20°C In DMSO Greger JG, Eastman SD, Zhang V, et al. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor SK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther. 2012 Apr;11(4):909-20. PMID: 22389471. Not dangerous goods.

LKT G7342 GSK-2126458 5 mg 339.8 p110α PI3K and mTOR inhibitor. GSK458 1086062-66-9 ≥99% 505.5 C25H17F2N5O3S COC1=C(C=C(C=N1)C2=CC3=C(C=CN=C3C=C2)C4=CN=NC=C4)NS(=O)(=O)C5=C(C=C(C=C5)F)F Ambient -20°C In DMSO Greger JG, Eastman SD, Zhang V, et al. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor SK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther. 2012 Apr;11(4):909-20. PMID: 22389471. Not dangerous goods.

LKT G7342 GSK-2126458 25 mg 679.5 p110α PI3K and mTOR inhibitor. GSK458 1086062-66-9 ≥99% 505.5 C25H17F2N5O3S COC1=C(C=C(C=N1)C2=CC3=C(C=CN=C3C=C2)C4=CN=NC=C4)NS(=O)(=O)C5=C(C=C(C=C5)F)F Ambient -20°C In DMSO Greger JG, Eastman SD, Zhang V, et al. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor SK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther. 2012 Apr;11(4):909-20. PMID: 22389471. Not dangerous goods.

LKT G7344 GSK-2334470 1 mg 101.9 PI3K and PDK1 inhibitor. 1227911-45-6 ≥99%, ≥99%ee 462.59 C25H34N8O CC1CCC(CN1C2=NC(=NC(=C2)C3=CC4=C(C=C3)C(=NN4)N)NC)C(=O)NC5CCCCC5 Ambient -20°C Soluble in DMSO Najafov A, Sommer EM, Axten JM, et al. Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1. Biochem J. 2011 Jan 15;433(2):357-69. PMID: 21087210. Not dangerous goods.

LKT G7344 GSK-2334470 5 mg 244.5 PI3K and PDK1 inhibitor. 1227911-45-6 ≥99%, ≥99%ee 462.59 C25H34N8O CC1CCC(CN1C2=NC(=NC(=C2)C3=CC4=C(C=C3)C(=NN4)N)NC)C(=O)NC5CCCCC5 Ambient -20°C Soluble in DMSO Najafov A, Sommer EM, Axten JM, et al. Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1. Biochem J. 2011 Jan 15;433(2):357-69. PMID: 21087210. Not dangerous goods.

LKT G7344 GSK-2334470 25 mg 577.6 PI3K and PDK1 inhibitor. 1227911-45-6 ≥99%, ≥99%ee 462.59 C25H34N8O CC1CCC(CN1C2=NC(=NC(=C2)C3=CC4=C(C=C3)C(=NN4)N)NC)C(=O)NC5CCCCC5 Ambient -20°C Soluble in DMSO Najafov A, Sommer EM, Axten JM, et al. Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1. Biochem J. 2011 Jan 15;433(2):357-69. PMID: 21087210. Not dangerous goods.

LKT G7346 GSK-2636771 1 mg 203.8 p110β PI3K inhibitor. 1372540-25-4 ≥98.5% 433.42 C22H22F3N3O3 CC1=C(C=CC=C1C(F)(F)F)CN2C(=NC3=C2C=C(C=C3C(=O)O)N4CCOCC4)C Ambient -20°C Soluble in DMSO, and water with 1 eq. of base Weigelt B, Warne PH, Lambros MB, et al. PI3K Pathway Dependencies in Endometrioid Endometrial Cancer Cell Lines. Clin Cancer Res. 2013 Jul 1;19(13):3533-44. PMID: 23674493. Not dangerous goods.

LKT G7346 GSK-2636771 5 mg 543.6 p110β PI3K inhibitor. 1372540-25-4 ≥98.5% 433.42 C22H22F3N3O3 CC1=C(C=CC=C1C(F)(F)F)CN2C(=NC3=C2C=C(C=C3C(=O)O)N4CCOCC4)C Ambient -20°C Soluble in DMSO, and water with 1 eq. of base Weigelt B, Warne PH, Lambros MB, et al. PI3K Pathway Dependencies in Endometrioid Endometrial Cancer Cell Lines. Clin Cancer Res. 2013 Jul 1;19(13):3533-44. PMID: 23674493. Not dangerous goods.

LKT I5440 INK128 1 mg 108.8 mTOR inhibitor. MLN-0128 1224844-38-5 ≥99% 309.33 C15H15N7O CC(C)N1C2=C(C(=N1)C3=CC4=C(C=C3)OC(=N4)N)C(=NC=N2)N Ambient -20°C In DMSO "Janes MR, Vu C, Mallya S, et al. Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia. Leukemia. 2013 Mar;27(3):586-94. PMID: 23090679.

 

Hsieh AC, Liu Y, Edlind MP, et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature. 2012 Feb 22;485(7396):55-61. PMID: 22367541.

 

Maiso P, Liu Y, Morgan B, et al. Defining the role of TORC1/2 in multiple myeloma. Blood. 2011 Dec 22;118(26):6860-70. PMID: 22045983.

" Not dangerous goods.

LKT I5440 INK128 5 mg 271.7 mTOR inhibitor. MLN-0128 1224844-38-5 ≥99% 309.33 C15H15N7O CC(C)N1C2=C(C(=N1)C3=CC4=C(C=C3)OC(=N4)N)C(=NC=N2)N Ambient -20°C In DMSO "Janes MR, Vu C, Mallya S, et al. Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia. Leukemia. 2013 Mar;27(3):586-94. PMID: 23090679.

 

Hsieh AC, Liu Y, Edlind MP, et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature. 2012 Feb 22;485(7396):55-61. PMID: 22367541.

 

Maiso P, Liu Y, Morgan B, et al. Defining the role of TORC1/2 in multiple myeloma. Blood. 2011 Dec 22;118(26):6860-70. PMID: 22045983.

" Not dangerous goods.

LKT I5440 INK128 25 mg 611.5 mTOR inhibitor. MLN-0128 1224844-38-5 ≥99% 309.33 C15H15N7O CC(C)N1C2=C(C(=N1)C3=CC4=C(C=C3)OC(=N4)N)C(=NC=N2)N Ambient -20°C In DMSO "Janes MR, Vu C, Mallya S, et al. Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia. Leukemia. 2013 Mar;27(3):586-94. PMID: 23090679.

 

Hsieh AC, Liu Y, Edlind MP, et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature. 2012 Feb 22;485(7396):55-61. PMID: 22367541.

 

Maiso P, Liu Y, Morgan B, et al. Defining the role of TORC1/2 in multiple myeloma. Blood. 2011 Dec 22;118(26):6860-70. PMID: 22045983.

" Not dangerous goods.

LKT L1044 LCL-161 1 mg 224.3 SMAC mimetic; PXR agonist, IAP inhibitor. LCL161 1005342-46-0 ≥99%, ≥99%ee, de 500.63 C26H33FN4O3S CC(C(=O)NC(C1CCCCC1)C(=O)N2CCCC2C3=NC(=CS3)C(=O)C4=CC=C(C=C4)F)NC Ambient -20°C In DMSO "Dhuria S, Einolf H, Mangold J, et al. Time-dependent inhibition and induction of human cytochrome P4503A4/5 by an oral IAP antagonist, LCL161, in vitro and in vivo in healthy subjects. J Clin Pharmacol. 2013 Jun;53(6):642-53. PMID: 23585187. 

 

Houghton PJ, Kang MH, Reynolds CP, et al. Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2012 Apr;58(4):636-9. PMID: 21681929.

" Not dangerous goods.

LKT L1044 LCL-161 5 mg 577.6 SMAC mimetic; PXR agonist, IAP inhibitor. LCL161 1005342-46-0 ≥99%, ≥99%ee, de 500.63 C26H33FN4O3S CC(C(=O)NC(C1CCCCC1)C(=O)N2CCCC2C3=NC(=CS3)C(=O)C4=CC=C(C=C4)F)NC Ambient -20°C In DMSO "Dhuria S, Einolf H, Mangold J, et al. Time-dependent inhibition and induction of human cytochrome P4503A4/5 by an oral IAP antagonist, LCL161, in vitro and in vivo in healthy subjects. J Clin Pharmacol. 2013 Jun;53(6):642-53. PMID: 23585187. 

 

Houghton PJ, Kang MH, Reynolds CP, et al. Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2012 Apr;58(4):636-9. PMID: 21681929.

" Not dangerous goods.

LKT L1340 LDK378 1 mg 92.5 ALK and IGF-1R inhibitor. LDK-378; Ceritinib 1032900-25-6 ≥99% 558.13 C28H36ClN5O3S CC1=CC(=C(C=C1C2CCNCC2)OC(C)C)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)C(C)C)Cl Ambient -20°C In DMSO "Iams WT, Lovly CM. Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer. Cancer J. 2015 Sep-Oct;21(5):378-82. PMID: 26389762.

 

Nishio M, Murakami H, Horiike A, et al. Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer or Other Tumors. J Thorac Oncol. 2015 Jul;10(7):1058-66.  PMID: 26010125.

 

Marsilje TH, Pei W, Chen B, et al. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem. 2013 Jul 25;56(14):5675-90. PMID: 23742252." Not dangerous goods.

LKT L1340 LDK378 5 mg 237.8 ALK and IGF-1R inhibitor. LDK-378; Ceritinib 1032900-25-6 ≥99% 558.13 C28H36ClN5O3S CC1=CC(=C(C=C1C2CCNCC2)OC(C)C)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)C(C)C)Cl Ambient -20°C In DMSO "Iams WT, Lovly CM. Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer. Cancer J. 2015 Sep-Oct;21(5):378-82. PMID: 26389762.

 

Nishio M, Murakami H, Horiike A, et al. Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer or Other Tumors. J Thorac Oncol. 2015 Jul;10(7):1058-66.  PMID: 26010125.

 

Marsilje TH, Pei W, Chen B, et al. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem. 2013 Jul 25;56(14):5675-90. PMID: 23742252." Not dangerous goods.

LKT L1340 LDK378 25 mg 570.8 ALK and IGF-1R inhibitor. LDK-378; Ceritinib 1032900-25-6 ≥99% 558.13 C28H36ClN5O3S CC1=CC(=C(C=C1C2CCNCC2)OC(C)C)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)C(C)C)Cl Ambient -20°C In DMSO "Iams WT, Lovly CM. Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer. Cancer J. 2015 Sep-Oct;21(5):378-82. PMID: 26389762.

 

Nishio M, Murakami H, Horiike A, et al. Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer or Other Tumors. J Thorac Oncol. 2015 Jul;10(7):1058-66.  PMID: 26010125.

 

Marsilje TH, Pei W, Chen B, et al. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem. 2013 Jul 25;56(14):5675-90. PMID: 23742252." Not dangerous goods.

LKT M4000 MK-2206 1 mg 101.9 Akt inhibitor. MK-2206 hydrochloride 1032349-77-1 ≥99% 443.93 C25H22ClN5O C1CC(C1)(C2=CC=C(C=C2)C3=C(C=C4C(=N3)C=CN5C4=NNC5=O)C6=CC=CC=C6)N.Cl Ambient -20°C Soluble in DMSO, water with 1 eq. of acid "Zhao YY, Tian Y, Zhang J, et al. Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo. Drug Des Devel Ther. 2014 Oct 10;8:1827-37. pMID: 25336925.

 

Burke JF, Schlosser L, Harrison AD, et al. MK-2206 Causes Growth Suppression and Reduces Neuroendocrine Tumor Marker Production in Medullary Thyroid Cancer Through Akt Inhibition. Ann Surg Oncol. 2013 Nov;20(12):3862-8. PMID: 23900743.

 

Jiao P, Zhou YS, Yang JX, et al. MK-2206 induces cell cycle arrest and apoptosis in HepG2 cells and sensitizes TRAIL-mediated cell death. Mol Cell Biochem. 2013 Jun 25. [Epub ahead of print] PMID: 23797319. 

 

Jin R, Nakada M, Teng L, et al. Combination therapy using Notch and Akt inhibitors is effective for suppressing invasion but not proliferation in glioma cells. Neurosci Lett. 2013 Feb 8;534:316-21. PMID: 23262078.

 

Quayle SN, Lee JY, Cheung LW, et al. Somatic mutations of PIK3R1 promote gliomagenesis. PLoS One. 2012;7(11):e49466. PMID: 23166678.

 

Iida M, Brand TM, Campbell DA, et al. Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximab. Cancer Biol Ther. 2013 Jun;14(6):481-91. PMID: 23760490.

 

Davies BR, Greenwood H, Dudley P, et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther. 2012 Apr;11(4):873-87. PMID: 22294718.

 

Cheng Y, Zhang Y, Zhang L, et al. MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis. Mol Cancer Ther. 2012 Jan;11(1):154-64. PMID: 22057914." Not dangerous goods.

LKT M4000 MK-2206 5 mg 244.5 Akt inhibitor. MK-2206 hydrochloride 1032349-77-1 ≥99% 443.93 C25H22ClN5O C1CC(C1)(C2=CC=C(C=C2)C3=C(C=C4C(=N3)C=CN5C4=NNC5=O)C6=CC=CC=C6)N.Cl Ambient -20°C Soluble in DMSO, water with 1 eq. of acid "Zhao YY, Tian Y, Zhang J, et al. Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo. Drug Des Devel Ther. 2014 Oct 10;8:1827-37. pMID: 25336925.

 

Burke JF, Schlosser L, Harrison AD, et al. MK-2206 Causes Growth Suppression and Reduces Neuroendocrine Tumor Marker Production in Medullary Thyroid Cancer Through Akt Inhibition. Ann Surg Oncol. 2013 Nov;20(12):3862-8. PMID: 23900743.

 

Jiao P, Zhou YS, Yang JX, et al. MK-2206 induces cell cycle arrest and apoptosis in HepG2 cells and sensitizes TRAIL-mediated cell death. Mol Cell Biochem. 2013 Jun 25. [Epub ahead of print] PMID: 23797319. 

 

Jin R, Nakada M, Teng L, et al. Combination therapy using Notch and Akt inhibitors is effective for suppressing invasion but not proliferation in glioma cells. Neurosci Lett. 2013 Feb 8;534:316-21. PMID: 23262078.

 

Quayle SN, Lee JY, Cheung LW, et al. Somatic mutations of PIK3R1 promote gliomagenesis. PLoS One. 2012;7(11):e49466. PMID: 23166678.

 

Iida M, Brand TM, Campbell DA, et al. Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximab. Cancer Biol Ther. 2013 Jun;14(6):481-91. PMID: 23760490.

 

Davies BR, Greenwood H, Dudley P, et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther. 2012 Apr;11(4):873-87. PMID: 22294718.

 

Cheng Y, Zhang Y, Zhang L, et al. MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis. Mol Cancer Ther. 2012 Jan;11(1):154-64. PMID: 22057914." Not dangerous goods.

LKT M4000 MK-2206 25 mg 570.8 Akt inhibitor. MK-2206 hydrochloride 1032349-77-1 ≥99% 443.93 C25H22ClN5O C1CC(C1)(C2=CC=C(C=C2)C3=C(C=C4C(=N3)C=CN5C4=NNC5=O)C6=CC=CC=C6)N.Cl Ambient -20°C Soluble in DMSO, water with 1 eq. of acid "Zhao YY, Tian Y, Zhang J, et al. Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo. Drug Des Devel Ther. 2014 Oct 10;8:1827-37. pMID: 25336925.

 

Burke JF, Schlosser L, Harrison AD, et al. MK-2206 Causes Growth Suppression and Reduces Neuroendocrine Tumor Marker Production in Medullary Thyroid Cancer Through Akt Inhibition. Ann Surg Oncol. 2013 Nov;20(12):3862-8. PMID: 23900743.

 

Jiao P, Zhou YS, Yang JX, et al. MK-2206 induces cell cycle arrest and apoptosis in HepG2 cells and sensitizes TRAIL-mediated cell death. Mol Cell Biochem. 2013 Jun 25. [Epub ahead of print] PMID: 23797319. 

 

Jin R, Nakada M, Teng L, et al. Combination therapy using Notch and Akt inhibitors is effective for suppressing invasion but not proliferation in glioma cells. Neurosci Lett. 2013 Feb 8;534:316-21. PMID: 23262078.

 

Quayle SN, Lee JY, Cheung LW, et al. Somatic mutations of PIK3R1 promote gliomagenesis. PLoS One. 2012;7(11):e49466. PMID: 23166678.

 

Iida M, Brand TM, Campbell DA, et al. Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximab. Cancer Biol Ther. 2013 Jun;14(6):481-91. PMID: 23760490.

 

Davies BR, Greenwood H, Dudley P, et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther. 2012 Apr;11(4):873-87. PMID: 22294718.

 

Cheng Y, Zhang Y, Zhang L, et al. MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis. Mol Cancer Ther. 2012 Jan;11(1):154-64. PMID: 22057914." Not dangerous goods.

LKT P0244 Palbociclib Hydrochloride 1 mg 88.3 CDK4/6 inhibitor. PD-0332991 827022-32-2 ≥99% 483.99 C24H29N7O2 HCl CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C.Cl Ambient -20°C Soluble in DMSO and water "Logan JE, Mostofizadeh N, Desai AJ, et al. PD-0332991, a Potent and Selective Inhibitor of Cyclin-dependent Kinase 4/6, Demonstrates Inhibition of Proliferation in Renal Cell Carcinoma at Nanomolar Concentrations and Molecular Markers Predict for Sensitivity. Anticancer Res. 2013 Aug;33(8):2997-3004. PMID: 23898052.

 

Roberts PJ, Bisi JE, Strum JC, et al. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. J Natl Cancer Inst. 2012 Mar 21;104(6):476-87. PMID: 22302033.

 

Rivadeneira DB, Mayhew CN, Thangavel C, et al. Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells. Gastroenterology. 2010 May;138(5):1920-30. PMID: 20100483.

" Not dangerous goods.

LKT P0244 Palbociclib Hydrochloride 5 mg 224.3 CDK4/6 inhibitor. PD-0332991 827022-32-2 ≥99% 483.99 C24H29N7O2 HCl CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C.Cl Ambient -20°C Soluble in DMSO and water "Logan JE, Mostofizadeh N, Desai AJ, et al. PD-0332991, a Potent and Selective Inhibitor of Cyclin-dependent Kinase 4/6, Demonstrates Inhibition of Proliferation in Renal Cell Carcinoma at Nanomolar Concentrations and Molecular Markers Predict for Sensitivity. Anticancer Res. 2013 Aug;33(8):2997-3004. PMID: 23898052.

 

Roberts PJ, Bisi JE, Strum JC, et al. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. J Natl Cancer Inst. 2012 Mar 21;104(6):476-87. PMID: 22302033.

 

Rivadeneira DB, Mayhew CN, Thangavel C, et al. Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells. Gastroenterology. 2010 May;138(5):1920-30. PMID: 20100483.

" Not dangerous goods.

LKT P0244 Palbociclib Hydrochloride 25 mg 516.4 CDK4/6 inhibitor. PD-0332991 827022-32-2 ≥99% 483.99 C24H29N7O2 HCl CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C.Cl Ambient -20°C Soluble in DMSO and water "Logan JE, Mostofizadeh N, Desai AJ, et al. PD-0332991, a Potent and Selective Inhibitor of Cyclin-dependent Kinase 4/6, Demonstrates Inhibition of Proliferation in Renal Cell Carcinoma at Nanomolar Concentrations and Molecular Markers Predict for Sensitivity. Anticancer Res. 2013 Aug;33(8):2997-3004. PMID: 23898052.

 

Roberts PJ, Bisi JE, Strum JC, et al. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. J Natl Cancer Inst. 2012 Mar 21;104(6):476-87. PMID: 22302033.

 

Rivadeneira DB, Mayhew CN, Thangavel C, et al. Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells. Gastroenterology. 2010 May;138(5):1920-30. PMID: 20100483.

" Not dangerous goods.

LKT P2000 PF-03758309 Dihydrochloride 1 mg 88.3 PAK4 inhibitor. PF-3758309 1279034-84-2 ≥99%, ≥99%ee 563.55 C25H30N8OS 2HCl CC1=NC2=C(C(=N1)NC3=NNC4=C3CN(C4(C)C)C(=O)NC(CN(C)C)C5=CC=CC=C5)SC=C2.Cl Ambient -20°C Soluble in DMSO, water and alcohols. "Choi SW, Yeon JT, Ryu BJ, et al. Repositioning Potential of PAK4 to Osteoclastic Bone Resorption. J Bone Miner Res. 2015 Jan 31. [Epub ahead of print]. PMID: 25640698.

 

Ryu BJ, Lee H, Kim SH, et al. PF-3758309, p21-activated kinase 4 inhibitor, suppresses migration and invasion of A549 human lung cancer cells via regulation of CREB, NF-κB, and β-catenin signalings Mol Cell Biochem. 2014 Apr;389(1-2):69-77. PMID: 24366569.

 

Murray BW, Guo C, Piraino J, et al. Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. Proc Natl Acad Sci U S A. 2010 May 18;107(20):9446-51. PMID: 20439741.

 

 

LKT P2000 PF-03758309 Dihydrochloride 5 mg 203.8 PAK4 inhibitor. PF-3758309 1279034-84-2 ≥99%, ≥99%ee 563.55 C25H30N8OS 2HCl CC1=NC2=C(C(=N1)NC3=NNC4=C3CN(C4(C)C)C(=O)NC(CN(C)C)C5=CC=CC=C5)SC=C2.Cl Ambient -20°C Soluble in DMSO, water and alcohols. "Choi SW, Yeon JT, Ryu BJ, et al. Repositioning Potential of PAK4 to Osteoclastic Bone Resorption. J Bone Miner Res. 2015 Jan 31. [Epub ahead of print]. PMID: 25640698.

 

Ryu BJ, Lee H, Kim SH, et al. PF-3758309, p21-activated kinase 4 inhibitor, suppresses migration and invasion of A549 human lung cancer cells via regulation of CREB, NF-κB, and β-catenin signalings Mol Cell Biochem. 2014 Apr;389(1-2):69-77. PMID: 24366569.

 

Murray BW, Guo C, Piraino J, et al. Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. Proc Natl Acad Sci U S A. 2010 May 18;107(20):9446-51. PMID: 20439741.

 

LKT P2000 PF-03758309 Dihydrochloride 25 mg 475.7 PAK4 inhibitor. PF-3758309 1279034-84-2 ≥99%, ≥99%ee 563.55 C25H30N8OS 2HCl CC1=NC2=C(C(=N1)NC3=NNC4=C3CN(C4(C)C)C(=O)NC(CN(C)C)C5=CC=CC=C5)SC=C2.Cl Ambient -20°C Soluble in DMSO, water and alcohols. "Choi SW, Yeon JT, Ryu BJ, et al. Repositioning Potential of PAK4 to Osteoclastic Bone Resorption. J Bone Miner Res. 2015 Jan 31. [Epub ahead of print]. PMID: 25640698.

 

Ryu BJ, Lee H, Kim SH, et al. PF-3758309, p21-activated kinase 4 inhibitor, suppresses migration and invasion of A549 human lung cancer cells via regulation of CREB, NF-κB, and β-catenin signalings Mol Cell Biochem. 2014 Apr;389(1-2):69-77. PMID: 24366569.

 

Murray BW, Guo C, Piraino J, et al. Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. Proc Natl Acad Sci U S A. 2010 May 18;107(20):9446-51. PMID: 20439741.

 

LKT R1626 Regorafenib Monohydrate 1 mg 88.3 VEGFR1/2/3, TIE2, PDGFRβ, FGFR1, c-Kit, RET, B-Raf inhibitor. BAY73-4506 1019206-88-2 ≥99% 500.83 C21H15ClF4N4O3 H2O CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F.O Ambient -20°C In DMSO "Abou-Elkacem L, Arns S, Brix G, et al. Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model. Mol Cancer Ther. 2013 Jul;12(7):1322-31. PMID: 23619301. 

 

Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011 Jul 1;129(1):245-55. PMID: 21170960.

" Not dangerous goods.

LKT R1626 Regorafenib Monohydrate 5 mg 203.8 VEGFR1/2/3, TIE2, PDGFRβ, FGFR1, c-Kit, RET, B-Raf inhibitor. BAY73-4506 1019206-88-2 ≥99% 500.83 C21H15ClF4N4O3 H2O CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F.O Ambient -20°C In DMSO "Abou-Elkacem L, Arns S, Brix G, et al. Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model. Mol Cancer Ther. 2013 Jul;12(7):1322-31. PMID: 23619301. 

 

Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011 Jul 1;129(1):245-55. PMID: 21170960.

" Not dangerous goods.

LKT R1626 Regorafenib Monohydrate 25 mg 441.6 VEGFR1/2/3, TIE2, PDGFRβ, FGFR1, c-Kit, RET, B-Raf inhibitor. BAY73-4506 1019206-88-2 ≥99% 500.83 C21H15ClF4N4O3 H2O CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F.O Ambient -20°C In DMSO "Abou-Elkacem L, Arns S, Brix G, et al. Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model. Mol Cancer Ther. 2013 Jul;12(7):1322-31. PMID: 23619301. 

 

Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011 Jul 1;129(1):245-55. PMID: 21170960.

" Not dangerous goods.

LKT T8000 Tubacin 1 mg 244.5 HDAC6 inhibitor. 537049-40-4 ≥98% 721.86 C41H43N3O7S C1C(OC(OC1C2=CC=C(C=C2)CO)C3=CC=C(C=C3)NC(=O)CCCCCCC(=O)NO)CSC4=NC(=C(O4)C5=CC=CC=C5)C6=CC=CC=C6 Ambient -20°C In DMSO "Liu W, Fan LX, Zhou X, et al. HDAC6 regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation in renal epithelial cells. PLoS One. 2012;7(11):e49418. d PMID: 23152903.

 

Aldana-Masangkay GI, Rodriguez-Gonzalez A, Lin T, et al. Tubacin suppresses proliferation and induces apoptosis of acute lymphoblastic leukemia cells. Leuk Lymphoma. 2011 Aug;52(8):1544-55. PMID: 21699378.

 

Hideshima T, Bradner JE, Wong J, et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8567-72. PMID: 15937109.

 

Haggarty SJ, Koeller KM, Wong JC, et al. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4389-94. PMID: 12677000.

" Not dangerous goods.

LKT T8000 Tubacin 5 mg 706.7 HDAC6 inhibitor. 537049-40-4 ≥98% 721.86 C41H43N3O7S C1C(OC(OC1C2=CC=C(C=C2)CO)C3=CC=C(C=C3)NC(=O)CCCCCCC(=O)NO)CSC4=NC(=C(O4)C5=CC=CC=C5)C6=CC=CC=C6 Ambient -20°C In DMSO "Liu W, Fan LX, Zhou X, et al. HDAC6 regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation in renal epithelial cells. PLoS One. 2012;7(11):e49418. d PMID: 23152903.

 

Aldana-Masangkay GI, Rodriguez-Gonzalez A, Lin T, et al. Tubacin suppresses proliferation and induces apoptosis of acute lymphoblastic leukemia cells. Leuk Lymphoma. 2011 Aug;52(8):1544-55. PMID: 21699378.

 

Hideshima T, Bradner JE, Wong J, et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8567-72. PMID: 15937109.

 

Haggarty SJ, Koeller KM, Wong JC, et al. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4389-94. PMID: 12677000.

" Not dangerous goods.

LKT V1745 Veliparib 25 mg 475.7 PARP inhibitor. ABT-888 912444-00-9 ≥98% 244.29 C13H16N4O CC1(CCCN1)C2=NC3=C(C=CC=C3N2)C(=O)N Ambient Ambient "Owonikoko TK, Zhang G, Deng X et al. Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer. Cancer Med. 2014 Dec;3(6):1579-94. PMID: 25124282.

 

Barazzuol L, Jena R, Burnet NG, et al. Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma. Radiat Oncol. 2013 Mar 19;8:65. PMID: 23510353.

 

Ta LE, Schmelzer JD, Bieber AJ, et al. A novel and selective poly (ADP-ribose) polymerase inhibitor ameliorates chemotherapy-induced painful neuropathy. PLoS One. 2013;8(1):e54161. PMID: 23326593.

 

Anjos SM, Robert R, Waller D, et al. Decreasing Poly(ADP-Ribose) Polymerase Activity Restores ΔF508 CFTR Trafficking. Front Pharmacol. 2012;3:165. PMID: 22988441." Not dangerous goods.

LKT V1745 Veliparib 1 mg 81.6 PARP inhibitor. ABT-888 912444-00-9 ≥98% 244.29 C13H16N4O CC1(CCCN1)C2=NC3=C(C=CC=C3N2)C(=O)N Ambient Ambient "Owonikoko TK, Zhang G, Deng X et al. Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer. Cancer Med. 2014 Dec;3(6):1579-94. PMID: 25124282.

 

Barazzuol L, Jena R, Burnet NG, et al. Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma. Radiat Oncol. 2013 Mar 19;8:65. PMID: 23510353.

 

Ta LE, Schmelzer JD, Bieber AJ, et al. A novel and selective poly (ADP-ribose) polymerase inhibitor ameliorates chemotherapy-induced painful neuropathy. PLoS One. 2013;8(1):e54161. PMID: 23326593.

 

Anjos SM, Robert R, Waller D, et al. Decreasing Poly(ADP-Ribose) Polymerase Activity Restores ΔF508 CFTR Trafficking. Front Pharmacol. 2012;3:165. PMID: 22988441." Not dangerous goods.

LKT T5608 α-Tocotrienol 1 mg 47.6 Antioxidant, vitamin E derivative found in vegetables, nuts, grains; HMG-CoA reductase negative modulator. alpha-tocotrienol 58864-81-6 ≥98% 424.66 C29H44O2 CC1=C(C(=C2CCC(OC2=C1C)(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C)O Ambient -20°C Soluble in ethanol, hexanes, DMSO, DMF "Yap WN, Chang PN, Han HY, et al. Gamma-tocotrienol suppresses prostate cancer cell proliferation and invasion through multiple-signalling pathways. Br J Cancer. 2008 Dec 2;99(11):1832-41. PMID: 19002171.

 

Sen CK, Khanna S, Roy S. Tocotrienols: Vitamin E beyond tocopherols. Life Sci. 2006 Mar 27;78(18):2088-98. PMID: 16458936.

 

Inokuchi H, Hirokane H, Tsuzuki T, et al. Anti-angiogenic activity of tocotrienol. Biosci Biotechnol Biochem. 2003 Jul;67(7):1623-7. PMID: 12913317.

 

Parker RA, Pearce BC, Clark RW, et al. Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Biol Chem. 1993 May 25;268(15):11230-8. PMID: 8388388.

 

Serbinova E, Kagan V, Han D, et al. Free radical recycling and intramembrane mobility in the antioxidant properties of alpha-tocopherol and alpha-tocotrienol. Free Radic Biol Med. 1991;10(5):263-75. PMID: 1649783.

" Not dangerous goods.

LKT T5608 α-Tocotrienol 5 mg 133.2 Antioxidant, vitamin E derivative found in vegetables, nuts, grains; HMG-CoA reductase negative modulator. alpha-tocotrienol 58864-81-6 ≥98% 424.66 C29H44O2 CC1=C(C(=C2CCC(OC2=C1C)(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C)O Ambient -20°C Soluble in ethanol, hexanes, DMSO, DMF "Yap WN, Chang PN, Han HY, et al. Gamma-tocotrienol suppresses prostate cancer cell proliferation and invasion through multiple-signalling pathways. Br J Cancer. 2008 Dec 2;99(11):1832-41. PMID: 19002171.

 

Sen CK, Khanna S, Roy S. Tocotrienols: Vitamin E beyond tocopherols. Life Sci. 2006 Mar 27;78(18):2088-98. PMID: 16458936.

 

Inokuchi H, Hirokane H, Tsuzuki T, et al. Anti-angiogenic activity of tocotrienol. Biosci Biotechnol Biochem. 2003 Jul;67(7):1623-7. PMID: 12913317.

 

Parker RA, Pearce BC, Clark RW, et al. Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Biol Chem. 1993 May 25;268(15):11230-8. PMID: 8388388.

 

Serbinova E, Kagan V, Han D, et al. Free radical recycling and intramembrane mobility in the antioxidant properties of alpha-tocopherol and alpha-tocotrienol. Free Radic Biol Med. 1991;10(5):263-75. PMID: 1649783.

" Not dangerous goods.

LKT T5608 α-Tocotrienol 10 mg 237.8 Antioxidant, vitamin E derivative found in vegetables, nuts, grains; HMG-CoA reductase negative modulator. alpha-tocotrienol 58864-81-6 ≥98% 424.66 C29H44O2 CC1=C(C(=C2CCC(OC2=C1C)(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C)O Ambient -20°C Soluble in ethanol, hexanes, DMSO, DMF "Yap WN, Chang PN, Han HY, et al. Gamma-tocotrienol suppresses prostate cancer cell proliferation and invasion through multiple-signalling pathways. Br J Cancer. 2008 Dec 2;99(11):1832-41. PMID: 19002171.

 

Sen CK, Khanna S, Roy S. Tocotrienols: Vitamin E beyond tocopherols. Life Sci. 2006 Mar 27;78(18):2088-98. PMID: 16458936.

 

Inokuchi H, Hirokane H, Tsuzuki T, et al. Anti-angiogenic activity of tocotrienol. Biosci Biotechnol Biochem. 2003 Jul;67(7):1623-7. PMID: 12913317.

 

Parker RA, Pearce BC, Clark RW, et al. Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Biol Chem. 1993 May 25;268(15):11230-8. PMID: 8388388.

 

Serbinova E, Kagan V, Han D, et al. Free radical recycling and intramembrane mobility in the antioxidant properties of alpha-tocopherol and alpha-tocotrienol. Free Radic Biol Med. 1991;10(5):263-75. PMID: 1649783.

" Not dangerous goods.

LKT T5609 β-Tocotrienol 1 mg 88.3 Antioxidant, vitamin E derivative found in vegetables, nuts, grains; HMG-CoA reductase negative modulator. beta-tocotrienol 490-23-3 ≥98% 410.63 C28H42O2 CC1=CC(=C(C2=C1OC(CC2)(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C)O Ambient -20°C Soluble in ethanol, hexanes, DMSO, DMF "Yap WN, Chang PN, Han HY, et al. Gamma-tocotrienol suppresses prostate cancer cell proliferation and invasion through multiple-signalling pathways. Br J Cancer. 2008 Dec 2;99(11):1832-41. PMID: 19002171.

 

Sen CK, Khanna S, Roy S. Tocotrienols: Vitamin E beyond tocopherols. Life Sci. 2006 Mar 27;78(18):2088-98. PMID: 16458936.

 

Inokuchi H, Hirokane H, Tsuzuki T, et al. Anti-angiogenic activity of tocotrienol. Biosci Biotechnol Biochem. 2003 Jul;67(7):1623-7. PMID: 12913317.

 

Parker RA, Pearce BC, Clark RW, et al. Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Biol Chem. 1993 May 25;268(15):11230-8. PMID: 8388388.

 

Serbinova E, Kagan V, Han D, et al. Free radical recycling and intramembrane mobility in the antioxidant properties of alpha-tocopherol and alpha-tocotrienol. Free Radic Biol Med. 1991;10(5):263-75. PMID: 1649783.

" Not dangerous goods.

LKT T5609 β-Tocotrienol 5 mg 265 Antioxidant, vitamin E derivative found in vegetables, nuts, grains; HMG-CoA reductase negative modulator. beta-tocotrienol 490-23-3 ≥98% 410.63 C28H42O2 CC1=CC(=C(C2=C1OC(CC2)(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C)O Ambient -20°C Soluble in ethanol, hexanes, DMSO, DMF "Yap WN, Chang PN, Han HY, et al. Gamma-tocotrienol suppresses prostate cancer cell proliferation and invasion through multiple-signalling pathways. Br J Cancer. 2008 Dec 2;99(11):1832-41. PMID: 19002171.

 

Sen CK, Khanna S, Roy S. Tocotrienols: Vitamin E beyond tocopherols. Life Sci. 2006 Mar 27;78(18):2088-98. PMID: 16458936.

 

Inokuchi H, Hirokane H, Tsuzuki T, et al. Anti-angiogenic activity of tocotrienol. Biosci Biotechnol Biochem. 2003 Jul;67(7):1623-7. PMID: 12913317.

 

Parker RA, Pearce BC, Clark RW, et al. Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Biol Chem. 1993 May 25;268(15):11230-8. PMID: 8388388.

 

Serbinova E, Kagan V, Han D, et al. Free radical recycling and intramembrane mobility in the antioxidant properties of alpha-tocopherol and alpha-tocotrienol. Free Radic Biol Med. 1991;10(5):263-75. PMID: 1649783.

" Not dangerous goods.

LKT T5609 β-Tocotrienol 10 mg 509.7 Antioxidant, vitamin E derivative found in vegetables, nuts, grains; HMG-CoA reductase negative modulator. beta-tocotrienol 490-23-3 ≥98% 410.63 C28H42O2 CC1=CC(=C(C2=C1OC(CC2)(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C)O Ambient -20°C Soluble in ethanol, hexanes, DMSO, DMF "Yap WN, Chang PN, Han HY, et al. Gamma-tocotrienol suppresses prostate cancer cell proliferation and invasion through multiple-signalling pathways. Br J Cancer. 2008 Dec 2;99(11):1832-41. PMID: 19002171.

 

Sen CK, Khanna S, Roy S. Tocotrienols: Vitamin E beyond tocopherols. Life Sci. 2006 Mar 27;78(18):2088-98. PMID: 16458936.

 

Inokuchi H, Hirokane H, Tsuzuki T, et al. Anti-angiogenic activity of tocotrienol. Biosci Biotechnol Biochem. 2003 Jul;67(7):1623-7. PMID: 12913317.

 

Parker RA, Pearce BC, Clark RW, et al. Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Biol Chem. 1993 May 25;268(15):11230-8. PMID: 8388388.

 

Serbinova E, Kagan V, Han D, et al. Free radical recycling and intramembrane mobility in the antioxidant properties of alpha-tocopherol and alpha-tocotrienol. Free Radic Biol Med. 1991;10(5):263-75. PMID: 1649783.

" Not dangerous goods.

LKT T5610 γ-Tocotrienol 1 mg 61.1 Antioxidant, vitamin E derivative found in vegetables, nuts, grains; HMG-CoA reductase negative modulator. gamma-Tocotrienol 14101-61-2 ≥98% 410.63 C28H42O2 CC1=C(C=C2CCC(OC2=C1C)(C)CCC=C(C)CCC=C(C)CCC=C(C)C)O Ambient -20°C Soluble in ethanol, hexanes, DMSO, DMF "Yap WN, Chang PN, Han HY, et al. Gamma-tocotrienol suppresses prostate cancer cell proliferation and invasion through multiple-signalling pathways. Br J Cancer. 2008 Dec 2;99(11):1832-41. PMID: 19002171.

 

Sen CK, Khanna S, Roy S. Tocotrienols: Vitamin E beyond tocopherols. Life Sci. 2006 Mar 27;78(18):2088-98. PMID: 16458936.

 

Inokuchi H, Hirokane H, Tsuzuki T, et al. Anti-angiogenic activity of tocotrienol. Biosci Biotechnol Biochem. 2003 Jul;67(7):1623-7. PMID: 12913317.

 

Parker RA, Pearce BC, Clark RW, et al. Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Biol Chem. 1993 May 25;268(15):11230-8. PMID: 8388388.

 

Serbinova E, Kagan V, Han D, et al. Free radical recycling and intramembrane mobility in the antioxidant properties of alpha-tocopherol and alpha-tocotrienol. Free Radic Biol Med. 1991;10(5):263-75. PMID: 1649783.

" Not dangerous goods.

LKT T5610 γ-Tocotrienol 5 mg 224.3 Antioxidant, vitamin E derivative found in vegetables, nuts, grains; HMG-CoA reductase negative modulator. gamma-Tocotrienol 14101-61-2 ≥98% 410.63 C28H42O2 CC1=C(C=C2CCC(OC2=C1C)(C)CCC=C(C)CCC=C(C)CCC=C(C)C)O Ambient -20°C Soluble in ethanol, hexanes, DMSO, DMF "Yap WN, Chang PN, Han HY, et al. Gamma-tocotrienol suppresses prostate cancer cell proliferation and invasion through multiple-signalling pathways. Br J Cancer. 2008 Dec 2;99(11):1832-41. PMID: 19002171.

 

Sen CK, Khanna S, Roy S. Tocotrienols: Vitamin E beyond tocopherols. Life Sci. 2006 Mar 27;78(18):2088-98. PMID: 16458936.

 

Inokuchi H, Hirokane H, Tsuzuki T, et al. Anti-angiogenic activity of tocotrienol. Biosci Biotechnol Biochem. 2003 Jul;67(7):1623-7. PMID: 12913317.

 

Parker RA, Pearce BC, Clark RW, et al. Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Biol Chem. 1993 May 25;268(15):11230-8. PMID: 8388388.

 

Serbinova E, Kagan V, Han D, et al. Free radical recycling and intramembrane mobility in the antioxidant properties of alpha-tocopherol and alpha-tocotrienol. Free Radic Biol Med. 1991;10(5):263-75. PMID: 1649783.

" Not dangerous goods.

LKT T5610 γ-Tocotrienol 10 mg 373.7 Antioxidant, vitamin E derivative found in vegetables, nuts, grains; HMG-CoA reductase negative modulator. gamma-Tocotrienol 14101-61-2 ≥98% 410.63 C28H42O2 CC1=C(C=C2CCC(OC2=C1C)(C)CCC=C(C)CCC=C(C)CCC=C(C)C)O Ambient -20°C Soluble in ethanol, hexanes, DMSO, DMF "Yap WN, Chang PN, Han HY, et al. Gamma-tocotrienol suppresses prostate cancer cell proliferation and invasion through multiple-signalling pathways. Br J Cancer. 2008 Dec 2;99(11):1832-41. PMID: 19002171.

 

Sen CK, Khanna S, Roy S. Tocotrienols: Vitamin E beyond tocopherols. Life Sci. 2006 Mar 27;78(18):2088-98. PMID: 16458936.

 

Inokuchi H, Hirokane H, Tsuzuki T, et al. Anti-angiogenic activity of tocotrienol. Biosci Biotechnol Biochem. 2003 Jul;67(7):1623-7. PMID: 12913317.

 

Parker RA, Pearce BC, Clark RW, et al. Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Biol Chem. 1993 May 25;268(15):11230-8. PMID: 8388388.

 

Serbinova E, Kagan V, Han D, et al. Free radical recycling and intramembrane mobility in the antioxidant properties of alpha-tocopherol and alpha-tocotrienol. Free Radic Biol Med. 1991;10(5):263-75. PMID: 1649783.

" Not dangerous goods.

LKT T5611 δ-Tocotrienol 1 mg 43.5 Antioxidant, vitamin E derivative found in vegetables, nuts, grains; HMG-CoA reductase negative modulator. delta-Tocotrienol 25612-59-3 ≥98% 396.61 C27H40O2 CC1=C2C(=CC(=C1)O)CCC(O2)(C)CCC=C(C)CCC=C(C)CCC=C(C)C Ambient -20°C Soluble in ethanol, hexanes, DMSO, DMF "Yap WN, Chang PN, Han HY, et al. Gamma-tocotrienol suppresses prostate cancer cell proliferation and invasion through multiple-signalling pathways. Br J Cancer. 2008 Dec 2;99(11):1832-41. PMID: 19002171.

 

Sen CK, Khanna S, Roy S. Tocotrienols: Vitamin E beyond tocopherols. Life Sci. 2006 Mar 27;78(18):2088-98. PMID: 16458936.

 

Inokuchi H, Hirokane H, Tsuzuki T, et al. Anti-angiogenic activity of tocotrienol. Biosci Biotechnol Biochem. 2003 Jul;67(7):1623-7. PMID: 12913317.

 

Parker RA, Pearce BC, Clark RW, et al. Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Biol Chem. 1993 May 25;268(15):11230-8. PMID: 8388388.

 

Serbinova E, Kagan V, Han D, et al. Free radical recycling and intramembrane mobility in the antioxidant properties of alpha-tocopherol and alpha-tocotrienol. Free Radic Biol Med. 1991;10(5):263-75. PMID: 1649783.

" Not dangerous goods.

LKT T5611 δ-Tocotrienol 5 mg 115.5 Antioxidant, vitamin E derivative found in vegetables, nuts, grains; HMG-CoA reductase negative modulator. delta-Tocotrienol 25612-59-3 ≥98% 396.61 C27H40O2 CC1=C2C(=CC(=C1)O)CCC(O2)(C)CCC=C(C)CCC=C(C)CCC=C(C)C Ambient -20°C Soluble in ethanol, hexanes, DMSO, DMF "Yap WN, Chang PN, Han HY, et al. Gamma-tocotrienol suppresses prostate cancer cell proliferation and invasion through multiple-signalling pathways. Br J Cancer. 2008 Dec 2;99(11):1832-41. PMID: 19002171.

 

Sen CK, Khanna S, Roy S. Tocotrienols: Vitamin E beyond tocopherols. Life Sci. 2006 Mar 27;78(18):2088-98. PMID: 16458936.

 

Inokuchi H, Hirokane H, Tsuzuki T, et al. Anti-angiogenic activity of tocotrienol. Biosci Biotechnol Biochem. 2003 Jul;67(7):1623-7. PMID: 12913317.

 

Parker RA, Pearce BC, Clark RW, et al. Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Biol Chem. 1993 May 25;268(15):11230-8. PMID: 8388388.

 

Serbinova E, Kagan V, Han D, et al. Free radical recycling and intramembrane mobility in the antioxidant properties of alpha-tocopherol and alpha-tocotrienol. Free Radic Biol Med. 1991;10(5):263-75. PMID: 1649783.

" Not dangerous goods.

LKT T5611 δ-Tocotrienol 10 mg 224.3 Antioxidant, vitamin E derivative found in vegetables, nuts, grains; HMG-CoA reductase negative modulator. delta-Tocotrienol 25612-59-3 ≥98% 396.61 C27H40O2 CC1=C2C(=CC(=C1)O)CCC(O2)(C)CCC=C(C)CCC=C(C)CCC=C(C)C Ambient -20°C Soluble in ethanol, hexanes, DMSO, DMF "Yap WN, Chang PN, Han HY, et al. Gamma-tocotrienol suppresses prostate cancer cell proliferation and invasion through multiple-signalling pathways. Br J Cancer. 2008 Dec 2;99(11):1832-41. PMID: 19002171.

 

Sen CK, Khanna S, Roy S. Tocotrienols: Vitamin E beyond tocopherols. Life Sci. 2006 Mar 27;78(18):2088-98. PMID: 16458936.

 

Inokuchi H, Hirokane H, Tsuzuki T, et al. Anti-angiogenic activity of tocotrienol. Biosci Biotechnol Biochem. 2003 Jul;67(7):1623-7. PMID: 12913317.

 

Parker RA, Pearce BC, Clark RW, et al. Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Biol Chem. 1993 May 25;268(15):11230-8. PMID: 8388388.

 

Serbinova E, Kagan V, Han D, et al. Free radical recycling and intramembrane mobility in the antioxidant properties of alpha-tocopherol and alpha-tocotrienol. Free Radic Biol Med. 1991;10(5):263-75. PMID: 1649783.

" Not dangerous goods.

LKT A9612 AZD-2461 5 mg 129 PARP1 inhibitor. 1174043-16-3 ≥98% 395.43 C22H22FN3O3 COC1CCN(CC1)C(=O)C2=C(C=CC(=C2)CC3=NNC(=O)C4=CC=CC=C43)F Ambient -20°C Jaspers JE, Kersbergen A, Boon U, et al. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov. 2013 Jan;3(1):68-81. PMID: 23103855. Not dangerous goods.

LKT A9612 AZD-2461 25 mg 475.7 PARP1 inhibitor. 1174043-16-3 ≥98% 395.43 C22H22FN3O3 COC1CCN(CC1)C(=O)C2=C(C=CC(=C2)CC3=NNC(=O)C4=CC=CC=C43)F Ambient -20°C Jaspers JE, Kersbergen A, Boon U, et al. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov. 2013 Jan;3(1):68-81. PMID: 23103855. Not dangerous goods.

LKT A6818 Arenobufagin 1 mg 61.1 Bufanolide steroid found in Bufo arenarum;VEGFR2 inhibitor, cardiovascular Na+/K+ ATPase inhibitor. 464-74-4 ≥98% 416.51 C24H32O6 CC12CCC(CC1CCC3C2C(C(=O)C4(C3(CCC4C5=COC(=O)C=C5)O)C)O)O Ambient -20°C "Zhang DM, Liu JS, Deng LJ, et al. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway. Carcinogenesis. 2013 Jun;34(6):1331-42. PMID: 23393227.

 

Li M, Wu S, Liu Z, et al. Arenobufagin, a bufadienolide compound from toad venom, inhibits VEGF-mediated angiogenesis through suppression of VEGFR-2 signaling pathway. Biochem Pharmacol. 2012 May 1;83(9):1251-60. PMID: 22305746.

 

Cruz Jdos S, Matsuda H. Arenobufagin, a compound in toad venom, blocks Na(+)-K+ pump current in cardiac myocytes. Eur J Pharmacol. 1993 Aug 3;239(1-3):223-6. PMID: 8223897.

 

Garraffo HM, Gros EG. Biosynthesis of bufadienolides in toads. VI. Experiments with [1,2-3H]cholesterol, [21-14C]coprostanol, and 5 beta-[21-14 C]pregnanolone in the toad Bufo arenarum. Steroids. 1986 Sep-Oct;48(3-4):251-7. PMID: 3127947.

"

LKT A6818 Arenobufagin 5 mg 169.9 Bufanolide steroid found in Bufo arenarum;VEGFR2 inhibitor, cardiovascular Na+/K+ ATPase inhibitor. 464-74-4 ≥98% 416.51 C24H32O6 CC12CCC(CC1CCC3C2C(C(=O)C4(C3(CCC4C5=COC(=O)C=C5)O)C)O)O Ambient -20°C "Zhang DM, Liu JS, Deng LJ, et al. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway. Carcinogenesis. 2013 Jun;34(6):1331-42. PMID: 23393227.

 

Li M, Wu S, Liu Z, et al. Arenobufagin, a bufadienolide compound from toad venom, inhibits VEGF-mediated angiogenesis through suppression of VEGFR-2 signaling pathway. Biochem Pharmacol. 2012 May 1;83(9):1251-60. PMID: 22305746.

 

Cruz Jdos S, Matsuda H. Arenobufagin, a compound in toad venom, blocks Na(+)-K+ pump current in cardiac myocytes. Eur J Pharmacol. 1993 Aug 3;239(1-3):223-6. PMID: 8223897.

 

Garraffo HM, Gros EG. Biosynthesis of bufadienolides in toads. VI. Experiments with [1,2-3H]cholesterol, [21-14C]coprostanol, and 5 beta-[21-14 C]pregnanolone in the toad Bufo arenarum. Steroids. 1986 Sep-Oct;48(3-4):251-7. PMID: 3127947.

"

LKT A6818 Arenobufagin 25 mg 611.5 Bufanolide steroid found in Bufo arenarum;VEGFR2 inhibitor, cardiovascular Na+/K+ ATPase inhibitor. 464-74-4 ≥98% 416.51 C24H32O6 CC12CCC(CC1CCC3C2C(C(=O)C4(C3(CCC4C5=COC(=O)C=C5)O)C)O)O Ambient -20°C "Zhang DM, Liu JS, Deng LJ, et al. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway. Carcinogenesis. 2013 Jun;34(6):1331-42. PMID: 23393227.

 

Li M, Wu S, Liu Z, et al. Arenobufagin, a bufadienolide compound from toad venom, inhibits VEGF-mediated angiogenesis through suppression of VEGFR-2 signaling pathway. Biochem Pharmacol. 2012 May 1;83(9):1251-60. PMID: 22305746.

 

Cruz Jdos S, Matsuda H. Arenobufagin, a compound in toad venom, blocks Na(+)-K+ pump current in cardiac myocytes. Eur J Pharmacol. 1993 Aug 3;239(1-3):223-6. PMID: 8223897.

 

Garraffo HM, Gros EG. Biosynthesis of bufadienolides in toads. VI. Experiments with [1,2-3H]cholesterol, [21-14C]coprostanol, and 5 beta-[21-14 C]pregnanolone in the toad Bufo arenarum. Steroids. 1986 Sep-Oct;48(3-4):251-7. PMID: 3127947.

"

LKT E7209 Escitalopram Oxalate 10 mg 47.6 S-enantiomer of citalopram; SERT inhibitor. 219861-08-2 ≥99% 414.43 C22H21FN2O C2H2O4 CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.C(=O)(C(=O)O)O Ambient Ambient "Hodge JM, Wang Y, Berk M, et al. Selective serotonin reuptake inhibitors inhibit human osteoclast and osteoblast formation and function. Biol Psychiatry. 2013 Jul 1;74(1):32-9. PMID: 23260229.

 

Tynan RJ, Weidenhofer J, Hinwood M, et al. A comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia. Brain Behav Immun. 2012 Mar;26(3):469-79. PMID: 22251606.

 

Zhong H, Haddjeri N, Sánchez C. Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter--a review of current understanding of its mechanism of action. Psychopharmacology (Berl). 2012 Jan;219(1):1-13. PMID: 21901317.

 

van Gorp F, Whyte IM, Isbister GK. Clinical and ECG effects of escitalopram overdose. Ann Emerg Med. 2009 Sep;54(3):404-8. PMID: 19556032.

 

Stein DJ, Andersen EW, Tonnoir B, et al. Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study. Curr Med Res Opin. 2007 Apr;23(4):701-11. PMID: 17407626.

 

Kasper S, Stein DJ, Loft H, et al. Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. Br J Psychiatry. 2005 Mar;186:222-6. PMID: 15738503.

" Not dangerous goods.

LKT E7209 Escitalopram Oxalate 50 mg 122.3 S-enantiomer of citalopram; SERT inhibitor. 219861-08-2 ≥99% 414.43 C22H21FN2O C2H2O4 CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.C(=O)(C(=O)O)O Ambient Ambient "Hodge JM, Wang Y, Berk M, et al. Selective serotonin reuptake inhibitors inhibit human osteoclast and osteoblast formation and function. Biol Psychiatry. 2013 Jul 1;74(1):32-9. PMID: 23260229.

 

Tynan RJ, Weidenhofer J, Hinwood M, et al. A comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia. Brain Behav Immun. 2012 Mar;26(3):469-79. PMID: 22251606.

 

Zhong H, Haddjeri N, Sánchez C. Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter--a review of current understanding of its mechanism of action. Psychopharmacology (Berl). 2012 Jan;219(1):1-13. PMID: 21901317.

 

van Gorp F, Whyte IM, Isbister GK. Clinical and ECG effects of escitalopram overdose. Ann Emerg Med. 2009 Sep;54(3):404-8. PMID: 19556032.

 

Stein DJ, Andersen EW, Tonnoir B, et al. Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study. Curr Med Res Opin. 2007 Apr;23(4):701-11. PMID: 17407626.

 

Kasper S, Stein DJ, Loft H, et al. Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. Br J Psychiatry. 2005 Mar;186:222-6. PMID: 15738503.

" Not dangerous goods.

LKT E7209 Escitalopram Oxalate 100 mg 203.8 S-enantiomer of citalopram; SERT inhibitor. 219861-08-2 ≥99% 414.43 C22H21FN2O C2H2O4 CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.C(=O)(C(=O)O)O Ambient Ambient "Hodge JM, Wang Y, Berk M, et al. Selective serotonin reuptake inhibitors inhibit human osteoclast and osteoblast formation and function. Biol Psychiatry. 2013 Jul 1;74(1):32-9. PMID: 23260229.

 

Tynan RJ, Weidenhofer J, Hinwood M, et al. A comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia. Brain Behav Immun. 2012 Mar;26(3):469-79. PMID: 22251606.

 

Zhong H, Haddjeri N, Sánchez C. Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter--a review of current understanding of its mechanism of action. Psychopharmacology (Berl). 2012 Jan;219(1):1-13. PMID: 21901317.

 

van Gorp F, Whyte IM, Isbister GK. Clinical and ECG effects of escitalopram overdose. Ann Emerg Med. 2009 Sep;54(3):404-8. PMID: 19556032.

 

Stein DJ, Andersen EW, Tonnoir B, et al. Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study. Curr Med Res Opin. 2007 Apr;23(4):701-11. PMID: 17407626.

 

Kasper S, Stein DJ, Loft H, et al. Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. Br J Psychiatry. 2005 Mar;186:222-6. PMID: 15738503.

" Not dangerous goods.

LKT V3444 Vilazodone 10 mg 129 5-HT1A partial agonist, SERT inhibitor. 163521-12-8 ≥98% 441.52 C26H27N5O2 C1CN(CCN1CCCCC2=CNC3=C2C=C(C=C3)C#N)C4=CC5=C(C=C4)OC(=C5)C(=O)N Ambient Ambient "Edwards J, Sperry V, Adams MH, et al. Vilazodone lacks proarrhythmogenic potential in healthy participants: a thorough ECG study. Int J Clin Pharmacol Ther. 2013 Jun;51(6):456-65. PMID: 23611569.

 

Hughes ZA, Starr KR, Langmead CJ, et al. Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone. Eur J Pharmacol. 2005 Mar 7;510(1-2):49-57. PMID: 15740724.

 

Treit D, Degroot A, kashluba S, et al. Systemic EMD 68843 injections reduce anxiety in the shock-probe, but not the plus-maze test. Eur J Pharmacol. 2001 Mar 2;414(2-3):245-8. PMID: 11239925.

" Not dangerous goods.

LKT V3444 Vilazodone 50 mg 475.7 5-HT1A partial agonist, SERT inhibitor. 163521-12-8 ≥98% 441.52 C26H27N5O2 C1CN(CCN1CCCCC2=CNC3=C2C=C(C=C3)C#N)C4=CC5=C(C=C4)OC(=C5)C(=O)N Ambient Ambient "Edwards J, Sperry V, Adams MH, et al. Vilazodone lacks proarrhythmogenic potential in healthy participants: a thorough ECG study. Int J Clin Pharmacol Ther. 2013 Jun;51(6):456-65. PMID: 23611569.

 

Hughes ZA, Starr KR, Langmead CJ, et al. Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone. Eur J Pharmacol. 2005 Mar 7;510(1-2):49-57. PMID: 15740724.

 

Treit D, Degroot A, kashluba S, et al. Systemic EMD 68843 injections reduce anxiety in the shock-probe, but not the plus-maze test. Eur J Pharmacol. 2001 Mar 2;414(2-3):245-8. PMID: 11239925.

" Not dangerous goods.

LKT V3444 Vilazodone 100 mg 679.5 5-HT1A partial agonist, SERT inhibitor. 163521-12-8 ≥98% 441.52 C26H27N5O2 C1CN(CCN1CCCCC2=CNC3=C2C=C(C=C3)C#N)C4=CC5=C(C=C4)OC(=C5)C(=O)N Ambient Ambient "Edwards J, Sperry V, Adams MH, et al. Vilazodone lacks proarrhythmogenic potential in healthy participants: a thorough ECG study. Int J Clin Pharmacol Ther. 2013 Jun;51(6):456-65. PMID: 23611569.

 

Hughes ZA, Starr KR, Langmead CJ, et al. Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone. Eur J Pharmacol. 2005 Mar 7;510(1-2):49-57. PMID: 15740724.

 

Treit D, Degroot A, kashluba S, et al. Systemic EMD 68843 injections reduce anxiety in the shock-probe, but not the plus-maze test. Eur J Pharmacol. 2001 Mar 2;414(2-3):245-8. PMID: 11239925.

" Not dangerous goods.

LKT V5870 Vortioxetine 5 mg 133.2 5-HT1A agonist, 5-HT1B partial agonist, 5-HT3A/7 antagonist, SERT inhibitor, potential β1-adrenergic agonist. 508233-74-7 ≥98% 298.45 C18H22N2S CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C Ambient Ambient "du Jardin KG, Jensen JB, Sanchez C, et al. Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: A potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism. Eur Neuropsychopharmacol. 2013 Aug 2. [Epub ahead of print]. PMID: 23916504.

 

Henigsberg N, Mahableshwarkar AR, Jacobsen P, et al. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. J Clin Psychiatry. 2012 Jul;73(7):953-9. PMID: 22901346.

 

Bang-Andersen B, Ruhland T, Jørgensen M, et al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011 May 12;54(9):3206-21. PMID: 21486038.

"

LKT V5870 Vortioxetine 10 mg 224.3 5-HT1A agonist, 5-HT1B partial agonist, 5-HT3A/7 antagonist, SERT inhibitor, potential β1-adrenergic agonist. 508233-74-7 ≥98% 298.45 C18H22N2S CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C Ambient Ambient "du Jardin KG, Jensen JB, Sanchez C, et al. Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: A potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism. Eur Neuropsychopharmacol. 2013 Aug 2. [Epub ahead of print]. PMID: 23916504.

 

Henigsberg N, Mahableshwarkar AR, Jacobsen P, et al. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. J Clin Psychiatry. 2012 Jul;73(7):953-9. PMID: 22901346.

 

Bang-Andersen B, Ruhland T, Jørgensen M, et al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011 May 12;54(9):3206-21. PMID: 21486038.

"

LKT V5870 Vortioxetine 25 mg 434.9 5-HT1A agonist, 5-HT1B partial agonist, 5-HT3A/7 antagonist, SERT inhibitor, potential β1-adrenergic agonist. 508233-74-7 ≥98% 298.45 C18H22N2S CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C Ambient Ambient "du Jardin KG, Jensen JB, Sanchez C, et al. Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: A potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism. Eur Neuropsychopharmacol. 2013 Aug 2. [Epub ahead of print]. PMID: 23916504.

 

Henigsberg N, Mahableshwarkar AR, Jacobsen P, et al. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. J Clin Psychiatry. 2012 Jul;73(7):953-9. PMID: 22901346.

 

Bang-Andersen B, Ruhland T, Jørgensen M, et al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011 May 12;54(9):3206-21. PMID: 21486038.

"

LKT V5870 Vortioxetine 100 mg 1331.8 5-HT1A agonist, 5-HT1B partial agonist, 5-HT3A/7 antagonist, SERT inhibitor, potential β1-adrenergic agonist. 508233-74-7 ≥98% 298.45 C18H22N2S CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C Ambient Ambient "du Jardin KG, Jensen JB, Sanchez C, et al. Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: A potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism. Eur Neuropsychopharmacol. 2013 Aug 2. [Epub ahead of print]. PMID: 23916504.

 

Henigsberg N, Mahableshwarkar AR, Jacobsen P, et al. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. J Clin Psychiatry. 2012 Jul;73(7):953-9. PMID: 22901346.

 

Bang-Andersen B, Ruhland T, Jørgensen M, et al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011 May 12;54(9):3206-21. PMID: 21486038.

"

LKT E2002 Efaroxan Hydrochloride 25 mg 85.5 α2-adrenergic and imidazoline-1 antagonist, ATP-sensitive K+ channel blocker. 89197-00-2 ≥99% 252.74 C13H17ClN2O CCC1(CC2=CC=CC=C2O1)C3=NCCN3.Cl Ambient Ambient Soluble to 100 mM in water "Milne B, Jhamandas K, Sutak M, et al. Stereo-selective inhibition of spinal morphine tolerance and hyperalgesia by an ultra-low dose of the alpha-2-adrenoceptor antagonist efaroxan. Eur J Pharmacol. 2013 Feb 28;702(1-3):227-34. PMID: 23376415.

 

Lehner Z, Stadlbauer K, Adorjan I, et al. Mechanisms of antihyperglycaemic action of efaroxan in mice: time for reappraisal of α2A-adrenergic antagonism in the treatment of type 2 diabetes? Diabetologia. 2012 Nov;55(11):3071-82. PMID: 22898767.

 

Le Brigand L, Virsolvy A, Manechez D, et al. In vitro mechanism of action on insulin release of S-22068, a new putative antidiabetic compound. Br J Pharmacol. 1999 Nov;128(5):1021-6. PMID: 10556939.

 

Chopin P, Colpaert FC, Marien M. Effects of alpha-2 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway. J. Pharmacol. Exp. Ther. 1999. 288 (2): 798–804. PMID 9918591.

 

Chan SL, Dunne MJ, Stillings MR, et al. The alpha 2-adrenoceptor antagonist efaroxan modulates K+ATP channels in insulin-secreting cells. Eur J Pharmacol. 1991 Oct 29;204(1):41-8. PMID: 1687123.

" "UN number: 2811     Class: 6.1     Packing Group: III

Proper shipping name: Toxic solid, organic, n.o.s. (Efaroxan hydrochloride)"

LKT E2002 Efaroxan Hydrochloride 100 mg 218.4 α2-adrenergic and imidazoline-1 antagonist, ATP-sensitive K+ channel blocker. 89197-00-2 ≥99% 252.74 C13H17ClN2O CCC1(CC2=CC=CC=C2O1)C3=NCCN3.Cl Ambient Ambient Soluble to 100 mM in water "Milne B, Jhamandas K, Sutak M, et al. Stereo-selective inhibition of spinal morphine tolerance and hyperalgesia by an ultra-low dose of the alpha-2-adrenoceptor antagonist efaroxan. Eur J Pharmacol. 2013 Feb 28;702(1-3):227-34. PMID: 23376415.

 

Lehner Z, Stadlbauer K, Adorjan I, et al. Mechanisms of antihyperglycaemic action of efaroxan in mice: time for reappraisal of α2A-adrenergic antagonism in the treatment of type 2 diabetes? Diabetologia. 2012 Nov;55(11):3071-82. PMID: 22898767.

 

Le Brigand L, Virsolvy A, Manechez D, et al. In vitro mechanism of action on insulin release of S-22068, a new putative antidiabetic compound. Br J Pharmacol. 1999 Nov;128(5):1021-6. PMID: 10556939.

 

Chopin P, Colpaert FC, Marien M. Effects of alpha-2 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway. J. Pharmacol. Exp. Ther. 1999. 288 (2): 798–804. PMID 9918591.

 

Chan SL, Dunne MJ, Stillings MR, et al. The alpha 2-adrenoceptor antagonist efaroxan modulates K+ATP channels in insulin-secreting cells. Eur J Pharmacol. 1991 Oct 29;204(1):41-8. PMID: 1687123.

" "UN number: 2811     Class: 6.1     Packing Group: III

Proper shipping name: Toxic solid, organic, n.o.s. (Efaroxan hydrochloride)"

LKT E2002 Efaroxan Hydrochloride 250 mg 482.9 α2-adrenergic and imidazoline-1 antagonist, ATP-sensitive K+ channel blocker. 89197-00-2 ≥99% 252.74 C13H17ClN2O CCC1(CC2=CC=CC=C2O1)C3=NCCN3.Cl Ambient Ambient Soluble to 100 mM in water "Milne B, Jhamandas K, Sutak M, et al. Stereo-selective inhibition of spinal morphine tolerance and hyperalgesia by an ultra-low dose of the alpha-2-adrenoceptor antagonist efaroxan. Eur J Pharmacol. 2013 Feb 28;702(1-3):227-34. PMID: 23376415.

 

Lehner Z, Stadlbauer K, Adorjan I, et al. Mechanisms of antihyperglycaemic action of efaroxan in mice: time for reappraisal of α2A-adrenergic antagonism in the treatment of type 2 diabetes? Diabetologia. 2012 Nov;55(11):3071-82. PMID: 22898767.

 

Le Brigand L, Virsolvy A, Manechez D, et al. In vitro mechanism of action on insulin release of S-22068, a new putative antidiabetic compound. Br J Pharmacol. 1999 Nov;128(5):1021-6. PMID: 10556939.

 

Chopin P, Colpaert FC, Marien M. Effects of alpha-2 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway. J. Pharmacol. Exp. Ther. 1999. 288 (2): 798–804. PMID 9918591.

 

Chan SL, Dunne MJ, Stillings MR, et al. The alpha 2-adrenoceptor antagonist efaroxan modulates K+ATP channels in insulin-secreting cells. Eur J Pharmacol. 1991 Oct 29;204(1):41-8. PMID: 1687123.

" "UN number: 2811     Class: 6.1     Packing Group: III

Proper shipping name: Toxic solid, organic, n.o.s. (Efaroxan hydrochloride)"

LKT C4457 Clomipramine Hydrochloride 1 g 43.5 FIASMA, mAChR, 5-HT2/3/6/7, α1/2-adrenergic antagonist, SERT and NET inhibitor, hERG K+ and L-type Ca2+ channel blocker. 17321-77-6 ≥98% 351.32 C19H23ClN2  HCl CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl.Cl Ambient Ambient "Kostadinov ID, Delev DP, Kostadinova II. Antinociceptive effect of clomipramine through interaction with serotonin 5-HT2 and 5-HT3 receptor subtypes. Folia Med (Plovdiv). 2012 Oct-Dec;54(4):69-77. PMID: 23441472.

 

Jo SH, Hong HK, Chong SH, et al. Clomipramine block of the hERG K+ channel: accessibility to F656 and Y652. Eur J Pharmacol. 2008 Sep 11;592(1-3):19-25.  PMID: 18634780.

 

Zahradník I, Minarovic I, Zahradníková A. Inhibition of the cardiac L-type calcium channel current by antidepressant drugs. J Pharmacol Exp Ther. 2008 Mar;324(3):977-84. PMID: 18048694.

 

Millan MJ, Gobert A, Lejeune F, et al. S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlaFAine, reboxetine, citalopram, and clomipramine. J Pharmacol Exp Ther. 2001 Aug;298(2):565-80. PMID: 11454918.

 

Greist JH, Jefferson JW, Kobak KA, et al. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis. Arch Gen Psychiatry. 1995 Jan;52(1):53-60. PMID: 7811162.

" Not dangerous goods.

LKT C4457 Clomipramine Hydrochloride 5 g 163.2 FIASMA, mAChR, 5-HT2/3/6/7, α1/2-adrenergic antagonist, SERT and NET inhibitor, hERG K+ and L-type Ca2+ channel blocker. 17321-77-6 ≥98% 351.32 C19H23ClN2  HCl CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl.Cl Ambient Ambient "Kostadinov ID, Delev DP, Kostadinova II. Antinociceptive effect of clomipramine through interaction with serotonin 5-HT2 and 5-HT3 receptor subtypes. Folia Med (Plovdiv). 2012 Oct-Dec;54(4):69-77. PMID: 23441472.

 

Jo SH, Hong HK, Chong SH, et al. Clomipramine block of the hERG K+ channel: accessibility to F656 and Y652. Eur J Pharmacol. 2008 Sep 11;592(1-3):19-25.  PMID: 18634780.

 

Zahradník I, Minarovic I, Zahradníková A. Inhibition of the cardiac L-type calcium channel current by antidepressant drugs. J Pharmacol Exp Ther. 2008 Mar;324(3):977-84. PMID: 18048694.

 

Millan MJ, Gobert A, Lejeune F, et al. S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlaFAine, reboxetine, citalopram, and clomipramine. J Pharmacol Exp Ther. 2001 Aug;298(2):565-80. PMID: 11454918.

 

Greist JH, Jefferson JW, Kobak KA, et al. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis. Arch Gen Psychiatry. 1995 Jan;52(1):53-60. PMID: 7811162.

" Not dangerous goods.

LKT D0263 Dapoxetine Hydrochloride 10 mg 47.6 SERT inhibitor, potential voltage-gated K+ channel blocker. 129938-20-1 ≥99% 341.87 C21H24ClNO CN(C)C(CCOC1=CC=CC2=CC=CC=C21)C3=CC=CC=C3.Cl Ambient Ambient "McMahon CG. Dapoxetine: a new option in the medical management of premature ejaculation. Ther Adv Urol. 2012 Oct;4(5):233-51. PMID: 23024705.

 

Jeong I, Yoon SH, Hahn SJ. Effects of dapoxetine on cloned Kv1.5 channels expressed in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 2012 Jul;385(7):707-16. PMID: 22568341.

 

Jeong I, Kim SW, Yoon SH, et al. Block of cloned Kv4.3 potassium channels by dapoxetine. Neuropharmacology. 2012 Jun;62(7):2261-6. PMID: 22192593.

 

Clément P, Bernabé J, Gengo P, et al. Supraspinal site of action for the inhibition of ejaculatory reflex by dapoxetine. Eur Urol. 2007 Mar;51(3):825-32. PMID: 17064843.

" Not dangerous goods.

LKT D0263 Dapoxetine Hydrochloride 50 mg 163.2 SERT inhibitor, potential voltage-gated K+ channel blocker. 129938-20-1 ≥99% 341.87 C21H24ClNO CN(C)C(CCOC1=CC=CC2=CC=CC=C21)C3=CC=CC=C3.Cl Ambient Ambient "McMahon CG. Dapoxetine: a new option in the medical management of premature ejaculation. Ther Adv Urol. 2012 Oct;4(5):233-51. PMID: 23024705.

 

Jeong I, Yoon SH, Hahn SJ. Effects of dapoxetine on cloned Kv1.5 channels expressed in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 2012 Jul;385(7):707-16. PMID: 22568341.

 

Jeong I, Kim SW, Yoon SH, et al. Block of cloned Kv4.3 potassium channels by dapoxetine. Neuropharmacology. 2012 Jun;62(7):2261-6. PMID: 22192593.

 

Clément P, Bernabé J, Gengo P, et al. Supraspinal site of action for the inhibition of ejaculatory reflex by dapoxetine. Eur Urol. 2007 Mar;51(3):825-32. PMID: 17064843.

" Not dangerous goods.

LKT D0263 Dapoxetine Hydrochloride 100 mg 271.7 SERT inhibitor, potential voltage-gated K+ channel blocker. 129938-20-1 ≥99% 341.87 C21H24ClNO CN(C)C(CCOC1=CC=CC2=CC=CC=C21)C3=CC=CC=C3.Cl Ambient Ambient "McMahon CG. Dapoxetine: a new option in the medical management of premature ejaculation. Ther Adv Urol. 2012 Oct;4(5):233-51. PMID: 23024705.

 

Jeong I, Yoon SH, Hahn SJ. Effects of dapoxetine on cloned Kv1.5 channels expressed in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 2012 Jul;385(7):707-16. PMID: 22568341.

 

Jeong I, Kim SW, Yoon SH, et al. Block of cloned Kv4.3 potassium channels by dapoxetine. Neuropharmacology. 2012 Jun;62(7):2261-6. PMID: 22192593.

 

Clément P, Bernabé J, Gengo P, et al. Supraspinal site of action for the inhibition of ejaculatory reflex by dapoxetine. Eur Urol. 2007 Mar;51(3):825-32. PMID: 17064843.

" Not dangerous goods.

LKT S8344 R,S-(±)-Sulpiride 5 g 40.7 GHB agonist, D2/3 antagonist. 15676-16-1 ≥98% 341.42 C15H23N3O4S CCN1CCCC1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC Ambient Ambient "Valencia NA, Thompson DL Jr, Mitcham PB. Changes in plasma melanocyte-stimulating hormone, ACTH, prolactin, GH, LH, FSH, and thyroid-stimulating hormone in response to injection of sulpiride, thyrotropin-releasing hormone, or vehicle in insulin-sensitive and -insensitive mares. Domest Anim Endocrinol. 2013 May;44(4):204-12. PMID: 23571008.

 

Pezze MA, Dalley JW, Robbins TW. Remediation of attentional dysfunction in rats with lesions of the medial prefrontal cortex by intra-accumbens administration of the dopamine D(2/3) receptor antagonist sulpiride. Psychopharmacology (Berl). 2009 Jan;202(1-3):307-13. PMID: 18985321.

 

Ratomponirina C, Gobaille S, Hodé Y, et al. Sulpiride, but not haloperidol, up-regulates gamma-hydroxybutyrate receptors in vivo and in cultured cells. Eur J Pharmacol. 1998 Apr 10;346(2-3):331-7. PMID: 9862377.

" Not dangerous goods.

LKT S8344 R,S-(±)-Sulpiride 25 g 95.9 GHB agonist, D2/3 antagonist. 15676-16-1 ≥98% 341.42 C15H23N3O4S CCN1CCCC1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC Ambient Ambient "Valencia NA, Thompson DL Jr, Mitcham PB. Changes in plasma melanocyte-stimulating hormone, ACTH, prolactin, GH, LH, FSH, and thyroid-stimulating hormone in response to injection of sulpiride, thyrotropin-releasing hormone, or vehicle in insulin-sensitive and -insensitive mares. Domest Anim Endocrinol. 2013 May;44(4):204-12. PMID: 23571008.

 

Pezze MA, Dalley JW, Robbins TW. Remediation of attentional dysfunction in rats with lesions of the medial prefrontal cortex by intra-accumbens administration of the dopamine D(2/3) receptor antagonist sulpiride. Psychopharmacology (Berl). 2009 Jan;202(1-3):307-13. PMID: 18985321.

 

Ratomponirina C, Gobaille S, Hodé Y, et al. Sulpiride, but not haloperidol, up-regulates gamma-hydroxybutyrate receptors in vivo and in cultured cells. Eur J Pharmacol. 1998 Apr 10;346(2-3):331-7. PMID: 9862377.

" Not dangerous goods.

LKT S8344 R,S-(±)-Sulpiride 100 g 325.2 GHB agonist, D2/3 antagonist. 15676-16-1 ≥98% 341.42 C15H23N3O4S CCN1CCCC1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC Ambient Ambient "Valencia NA, Thompson DL Jr, Mitcham PB. Changes in plasma melanocyte-stimulating hormone, ACTH, prolactin, GH, LH, FSH, and thyroid-stimulating hormone in response to injection of sulpiride, thyrotropin-releasing hormone, or vehicle in insulin-sensitive and -insensitive mares. Domest Anim Endocrinol. 2013 May;44(4):204-12. PMID: 23571008.

 

Pezze MA, Dalley JW, Robbins TW. Remediation of attentional dysfunction in rats with lesions of the medial prefrontal cortex by intra-accumbens administration of the dopamine D(2/3) receptor antagonist sulpiride. Psychopharmacology (Berl). 2009 Jan;202(1-3):307-13. PMID: 18985321.

 

Ratomponirina C, Gobaille S, Hodé Y, et al. Sulpiride, but not haloperidol, up-regulates gamma-hydroxybutyrate receptors in vivo and in cultured cells. Eur J Pharmacol. 1998 Apr 10;346(2-3):331-7. PMID: 9862377.

" Not dangerous goods.

LKT S8345 S-(−)-Sulpiride 1 g 40.7 GHB agonist, D2/3 antagonist. 23672-07-3 ≥99% 341.43 C15H23N3O4S CCN1CCCC1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC Ambient Ambient "Valencia NA, Thompson DL Jr, Mitcham PB. Changes in plasma melanocyte-stimulating hormone, ACTH, prolactin, GH, LH, FSH, and thyroid-stimulating hormone in response to injection of sulpiride, thyrotropin-releasing hormone, or vehicle in insulin-sensitive and -insensitive mares. Domest Anim Endocrinol. 2013 May;44(4):204-12. PMID: 23571008.

 

Pezze MA, Dalley JW, Robbins TW. Remediation of attentional dysfunction in rats with lesions of the medial prefrontal cortex by intra-accumbens administration of the dopamine D(2/3) receptor antagonist sulpiride. Psychopharmacology (Berl). 2009 Jan;202(1-3):307-13. PMID: 18985321.

 

Ratomponirina C, Gobaille S, Hodé Y, et al. Sulpiride, but not haloperidol, up-regulates gamma-hydroxybutyrate receptors in vivo and in cultured cells. Eur J Pharmacol. 1998 Apr 10;346(2-3):331-7. PMID: 9862377.

" Not dangerous goods.

LKT S8345 S-(−)-Sulpiride 5 g 79.4 GHB agonist, D2/3 antagonist. 23672-07-3 ≥99% 341.43 C15H23N3O4S CCN1CCCC1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC Ambient Ambient "Valencia NA, Thompson DL Jr, Mitcham PB. Changes in plasma melanocyte-stimulating hormone, ACTH, prolactin, GH, LH, FSH, and thyroid-stimulating hormone in response to injection of sulpiride, thyrotropin-releasing hormone, or vehicle in insulin-sensitive and -insensitive mares. Domest Anim Endocrinol. 2013 May;44(4):204-12. PMID: 23571008.

 

Pezze MA, Dalley JW, Robbins TW. Remediation of attentional dysfunction in rats with lesions of the medial prefrontal cortex by intra-accumbens administration of the dopamine D(2/3) receptor antagonist sulpiride. Psychopharmacology (Berl). 2009 Jan;202(1-3):307-13. PMID: 18985321.

 

Ratomponirina C, Gobaille S, Hodé Y, et al. Sulpiride, but not haloperidol, up-regulates gamma-hydroxybutyrate receptors in vivo and in cultured cells. Eur J Pharmacol. 1998 Apr 10;346(2-3):331-7. PMID: 9862377.

" Not dangerous goods.

LKT S8345 S-(−)-Sulpiride 10 g 148.1 GHB agonist, D2/3 antagonist. 23672-07-3 ≥99% 341.43 C15H23N3O4S CCN1CCCC1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC Ambient Ambient "Valencia NA, Thompson DL Jr, Mitcham PB. Changes in plasma melanocyte-stimulating hormone, ACTH, prolactin, GH, LH, FSH, and thyroid-stimulating hormone in response to injection of sulpiride, thyrotropin-releasing hormone, or vehicle in insulin-sensitive and -insensitive mares. Domest Anim Endocrinol. 2013 May;44(4):204-12. PMID: 23571008.

 

Pezze MA, Dalley JW, Robbins TW. Remediation of attentional dysfunction in rats with lesions of the medial prefrontal cortex by intra-accumbens administration of the dopamine D(2/3) receptor antagonist sulpiride. Psychopharmacology (Berl). 2009 Jan;202(1-3):307-13. PMID: 18985321.

 

Ratomponirina C, Gobaille S, Hodé Y, et al. Sulpiride, but not haloperidol, up-regulates gamma-hydroxybutyrate receptors in vivo and in cultured cells. Eur J Pharmacol. 1998 Apr 10;346(2-3):331-7. PMID: 9862377.

" Not dangerous goods.

LKT S8345 S-(−)-Sulpiride 25 g 260.9 GHB agonist, D2/3 antagonist. 23672-07-3 ≥99% 341.43 C15H23N3O4S CCN1CCCC1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC Ambient Ambient "Valencia NA, Thompson DL Jr, Mitcham PB. Changes in plasma melanocyte-stimulating hormone, ACTH, prolactin, GH, LH, FSH, and thyroid-stimulating hormone in response to injection of sulpiride, thyrotropin-releasing hormone, or vehicle in insulin-sensitive and -insensitive mares. Domest Anim Endocrinol. 2013 May;44(4):204-12. PMID: 23571008.

 

Pezze MA, Dalley JW, Robbins TW. Remediation of attentional dysfunction in rats with lesions of the medial prefrontal cortex by intra-accumbens administration of the dopamine D(2/3) receptor antagonist sulpiride. Psychopharmacology (Berl). 2009 Jan;202(1-3):307-13. PMID: 18985321.

 

Ratomponirina C, Gobaille S, Hodé Y, et al. Sulpiride, but not haloperidol, up-regulates gamma-hydroxybutyrate receptors in vivo and in cultured cells. Eur J Pharmacol. 1998 Apr 10;346(2-3):331-7. PMID: 9862377.

" Not dangerous goods.

LKT T7003 Trazodone Hydrochloride 1 g 47.6 5-HT1A partial agonist, 5-HT2, histamine, α1/2-adrenergic  antagonist, SERT inhibitor, voltage-gated K+ channel blocker. 25332-39-2 ≥98% 408.33 C19H23Cl2N5O C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl.Cl Ambient Ambient "Chae YJ, Choi JS, Hahn SJ. Inhibition of Kv4.3 potassium channels by trazodone. Naunyn Schmiedebergs Arch Pharmacol. 2013 Aug;386(8):711-9. PMID: 23615873.

 

Odagaki Y, Toyoshima R, Yamauchi T. Trazodone and its active metabolite m-chlorophenylpiperazine as partial agonists at 5-HT1A receptors assessed by [35S]GTPgammaS binding. J Psychopharmacol. 2005 May;19(3):235-41. PMID: 15888508.

 

Otani K, Yasui N, Kaneko S, et al. Trazodone treatment increases plasma prolactin concentrations in depressed patients. Int Clin Psychopharmacol. 1995 Jun;10(2):115-7. PMID: 7673654.

 

Haria M, Fitton A, McTavish D. Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs Aging. 1994 Apr;4(4):331-55. PMID: 8019056.

 

Marek GJ, McDougle CJ, Price LH, et al. A comparison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action. Psychopharmacology (Berl). 1992;109(1-2):2-11. PMID: 1365657.

 

Scharf MB, Sachais BA. Sleep laboratory evaluation of the effects and efficacy of trazodone in depressed insomniac patients. J Clin Psychiatry. 1990 Sep;51 Suppl:13-7. PMID: 2211559.

" Not dangerous goods.

LKT T7003 Trazodone Hydrochloride 5 g 136 5-HT1A partial agonist, 5-HT2, histamine, α1/2-adrenergic  antagonist, SERT inhibitor, voltage-gated K+ channel blocker. 25332-39-2 ≥98% 408.33 C19H23Cl2N5O C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl.Cl Ambient Ambient "Chae YJ, Choi JS, Hahn SJ. Inhibition of Kv4.3 potassium channels by trazodone. Naunyn Schmiedebergs Arch Pharmacol. 2013 Aug;386(8):711-9. PMID: 23615873.

 

Odagaki Y, Toyoshima R, Yamauchi T. Trazodone and its active metabolite m-chlorophenylpiperazine as partial agonists at 5-HT1A receptors assessed by [35S]GTPgammaS binding. J Psychopharmacol. 2005 May;19(3):235-41. PMID: 15888508.

 

Otani K, Yasui N, Kaneko S, et al. Trazodone treatment increases plasma prolactin concentrations in depressed patients. Int Clin Psychopharmacol. 1995 Jun;10(2):115-7. PMID: 7673654.

 

Haria M, Fitton A, McTavish D. Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs Aging. 1994 Apr;4(4):331-55. PMID: 8019056.

 

Marek GJ, McDougle CJ, Price LH, et al. A comparison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action. Psychopharmacology (Berl). 1992;109(1-2):2-11. PMID: 1365657.

 

Scharf MB, Sachais BA. Sleep laboratory evaluation of the effects and efficacy of trazodone in depressed insomniac patients. J Clin Psychiatry. 1990 Sep;51 Suppl:13-7. PMID: 2211559.

" Not dangerous goods.

LKT T7003 Trazodone Hydrochloride 25 g 475.7 5-HT1A partial agonist, 5-HT2, histamine, α1/2-adrenergic  antagonist, SERT inhibitor, voltage-gated K+ channel blocker. 25332-39-2 ≥98% 408.33 C19H23Cl2N5O C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl.Cl Ambient Ambient "Chae YJ, Choi JS, Hahn SJ. Inhibition of Kv4.3 potassium channels by trazodone. Naunyn Schmiedebergs Arch Pharmacol. 2013 Aug;386(8):711-9. PMID: 23615873.

 

Odagaki Y, Toyoshima R, Yamauchi T. Trazodone and its active metabolite m-chlorophenylpiperazine as partial agonists at 5-HT1A receptors assessed by [35S]GTPgammaS binding. J Psychopharmacol. 2005 May;19(3):235-41. PMID: 15888508.

 

Otani K, Yasui N, Kaneko S, et al. Trazodone treatment increases plasma prolactin concentrations in depressed patients. Int Clin Psychopharmacol. 1995 Jun;10(2):115-7. PMID: 7673654.

 

Haria M, Fitton A, McTavish D. Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs Aging. 1994 Apr;4(4):331-55. PMID: 8019056.

 

Marek GJ, McDougle CJ, Price LH, et al. A comparison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action. Psychopharmacology (Berl). 1992;109(1-2):2-11. PMID: 1365657.

 

Scharf MB, Sachais BA. Sleep laboratory evaluation of the effects and efficacy of trazodone in depressed insomniac patients. J Clin Psychiatry. 1990 Sep;51 Suppl:13-7. PMID: 2211559.

" Not dangerous goods.

LKT M1845 Melitracen Hydrochloride 5 mg 61.1 Tricyclic antidepressant; potential D1/2 antagonist. 10563-70-9 ≥99% 327.89 C21H25N HCl CC1(C2=CC=CC=C2C(=CCCN(C)C)C3=CC=CC=C31)C.Cl Ambient Ambient "Liu EJ, Zhang WL, Bai YP. [Observation on clinical efficacy of depression treated with the alliance of acupuncture and medication]. Zhongguo Zhen Jiu. 2013 Jun;33(6):497-500. PMID: 23967634.

 

Hashash JG, Abdul-Baki H, Azar C, et al. Clinical trial: a randomized controlled cross-over study of flupenthixol + melitracen in functional dyspepsia. Aliment Pharmacol Ther. 2008 Jun 1;27(11):1148-55. PMID: 18331614.

 

Bin Yaacob H. Flupenthixol and Melitracen in the management of trigeminal neuralgia. Dent J Malays. 1985 Apr;8(2):37-8. PMID: 3917005.

 

Martini C, Fici F. Acute poisoning with melitracen--absence of ECG changes. Int J Clin Pharmacol Biopharm. 1978 Mar;16(3):129-31. PMID: 649231.

" "UN number: 2811    Class: 6.1     Packing Group: III

Proper shipping name: Toxic solid, organic, n.o.s. (Melitracen hydrochloride)"

LKT M1845 Melitracen Hydrochloride 25 mg 203.8 Tricyclic antidepressant; potential D1/2 antagonist. 10563-70-9 ≥99% 327.89 C21H25N HCl CC1(C2=CC=CC=C2C(=CCCN(C)C)C3=CC=CC=C31)C.Cl Ambient Ambient "Liu EJ, Zhang WL, Bai YP. [Observation on clinical efficacy of depression treated with the alliance of acupuncture and medication]. Zhongguo Zhen Jiu. 2013 Jun;33(6):497-500. PMID: 23967634.

 

Hashash JG, Abdul-Baki H, Azar C, et al. Clinical trial: a randomized controlled cross-over study of flupenthixol + melitracen in functional dyspepsia. Aliment Pharmacol Ther. 2008 Jun 1;27(11):1148-55. PMID: 18331614.

 

Bin Yaacob H. Flupenthixol and Melitracen in the management of trigeminal neuralgia. Dent J Malays. 1985 Apr;8(2):37-8. PMID: 3917005.

 

Martini C, Fici F. Acute poisoning with melitracen--absence of ECG changes. Int J Clin Pharmacol Biopharm. 1978 Mar;16(3):129-31. PMID: 649231.

" "UN number: 2811    Class: 6.1     Packing Group: III

Proper shipping name: Toxic solid, organic, n.o.s. (Melitracen hydrochloride)"

LKT M1845 Melitracen Hydrochloride 100 mg 543.6 Tricyclic antidepressant; potential D1/2 antagonist. 10563-70-9 ≥99% 327.89 C21H25N HCl CC1(C2=CC=CC=C2C(=CCCN(C)C)C3=CC=CC=C31)C.Cl Ambient Ambient "Liu EJ, Zhang WL, Bai YP. [Observation on clinical efficacy of depression treated with the alliance of acupuncture and medication]. Zhongguo Zhen Jiu. 2013 Jun;33(6):497-500. PMID: 23967634.

 

Hashash JG, Abdul-Baki H, Azar C, et al. Clinical trial: a randomized controlled cross-over study of flupenthixol + melitracen in functional dyspepsia. Aliment Pharmacol Ther. 2008 Jun 1;27(11):1148-55. PMID: 18331614.

 

Bin Yaacob H. Flupenthixol and Melitracen in the management of trigeminal neuralgia. Dent J Malays. 1985 Apr;8(2):37-8. PMID: 3917005.

 

Martini C, Fici F. Acute poisoning with melitracen--absence of ECG changes. Int J Clin Pharmacol Biopharm. 1978 Mar;16(3):129-31. PMID: 649231.

" "UN number: 2811    Class: 6.1     Packing Group: III

Proper shipping name: Toxic solid, organic, n.o.s. (Melitracen hydrochloride)"

LKT R1877 all-trans-Retinol, ≥98 % 25 mg 57.1 Diterpene vitamin A; RAR/RXR agonist. 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclchexen-1-yl)-2,4,6,8-nonatetraen-1-ol Alphasterol; Retinol; Avitol; Vitamin A 68-26-8 ≥98% 286.45 C20H30O CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CCO)C)C Blue Ice -20°C "Friedman MD, Jeevan DS, Tobias M, et al. Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid. Oncol Rep. 2013 Oct;30(4):1645-50. PMID: 23877261.

 

Farhangi MA, Keshavarz SA, Eshraghian M, et al. Vitamin a supplementation and serum Th1- and th2-associated cytokine response in women. J Am Coll Nutr. 2013 Aug;32(4):280-5. PMID: 24024773.

 

Sharma RB, Wang Q, Khillan JS. Amplification of tumor inducing putative cancer stem cells (CSCs) by vitamin A/retinol from mammary tumors. Biochem Biophys Res Commun. 2013 Jul 12;436(4):625-31. PMID: 23764401.

 

Zhan XX, Liu Y, Yang JF, et al. All-trans-retinoic acid ameliorates experimental allergic encephalomyelitis by affecting dendritic cell and monocyte development. Immunology. 2013 Apr;138(4):333-45. PMID: 23181531.

 

Duester G. Retinoic acid synthesis and signaling during early organogenesis. Cell. 2008 Sep 19;134(6):921-31. PMID: 18805086.

 

" Not dangerous goods.

LKT R1877 all-trans-Retinol, ≥98 % 250 mg 174 Diterpene vitamin A; RAR/RXR agonist. 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclchexen-1-yl)-2,4,6,8-nonatetraen-1-ol Alphasterol; Retinol; Avitol; Vitamin A 68-26-8 ≥98% 286.45 C20H30O CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CCO)C)C Blue Ice -20°C "Friedman MD, Jeevan DS, Tobias M, et al. Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid. Oncol Rep. 2013 Oct;30(4):1645-50. PMID: 23877261.

 

Farhangi MA, Keshavarz SA, Eshraghian M, et al. Vitamin a supplementation and serum Th1- and th2-associated cytokine response in women. J Am Coll Nutr. 2013 Aug;32(4):280-5. PMID: 24024773.

 

Sharma RB, Wang Q, Khillan JS. Amplification of tumor inducing putative cancer stem cells (CSCs) by vitamin A/retinol from mammary tumors. Biochem Biophys Res Commun. 2013 Jul 12;436(4):625-31. PMID: 23764401.

 

Zhan XX, Liu Y, Yang JF, et al. All-trans-retinoic acid ameliorates experimental allergic encephalomyelitis by affecting dendritic cell and monocyte development. Immunology. 2013 Apr;138(4):333-45. PMID: 23181531.

 

Duester G. Retinoic acid synthesis and signaling during early organogenesis. Cell. 2008 Sep 19;134(6):921-31. PMID: 18805086.

 

" Not dangerous goods.

LKT A4617 Aloe Emodin 25 mg 47.6 Anthraquinone found in aloe; CTFR Cl- channel activator. 1,8-Dihydroxy-3-(hydroxymethyl)-9,10-anthracenedione 481-72-1 ≥98% 270.24 C15H10O5 C1=CC2=C(C(=C1)O)C(=O)C3=C(C=C(C=C3C2=O)CO)O ambient -20°C "Ismail S, Haris K, Abdul Ghani AR, et al. Enhanced induction of cell cycle arrest and apoptosis via the mitochondrial membrane potential disruption in human U87 malignant glioma cells by aloe emodin. J Asian Nat Prod Res. 2013 Jul 22. [Epub ahead of print]. PMID: 23869465.

 

Huang PH, Huang CY, Chen MC, et al. Emodin and Aloe-Emodin Suppress Breast Cancer Cell Proliferation through ER α Inhibition. Evid Based Complement Alternat Med. 2013; Epub 2013 Jun 24. PMID: 23864887.

 

Zhang W, Chen H, Liu DL, et al. Emodin sensitizes the gemcitabine-resistant cell line Bxpc-3/Gem to gemcitabine via downregulation of NF-κB and its regulated targets. Int J Oncol. 2013 Apr;42(4):1189-96.  PMID: 23440366.

 

Liu K, Park C, Li S, et al. Aloe-emodin suppresses prostate cancer by targeting the mTOR complex 2. Carcinogenesis. 2012 Jul;33(7):1406-11. PMID: 22532249.

 

Yang H, Xu LN, He CY, et al. CFTR chloride channel as a molecular target of anthraquinone compounds in herbal laxatives. Acta Pharmacol Sin. 2011 Jun;32(6):834-9. PMID: 21602836.

 

Srinivas G, Babykutty S, Sathiadevan PP, et al. Molecular mechanism of emodin action: transition from laxative ingredient to an antitumor agent. Med Res Rev. 2007 Sep;27(5):591-608. PMID: 17019678.

" Not dangerous goods.

LKT A4617 Aloe Emodin 100 mg 136 Anthraquinone found in aloe; CTFR Cl- channel activator. 1,8-Dihydroxy-3-(hydroxymethyl)-9,10-anthracenedione 481-72-1 ≥98% 270.24 C15H10O5 C1=CC2=C(C(=C1)O)C(=O)C3=C(C=C(C=C3C2=O)CO)O ambient -20°C "Ismail S, Haris K, Abdul Ghani AR, et al. Enhanced induction of cell cycle arrest and apoptosis via the mitochondrial membrane potential disruption in human U87 malignant glioma cells by aloe emodin. J Asian Nat Prod Res. 2013 Jul 22. [Epub ahead of print]. PMID: 23869465.

 

Huang PH, Huang CY, Chen MC, et al. Emodin and Aloe-Emodin Suppress Breast Cancer Cell Proliferation through ER α Inhibition. Evid Based Complement Alternat Med. 2013; Epub 2013 Jun 24. PMID: 23864887.

 

Zhang W, Chen H, Liu DL, et al. Emodin sensitizes the gemcitabine-resistant cell line Bxpc-3/Gem to gemcitabine via downregulation of NF-κB and its regulated targets. Int J Oncol. 2013 Apr;42(4):1189-96.  PMID: 23440366.

 

Liu K, Park C, Li S, et al. Aloe-emodin suppresses prostate cancer by targeting the mTOR complex 2. Carcinogenesis. 2012 Jul;33(7):1406-11. PMID: 22532249.

 

Yang H, Xu LN, He CY, et al. CFTR chloride channel as a molecular target of anthraquinone compounds in herbal laxatives. Acta Pharmacol Sin. 2011 Jun;32(6):834-9. PMID: 21602836.

 

Srinivas G, Babykutty S, Sathiadevan PP, et al. Molecular mechanism of emodin action: transition from laxative ingredient to an antitumor agent. Med Res Rev. 2007 Sep;27(5):591-608. PMID: 17019678.

" Not dangerous goods.

LKT A4617 Aloe Emodin 250 mg 237.8 Anthraquinone found in aloe; CTFR Cl- channel activator. 1,8-Dihydroxy-3-(hydroxymethyl)-9,10-anthracenedione 481-72-1 ≥98% 270.24 C15H10O5 C1=CC2=C(C(=C1)O)C(=O)C3=C(C=C(C=C3C2=O)CO)O ambient -20°C "Ismail S, Haris K, Abdul Ghani AR, et al. Enhanced induction of cell cycle arrest and apoptosis via the mitochondrial membrane potential disruption in human U87 malignant glioma cells by aloe emodin. J Asian Nat Prod Res. 2013 Jul 22. [Epub ahead of print]. PMID: 23869465.

 

Huang PH, Huang CY, Chen MC, et al. Emodin and Aloe-Emodin Suppress Breast Cancer Cell Proliferation through ER α Inhibition. Evid Based Complement Alternat Med. 2013; Epub 2013 Jun 24. PMID: 23864887.

 

Zhang W, Chen H, Liu DL, et al. Emodin sensitizes the gemcitabine-resistant cell line Bxpc-3/Gem to gemcitabine via downregulation of NF-κB and its regulated targets. Int J Oncol. 2013 Apr;42(4):1189-96.  PMID: 23440366.

 

Liu K, Park C, Li S, et al. Aloe-emodin suppresses prostate cancer by targeting the mTOR complex 2. Carcinogenesis. 2012 Jul;33(7):1406-11. PMID: 22532249.

 

Yang H, Xu LN, He CY, et al. CFTR chloride channel as a molecular target of anthraquinone compounds in herbal laxatives. Acta Pharmacol Sin. 2011 Jun;32(6):834-9. PMID: 21602836.

 

Srinivas G, Babykutty S, Sathiadevan PP, et al. Molecular mechanism of emodin action: transition from laxative ingredient to an antitumor agent. Med Res Rev. 2007 Sep;27(5):591-608. PMID: 17019678.

" Not dangerous goods.

LKT O4658 Olopatadine Hydrochloride 10 mg 40.7 Mast cell stabilizer; histamine H1/2/3 antagonist. 140462-76-6 ≥99% 373.87 C21H23NO3 HCl CN(C)CCC=C1C2=CC=CC=C2COC3=C1C=C(C=C3)CC(=O)O.Cl Ambient Ambient "Tamura T. Olopatadine ophthalmic solution suppresses substance P release in the conjunctivitis models. Asia Pac Allergy. 2012 Apr;2(2):115-21. PMID: 22701861.

 

Tamura T. Investigation of the antiallergic activity of olopatadine on rhinitis induced by intranasal instillation of antigen in sensitized rats using thermography. Asia Pac Allergy. 2011 Oct;1(3):138-44. PMID: 22053310.

 

Roland PS, Ryan MW, Wall GM. Olopatadine nasal spray for the treatment of seasonal allergic rhinitis in patients aged 6 years and older. Expert Opin Pharmacother. 2010 Jun;11(9):1559-67. PMID: 20482305.

 

Leonardi A, Quintieri L. Olopatadine: a drug for allergic conjunctivitis targeting the mast cell. Expert Opin Pharmacother. 2010 Apr;11(6):969-81. PMID: 20307221.

 

Sharif NA, Xu SX, Yanni JM. Olopatadine (AL-4943A): ligand binding and functional studies on a novel, long acting H1-selective histamine antagonist and anti-allergic agent for use in allergic conjunctivitis. J Ocul Pharmacol Ther. 1996 Winter;12(4):401-7. PMID: 8951676.

 

Yanni JM, Stephens DJ, Miller ST, et al. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent. J Ocul Pharmacol Ther. 1996 Winter;12(4):389-400. PMID: 8951675.

" Not dangerous goods.

LKT O4658 Olopatadine Hydrochloride 25 mg 81.6 Mast cell stabilizer; histamine H1/2/3 antagonist. 140462-76-6 ≥99% 373.87 C21H23NO3 HCl CN(C)CCC=C1C2=CC=CC=C2COC3=C1C=C(C=C3)CC(=O)O.Cl Ambient Ambient "Tamura T. Olopatadine ophthalmic solution suppresses substance P release in the conjunctivitis models. Asia Pac Allergy. 2012 Apr;2(2):115-21. PMID: 22701861.

 

Tamura T. Investigation of the antiallergic activity of olopatadine on rhinitis induced by intranasal instillation of antigen in sensitized rats using thermography. Asia Pac Allergy. 2011 Oct;1(3):138-44. PMID: 22053310.

 

Roland PS, Ryan MW, Wall GM. Olopatadine nasal spray for the treatment of seasonal allergic rhinitis in patients aged 6 years and older. Expert Opin Pharmacother. 2010 Jun;11(9):1559-67. PMID: 20482305.

 

Leonardi A, Quintieri L. Olopatadine: a drug for allergic conjunctivitis targeting the mast cell. Expert Opin Pharmacother. 2010 Apr;11(6):969-81. PMID: 20307221.

 

Sharif NA, Xu SX, Yanni JM. Olopatadine (AL-4943A): ligand binding and functional studies on a novel, long acting H1-selective histamine antagonist and anti-allergic agent for use in allergic conjunctivitis. J Ocul Pharmacol Ther. 1996 Winter;12(4):401-7. PMID: 8951676.

 

Yanni JM, Stephens DJ, Miller ST, et al. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent. J Ocul Pharmacol Ther. 1996 Winter;12(4):389-400. PMID: 8951675.

" Not dangerous goods.

LKT O4658 Olopatadine Hydrochloride 100 mg 224.3 Mast cell stabilizer; histamine H1/2/3 antagonist. 140462-76-6 ≥99% 373.87 C21H23NO3 HCl CN(C)CCC=C1C2=CC=CC=C2COC3=C1C=C(C=C3)CC(=O)O.Cl Ambient Ambient "Tamura T. Olopatadine ophthalmic solution suppresses substance P release in the conjunctivitis models. Asia Pac Allergy. 2012 Apr;2(2):115-21. PMID: 22701861.

 

Tamura T. Investigation of the antiallergic activity of olopatadine on rhinitis induced by intranasal instillation of antigen in sensitized rats using thermography. Asia Pac Allergy. 2011 Oct;1(3):138-44. PMID: 22053310.

 

Roland PS, Ryan MW, Wall GM. Olopatadine nasal spray for the treatment of seasonal allergic rhinitis in patients aged 6 years and older. Expert Opin Pharmacother. 2010 Jun;11(9):1559-67. PMID: 20482305.

 

Leonardi A, Quintieri L. Olopatadine: a drug for allergic conjunctivitis targeting the mast cell. Expert Opin Pharmacother. 2010 Apr;11(6):969-81. PMID: 20307221.

 

Sharif NA, Xu SX, Yanni JM. Olopatadine (AL-4943A): ligand binding and functional studies on a novel, long acting H1-selective histamine antagonist and anti-allergic agent for use in allergic conjunctivitis. J Ocul Pharmacol Ther. 1996 Winter;12(4):401-7. PMID: 8951676.

 

Yanni JM, Stephens DJ, Miller ST, et al. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent. J Ocul Pharmacol Ther. 1996 Winter;12(4):389-400. PMID: 8951675.

" Not dangerous goods.

LKT M4454 MLN-4924 1 mg 88.3 Nedd8-activating enzyme inhibitor. MLN4924, Pevonedistat 905579-51-3 ≥99% 443.16 C21H25N5O4S C1CC2=CC=CC=C2C1NC3=NC=NC4=C3C=CN4C5CC(C(C5)O)COS(=O)(=O)N Ambient -20°C "Ethanol (12.5 mg/ml)

DMSO (20 mg/ml)

DMF (20 mg/ml)" "Yan ZH, Burkhardt A, Loke HK, et al. Quantifiable analysis of cellular pathway inhibition of a Nedd8-activating enzyme inhibitor, MLN4924, using AlphaScreen. Anal Biochem. 2013 Aug 15;439(2):109-15. PMID: 23624319.

 

Li L, Liu B, Dong T, et al. Neddylation pathway regulates the proliferation and survival of macrophages. Biochem Biophys Res Commun. 2013 Mar 15;432(3):494-8. PMID: 23416079.

 

Zhao Y, Xiong X, Jia L, et al. Targeting Cullin-RING ligases by MLN4924 induces autophagy via modulating the HIF1-REDD1-TSC1-mTORC1-DEPTOR axis. Cell Death Dis. 2012 Sep 6;3:e386. PMID: 22951983.

 

Luo Z, Pan Y, Jeong LS, et al. Inactivation of the Cullin (CUL)-RING E3 ligase by the NEDD8-activating enzyme inhibitor MLN4924 triggers protective autophagy in cancer cells. Autophagy. 2012 Nov;8(11):1677-9. PMID: 22874562.

 

Nawrocki ST, Griffin P, Kelly KR, et al. MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy. Expert Opin Investig Drugs. 2012 Oct;21(10):1563-73. PMID: 22799561.

 

Yang D, Tan M, Wang G, et al. The p21-dependent radiosensitization of human breast cancer cells by MLN4924, an investigational inhibitor of NEDD8 activating enzyme. PLoS One. 2012;7(3):e34079. PMID: 22457814.

" Not dangerous goods.

LKT M4454 MLN-4924 5 mg 271.7 Nedd8-activating enzyme inhibitor. MLN4924, Pevonedistat 905579-51-3 ≥99% 443.16 C21H25N5O4S C1CC2=CC=CC=C2C1NC3=NC=NC4=C3C=CN4C5CC(C(C5)O)COS(=O)(=O)N Ambient -20°C "Ethanol (12.5 mg/ml)

DMSO (20 mg/ml)

DMF (20 mg/ml)" "Yan ZH, Burkhardt A, Loke HK, et al. Quantifiable analysis of cellular pathway inhibition of a Nedd8-activating enzyme inhibitor, MLN4924, using AlphaScreen. Anal Biochem. 2013 Aug 15;439(2):109-15. PMID: 23624319.

 

Li L, Liu B, Dong T, et al. Neddylation pathway regulates the proliferation and survival of macrophages. Biochem Biophys Res Commun. 2013 Mar 15;432(3):494-8. PMID: 23416079.

 

Zhao Y, Xiong X, Jia L, et al. Targeting Cullin-RING ligases by MLN4924 induces autophagy via modulating the HIF1-REDD1-TSC1-mTORC1-DEPTOR axis. Cell Death Dis. 2012 Sep 6;3:e386. PMID: 22951983.

 

Luo Z, Pan Y, Jeong LS, et al. Inactivation of the Cullin (CUL)-RING E3 ligase by the NEDD8-activating enzyme inhibitor MLN4924 triggers protective autophagy in cancer cells. Autophagy. 2012 Nov;8(11):1677-9. PMID: 22874562.

 

Nawrocki ST, Griffin P, Kelly KR, et al. MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy. Expert Opin Investig Drugs. 2012 Oct;21(10):1563-73. PMID: 22799561.

 

Yang D, Tan M, Wang G, et al. The p21-dependent radiosensitization of human breast cancer cells by MLN4924, an investigational inhibitor of NEDD8 activating enzyme. PLoS One. 2012;7(3):e34079. PMID: 22457814.

" Not dangerous goods.

LKT M4454 MLN-4924 25 mg 951.3 Nedd8-activating enzyme inhibitor. MLN4924, Pevonedistat 905579-51-3 ≥99% 443.16 C21H25N5O4S C1CC2=CC=CC=C2C1NC3=NC=NC4=C3C=CN4C5CC(C(C5)O)COS(=O)(=O)N Ambient -20°C "Ethanol (12.5 mg/ml)

DMSO (20 mg/ml)

DMF (20 mg/ml)" "Yan ZH, Burkhardt A, Loke HK, et al. Quantifiable analysis of cellular pathway inhibition of a Nedd8-activating enzyme inhibitor, MLN4924, using AlphaScreen. Anal Biochem. 2013 Aug 15;439(2):109-15. PMID: 23624319.

 

Li L, Liu B, Dong T, et al. Neddylation pathway regulates the proliferation and survival of macrophages. Biochem Biophys Res Commun. 2013 Mar 15;432(3):494-8. PMID: 23416079.

 

Zhao Y, Xiong X, Jia L, et al. Targeting Cullin-RING ligases by MLN4924 induces autophagy via modulating the HIF1-REDD1-TSC1-mTORC1-DEPTOR axis. Cell Death Dis. 2012 Sep 6;3:e386. PMID: 22951983.

 

Luo Z, Pan Y, Jeong LS, et al. Inactivation of the Cullin (CUL)-RING E3 ligase by the NEDD8-activating enzyme inhibitor MLN4924 triggers protective autophagy in cancer cells. Autophagy. 2012 Nov;8(11):1677-9. PMID: 22874562.

 

Nawrocki ST, Griffin P, Kelly KR, et al. MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy. Expert Opin Investig Drugs. 2012 Oct;21(10):1563-73. PMID: 22799561.

 

Yang D, Tan M, Wang G, et al. The p21-dependent radiosensitization of human breast cancer cells by MLN4924, an investigational inhibitor of NEDD8 activating enzyme. PLoS One. 2012;7(3):e34079. PMID: 22457814.

" Not dangerous goods.

LKT S0400 SB-431542 1 mg 47.6 ALK4/5/7 (activin-like) inhibitor, TGF-β inhibitor. 301836-41-9 ≥98% 384.39 C22H16N4O3 C1OC2=C(O1)C=C(C=C2)C3=C(NC(=N3)C4=CC=C(C=C4)C(=O)N)C5=CC=CC=N5 Ambient Ambient "Tanaka H, Shinto O, Yashiro M, et al. Transforming growth factor β signaling inhibitor, SB-431542, induces maturation of dendritic cells and enhances anti-tumor activity. Oncol Rep. 2010 Dec;24(6):1637-43. PMID: 21042762.

 

Halder SK, Beauchamp RD, Datta PK. A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers. Neoplasia. 2005 May;7(5):509-21. PMID: 15967103.

 

Hjelmeland MD, Hjelmeland AB, Sathornsumetee S, et al. SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol Cancer Ther. 2004 Jun;3(6):737-45. PMID: 15210860.

 

Inman GJ, Nicolás FJ, Callahan JF, et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol. 2002 Jul;62(1):65-74. PMID: 12065756.

" Not dangerous goods.

LKT S0400 SB-431542 5 mg 163.2 ALK4/5/7 (activin-like) inhibitor, TGF-β inhibitor. 301836-41-9 ≥98% 384.39 C22H16N4O3 C1OC2=C(O1)C=C(C=C2)C3=C(NC(=N3)C4=CC=C(C=C4)C(=O)N)C5=CC=CC=N5 Ambient Ambient "Tanaka H, Shinto O, Yashiro M, et al. Transforming growth factor β signaling inhibitor, SB-431542, induces maturation of dendritic cells and enhances anti-tumor activity. Oncol Rep. 2010 Dec;24(6):1637-43. PMID: 21042762.

 

Halder SK, Beauchamp RD, Datta PK. A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers. Neoplasia. 2005 May;7(5):509-21. PMID: 15967103.

 

Hjelmeland MD, Hjelmeland AB, Sathornsumetee S, et al. SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol Cancer Ther. 2004 Jun;3(6):737-45. PMID: 15210860.

 

Inman GJ, Nicolás FJ, Callahan JF, et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol. 2002 Jul;62(1):65-74. PMID: 12065756.

" Not dangerous goods.

LKT S0400 SB-431542 25 mg 434.9 ALK4/5/7 (activin-like) inhibitor, TGF-β inhibitor. 301836-41-9 ≥98% 384.39 C22H16N4O3 C1OC2=C(O1)C=C(C=C2)C3=C(NC(=N3)C4=CC=C(C=C4)C(=O)N)C5=CC=CC=N5 Ambient Ambient "Tanaka H, Shinto O, Yashiro M, et al. Transforming growth factor β signaling inhibitor, SB-431542, induces maturation of dendritic cells and enhances anti-tumor activity. Oncol Rep. 2010 Dec;24(6):1637-43. PMID: 21042762.

 

Halder SK, Beauchamp RD, Datta PK. A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers. Neoplasia. 2005 May;7(5):509-21. PMID: 15967103.

 

Hjelmeland MD, Hjelmeland AB, Sathornsumetee S, et al. SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol Cancer Ther. 2004 Jun;3(6):737-45. PMID: 15210860.

 

Inman GJ, Nicolás FJ, Callahan JF, et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol. 2002 Jul;62(1):65-74. PMID: 12065756.

" Not dangerous goods.

LKT P0932 PCI-32765 1 mg 67.9 BTK and IL-2-inducible kinase inhibitor. Ibrutinib 936563-96-1 ≥99% 440.5 C25H24N6O2 C=CC(=O)N1CCCC(C1)N2C3=C(C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)C(=NC=N3)N Ambient Ambient "Massó-Vallés D, Jauset T, Serrano E, et al. Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma. Cancer Res. 2015 Apr 15;75(8):1675-81. PMID: 25878147.

 

Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1 selective pressure in T-lymphocytes. Blood. 2013 Jul 25. [Epub ahead of print]. PMID: 23886836.

 

Ponader S, Chen SS, Buggy JJ, et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012 Feb 2;119(5):1182-9. PMID: 22180443.

 

Chang BY, Huang MM, Francesco M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res Ther. 2011 Jul 13;13(4):R115. PMID: 21752263.

 

MacGlashan D Jr, Honigberg LA, Smith A, et al. Inhibition of IgE-mediated secretion from human basophils with a highly selective Bruton's tyrosine kinase, Btk, inhibitor. Int Immunopharmacol. 2011 Apr;11(4):475-9. PMID: 21238622.

 

Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13075-80. PMID: 20615965.

" Not dangerous goods.

LKT P0932 PCI-32765 5 mg 203.8 BTK and IL-2-inducible kinase inhibitor. Ibrutinib 936563-96-1 ≥99% 440.5 C25H24N6O2 C=CC(=O)N1CCCC(C1)N2C3=C(C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)C(=NC=N3)N Ambient Ambient "Massó-Vallés D, Jauset T, Serrano E, et al. Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma. Cancer Res. 2015 Apr 15;75(8):1675-81. PMID: 25878147.

 

Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1 selective pressure in T-lymphocytes. Blood. 2013 Jul 25. [Epub ahead of print]. PMID: 23886836.

 

Ponader S, Chen SS, Buggy JJ, et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012 Feb 2;119(5):1182-9. PMID: 22180443.

 

Chang BY, Huang MM, Francesco M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res Ther. 2011 Jul 13;13(4):R115. PMID: 21752263.

 

MacGlashan D Jr, Honigberg LA, Smith A, et al. Inhibition of IgE-mediated secretion from human basophils with a highly selective Bruton's tyrosine kinase, Btk, inhibitor. Int Immunopharmacol. 2011 Apr;11(4):475-9. PMID: 21238622.

 

Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13075-80. PMID: 20615965.

" Not dangerous goods.

LKT P0932 PCI-32765 25 mg 543.6 BTK and IL-2-inducible kinase inhibitor. Ibrutinib 936563-96-1 ≥99% 440.5 C25H24N6O2 C=CC(=O)N1CCCC(C1)N2C3=C(C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)C(=NC=N3)N Ambient Ambient "Massó-Vallés D, Jauset T, Serrano E, et al. Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma. Cancer Res. 2015 Apr 15;75(8):1675-81. PMID: 25878147.

 

Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1 selective pressure in T-lymphocytes. Blood. 2013 Jul 25. [Epub ahead of print]. PMID: 23886836.

 

Ponader S, Chen SS, Buggy JJ, et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012 Feb 2;119(5):1182-9. PMID: 22180443.

 

Chang BY, Huang MM, Francesco M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res Ther. 2011 Jul 13;13(4):R115. PMID: 21752263.

 

MacGlashan D Jr, Honigberg LA, Smith A, et al. Inhibition of IgE-mediated secretion from human basophils with a highly selective Bruton's tyrosine kinase, Btk, inhibitor. Int Immunopharmacol. 2011 Apr;11(4):475-9. PMID: 21238622.

 

Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13075-80. PMID: 20615965.

" Not dangerous goods.

LKT M0009 Macitentan 1 mg 74.8 ET-A/B antagonist. ACT-064992, Actelion-1 441798-33-0 ≥99% 588.27 C19H20Br2N6O4S CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br Ambient Ambient "Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013 Aug 29;369(9):809-18. PMID: 23984728.

 

Corallo C, Pecetti G, Iglarz M, et al. Macitentan slows down the dermal fibrotic process in systemic sclerosis: in vitro findings. J Biol Regul Homeost Agents. 2013 Apr-Jun;27(2):455-62. PMID: 23830395.

 

Gatfield J, Mueller Grandjean C, Sasse T, et al. Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells. PLoS One. 2012;7(10):e47662. PMID: 23077657.

 

Kim SJ, Kim JS, Kim SW, et al. Antivascular therapy for multidrug-resistant ovarian tumors by macitentan, a dual endothelin receptor antagonist. Transl Oncol. 2012 Feb;5(1):39-47. PMID: 22348175.

 

Kim SJ, Kim JS, Kim SW, et al. Macitentan (ACT-064992), a tissue-targeting endothelin receptor antagonist, enhances therapeutic efficacy of paclitaxel by modulating survival pathways in orthotopic models of metastatic human ovarian cancer. Neoplasia. 2011 Feb;13(2):167-79. PMID: 21403842.

 

Iglarz M, Binkert C, Morrison K, et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther. 2008 Dec;327(3):736-45. PMID: 18780830.

" Not dangerous goods.

LKT M0009 Macitentan 5 mg 224.3 ET-A/B antagonist. ACT-064992, Actelion-1 441798-33-0 ≥99% 588.27 C19H20Br2N6O4S CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br Ambient Ambient "Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013 Aug 29;369(9):809-18. PMID: 23984728.

 

Corallo C, Pecetti G, Iglarz M, et al. Macitentan slows down the dermal fibrotic process in systemic sclerosis: in vitro findings. J Biol Regul Homeost Agents. 2013 Apr-Jun;27(2):455-62. PMID: 23830395.

 

Gatfield J, Mueller Grandjean C, Sasse T, et al. Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells. PLoS One. 2012;7(10):e47662. PMID: 23077657.

 

Kim SJ, Kim JS, Kim SW, et al. Antivascular therapy for multidrug-resistant ovarian tumors by macitentan, a dual endothelin receptor antagonist. Transl Oncol. 2012 Feb;5(1):39-47. PMID: 22348175.

 

Kim SJ, Kim JS, Kim SW, et al. Macitentan (ACT-064992), a tissue-targeting endothelin receptor antagonist, enhances therapeutic efficacy of paclitaxel by modulating survival pathways in orthotopic models of metastatic human ovarian cancer. Neoplasia. 2011 Feb;13(2):167-79. PMID: 21403842.

 

Iglarz M, Binkert C, Morrison K, et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther. 2008 Dec;327(3):736-45. PMID: 18780830.

" Not dangerous goods.

LKT M0009 Macitentan 25 mg 611.5 ET-A/B antagonist. ACT-064992, Actelion-1 441798-33-0 ≥99% 588.27 C19H20Br2N6O4S CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br Ambient Ambient "Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013 Aug 29;369(9):809-18. PMID: 23984728.

 

Corallo C, Pecetti G, Iglarz M, et al. Macitentan slows down the dermal fibrotic process in systemic sclerosis: in vitro findings. J Biol Regul Homeost Agents. 2013 Apr-Jun;27(2):455-62. PMID: 23830395.

 

Gatfield J, Mueller Grandjean C, Sasse T, et al. Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells. PLoS One. 2012;7(10):e47662. PMID: 23077657.

 

Kim SJ, Kim JS, Kim SW, et al. Antivascular therapy for multidrug-resistant ovarian tumors by macitentan, a dual endothelin receptor antagonist. Transl Oncol. 2012 Feb;5(1):39-47. PMID: 22348175.

 

Kim SJ, Kim JS, Kim SW, et al. Macitentan (ACT-064992), a tissue-targeting endothelin receptor antagonist, enhances therapeutic efficacy of paclitaxel by modulating survival pathways in orthotopic models of metastatic human ovarian cancer. Neoplasia. 2011 Feb;13(2):167-79. PMID: 21403842.

 

Iglarz M, Binkert C, Morrison K, et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther. 2008 Dec;327(3):736-45. PMID: 18780830.

" Not dangerous goods.

LKT Y1000 Y27632 Dihydrochloride 1 mg 61.1 ROCK inhibitor. 129830-38-2 ≥99% 320.26 C14H21N3O 2HCl CC(C1CCC(CC1)C(=O)NC2=CC=NC=C2)N.Cl.Cl Ambient Ambient "Rodriguez-Perez AI, Dominguez-Meijide A, Lanciego JL, et al. Inhibition of Rho kinase mediates the neuroprotective effects of estrogen in the MPTP model of Parkinson's disease. Neurobiol Dis. 2013 Oct;58:209-19. PMID: 23774254.

 

Wang J, Wang YH, Hou YY, et al. The small GTPase RhoA, but not Rac1, is essential for conditioned aversive memory formation through regulation of actin rearrangements in rat dorsal hippocampus. Acta Pharmacol Sin. 2013 Jun;34(6):811-8. PMID: 23564082.

 

Zhang XH, Sun NX, Feng ZH, et al. Interference of Y-27632 on the signal transduction of transforming growth factor beta type 1 in ocular Tenon capsule fibroblasts. Int J Ophthalmol. 2012;5(5):576-81. PMID: 23166867.

 

Ishizaki T, Uehata M, Tamechika I, et al. Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol Pharmacol. 2000 May;57(5):976-83. PMID: 10779382.

 

Kuwahara K, Saito Y, Nakagawa O, et al. The effects of the selective ROCK inhibitor, Y27632, on ET-1-induced hypertrophic response in neonatal rat cardiac myocytes--possible involvement of Rho/ROCK pathway in cardiac muscle cell hypertrophy. FEBS Lett. 1999 Jun 11;452(3):314-8. PMID: 10386613.

 

Hirose M, Ishizaki T, Watanabe N, et al. Molecular dissection of the Rho-associated protein kinase (p160ROCK)-regulated neurite remodeling in neuroblastoma N1E-115 cells. J Cell Biol. 1998 Jun 29;141(7):1625-36. PMID: 9647654.

" Not dangerous goods.

LKT Y1000 Y27632 Dihydrochloride 5 mg 163.2 ROCK inhibitor. 129830-38-2 ≥99% 320.26 C14H21N3O 2HCl CC(C1CCC(CC1)C(=O)NC2=CC=NC=C2)N.Cl.Cl Ambient Ambient "Rodriguez-Perez AI, Dominguez-Meijide A, Lanciego JL, et al. Inhibition of Rho kinase mediates the neuroprotective effects of estrogen in the MPTP model of Parkinson's disease. Neurobiol Dis. 2013 Oct;58:209-19. PMID: 23774254.

 

Wang J, Wang YH, Hou YY, et al. The small GTPase RhoA, but not Rac1, is essential for conditioned aversive memory formation through regulation of actin rearrangements in rat dorsal hippocampus. Acta Pharmacol Sin. 2013 Jun;34(6):811-8. PMID: 23564082.

 

Zhang XH, Sun NX, Feng ZH, et al. Interference of Y-27632 on the signal transduction of transforming growth factor beta type 1 in ocular Tenon capsule fibroblasts. Int J Ophthalmol. 2012;5(5):576-81. PMID: 23166867.

 

Ishizaki T, Uehata M, Tamechika I, et al. Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol Pharmacol. 2000 May;57(5):976-83. PMID: 10779382.

 

Kuwahara K, Saito Y, Nakagawa O, et al. The effects of the selective ROCK inhibitor, Y27632, on ET-1-induced hypertrophic response in neonatal rat cardiac myocytes--possible involvement of Rho/ROCK pathway in cardiac muscle cell hypertrophy. FEBS Lett. 1999 Jun 11;452(3):314-8. PMID: 10386613.

 

Hirose M, Ishizaki T, Watanabe N, et al. Molecular dissection of the Rho-associated protein kinase (p160ROCK)-regulated neurite remodeling in neuroblastoma N1E-115 cells. J Cell Biol. 1998 Jun 29;141(7):1625-36. PMID: 9647654.

" Not dangerous goods.

LKT Y1000 Y27632 Dihydrochloride 25 mg 475.7 ROCK inhibitor. 129830-38-2 ≥99% 320.26 C14H21N3O 2HCl CC(C1CCC(CC1)C(=O)NC2=CC=NC=C2)N.Cl.Cl Ambient Ambient "Rodriguez-Perez AI, Dominguez-Meijide A, Lanciego JL, et al. Inhibition of Rho kinase mediates the neuroprotective effects of estrogen in the MPTP model of Parkinson's disease. Neurobiol Dis. 2013 Oct;58:209-19. PMID: 23774254.

 

Wang J, Wang YH, Hou YY, et al. The small GTPase RhoA, but not Rac1, is essential for conditioned aversive memory formation through regulation of actin rearrangements in rat dorsal hippocampus. Acta Pharmacol Sin. 2013 Jun;34(6):811-8. PMID: 23564082.

 

Zhang XH, Sun NX, Feng ZH, et al. Interference of Y-27632 on the signal transduction of transforming growth factor beta type 1 in ocular Tenon capsule fibroblasts. Int J Ophthalmol. 2012;5(5):576-81. PMID: 23166867.

 

Ishizaki T, Uehata M, Tamechika I, et al. Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol Pharmacol. 2000 May;57(5):976-83. PMID: 10779382.

 

Kuwahara K, Saito Y, Nakagawa O, et al. The effects of the selective ROCK inhibitor, Y27632, on ET-1-induced hypertrophic response in neonatal rat cardiac myocytes--possible involvement of Rho/ROCK pathway in cardiac muscle cell hypertrophy. FEBS Lett. 1999 Jun 11;452(3):314-8. PMID: 10386613.

 

Hirose M, Ishizaki T, Watanabe N, et al. Molecular dissection of the Rho-associated protein kinase (p160ROCK)-regulated neurite remodeling in neuroblastoma N1E-115 cells. J Cell Biol. 1998 Jun 29;141(7):1625-36. PMID: 9647654.

" Not dangerous goods.

LKT C0274 Caspofungin Diacetate 5 mg 81.6 Lipopeptide; 1,3-β-Glucan synthase inhibitor. 179463-17-3 ≥95% 1213.42 C52H88N10O15 C4H8O4 CCC(C)CC(C)CCCCCCCCC(=O)NC1CC(C(NC(=O)C2C(CCN2C(=O)C(NC(=O)C(NC(=O)C3CC(CN3C(=O)C(NC1=O)C(C)O)O)C(C(C4=CC=C(C=C4)O)O)O)C(CCN)O)O)NCCN)O.CC(=O)O.CC(=O)O Ambient -20°C "El-Kirat-Chatel S, Beaussart A, Alsteens D, et al. Nanoscale analysis of caspofungin-induced cell surface remodelling in Candida albicans. Nanoscale. 2013 Feb 7;5(3):1105-15. PMID: 23262781.

 

Pacetti SA, Gelone SP. Caspofungin acetate for treatment of invasive fungal infections. Ann Pharmacother. 2003 Jan;37(1):90-8. PMID: 12503942.

 

Mio T, Adachi-Shimizu M, Tachibana Y, et al. Cloning of the Candida albicans homolog of Saccharomyces cerevisiae GSC1/FKS1 and its involvement in beta-1,3-glucan synthesis. J Bacteriol. 1997 Jul;179(13):4096-105. PMID: 9209021.

" Not dangerous goods

LKT C0274 Caspofungin Diacetate 25 mg 333 Lipopeptide; 1,3-β-Glucan synthase inhibitor. 179463-17-3 ≥95% 1213.42 C52H88N10O15 C4H8O4 CCC(C)CC(C)CCCCCCCCC(=O)NC1CC(C(NC(=O)C2C(CCN2C(=O)C(NC(=O)C(NC(=O)C3CC(CN3C(=O)C(NC1=O)C(C)O)O)C(C(C4=CC=C(C=C4)O)O)O)C(CCN)O)O)NCCN)O.CC(=O)O.CC(=O)O Ambient -20°C "El-Kirat-Chatel S, Beaussart A, Alsteens D, et al. Nanoscale analysis of caspofungin-induced cell surface remodelling in Candida albicans. Nanoscale. 2013 Feb 7;5(3):1105-15. PMID: 23262781.

 

Pacetti SA, Gelone SP. Caspofungin acetate for treatment of invasive fungal infections. Ann Pharmacother. 2003 Jan;37(1):90-8. PMID: 12503942.

 

Mio T, Adachi-Shimizu M, Tachibana Y, et al. Cloning of the Candida albicans homolog of Saccharomyces cerevisiae GSC1/FKS1 and its involvement in beta-1,3-glucan synthesis. J Bacteriol. 1997 Jul;179(13):4096-105. PMID: 9209021.

" Not dangerous goods

LKT C0274 Caspofungin Diacetate 100 mg 1019.2 Lipopeptide; 1,3-β-Glucan synthase inhibitor. 179463-17-3 ≥95% 1213.42 C52H88N10O15 C4H8O4 CCC(C)CC(C)CCCCCCCCC(=O)NC1CC(C(NC(=O)C2C(CCN2C(=O)C(NC(=O)C(NC(=O)C3CC(CN3C(=O)C(NC1=O)C(C)O)O)C(C(C4=CC=C(C=C4)O)O)O)C(CCN)O)O)NCCN)O.CC(=O)O.CC(=O)O Ambient -20°C "El-Kirat-Chatel S, Beaussart A, Alsteens D, et al. Nanoscale analysis of caspofungin-induced cell surface remodelling in Candida albicans. Nanoscale. 2013 Feb 7;5(3):1105-15. PMID: 23262781.

 

Pacetti SA, Gelone SP. Caspofungin acetate for treatment of invasive fungal infections. Ann Pharmacother. 2003 Jan;37(1):90-8. PMID: 12503942.

 

Mio T, Adachi-Shimizu M, Tachibana Y, et al. Cloning of the Candida albicans homolog of Saccharomyces cerevisiae GSC1/FKS1 and its involvement in beta-1,3-glucan synthesis. J Bacteriol. 1997 Jul;179(13):4096-105. PMID: 9209021.

" Not dangerous goods

LKT P3600 PJ34 Hydrochloride 1 mg 61.1 PARP inhibitor; potential Pim1 inhibitor. 344458-15-7 ≥95% 331.8 C17H17N3O2 HCl CN(C)CC(=O)NC1=CC2=C(C=C1)NC(=O)C3=CC=CC=C32.Cl Ambient -20°C "Antolín AA, Jalencas X, Yélamos J, et al. Identification of pim kinases as novel targets for PJ34 with confounding effects in PARP biology. ACS Chem Biol. 2012 Dec 21;7(12):1962-7. PMID: 23025350.

 

Gangopadhyay NN, Luketich JD, Opest A, et al. Inhibition of poly(ADP-ribose) polymerase (PARP) induces apoptosis in lung cancer cell lines. Cancer Invest. 2011 Nov;29(9):608-16. PMID: 22011283.

 

Madison DL, Stauffer D, Lundblad JR. The PARP inhibitor PJ34 causes a PARP1-independent, p21 dependent mitotic arrest. DNA Repair (Amst). 2011 Oct 10;10(10):1003-13. PMID: 21840268.

 

Scott GS, Kean RB, Mikheeva T, et al. The therapeutic effects of PJ34 [N-(6-oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide.HCl], a selective inhibitor of poly(ADP-ribose) polymerase, in experimental allergic encephalomyelitis are associated with immunomodulation. J Pharmacol Exp Ther. 2004 Sep;310(3):1053-61. PMID: 15159442.

 

Suarez-Pinzon WL, Mabley JG, Power R, et al. Poly (ADP-ribose) polymerase inhibition prevents spontaneous and recurrent autoimmune diabetes in NOD mice by inducing apoptosis of islet-infiltrating leukocytes. Diabetes. 2003 Jul;52(7):1683-8. PMID: 12829633.

 

Faro R, Toyoda Y, McCully JD, et al. Myocardial protection by PJ34, a novel potent poly (ADP-ribose) synthetase inhibitor. Ann Thorac Surg. 2002 Feb;73(2):575-81. PMID: 11845877.

 

Abdelkarim GE, Gertz K, Harms C, et al. Protective effects of PJ34, a novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP) in in vitro and in vivo models of stroke. Int J Mol Med. 2001 Mar;7(3):255-60. PMID: 11179503.

" Not dangerous goods.

LKT P3600 PJ34 Hydrochloride 5 mg 156.2 PARP inhibitor; potential Pim1 inhibitor. 344458-15-7 ≥95% 331.8 C17H17N3O2 HCl CN(C)CC(=O)NC1=CC2=C(C=C1)NC(=O)C3=CC=CC=C32.Cl Ambient -20°C "Antolín AA, Jalencas X, Yélamos J, et al. Identification of pim kinases as novel targets for PJ34 with confounding effects in PARP biology. ACS Chem Biol. 2012 Dec 21;7(12):1962-7. PMID: 23025350.

 

Gangopadhyay NN, Luketich JD, Opest A, et al. Inhibition of poly(ADP-ribose) polymerase (PARP) induces apoptosis in lung cancer cell lines. Cancer Invest. 2011 Nov;29(9):608-16. PMID: 22011283.

 

Madison DL, Stauffer D, Lundblad JR. The PARP inhibitor PJ34 causes a PARP1-independent, p21 dependent mitotic arrest. DNA Repair (Amst). 2011 Oct 10;10(10):1003-13. PMID: 21840268.

 

Scott GS, Kean RB, Mikheeva T, et al. The therapeutic effects of PJ34 [N-(6-oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide.HCl], a selective inhibitor of poly(ADP-ribose) polymerase, in experimental allergic encephalomyelitis are associated with immunomodulation. J Pharmacol Exp Ther. 2004 Sep;310(3):1053-61. PMID: 15159442.

 

Suarez-Pinzon WL, Mabley JG, Power R, et al. Poly (ADP-ribose) polymerase inhibition prevents spontaneous and recurrent autoimmune diabetes in NOD mice by inducing apoptosis of islet-infiltrating leukocytes. Diabetes. 2003 Jul;52(7):1683-8. PMID: 12829633.

 

Faro R, Toyoda Y, McCully JD, et al. Myocardial protection by PJ34, a novel potent poly (ADP-ribose) synthetase inhibitor. Ann Thorac Surg. 2002 Feb;73(2):575-81. PMID: 11845877.

 

Abdelkarim GE, Gertz K, Harms C, et al. Protective effects of PJ34, a novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP) in in vitro and in vivo models of stroke. Int J Mol Med. 2001 Mar;7(3):255-60. PMID: 11179503.

" Not dangerous goods.

LKT P3600 PJ34 Hydrochloride 25 mg 475.7 PARP inhibitor; potential Pim1 inhibitor. 344458-15-7 ≥95% 331.8 C17H17N3O2 HCl CN(C)CC(=O)NC1=CC2=C(C=C1)NC(=O)C3=CC=CC=C32.Cl Ambient -20°C "Antolín AA, Jalencas X, Yélamos J, et al. Identification of pim kinases as novel targets for PJ34 with confounding effects in PARP biology. ACS Chem Biol. 2012 Dec 21;7(12):1962-7. PMID: 23025350.

 

Gangopadhyay NN, Luketich JD, Opest A, et al. Inhibition of poly(ADP-ribose) polymerase (PARP) induces apoptosis in lung cancer cell lines. Cancer Invest. 2011 Nov;29(9):608-16. PMID: 22011283.

 

Madison DL, Stauffer D, Lundblad JR. The PARP inhibitor PJ34 causes a PARP1-independent, p21 dependent mitotic arrest. DNA Repair (Amst). 2011 Oct 10;10(10):1003-13. PMID: 21840268.

 

Scott GS, Kean RB, Mikheeva T, et al. The therapeutic effects of PJ34 [N-(6-oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide.HCl], a selective inhibitor of poly(ADP-ribose) polymerase, in experimental allergic encephalomyelitis are associated with immunomodulation. J Pharmacol Exp Ther. 2004 Sep;310(3):1053-61. PMID: 15159442.

 

Suarez-Pinzon WL, Mabley JG, Power R, et al. Poly (ADP-ribose) polymerase inhibition prevents spontaneous and recurrent autoimmune diabetes in NOD mice by inducing apoptosis of islet-infiltrating leukocytes. Diabetes. 2003 Jul;52(7):1683-8. PMID: 12829633.

 

Faro R, Toyoda Y, McCully JD, et al. Myocardial protection by PJ34, a novel potent poly (ADP-ribose) synthetase inhibitor. Ann Thorac Surg. 2002 Feb;73(2):575-81. PMID: 11845877.

 

Abdelkarim GE, Gertz K, Harms C, et al. Protective effects of PJ34, a novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP) in in vitro and in vivo models of stroke. Int J Mol Med. 2001 Mar;7(3):255-60. PMID: 11179503.

" Not dangerous goods.

LKT M4100 MK-0524 1 mg 88.3 DP1 antagonist. Laropiprant 571170-77-9 ≥99% 435.9 C21H19ClFNO4S CS(=O)(=O)C1=C2C(=CC(=C1)F)C3=C(N2CC4=CC=C(C=C4)Cl)C(CC3)CC(=O)O Ambient Ambient "Labrecque P, Roy SJ, Fréchette L, et al. Inverse agonist and pharmacochaperone properties of MK-0524 on the prostanoid DP1 receptor. PLoS One. 2013 Jun 10;8(6):e65767. PMID: 23762421.

 

Philipose S, Konya V, Lazarevic M, et al. Laropiprant attenuates EP3 and TP prostanoid receptor-mediated thrombus formation. PLoS One. 2012;7(8):e40222. PMID: 22870195.

 

Guo N, Baglole CJ, O'Loughlin CW, et al. Mast cell-derived prostaglandin D2 controls hyaluronan synthesis in human orbital fibroblasts via DP1 activation: implications for thyroid eye disease. J Biol Chem. 2010 May 21;285(21):15794-804. PMID: 20308056.

 

Luo WL, Crumley T, Ebel D, et al. Single therapeutic and supratherapeutic doses of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, do not prolong the QTcF interval in healthy volunteers. J Clin Pharmacol. 2010 Nov;50(11):1273-9. PMID: 20107202.

 

Paolini JF, Bays HE, Ballantyne CM, et al. Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors. Cardiol Clin. 2008 Nov;26(4):547-60. PMID: 19031552.

" Not dangerous goods.

LKT M4100 MK-0524 5 mg 271.7 DP1 antagonist. Laropiprant 571170-77-9 ≥99% 435.9 C21H19ClFNO4S CS(=O)(=O)C1=C2C(=CC(=C1)F)C3=C(N2CC4=CC=C(C=C4)Cl)C(CC3)CC(=O)O Ambient Ambient "Labrecque P, Roy SJ, Fréchette L, et al. Inverse agonist and pharmacochaperone properties of MK-0524 on the prostanoid DP1 receptor. PLoS One. 2013 Jun 10;8(6):e65767. PMID: 23762421.

 

Philipose S, Konya V, Lazarevic M, et al. Laropiprant attenuates EP3 and TP prostanoid receptor-mediated thrombus formation. PLoS One. 2012;7(8):e40222. PMID: 22870195.

 

Guo N, Baglole CJ, O'Loughlin CW, et al. Mast cell-derived prostaglandin D2 controls hyaluronan synthesis in human orbital fibroblasts via DP1 activation: implications for thyroid eye disease. J Biol Chem. 2010 May 21;285(21):15794-804. PMID: 20308056.

 

Luo WL, Crumley T, Ebel D, et al. Single therapeutic and supratherapeutic doses of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, do not prolong the QTcF interval in healthy volunteers. J Clin Pharmacol. 2010 Nov;50(11):1273-9. PMID: 20107202.

 

Paolini JF, Bays HE, Ballantyne CM, et al. Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors. Cardiol Clin. 2008 Nov;26(4):547-60. PMID: 19031552.

" Not dangerous goods.

LKT M4100 MK-0524 25 mg 815.4 DP1 antagonist. Laropiprant 571170-77-9 ≥99% 435.9 C21H19ClFNO4S CS(=O)(=O)C1=C2C(=CC(=C1)F)C3=C(N2CC4=CC=C(C=C4)Cl)C(CC3)CC(=O)O Ambient Ambient "Labrecque P, Roy SJ, Fréchette L, et al. Inverse agonist and pharmacochaperone properties of MK-0524 on the prostanoid DP1 receptor. PLoS One. 2013 Jun 10;8(6):e65767. PMID: 23762421.

 

Philipose S, Konya V, Lazarevic M, et al. Laropiprant attenuates EP3 and TP prostanoid receptor-mediated thrombus formation. PLoS One. 2012;7(8):e40222. PMID: 22870195.

 

Guo N, Baglole CJ, O'Loughlin CW, et al. Mast cell-derived prostaglandin D2 controls hyaluronan synthesis in human orbital fibroblasts via DP1 activation: implications for thyroid eye disease. J Biol Chem. 2010 May 21;285(21):15794-804. PMID: 20308056.

 

Luo WL, Crumley T, Ebel D, et al. Single therapeutic and supratherapeutic doses of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, do not prolong the QTcF interval in healthy volunteers. J Clin Pharmacol. 2010 Nov;50(11):1273-9. PMID: 20107202.

 

Paolini JF, Bays HE, Ballantyne CM, et al. Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors. Cardiol Clin. 2008 Nov;26(4):547-60. PMID: 19031552.

" Not dangerous goods.

LKT V9200 VX-950 5 mg 101.9 NS3/4A serine protease inhibitor. Telaprevir 402957-28-2 ≥98% 679.85 C36H53N7O6 CCCC(C(=O)C(=O)NC1CC1)NC(=O)C2C3CCCC3CN2C(=O)C(C(C)(C)C)NC(=O)C(C4CCCCC4)NC(=O)C5=NC=CN=C5 Ambient Ambient "Matthews SJ, Lancaster JW. Telaprevir: a hepatitis C NS3/4A protease inhibitor. Clin Ther. 2012 Sep;34(9):1857-82. PMID: 22951253.

 

McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2012;362(14):1292–303. doi:10.1056/NEJMoa0908014. PMID 20375406

 

Gentile I, Viola C, Borgia F, et al. Telaprevir: a promising protease inhibitor for the treatment of hepatitis C virus infection. Curr Med Chem. 2009;16(9):1115-21. PMID: 19275615.

 

Lin C, Kwong AD, Perni RB. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect Disord Drug Targets. 2006 Mar;6(1):3–16. PMID: 16787300.

" Not dangerous goods

LKT V9200 VX-950 25 mg 339.8 NS3/4A serine protease inhibitor. Telaprevir 402957-28-2 ≥98% 679.85 C36H53N7O6 CCCC(C(=O)C(=O)NC1CC1)NC(=O)C2C3CCCC3CN2C(=O)C(C(C)(C)C)NC(=O)C(C4CCCCC4)NC(=O)C5=NC=CN=C5 Ambient Ambient "Matthews SJ, Lancaster JW. Telaprevir: a hepatitis C NS3/4A protease inhibitor. Clin Ther. 2012 Sep;34(9):1857-82. PMID: 22951253.

 

McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2012;362(14):1292–303. doi:10.1056/NEJMoa0908014. PMID 20375406

 

Gentile I, Viola C, Borgia F, et al. Telaprevir: a promising protease inhibitor for the treatment of hepatitis C virus infection. Curr Med Chem. 2009;16(9):1115-21. PMID: 19275615.

 

Lin C, Kwong AD, Perni RB. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect Disord Drug Targets. 2006 Mar;6(1):3–16. PMID: 16787300.

" Not dangerous goods

LKT V9200 VX-950 100 mg 1060 NS3/4A serine protease inhibitor. Telaprevir 402957-28-2 ≥98% 679.85 C36H53N7O6 CCCC(C(=O)C(=O)NC1CC1)NC(=O)C2C3CCCC3CN2C(=O)C(C(C)(C)C)NC(=O)C(C4CCCCC4)NC(=O)C5=NC=CN=C5 Ambient Ambient "Matthews SJ, Lancaster JW. Telaprevir: a hepatitis C NS3/4A protease inhibitor. Clin Ther. 2012 Sep;34(9):1857-82. PMID: 22951253.

 

McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2012;362(14):1292–303. doi:10.1056/NEJMoa0908014. PMID 20375406

 

Gentile I, Viola C, Borgia F, et al. Telaprevir: a promising protease inhibitor for the treatment of hepatitis C virus infection. Curr Med Chem. 2009;16(9):1115-21. PMID: 19275615.

 

Lin C, Kwong AD, Perni RB. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect Disord Drug Targets. 2006 Mar;6(1):3–16. PMID: 16787300.

" Not dangerous goods

LKT J6400 (+)-JQ-1 1 mg 61.1 Triazolothienodiazepine; BRD inhibitor. 1268524-70-4 ≥99% 456.99 C23H25ClN4O2S CC1=C(SC2=C1C(=NC(C3=NN=C(N32)C)CC(=O)OC(C)(C)C)C4=CC=C(C=C4)Cl)C Ambient -20°C "Cinar M, Rosenfelt F, Rokhsar S, et al. Concurrent inhibition of MYC and BCL2 is a potentially effective treatment strategy for double hit and triple hit B-cell lymphomas. Leuk Res. 2015 Apr 17. [Epub ahead of print]. PMID: 25916698.

 

Da Costa D, Agathanggelou A, Perry T, et al. BET inhibition as a single or combined therapeutic approach in primary paediatric B-precursor acute lymphoblastic leukaemia. Blood Cancer J. 2013 Jul 19;3:e126. PMID: 23872705.

 

Ott CJ, Kopp N, Bird L, et al. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood. 2012 Oct 4;120(14):2843-52. PMID: 22904298.

 

Banerjee C, Archin N, MichaeLS, et al. BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J Leukoc Biol. 2012 Dec;92(6):1147-54. PMID: 22802445.

 

Zuber J, Shi J, Wang E, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 2011 Aug 3;478(7370):524-8. PMID: 21814200.

 

Filippakopoulos P, Qi J, Picaud S, et al. Selective inhibition of BET bromodomains. Nature. 2010 Dec 23;468(7327):1067-73. PMID: 20871596.

" Not dangerous goods.

LKT J6400 (+)-JQ-1 5 mg 183.4 Triazolothienodiazepine; BRD inhibitor. 1268524-70-4 ≥99% 456.99 C23H25ClN4O2S CC1=C(SC2=C1C(=NC(C3=NN=C(N32)C)CC(=O)OC(C)(C)C)C4=CC=C(C=C4)Cl)C Ambient -20°C "Cinar M, Rosenfelt F, Rokhsar S, et al. Concurrent inhibition of MYC and BCL2 is a potentially effective treatment strategy for double hit and triple hit B-cell lymphomas. Leuk Res. 2015 Apr 17. [Epub ahead of print]. PMID: 25916698.

 

Da Costa D, Agathanggelou A, Perry T, et al. BET inhibition as a single or combined therapeutic approach in primary paediatric B-precursor acute lymphoblastic leukaemia. Blood Cancer J. 2013 Jul 19;3:e126. PMID: 23872705.

 

Ott CJ, Kopp N, Bird L, et al. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood. 2012 Oct 4;120(14):2843-52. PMID: 22904298.

 

Banerjee C, Archin N, MichaeLS, et al. BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J Leukoc Biol. 2012 Dec;92(6):1147-54. PMID: 22802445.

 

Zuber J, Shi J, Wang E, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 2011 Aug 3;478(7370):524-8. PMID: 21814200.

 

Filippakopoulos P, Qi J, Picaud S, et al. Selective inhibition of BET bromodomains. Nature. 2010 Dec 23;468(7327):1067-73. PMID: 20871596.

" Not dangerous goods.

LKT J6400 (+)-JQ-1 25 mg 706.7 Triazolothienodiazepine; BRD inhibitor. 1268524-70-4 ≥99% 456.99 C23H25ClN4O2S CC1=C(SC2=C1C(=NC(C3=NN=C(N32)C)CC(=O)OC(C)(C)C)C4=CC=C(C=C4)Cl)C Ambient -20°C "Cinar M, Rosenfelt F, Rokhsar S, et al. Concurrent inhibition of MYC and BCL2 is a potentially effective treatment strategy for double hit and triple hit B-cell lymphomas. Leuk Res. 2015 Apr 17. [Epub ahead of print]. PMID: 25916698.

 

Da Costa D, Agathanggelou A, Perry T, et al. BET inhibition as a single or combined therapeutic approach in primary paediatric B-precursor acute lymphoblastic leukaemia. Blood Cancer J. 2013 Jul 19;3:e126. PMID: 23872705.

 

Ott CJ, Kopp N, Bird L, et al. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood. 2012 Oct 4;120(14):2843-52. PMID: 22904298.

 

Banerjee C, Archin N, MichaeLS, et al. BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J Leukoc Biol. 2012 Dec;92(6):1147-54. PMID: 22802445.

 

Zuber J, Shi J, Wang E, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 2011 Aug 3;478(7370):524-8. PMID: 21814200.

 

Filippakopoulos P, Qi J, Picaud S, et al. Selective inhibition of BET bromodomains. Nature. 2010 Dec 23;468(7327):1067-73. PMID: 20871596.

" Not dangerous goods.

LKT C6132 CPI-203 1 mg 88.3 Triazolothienodiazepine, JQ-1 derivative; BRD inhibitor. ≥99% 399.9 C19H18ClN5OS CC1=C(SC2=C1C(=NC(C3=NN=C(N32)C)CC(=O)N)C4=CC=C(C=C4)Cl)C Ambient Ambient "King B, Trimarchi T, Reavie L, et al. The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. Cell. 2013 Jun 20;153(7):1552-66. PMID: 23791182.

 

Devaiah BN, Lewis BA, Cherman N, et al. BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxy-terminal domain. Proc Natl Acad Sci U S A. 2012 May 1;109(18):6927-32. PMID: 22509028.

" Not dangerous goods.

LKT C6132 CPI-203 5 mg 271.7 Triazolothienodiazepine, JQ-1 derivative; BRD inhibitor. ≥99% 399.9 C19H18ClN5OS CC1=C(SC2=C1C(=NC(C3=NN=C(N32)C)CC(=O)N)C4=CC=C(C=C4)Cl)C Ambient Ambient "King B, Trimarchi T, Reavie L, et al. The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. Cell. 2013 Jun 20;153(7):1552-66. PMID: 23791182.

 

Devaiah BN, Lewis BA, Cherman N, et al. BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxy-terminal domain. Proc Natl Acad Sci U S A. 2012 May 1;109(18):6927-32. PMID: 22509028.

" Not dangerous goods.

LKT C6132 CPI-203 25 mg 951.3 Triazolothienodiazepine, JQ-1 derivative; BRD inhibitor. ≥99% 399.9 C19H18ClN5OS CC1=C(SC2=C1C(=NC(C3=NN=C(N32)C)CC(=O)N)C4=CC=C(C=C4)Cl)C Ambient Ambient "King B, Trimarchi T, Reavie L, et al. The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. Cell. 2013 Jun 20;153(7):1552-66. PMID: 23791182.

 

Devaiah BN, Lewis BA, Cherman N, et al. BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxy-terminal domain. Proc Natl Acad Sci U S A. 2012 May 1;109(18):6927-32. PMID: 22509028.

" Not dangerous goods.

LKT L9609 Lycopene 10 mg 875 Carotene pigment found in red and green fruits and vegetables; RAR agonist. ψ,ψ-Carotene all-trans-Lycopene; Lycopene 7 502-65-8 ≥90% 536.88 C40H56 CC(=CCCC(=CC=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)C=CC=C(C)CCC=C(C)C)C)C)C)C Heat sensitive. Protect from light. Dry Ice -80°C Insoluble in water. Sparingly soluble in ethanol. Soluble in carbon disulfide, chloroform and benzene. "Chao HH, Sung LC, Chen CH, et al. Lycopene Inhibits Urotensin-II-Induced Cardiomyocyte Hypertrophy in Neonatal Rat Cardiomyocytes. Evid Based Complement Alternat Med. 2014;2014:724670. PMID: 24971153.

 

Gloria NF, Soares N, Brand C, et al. Lycopene and beta-carotene induce cell-cycle arrest and apoptosis in human breast cancer cell lines. Anticancer Res. 2014 Mar;34(3):1377-86. PMID: 24596385.

 

Bayramoglu G, Bayramoglu A, Altuner Y, et al. The effects of lycopene on hepatic ischemia/reperfusion injury in rats. Cytotechnology. 2014 Mar 4. [Epub ahead of print]. PMID: 24590927.

 

Aydemir G, Carlsen H, Blomhoff R, et al. Lycopene induces retinoic acid receptor transcriptional activation in mice. Mol Nutr Food Res. 2012 May;56(5):702-12. PMID: 22648617.

" None Not dangerous goods.

LKT T6833 Triacetyl Aloe-emodin (Impurity A) 5 mg 115.5 Derivative of aloe-emodin, anthraquinone found in aloe; CFTR Cl- channel activator. [4,5-bis(acetyloxy)-9,10-dioxo-9,10-dihydroanthracen-2-yl]methyl acetate 1,8-Bis(acetyloxy)-3-[(acetyloxy)methyl]-9,10-anthracenedione; 1,8-Dihydroxy-3-(hydroxymethyl)anthraquinone Triacetate; Aloe-emodin Impurity A 25395-11-3 ≥98% 396.35 C21H16O8 CC(=O)OCC1=CC(=C2C(=C1)C(=O)C3=C(C2=O)C(=CC=C3)OC(=O)C)OC(=O)C Ambient -20°C "Ismail S, Haris K, Abdul Ghani AR, et al. Enhanced induction of cell cycle arrest and apoptosis via the mitochondrial membrane potential disruption in human U87 malignant glioma cells by aloe emodin. J Asian Nat Prod Res. 2013 Jul 22. [Epub ahead of print]. PMID: 23869465.

 

Huang PH, Huang CY, Chen MC, et al. Emodin and Aloe-Emodin Suppress Breast Cancer Cell Proliferation through ER α Inhibition. Evid Based Complement Alternat Med. 2013; Epub 2013 Jun 24. PMID: 23864887.

 

Zhang W, Chen H, Liu DL, et al. Emodin sensitizes the gemcitabine-resistant cell line Bxpc-3/Gem to gemcitabine via downregulation of NF-κB and its regulated targets. Int J Oncol. 2013 Apr;42(4):1189-96.  PMID: 23440366.

 

Liu K, Park C, Li S, et al. Aloe-emodin suppresses prostate cancer by targeting the mTOR complex 2. Carcinogenesis. 2012 Jul;33(7):1406-11. PMID: 22532249.

 

Yang H, Xu LN, He CY, et al. CFTR chloride channel as a molecular target of anthraquinone compounds in herbal laxatives. Acta Pharmacol Sin. 2011 Jun;32(6):834-9. PMID: 21602836.

 

Srinivas G, Babykutty S, Sathiadevan PP, et al. Molecular mechanism of emodin action: transition from laxative ingredient to an antitumor agent. Med Res Rev. 2007 Sep;27(5):591-608. PMID: 17019678.

" Not dangerous goods.

LKT T6833 Triacetyl Aloe-emodin (Impurity A) 10 mg 163.2 Derivative of aloe-emodin, anthraquinone found in aloe; CFTR Cl- channel activator. [4,5-bis(acetyloxy)-9,10-dioxo-9,10-dihydroanthracen-2-yl]methyl acetate 1,8-Bis(acetyloxy)-3-[(acetyloxy)methyl]-9,10-anthracenedione; 1,8-Dihydroxy-3-(hydroxymethyl)anthraquinone Triacetate; Aloe-emodin Impurity A 25395-11-3 ≥98% 396.35 C21H16O8 CC(=O)OCC1=CC(=C2C(=C1)C(=O)C3=C(C2=O)C(=CC=C3)OC(=O)C)OC(=O)C Ambient -20°C "Ismail S, Haris K, Abdul Ghani AR, et al. Enhanced induction of cell cycle arrest and apoptosis via the mitochondrial membrane potential disruption in human U87 malignant glioma cells by aloe emodin. J Asian Nat Prod Res. 2013 Jul 22. [Epub ahead of print]. PMID: 23869465.

 

Huang PH, Huang CY, Chen MC, et al. Emodin and Aloe-Emodin Suppress Breast Cancer Cell Proliferation through ER α Inhibition. Evid Based Complement Alternat Med. 2013; Epub 2013 Jun 24. PMID: 23864887.

 

Zhang W, Chen H, Liu DL, et al. Emodin sensitizes the gemcitabine-resistant cell line Bxpc-3/Gem to gemcitabine via downregulation of NF-κB and its regulated targets. Int J Oncol. 2013 Apr;42(4):1189-96.  PMID: 23440366.

 

Liu K, Park C, Li S, et al. Aloe-emodin suppresses prostate cancer by targeting the mTOR complex 2. Carcinogenesis. 2012 Jul;33(7):1406-11. PMID: 22532249.

 

Yang H, Xu LN, He CY, et al. CFTR chloride channel as a molecular target of anthraquinone compounds in herbal laxatives. Acta Pharmacol Sin. 2011 Jun;32(6):834-9. PMID: 21602836.

 

Srinivas G, Babykutty S, Sathiadevan PP, et al. Molecular mechanism of emodin action: transition from laxative ingredient to an antitumor agent. Med Res Rev. 2007 Sep;27(5):591-608. PMID: 17019678.

" Not dangerous goods.

LKT T6833 Triacetyl Aloe-emodin (Impurity A) 25 mg 271.7 Derivative of aloe-emodin, anthraquinone found in aloe; CFTR Cl- channel activator. [4,5-bis(acetyloxy)-9,10-dioxo-9,10-dihydroanthracen-2-yl]methyl acetate 1,8-Bis(acetyloxy)-3-[(acetyloxy)methyl]-9,10-anthracenedione; 1,8-Dihydroxy-3-(hydroxymethyl)anthraquinone Triacetate; Aloe-emodin Impurity A 25395-11-3 ≥98% 396.35 C21H16O8 CC(=O)OCC1=CC(=C2C(=C1)C(=O)C3=C(C2=O)C(=CC=C3)OC(=O)C)OC(=O)C Ambient -20°C "Ismail S, Haris K, Abdul Ghani AR, et al. Enhanced induction of cell cycle arrest and apoptosis via the mitochondrial membrane potential disruption in human U87 malignant glioma cells by aloe emodin. J Asian Nat Prod Res. 2013 Jul 22. [Epub ahead of print]. PMID: 23869465.

 

Huang PH, Huang CY, Chen MC, et al. Emodin and Aloe-Emodin Suppress Breast Cancer Cell Proliferation through ER α Inhibition. Evid Based Complement Alternat Med. 2013; Epub 2013 Jun 24. PMID: 23864887.

 

Zhang W, Chen H, Liu DL, et al. Emodin sensitizes the gemcitabine-resistant cell line Bxpc-3/Gem to gemcitabine via downregulation of NF-κB and its regulated targets. Int J Oncol. 2013 Apr;42(4):1189-96.  PMID: 23440366.

 

Liu K, Park C, Li S, et al. Aloe-emodin suppresses prostate cancer by targeting the mTOR complex 2. Carcinogenesis. 2012 Jul;33(7):1406-11. PMID: 22532249.

 

Yang H, Xu LN, He CY, et al. CFTR chloride channel as a molecular target of anthraquinone compounds in herbal laxatives. Acta Pharmacol Sin. 2011 Jun;32(6):834-9. PMID: 21602836.

 

Srinivas G, Babykutty S, Sathiadevan PP, et al. Molecular mechanism of emodin action: transition from laxative ingredient to an antitumor agent. Med Res Rev. 2007 Sep;27(5):591-608. PMID: 17019678.

" Not dangerous goods.

LKT T6833 Triacetyl Aloe-emodin (Impurity A) 100 mg 1019.2 Derivative of aloe-emodin, anthraquinone found in aloe; CFTR Cl- channel activator. [4,5-bis(acetyloxy)-9,10-dioxo-9,10-dihydroanthracen-2-yl]methyl acetate 1,8-Bis(acetyloxy)-3-[(acetyloxy)methyl]-9,10-anthracenedione; 1,8-Dihydroxy-3-(hydroxymethyl)anthraquinone Triacetate; Aloe-emodin Impurity A 25395-11-3 ≥98% 396.35 C21H16O8 CC(=O)OCC1=CC(=C2C(=C1)C(=O)C3=C(C2=O)C(=CC=C3)OC(=O)C)OC(=O)C Ambient -20°C "Ismail S, Haris K, Abdul Ghani AR, et al. Enhanced induction of cell cycle arrest and apoptosis via the mitochondrial membrane potential disruption in human U87 malignant glioma cells by aloe emodin. J Asian Nat Prod Res. 2013 Jul 22. [Epub ahead of print]. PMID: 23869465.

 

Huang PH, Huang CY, Chen MC, et al. Emodin and Aloe-Emodin Suppress Breast Cancer Cell Proliferation through ER α Inhibition. Evid Based Complement Alternat Med. 2013; Epub 2013 Jun 24. PMID: 23864887.

 

Zhang W, Chen H, Liu DL, et al. Emodin sensitizes the gemcitabine-resistant cell line Bxpc-3/Gem to gemcitabine via downregulation of NF-κB and its regulated targets. Int J Oncol. 2013 Apr;42(4):1189-96.  PMID: 23440366.

 

Liu K, Park C, Li S, et al. Aloe-emodin suppresses prostate cancer by targeting the mTOR complex 2. Carcinogenesis. 2012 Jul;33(7):1406-11. PMID: 22532249.

 

Yang H, Xu LN, He CY, et al. CFTR chloride channel as a molecular target of anthraquinone compounds in herbal laxatives. Acta Pharmacol Sin. 2011 Jun;32(6):834-9. PMID: 21602836.

 

Srinivas G, Babykutty S, Sathiadevan PP, et al. Molecular mechanism of emodin action: transition from laxative ingredient to an antitumor agent. Med Res Rev. 2007 Sep;27(5):591-608. PMID: 17019678.

" Not dangerous goods.

LKT P2502 Phenethyl Glucosinolate Potassium 25 mg 788.7 Found in cruciferous vegetables. "Glucopyranose, 1-thio-, 1-hydrocinnamohydroximate NO-

(hydrogen sulfate), beta-D-" Gluconasturtiin 18425-76-8 ≥97% 461.55 C15H20NO9S2K Ambient -20°C Soluble in water. "Gupta P, Wright SE, Kim SH, et al. Phenethyl isothiocyanate: A comprehensive review of anti-cancer mechanisms. Biochim Biophys Acta. 2014 Aug 23;1846(2):405-424. PMID: 25152445.

 

Natella F, Maldini M, Leoni G, et al. Glucosinolates redox activities: can they act as antioxidants? Food Chem. 2014 Apr 15;149:226-32. PMID: 24295700.

" Not dangerous goods.

LKT P2515 3-Phenylpropyl Isothiocyanate 1 g 75.3 Synthetic ITC. 3-isothiocyanatopropylbenzene Phenylpropyl isothiocyanate 2627-27-2 ≥98% 177.27 C10H11NS C1=CC=C(C=C1)CCCN=C=S Ambient 4°C Soluble in DMSO. "Tayem Y, Green CJ, Motterlini R, et al. Isothiocyanate-cysteine conjugates protect renal tissue against cisplatin-induced apoptosis via induction of heme oxygenase-1. Pharmacol Res. 2014 Mar;81:1-9. PMID: 24434421.

 

Hecht SS, Upadhyaya P, Wang M, et al. Inhibition of lung tumorigenesis in A/J mice by N-acetyl-S-(N-2-phenethylthiocarbamoyl)-L-cysteine and myo-inositol, individually and in combination. Carcinogenesis. 2002 Sep;23(9):1455-61. PMID: 12189187.

" Xn, C "UN number: 2922     Class:  8     Packing group:  III

Proper shipping name:  CORROSIVE LIQUID, TOXIC, C.O.S. (3-Phenylpropyl isothiocyante)"

LKT A0918 N-Acetyl-L-Cysteine 100 g 121.4 Cysteine derivative, antioxidant, treats acetaminophen overdose. L-α-Acetamido-β-mercaptopropionic acid "Acetylcysteine; Brunac; Fabrol; Fluimucil; Fluprowit; Mucosil

" 616-91-1 ≥98% 163.2 C5H9NO3S CC(=O)NC(CS)C(=O)O Ambient Ambient Soluble in water. "Lim JH, Lee YM, Park SR, et al. Anticancer activity of hispidin via reactive oxygen species-mediated apoptosis in colon cancer cells. Anticancer Res. 2014 Aug;34(8):4087-93. PMID: 25075033.

 

Grosicka-Maciąg E, Szumiło M, Czeczot H, et al. Modulation of antioxidant defense system by the dithiocarbamate fungicides Maneb and Zineb in Chinese hamster V79 cells and the role of N-acetyl-L-cysteine. Food Chem Toxicol. 2013 Oct;60:130-4. PMID: 23871785.

 

Dean O, Giorlando F, Berk M. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci. 2011 Mar;36(2):78-86. PMID: 21118657.

 

Weiss L, Hildt E, Hofschneider PH. Anti-hepatitis B virus activity of N-acetyl-L-cysteine (NAC): new aspects of a well-established drug. Antiviral Res. 1996 Aug;32(1):43-53. PMID: 8863995.

 

Shibanuma M, Kuroki T, Nose K. Inhibition by N-acetyl-L-cysteine of interleukin-6 mRNA induction and activation of NF kappa B by tumor necrosis factor alpha in a mouse fibroblastic cell line, Balb/3T3. FEBS Lett. 1994 Oct 10;353(1):62-6. PMID: 7926024.

" Xi Not dangerous goods.

LKT B0133 Baicalin 25 mg 163.2 Flavone found in Scutellaria; prolyl oligopeptidase and neuraminidase inhibitor 7-D-Glucuronic acid-5,6-dihydroxyflavone 21967-41-9 ≥95% 446.36 C21H18O11 C1=CC=C(C=C1)C2=CC(=O)C3=C(C(=C(C=C3O2)OC4C(C(C(C(O4)C(=O)O)O)O)O)O)O Ambient -20°C Soluble in DMSO or ethanol. "Ding Y, Dou J, Teng Z, et al. Antiviral activity of baicalin against influenza A (H1N1/H3N2) virus in cell culture and in mice and its inhibition of neuraminidase. Arch Virol. 2014 Jul 31. [Epub ahead of print]. PMID: 25078390.

 

Min W, Liu X, Qian Q, et al. The effects of baicalin against UVA-induced photoaging in skin fibroblasts. Am J Chin Med. 2014;42(3):709-27. PMID: 24871661.

 

Zhang L, Pu Z, Wang J, et al. Baicalin inhibits hypoxia-induced pulmonary artery smooth muscle cell proliferation via the AKT/HIF-1α/p27-associated pathway. Int J Mol Sci. 2014 May 9;15(5):8153-68. PMID: 24821539.

 

Zhou QB, Jin YL, Jia Q, et al. Baicalin attenuates brain edema in a rat model of intracerebral hemorrhage. Inflammation. 2014 Feb;37(1):107-15. PMID: 23974988.

 

Zheng J, Hu JD, Huang Y, et al. Effects of baicalin on HL-60 cell xenografts in nude mice and its mechanism. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012 Oct;20(5):1066-71. PMID: 23114120.

 

Tarragó T, Kichik N, Claasen B, et al. Baicalin, a prodrug able to reach the CNS, is a prolyl oligopeptidase inhibitor. Bioorg Med Chem. 2008 Aug 1;16(15):7516-24. PMID: 18650094.

" Xi Not dangerous goods.

LKT B0133 Baicalin 100 mg 321.5 Flavone found in Scutellaria; prolyl oligopeptidase and neuraminidase inhibitor 7-D-Glucuronic acid-5,6-dihydroxyflavone 21967-41-9 ≥95% 446.36 C21H18O11 C1=CC=C(C=C1)C2=CC(=O)C3=C(C(=C(C=C3O2)OC4C(C(C(C(O4)C(=O)O)O)O)O)O)O Ambient -20°C Soluble in DMSO or ethanol. "Ding Y, Dou J, Teng Z, et al. Antiviral activity of baicalin against influenza A (H1N1/H3N2) virus in cell culture and in mice and its inhibition of neuraminidase. Arch Virol. 2014 Jul 31. [Epub ahead of print]. PMID: 25078390.

 

Min W, Liu X, Qian Q, et al. The effects of baicalin against UVA-induced photoaging in skin fibroblasts. Am J Chin Med. 2014;42(3):709-27. PMID: 24871661.

 

Zhang L, Pu Z, Wang J, et al. Baicalin inhibits hypoxia-induced pulmonary artery smooth muscle cell proliferation via the AKT/HIF-1α/p27-associated pathway. Int J Mol Sci. 2014 May 9;15(5):8153-68. PMID: 24821539.

 

Zhou QB, Jin YL, Jia Q, et al. Baicalin attenuates brain edema in a rat model of intracerebral hemorrhage. Inflammation. 2014 Feb;37(1):107-15. PMID: 23974988.

 

Zheng J, Hu JD, Huang Y, et al. Effects of baicalin on HL-60 cell xenografts in nude mice and its mechanism. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012 Oct;20(5):1066-71. PMID: 23114120.

 

Tarragó T, Kichik N, Claasen B, et al. Baicalin, a prodrug able to reach the CNS, is a prolyl oligopeptidase inhibitor. Bioorg Med Chem. 2008 Aug 1;16(15):7516-24. PMID: 18650094.

" Xi Not dangerous goods.

LKT E6996 Erythromycin Thiocyanate 5 g 87.4 Macrolide; protein translation inhibitor, mammalian mRNA splicing inhibitor. 7704-67-8 ≥90% 793.02 C37H67NO13 HSCN CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O.C(#N)S Ambient Ambient Soluble in alcohol. "Hertweck M, Hiller R, Mueller MW. Inhibition of nuclear pre-mRNA splicing by antibiotics in vitro. Eur J Biochem. 2002 Jan;269(1):175-83. PMID: 11784311.

 

Menninger JR, Otto DP. Erythromycin, carbomycin, and spiramycin inhibit protein synthesis by stimulating the dissociation of peptidyl-tRNA from ribosomes. Antimicrob Agents Chemother. 1982 May;21(5):811-8. PMID: 6179465." Not dangerous goods.

LKT L0109 Lactalbumin 500 g 200.2 Found in milk and whey, cation and fatty acid chelator. Albumins, colostrm; Sunlact N 21 9013-90-5 ≥80% Ambient Ambient "Barbana C, Sánchez L, Pérez MD. Bioactivity of α-lactalbumin related to its interaction with fatty acids: a review. Crit Rev Food Sci Nutr. 2011 Sep;51(8):783-94. PMID: 21838558.

 

Matsumoto H, Shimokawa Y, Ushida Y, et al. New biological function of bovine alpha-lactalbumin: protective effect against ethanol- and stress-induced gastric mucosal injury in rats. Biosci Biotechnol Biochem. 2001 May;65(5):1104-11. PMID: 11440124.

 

Permyakov EA, Berliner LJ. alpha-Lactalbumin: structure and function. FEBS Lett. 2000 May 19;473(3):269-74. PMID: 10818224." Not dangerous goods.

LKT L0109 Lactalbumin 1 kg 364 Found in milk and whey, cation and fatty acid chelator. Albumins, colostrm; Sunlact N 21 9013-90-5 ≥80% Ambient Ambient "Barbana C, Sánchez L, Pérez MD. Bioactivity of α-lactalbumin related to its interaction with fatty acids: a review. Crit Rev Food Sci Nutr. 2011 Sep;51(8):783-94. PMID: 21838558.

 

Matsumoto H, Shimokawa Y, Ushida Y, et al. New biological function of bovine alpha-lactalbumin: protective effect against ethanol- and stress-induced gastric mucosal injury in rats. Biosci Biotechnol Biochem. 2001 May;65(5):1104-11. PMID: 11440124.

 

Permyakov EA, Berliner LJ. alpha-Lactalbumin: structure and function. FEBS Lett. 2000 May 19;473(3):269-74. PMID: 10818224." Not dangerous goods.

LKT T1978 Tetrahydroberberine 1 mg 36.4 Isoquinoline alkaloid found in Corydalis; 5-HT1A agonist, D2 antagonist, ATP-sensitive K+ channel blocker. 522-97-4 ≥98% 339.39 C20H21NO4 COC1=C(C2=C(CC3C4=CC5=C(C=C4CCN3C2)OCO5)C=C1)OC Ambient 4°C "Ge HX, Zhang J, Chen L, et al. Chemical and microbial semi-synthesis of tetrahydroprotoberberines as inhibitors on tissue factor procoagulant activity. Bioorg Med Chem. 2013 Jan 1;21(1):62-9. PMID: 23199480.

 

Lee TH, Kim KH, Lee SO, et al. Tetrahydroberberine, an isoquinoline alkaloid isolated from corydalis tuber, enhances gastrointestinal motor function. J Pharmacol Exp Ther. 2011 Sep;338(3):917-24. PMID: 21659472.

 

Wu C, Yang K, Liu Q, et al. Tetrahydroberberine blocks ATP-sensitive potassium channels in dopamine neurons acutely-dissociated from rat substantia nigra pars compacta. Neuropharmacology. 2010 Dec;59(7-8):567-72. PMID: 20804776.

 

Xuan B, Wang W, Li DX. Inhibitory effect of tetrahydroberberine on platelet aggregation and thrombosis. Zhongguo Yao Li Xue Bao. 1994 Mar;15(2):133-5. PMID: 8010106.

 

Zhou J, Xuan B, Li DX. Effects of tetrahydroberberine on ischemic and reperfused myocardium in rats. Zhongguo Yao Li Xue Bao. 1993 Mar;14(2):130-3. PMID: 8352004.

" Not dangerous goods.

LKT T1978 Tetrahydroberberine 5 mg 91 Isoquinoline alkaloid found in Corydalis; 5-HT1A agonist, D2 antagonist, ATP-sensitive K+ channel blocker. 522-97-4 ≥98% 339.39 C20H21NO4 COC1=C(C2=C(CC3C4=CC5=C(C=C4CCN3C2)OCO5)C=C1)OC Ambient 4°C "Ge HX, Zhang J, Chen L, et al. Chemical and microbial semi-synthesis of tetrahydroprotoberberines as inhibitors on tissue factor procoagulant activity. Bioorg Med Chem. 2013 Jan 1;21(1):62-9. PMID: 23199480.

 

Lee TH, Kim KH, Lee SO, et al. Tetrahydroberberine, an isoquinoline alkaloid isolated from corydalis tuber, enhances gastrointestinal motor function. J Pharmacol Exp Ther. 2011 Sep;338(3):917-24. PMID: 21659472.

 

Wu C, Yang K, Liu Q, et al. Tetrahydroberberine blocks ATP-sensitive potassium channels in dopamine neurons acutely-dissociated from rat substantia nigra pars compacta. Neuropharmacology. 2010 Dec;59(7-8):567-72. PMID: 20804776.

 

Xuan B, Wang W, Li DX. Inhibitory effect of tetrahydroberberine on platelet aggregation and thrombosis. Zhongguo Yao Li Xue Bao. 1994 Mar;15(2):133-5. PMID: 8010106.

 

Zhou J, Xuan B, Li DX. Effects of tetrahydroberberine on ischemic and reperfused myocardium in rats. Zhongguo Yao Li Xue Bao. 1993 Mar;14(2):130-3. PMID: 8352004.

" Not dangerous goods.

LKT T1978 Tetrahydroberberine 25 mg 345.8 Isoquinoline alkaloid found in Corydalis; 5-HT1A agonist, D2 antagonist, ATP-sensitive K+ channel blocker. 522-97-4 ≥98% 339.39 C20H21NO4 COC1=C(C2=C(CC3C4=CC5=C(C=C4CCN3C2)OCO5)C=C1)OC Ambient 4°C "Ge HX, Zhang J, Chen L, et al. Chemical and microbial semi-synthesis of tetrahydroprotoberberines as inhibitors on tissue factor procoagulant activity. Bioorg Med Chem. 2013 Jan 1;21(1):62-9. PMID: 23199480.

 

Lee TH, Kim KH, Lee SO, et al. Tetrahydroberberine, an isoquinoline alkaloid isolated from corydalis tuber, enhances gastrointestinal motor function. J Pharmacol Exp Ther. 2011 Sep;338(3):917-24. PMID: 21659472.

 

Wu C, Yang K, Liu Q, et al. Tetrahydroberberine blocks ATP-sensitive potassium channels in dopamine neurons acutely-dissociated from rat substantia nigra pars compacta. Neuropharmacology. 2010 Dec;59(7-8):567-72. PMID: 20804776.

 

Xuan B, Wang W, Li DX. Inhibitory effect of tetrahydroberberine on platelet aggregation and thrombosis. Zhongguo Yao Li Xue Bao. 1994 Mar;15(2):133-5. PMID: 8010106.

 

Zhou J, Xuan B, Li DX. Effects of tetrahydroberberine on ischemic and reperfused myocardium in rats. Zhongguo Yao Li Xue Bao. 1993 Mar;14(2):130-3. PMID: 8352004.

" Not dangerous goods.

LKT N3577 Nitidine Chloride 1 mg 60.7 Benzophenanthridine alkaloid; topoisomerase I inhibitor. 13063-04-2 ≥98% 383.82 C21H18ClNO4 C[N+]1=CC2=CC(=C(C=C2C3=C1C4=CC5=C(C=C4C=C3)OCO5)OC)OC.[Cl-] Ambient Ambient "Fang Z, Tang Y, Jiao W, et al. Nitidine chloride inhibits renal cancer cell metastasis via suppressing AKT signaling pathway. Food Chem Toxicol. 2013 Oct;60:246-51. PMID: 23911800.

 

Liao J, Xu T, Zheng JX, et al. Nitidine chloride inhibits hepatocellular carcinoma cell growth in vivo through the suppression of the JAK1/STAT3 signaling pathway. Int J Mol Med. 2013 Jul;32(1):79-84. PMID: 23613111.

 

Wang Z, Jiang W, Zhang Z, et al. Nitidine chloride inhibits LPS-induced inflammatory cytokines production via MAPK and NF-kappaB pathway in RAW 264.7 cells. J Ethnopharmacol. 2012 Oct 31;144(1):145-50. PMID: 22971898.

 

Bai LP, Zhao ZZ, Cai Z, et al. DNA-binding affinities and sequence selectivity of quaternary benzophenanthridine alkaloids sanguinarine, chelerythrine, and nitidine. Bioorg Med Chem. 2006 Aug 15;14(16):5439-45. PMID: 16730995.

 

Nyangulu JM, Hargreaves SL, Sharples SL, et al. Antimalarial benzo[c]phenanthridines. Bioorg Med Chem Lett. 2005 Apr 15;15(8):2007-10. PMID: 15808457.

 

Li D, Zhao B, Sim SP, et al. 2,3-Dimethoxybenzo[i]phenanthridines: topoisomerase I-targeting anticancer agents. Bioorg Med Chem. 2003 Feb 20;11(4):521-8. PMID: 12538017.

 

Del Poeta M, Chen SF, Von Hoff D, et al. Comparison of in vitro activities of camptothecin and nitidine derivatives against fungal and cancer cells. Antimicrob Agents Chemother. 1999 Dec;43(12):2862-8. PMID: 10582872.

" Not dangerous goods.

LKT N3577 Nitidine Chloride 5 mg 97 Benzophenanthridine alkaloid; topoisomerase I inhibitor. 13063-04-2 ≥98% 383.82 C21H18ClNO4 C[N+]1=CC2=CC(=C(C=C2C3=C1C4=CC5=C(C=C4C=C3)OCO5)OC)OC.[Cl-] Ambient Ambient "Fang Z, Tang Y, Jiao W, et al. Nitidine chloride inhibits renal cancer cell metastasis via suppressing AKT signaling pathway. Food Chem Toxicol. 2013 Oct;60:246-51. PMID: 23911800.

 

Liao J, Xu T, Zheng JX, et al. Nitidine chloride inhibits hepatocellular carcinoma cell growth in vivo through the suppression of the JAK1/STAT3 signaling pathway. Int J Mol Med. 2013 Jul;32(1):79-84. PMID: 23613111.

 

Wang Z, Jiang W, Zhang Z, et al. Nitidine chloride inhibits LPS-induced inflammatory cytokines production via MAPK and NF-kappaB pathway in RAW 264.7 cells. J Ethnopharmacol. 2012 Oct 31;144(1):145-50. PMID: 22971898.

 

Bai LP, Zhao ZZ, Cai Z, et al. DNA-binding affinities and sequence selectivity of quaternary benzophenanthridine alkaloids sanguinarine, chelerythrine, and nitidine. Bioorg Med Chem. 2006 Aug 15;14(16):5439-45. PMID: 16730995.

 

Nyangulu JM, Hargreaves SL, Sharples SL, et al. Antimalarial benzo[c]phenanthridines. Bioorg Med Chem Lett. 2005 Apr 15;15(8):2007-10. PMID: 15808457.

 

Li D, Zhao B, Sim SP, et al. 2,3-Dimethoxybenzo[i]phenanthridines: topoisomerase I-targeting anticancer agents. Bioorg Med Chem. 2003 Feb 20;11(4):521-8. PMID: 12538017.

 

Del Poeta M, Chen SF, Von Hoff D, et al. Comparison of in vitro activities of camptothecin and nitidine derivatives against fungal and cancer cells. Antimicrob Agents Chemother. 1999 Dec;43(12):2862-8. PMID: 10582872.

" Not dangerous goods.

LKT N3577 Nitidine Chloride 25 mg 394.4 Benzophenanthridine alkaloid; topoisomerase I inhibitor. 13063-04-2 ≥98% 383.82 C21H18ClNO4 C[N+]1=CC2=CC(=C(C=C2C3=C1C4=CC5=C(C=C4C=C3)OCO5)OC)OC.[Cl-] Ambient Ambient "Fang Z, Tang Y, Jiao W, et al. Nitidine chloride inhibits renal cancer cell metastasis via suppressing AKT signaling pathway. Food Chem Toxicol. 2013 Oct;60:246-51. PMID: 23911800.

 

Liao J, Xu T, Zheng JX, et al. Nitidine chloride inhibits hepatocellular carcinoma cell growth in vivo through the suppression of the JAK1/STAT3 signaling pathway. Int J Mol Med. 2013 Jul;32(1):79-84. PMID: 23613111.

 

Wang Z, Jiang W, Zhang Z, et al. Nitidine chloride inhibits LPS-induced inflammatory cytokines production via MAPK and NF-kappaB pathway in RAW 264.7 cells. J Ethnopharmacol. 2012 Oct 31;144(1):145-50. PMID: 22971898.

 

Bai LP, Zhao ZZ, Cai Z, et al. DNA-binding affinities and sequence selectivity of quaternary benzophenanthridine alkaloids sanguinarine, chelerythrine, and nitidine. Bioorg Med Chem. 2006 Aug 15;14(16):5439-45. PMID: 16730995.

 

Nyangulu JM, Hargreaves SL, Sharples SL, et al. Antimalarial benzo[c]phenanthridines. Bioorg Med Chem Lett. 2005 Apr 15;15(8):2007-10. PMID: 15808457.

 

Li D, Zhao B, Sim SP, et al. 2,3-Dimethoxybenzo[i]phenanthridines: topoisomerase I-targeting anticancer agents. Bioorg Med Chem. 2003 Feb 20;11(4):521-8. PMID: 12538017.

 

Del Poeta M, Chen SF, Von Hoff D, et al. Comparison of in vitro activities of camptothecin and nitidine derivatives against fungal and cancer cells. Antimicrob Agents Chemother. 1999 Dec;43(12):2862-8. PMID: 10582872.

" Not dangerous goods.

LKT D3430 Dihydrosanguinarine 1 mg 42.4 Benzophenanthridine alkaloid, sanguinarine metabolite. 3606-45-9 ≥98% 333.34 C20H15NO4 CN1CC2=C(C=CC3=C2OCO3)C4=C1C5=CC6=C(C=C5C=C4)OCO6 Ambient 4°C "Chae HS, Kang OH, Keum JH, et al. Anti-inflammatory effects of Hylomecon hylomeconoides in RAW 264.7 cells. Eur Rev Med Pharmacol Sci. 2012 Jul;16 Suppl 3:121-5. PMID: 22957426.

 

Yao JY, Zhou ZM, Li XL, et al. Antiparasitic efficacy of dihydrosanguinarine and dihydrochelerythrine from Macleaya microcarpa against Ichthyophthirius multifiliis in richadsin (Squaliobarbus curriculus). Vet Parasitol. 2011 Dec 29;183(1-2):8-13. PMID: 21813242.

 

Feng G, Zhang J, Liu YQ. Inhibitory activity of dihydrosanguinarine and dihydrochelerythrine against phytopathogenic fungi. Nat Prod Res. 2011 Jul;25(11):1082-9. PMID: 21500094.

 

Choi JG, Kang OH, Chae HS, et al. Antibacterial activity of Hylomecon hylomeconoides against methicillin-resistant Staphylococcus aureus. Appl Biochem Biotechnol. 2010 Apr;160(8):2467-74. PMID: 19578993.

 

Vrba J, Dolezel P, Vicar J, et al. Cytotoxic activity of sanguinarine and dihydrosanguinarine in human promyelocytic leukemia HL-60 cells. Toxicol In Vitro. 2009 Jun;23(4):580-8. PMID: 19346183.

 

Bai LP, Zhao ZZ, Cai Z, et al. DNA-binding affinities and sequence selectivity of quaternary benzophenanthridine alkaloids sanguinarine, chelerythrine, and nitidine. Bioorg Med Chem. 2006 Aug 15;14(16):5439-45. PMID: 16730995.

 

Navarro V, Delgado G. Two antimicrobial alkaloids from Bocconia arborea. J Ethnopharmacol. 1999 Aug;66(2):223-6. PMID: 10433482.

" Not dangerous goods.

LKT D3430 Dihydrosanguinarine 5 mg 103.1 Benzophenanthridine alkaloid, sanguinarine metabolite. 3606-45-9 ≥98% 333.34 C20H15NO4 CN1CC2=C(C=CC3=C2OCO3)C4=C1C5=CC6=C(C=C5C=C4)OCO6 Ambient 4°C "Chae HS, Kang OH, Keum JH, et al. Anti-inflammatory effects of Hylomecon hylomeconoides in RAW 264.7 cells. Eur Rev Med Pharmacol Sci. 2012 Jul;16 Suppl 3:121-5. PMID: 22957426.

 

Yao JY, Zhou ZM, Li XL, et al. Antiparasitic efficacy of dihydrosanguinarine and dihydrochelerythrine from Macleaya microcarpa against Ichthyophthirius multifiliis in richadsin (Squaliobarbus curriculus). Vet Parasitol. 2011 Dec 29;183(1-2):8-13. PMID: 21813242.

 

Feng G, Zhang J, Liu YQ. Inhibitory activity of dihydrosanguinarine and dihydrochelerythrine against phytopathogenic fungi. Nat Prod Res. 2011 Jul;25(11):1082-9. PMID: 21500094.

 

Choi JG, Kang OH, Chae HS, et al. Antibacterial activity of Hylomecon hylomeconoides against methicillin-resistant Staphylococcus aureus. Appl Biochem Biotechnol. 2010 Apr;160(8):2467-74. PMID: 19578993.

 

Vrba J, Dolezel P, Vicar J, et al. Cytotoxic activity of sanguinarine and dihydrosanguinarine in human promyelocytic leukemia HL-60 cells. Toxicol In Vitro. 2009 Jun;23(4):580-8. PMID: 19346183.

 

Bai LP, Zhao ZZ, Cai Z, et al. DNA-binding affinities and sequence selectivity of quaternary benzophenanthridine alkaloids sanguinarine, chelerythrine, and nitidine. Bioorg Med Chem. 2006 Aug 15;14(16):5439-45. PMID: 16730995.

 

Navarro V, Delgado G. Two antimicrobial alkaloids from Bocconia arborea. J Ethnopharmacol. 1999 Aug;66(2):223-6. PMID: 10433482.

" Not dangerous goods.

LKT D3430 Dihydrosanguinarine 25 mg 388.3 Benzophenanthridine alkaloid, sanguinarine metabolite. 3606-45-9 ≥98% 333.34 C20H15NO4 CN1CC2=C(C=CC3=C2OCO3)C4=C1C5=CC6=C(C=C5C=C4)OCO6 Ambient 4°C "Chae HS, Kang OH, Keum JH, et al. Anti-inflammatory effects of Hylomecon hylomeconoides in RAW 264.7 cells. Eur Rev Med Pharmacol Sci. 2012 Jul;16 Suppl 3:121-5. PMID: 22957426.

 

Yao JY, Zhou ZM, Li XL, et al. Antiparasitic efficacy of dihydrosanguinarine and dihydrochelerythrine from Macleaya microcarpa against Ichthyophthirius multifiliis in richadsin (Squaliobarbus curriculus). Vet Parasitol. 2011 Dec 29;183(1-2):8-13. PMID: 21813242.

 

Feng G, Zhang J, Liu YQ. Inhibitory activity of dihydrosanguinarine and dihydrochelerythrine against phytopathogenic fungi. Nat Prod Res. 2011 Jul;25(11):1082-9. PMID: 21500094.

 

Choi JG, Kang OH, Chae HS, et al. Antibacterial activity of Hylomecon hylomeconoides against methicillin-resistant Staphylococcus aureus. Appl Biochem Biotechnol. 2010 Apr;160(8):2467-74. PMID: 19578993.

 

Vrba J, Dolezel P, Vicar J, et al. Cytotoxic activity of sanguinarine and dihydrosanguinarine in human promyelocytic leukemia HL-60 cells. Toxicol In Vitro. 2009 Jun;23(4):580-8. PMID: 19346183.

 

Bai LP, Zhao ZZ, Cai Z, et al. DNA-binding affinities and sequence selectivity of quaternary benzophenanthridine alkaloids sanguinarine, chelerythrine, and nitidine. Bioorg Med Chem. 2006 Aug 15;14(16):5439-45. PMID: 16730995.

 

Navarro V, Delgado G. Two antimicrobial alkaloids from Bocconia arborea. J Ethnopharmacol. 1999 Aug;66(2):223-6. PMID: 10433482.

" Not dangerous goods.

LKT D3428 Dihydrochelerythrine 1 mg 42.4 Benzophenanthridine alkaloid found in Garcinia. 6880-91-7 ≥98% 349.38 C21H19NO4 CN1CC2=C(C=CC(=C2OC)OC)C3=C1C4=CC5=C(C=C4C=C3)OCO5 Ambient 4°C "Yao JY, Zhou ZM, Li XL, et al. Antiparasitic efficacy of dihydrosanguinarine and dihydrochelerythrine from Macleaya microcarpa against Ichthyophthirius multifiliis in richadsin (Squaliobarbus curriculus). Vet Parasitol. 2011 Dec 29;183(1-2):8-13. PMID: 21813242.

 

Feng G, Zhang J, Liu YQ. Inhibitory activity of dihydrosanguinarine and dihydrochelerythrine against phytopathogenic fungi. Nat Prod Res. 2011 Jul;25(11):1082-9. PMID: 21500094.

 

Vrba J, Dolezel P, Vicar J, et al. Chelerythrine and dihydrochelerythrine induce G1 phase arrest and bimodal cell death in human leukemia HL-60 cells. Toxicol In Vitro. 2008 Jun;22(4):1008-17. PMID: 18358694.

 

Fotie J, Bohle DS, Olivier M, et al. Trypanocidal and antileishmanial dihydrochelerythrine derivatives from Garcinia lucida. J Nat Prod. 2007 Oct;70(10):1650-3. PMID: 17880175.

 

Hu J, Zhang WD, Liu RH, et al. Benzophenanthridine alkaloids from Zanthoxylum nitidum (Roxb.) DC, and their analgesic and anti-inflammatory activities. Chem Biodivers. 2006 Sep;3(9):990-5. PMID: 17193331.

 

Bai LP, Zhao ZZ, Cai Z, et al. DNA-binding affinities and sequence selectivity of quaternary benzophenanthridine alkaloids sanguinarine, chelerythrine, and nitidine. Bioorg Med Chem. 2006 Aug 15;14(16):5439-45. PMID: 16730995.

 

Navarro V, Delgado G. Two antimicrobial alkaloids from Bocconia arborea. J Ethnopharmacol. 1999 Aug;66(2):223-6. PMID: 10433482.

" Not dangerous goods.

LKT D3428 Dihydrochelerythrine 5 mg 103.1 Benzophenanthridine alkaloid found in Garcinia. 6880-91-7 ≥98% 349.38 C21H19NO4 CN1CC2=C(C=CC(=C2OC)OC)C3=C1C4=CC5=C(C=C4C=C3)OCO5 Ambient 4°C "Yao JY, Zhou ZM, Li XL, et al. Antiparasitic efficacy of dihydrosanguinarine and dihydrochelerythrine from Macleaya microcarpa against Ichthyophthirius multifiliis in richadsin (Squaliobarbus curriculus). Vet Parasitol. 2011 Dec 29;183(1-2):8-13. PMID: 21813242.

 

Feng G, Zhang J, Liu YQ. Inhibitory activity of dihydrosanguinarine and dihydrochelerythrine against phytopathogenic fungi. Nat Prod Res. 2011 Jul;25(11):1082-9. PMID: 21500094.

 

Vrba J, Dolezel P, Vicar J, et al. Chelerythrine and dihydrochelerythrine induce G1 phase arrest and bimodal cell death in human leukemia HL-60 cells. Toxicol In Vitro. 2008 Jun;22(4):1008-17. PMID: 18358694.

 

Fotie J, Bohle DS, Olivier M, et al. Trypanocidal and antileishmanial dihydrochelerythrine derivatives from Garcinia lucida. J Nat Prod. 2007 Oct;70(10):1650-3. PMID: 17880175.

 

Hu J, Zhang WD, Liu RH, et al. Benzophenanthridine alkaloids from Zanthoxylum nitidum (Roxb.) DC, and their analgesic and anti-inflammatory activities. Chem Biodivers. 2006 Sep;3(9):990-5. PMID: 17193331.

 

Bai LP, Zhao ZZ, Cai Z, et al. DNA-binding affinities and sequence selectivity of quaternary benzophenanthridine alkaloids sanguinarine, chelerythrine, and nitidine. Bioorg Med Chem. 2006 Aug 15;14(16):5439-45. PMID: 16730995.

 

Navarro V, Delgado G. Two antimicrobial alkaloids from Bocconia arborea. J Ethnopharmacol. 1999 Aug;66(2):223-6. PMID: 10433482.

" Not dangerous goods.

LKT D3428 Dihydrochelerythrine 25 mg 388.3 Benzophenanthridine alkaloid found in Garcinia. 6880-91-7 ≥98% 349.38 C21H19NO4 CN1CC2=C(C=CC(=C2OC)OC)C3=C1C4=CC5=C(C=C4C=C3)OCO5 Ambient 4°C "Yao JY, Zhou ZM, Li XL, et al. Antiparasitic efficacy of dihydrosanguinarine and dihydrochelerythrine from Macleaya microcarpa against Ichthyophthirius multifiliis in richadsin (Squaliobarbus curriculus). Vet Parasitol. 2011 Dec 29;183(1-2):8-13. PMID: 21813242.

 

Feng G, Zhang J, Liu YQ. Inhibitory activity of dihydrosanguinarine and dihydrochelerythrine against phytopathogenic fungi. Nat Prod Res. 2011 Jul;25(11):1082-9. PMID: 21500094.

 

Vrba J, Dolezel P, Vicar J, et al. Chelerythrine and dihydrochelerythrine induce G1 phase arrest and bimodal cell death in human leukemia HL-60 cells. Toxicol In Vitro. 2008 Jun;22(4):1008-17. PMID: 18358694.

 

Fotie J, Bohle DS, Olivier M, et al. Trypanocidal and antileishmanial dihydrochelerythrine derivatives from Garcinia lucida. J Nat Prod. 2007 Oct;70(10):1650-3. PMID: 17880175.

 

Hu J, Zhang WD, Liu RH, et al. Benzophenanthridine alkaloids from Zanthoxylum nitidum (Roxb.) DC, and their analgesic and anti-inflammatory activities. Chem Biodivers. 2006 Sep;3(9):990-5. PMID: 17193331.

 

Bai LP, Zhao ZZ, Cai Z, et al. DNA-binding affinities and sequence selectivity of quaternary benzophenanthridine alkaloids sanguinarine, chelerythrine, and nitidine. Bioorg Med Chem. 2006 Aug 15;14(16):5439-45. PMID: 16730995.

 

Navarro V, Delgado G. Two antimicrobial alkaloids from Bocconia arborea. J Ethnopharmacol. 1999 Aug;66(2):223-6. PMID: 10433482.

" Not dangerous goods.

LKT A7460 Asparaginase 1 mg 42.4 Catalyzes hydrolysis of asparagine. Colaspase ≥98% 31731.9 Ambient 4°C "He Y, Li B, Zhang H, et al. L-asparaginase induces in AML U937 cells apoptosis via an AIF-mediated mechanism. Front Biosci (Landmark Ed). 2014 Jan 1;19:515-27. PMID: 24389199.

 

Yu M, Henning R, Walker A, et al. L-asparaginase inhibits invasive and angiogenic activity and induces autophagy in ovarian cancer. J Cell Mol Med. 2012 Oct;16(10):2369-78. PMID: 22333033.

 

Nomme J, Su Y, Konrad M, et al. Structures of apo and product-bound human L-asparaginase: insights into the mechanism of autoproteolysis and substrate hydrolysis. Biochemistry. 2012 Aug 28;51(34):6816-26. PMID: 22861376.

 

Mitchell L, Andrew M, Hanna K, et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thromb Haemost. 2003 Aug;90(2):235-44. PMID: 12888870.

 

Cremer P, Lakomek M, Beck W, et al. The effect of L-asparaginase on lipid metabolism during induction chemotherapy of childhood lymphoblastic leukaemia. Eur J Pediatr. 1988 Jan;147(1):64-7. PMID: 3422190.

" Repr. Not dangerous goods.

LKT A7460 Asparaginase 5 mg 91 Catalyzes hydrolysis of asparagine. Colaspase ≥98% 31731.9 Ambient 4°C "He Y, Li B, Zhang H, et al. L-asparaginase induces in AML U937 cells apoptosis via an AIF-mediated mechanism. Front Biosci (Landmark Ed). 2014 Jan 1;19:515-27. PMID: 24389199.

 

Yu M, Henning R, Walker A, et al. L-asparaginase inhibits invasive and angiogenic activity and induces autophagy in ovarian cancer. J Cell Mol Med. 2012 Oct;16(10):2369-78. PMID: 22333033.

 

Nomme J, Su Y, Konrad M, et al. Structures of apo and product-bound human L-asparaginase: insights into the mechanism of autoproteolysis and substrate hydrolysis. Biochemistry. 2012 Aug 28;51(34):6816-26. PMID: 22861376.

 

Mitchell L, Andrew M, Hanna K, et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thromb Haemost. 2003 Aug;90(2):235-44. PMID: 12888870.

 

Cremer P, Lakomek M, Beck W, et al. The effect of L-asparaginase on lipid metabolism during induction chemotherapy of childhood lymphoblastic leukaemia. Eur J Pediatr. 1988 Jan;147(1):64-7. PMID: 3422190.

" Repr. Not dangerous goods.

LKT A7460 Asparaginase 25 mg 242.7 Catalyzes hydrolysis of asparagine. Colaspase ≥98% 31731.9 Ambient 4°C "He Y, Li B, Zhang H, et al. L-asparaginase induces in AML U937 cells apoptosis via an AIF-mediated mechanism. Front Biosci (Landmark Ed). 2014 Jan 1;19:515-27. PMID: 24389199.

 

Yu M, Henning R, Walker A, et al. L-asparaginase inhibits invasive and angiogenic activity and induces autophagy in ovarian cancer. J Cell Mol Med. 2012 Oct;16(10):2369-78. PMID: 22333033.

 

Nomme J, Su Y, Konrad M, et al. Structures of apo and product-bound human L-asparaginase: insights into the mechanism of autoproteolysis and substrate hydrolysis. Biochemistry. 2012 Aug 28;51(34):6816-26. PMID: 22861376.

 

Mitchell L, Andrew M, Hanna K, et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thromb Haemost. 2003 Aug;90(2):235-44. PMID: 12888870.

 

Cremer P, Lakomek M, Beck W, et al. The effect of L-asparaginase on lipid metabolism during induction chemotherapy of childhood lymphoblastic leukaemia. Eur J Pediatr. 1988 Jan;147(1):64-7. PMID: 3422190.

" Repr. Not dangerous goods.

LKT A0922 Acetyl-L-Carnitine Hydrochloride 1 g 36.4 Carnitine derivative, involved in energy homeostasis. 5080-50-2 ≥98% 239.7 C9H17NO4 HCl CC(=O)OC(CC(=O)O)C[N+](C)(C)C.[Cl-] Ambient Ambient "Cuccurazzu B, Bortolotto V, Valente MM, et al. Upregulation of mGlu2 receptors via NF-κB p65 acetylation is involved in the Proneurogenic and antidepressant effects of acetyl-l-carnitine. Neuropsychopharmacology. 2013 Oct;38(11):2220-30. PMID: 23670591.

 

Onofrj M, Ciccocioppo F, Varanese S, et al. Acetyl-L-carnitine: from a biological curiosity to a drug for the peripheral nervous system and beyond. Expert Rev Neurother. 2013 Aug;13(8):925-36. PMID: 23965166.

 

Virmani A, Koverech A, Ali SF, et al. Acetyl-L-Carnitine Modulates TP53 and IL10 Gene Expression Induced by 3-NPA Evoked Toxicity in PC12 Cells. Curr Neuropharmacol. 2011 Mar;9(1):195-9. PMID: 21886589.

 

Vivoli E, Di Cesare Mannelli L, Salvicchi A, et al. Acetyl-L-carnitine increases artemin level and prevents neurotrophic factor alterations during neuropathy. Neuroscience. 2010 Jun 2;167(4):1168-74. PMID: 20302919.

 

Epis R, Marcello E, Gardoni F, et al. Modulatory effect of acetyl-L-carnitine on amyloid precursor protein metabolism in hippocampal neurons. Eur J Pharmacol. 2008 Nov 12;597(1-3):51-6. PMID: 18801359.

 

Ghelardini C, Galeotti N, Calvani M, et al. Acetyl-l-carnitine induces muscarinic antinocieption in mice and rats. Neuropharmacology. 2002 Dec;43(7):1180-7. PMID: 12504925.

" Not dangerous goods.

LKT A0922 Acetyl-L-Carnitine Hydrochloride 5 g 118.9 Carnitine derivative, involved in energy homeostasis. 5080-50-2 ≥98% 239.7 C9H17NO4 HCl CC(=O)OC(CC(=O)O)C[N+](C)(C)C.[Cl-] Ambient Ambient "Cuccurazzu B, Bortolotto V, Valente MM, et al. Upregulation of mGlu2 receptors via NF-κB p65 acetylation is involved in the Proneurogenic and antidepressant effects of acetyl-l-carnitine. Neuropsychopharmacology. 2013 Oct;38(11):2220-30. PMID: 23670591.

 

Onofrj M, Ciccocioppo F, Varanese S, et al. Acetyl-L-carnitine: from a biological curiosity to a drug for the peripheral nervous system and beyond. Expert Rev Neurother. 2013 Aug;13(8):925-36. PMID: 23965166.

 

Virmani A, Koverech A, Ali SF, et al. Acetyl-L-Carnitine Modulates TP53 and IL10 Gene Expression Induced by 3-NPA Evoked Toxicity in PC12 Cells. Curr Neuropharmacol. 2011 Mar;9(1):195-9. PMID: 21886589.

 

Vivoli E, Di Cesare Mannelli L, Salvicchi A, et al. Acetyl-L-carnitine increases artemin level and prevents neurotrophic factor alterations during neuropathy. Neuroscience. 2010 Jun 2;167(4):1168-74. PMID: 20302919.

 

Epis R, Marcello E, Gardoni F, et al. Modulatory effect of acetyl-L-carnitine on amyloid precursor protein metabolism in hippocampal neurons. Eur J Pharmacol. 2008 Nov 12;597(1-3):51-6. PMID: 18801359.

 

Ghelardini C, Galeotti N, Calvani M, et al. Acetyl-l-carnitine induces muscarinic antinocieption in mice and rats. Neuropharmacology. 2002 Dec;43(7):1180-7. PMID: 12504925.

" Not dangerous goods.

LKT A0922 Acetyl-L-Carnitine Hydrochloride 25 g 200.2 Carnitine derivative, involved in energy homeostasis. 5080-50-2 ≥98% 239.7 C9H17NO4 HCl CC(=O)OC(CC(=O)O)C[N+](C)(C)C.[Cl-] Ambient Ambient "Cuccurazzu B, Bortolotto V, Valente MM, et al. Upregulation of mGlu2 receptors via NF-κB p65 acetylation is involved in the Proneurogenic and antidepressant effects of acetyl-l-carnitine. Neuropsychopharmacology. 2013 Oct;38(11):2220-30. PMID: 23670591.

 

Onofrj M, Ciccocioppo F, Varanese S, et al. Acetyl-L-carnitine: from a biological curiosity to a drug for the peripheral nervous system and beyond. Expert Rev Neurother. 2013 Aug;13(8):925-36. PMID: 23965166.

 

Virmani A, Koverech A, Ali SF, et al. Acetyl-L-Carnitine Modulates TP53 and IL10 Gene Expression Induced by 3-NPA Evoked Toxicity in PC12 Cells. Curr Neuropharmacol. 2011 Mar;9(1):195-9. PMID: 21886589.

 

Vivoli E, Di Cesare Mannelli L, Salvicchi A, et al. Acetyl-L-carnitine increases artemin level and prevents neurotrophic factor alterations during neuropathy. Neuroscience. 2010 Jun 2;167(4):1168-74. PMID: 20302919.

 

Epis R, Marcello E, Gardoni F, et al. Modulatory effect of acetyl-L-carnitine on amyloid precursor protein metabolism in hippocampal neurons. Eur J Pharmacol. 2008 Nov 12;597(1-3):51-6. PMID: 18801359.

 

Ghelardini C, Galeotti N, Calvani M, et al. Acetyl-l-carnitine induces muscarinic antinocieption in mice and rats. Neuropharmacology. 2002 Dec;43(7):1180-7. PMID: 12504925.

" Not dangerous goods.

LKT C5863 Coptisine Chloride 1 mg 36.4 Isoquinoline alkaloid found in a variety of plant sources; MAO-A inhibitor. 6020-18-4 ≥98% 355.77 C19H14ClNO4 C1C[N+]2=C(C=C3C=CC4=C(C3=C2)OCO4)C5=CC6=C(C=C51)OCO6.[Cl-] Ambient 4°C "Guo J, Wang SB, Yuan TY, et al. Coptisine protects rat heart against myocardial ischemia/reperfusion injury by suppressing myocardial apoptosis and inflammation. Atherosclerosis. 2013 Dec;231(2):384-91. PMID: 24267256.

 

Gong LL, Fang LH, Wang SB, et al. Coptisine exert cardioprotective effect through anti-oxidative and inhibition of RhoA/Rho kinase pathway on isoproterenol-induced myocardial infarction in rats. Atherosclerosis. 2012 May;222(1):50-8. PMID: 22387061.

 

Suzuki H, Tanabe H, Mizukami H, et al. Differential gene expression in rat vascular smooth muscle cells following treatment with coptisine exerts a selective antiproliferative effect. J Nat Prod. 2011 Apr 25;74(4):634-8. PMID: 21401114.

 

Yan D, Jin C, Xiao XH, et al. Antimicrobial properties of berberines alkaloids in Coptis chinensis Franch by microcalorimetry. J Biochem Biophys Methods. 2008 Apr 24;70(6):845-9. PMID: 17804078.

 

Tanabe H, Suzuki H, Mizukami H, et al. Double blockade of cell cycle progression by coptisine in vascular smooth muscle cells. Biochem Pharmacol. 2005 Oct 15;70(8):1176-84. PMID: 16140275.

 

Lin CC, Ng LT, Hsu FF, et al. Cytotoxic effects of Coptis chinensis and Epimedium sagittatum extracts and their major constituents (berberine, coptisine and icariin) on hepatoma and leukaemia cell growth. Clin Exp Pharmacol Physiol. 2004 Jan-Feb;31(1-2):65-9. PMID: 14756686.

 

Ro JS, Lee SS, Lee KS, et al. Inhibition of type A monoamine oxidase by coptisine in mouse brain. Life Sci. 2001 Dec 28;70(6):639-45. PMID: 11833714.

" Not dangerous goods.

LKT C5863 Coptisine Chloride 5 mg 116.6 Isoquinoline alkaloid found in a variety of plant sources; MAO-A inhibitor. 6020-18-4 ≥98% 355.77 C19H14ClNO4 C1C[N+]2=C(C=C3C=CC4=C(C3=C2)OCO4)C5=CC6=C(C=C51)OCO6.[Cl-] Ambient 4°C "Guo J, Wang SB, Yuan TY, et al. Coptisine protects rat heart against myocardial ischemia/reperfusion injury by suppressing myocardial apoptosis and inflammation. Atherosclerosis. 2013 Dec;231(2):384-91. PMID: 24267256.

 

Gong LL, Fang LH, Wang SB, et al. Coptisine exert cardioprotective effect through anti-oxidative and inhibition of RhoA/Rho kinase pathway on isoproterenol-induced myocardial infarction in rats. Atherosclerosis. 2012 May;222(1):50-8. PMID: 22387061.

 

Suzuki H, Tanabe H, Mizukami H, et al. Differential gene expression in rat vascular smooth muscle cells following treatment with coptisine exerts a selective antiproliferative effect. J Nat Prod. 2011 Apr 25;74(4):634-8. PMID: 21401114.

 

Yan D, Jin C, Xiao XH, et al. Antimicrobial properties of berberines alkaloids in Coptis chinensis Franch by microcalorimetry. J Biochem Biophys Methods. 2008 Apr 24;70(6):845-9. PMID: 17804078.

 

Tanabe H, Suzuki H, Mizukami H, et al. Double blockade of cell cycle progression by coptisine in vascular smooth muscle cells. Biochem Pharmacol. 2005 Oct 15;70(8):1176-84. PMID: 16140275.

 

Lin CC, Ng LT, Hsu FF, et al. Cytotoxic effects of Coptis chinensis and Epimedium sagittatum extracts and their major constituents (berberine, coptisine and icariin) on hepatoma and leukaemia cell growth. Clin Exp Pharmacol Physiol. 2004 Jan-Feb;31(1-2):65-9. PMID: 14756686.

 

Ro JS, Lee SS, Lee KS, et al. Inhibition of type A monoamine oxidase by coptisine in mouse brain. Life Sci. 2001 Dec 28;70(6):639-45. PMID: 11833714.

" Not dangerous goods.

LKT P7158 Protopine 1 mg 36.4 Isoquinoline alkaloid found in a variety of plant sources; voltage- and receptor-gated Ca2+ channel blocker. 130-86-9 ≥98% 353.37 C20H19NO5 CN1CCC2=CC3=C(C=C2C(=O)CC4=C(C1)C5=C(C=C4)OCO5)OCO3 Ambient 4°C "Bae DS, Kim YH, Pan CH, et al. Protopine reduces the inflammatory activity of lipopolysaccharide-stimulated murine macrophages. BMB Rep. 2012 Feb;45(2):108-13. PMID: 22360889.

 

Chen CH, Liao CH, Chang YL, et al. Protopine, a novel microtubule-stabilizing agent, causes mitotic arrest and apoptotic cell death in human hormone-refractory prostate cancer cell lines. Cancer Lett. 2012 Feb 1;315(1):1-11. PMID: 22033245.

 

Xiao X, Liu J, Hu J, et al. Protective effects of protopine on hydrogen peroxide-induced oxidative injury of PC12 cells via Ca(2+) antagonism and antioxidant mechanisms. Eur J Pharmacol. 2008 Sep 4;591(1-3):21-7. PMID: 18602385.

 

Xu Q, Jin RL, Wu YY. Opioid, calcium, and adrenergic receptor involvement in protopine analgesia. Zhongguo Yao Li Xue Bao. 1993 Nov;14(6):495-500. PMID: 8010045.

 

Ko FN, Wu TS, Lu ST, et al. Ca(2+)-channel blockade in rat thoracic aorta by protopine isolated from Corydalis tubers. Jpn J Pharmacol. 1992 Jan;58(1):1-9. PMID: 1322473.

" "UN number: 2811     Class: 6.1     Packing Group: III

Proper shipping name: Toxic solid, organic, n.o.s. (Protopine)"

LKT P7158 Protopine 5 mg 82.4 Isoquinoline alkaloid found in a variety of plant sources; voltage- and receptor-gated Ca2+ channel blocker. 130-86-9 ≥98% 353.37 C20H19NO5 CN1CCC2=CC3=C(C=C2C(=O)CC4=C(C1)C5=C(C=C4)OCO5)OCO3 Ambient 4°C "Bae DS, Kim YH, Pan CH, et al. Protopine reduces the inflammatory activity of lipopolysaccharide-stimulated murine macrophages. BMB Rep. 2012 Feb;45(2):108-13. PMID: 22360889.

 

Chen CH, Liao CH, Chang YL, et al. Protopine, a novel microtubule-stabilizing agent, causes mitotic arrest and apoptotic cell death in human hormone-refractory prostate cancer cell lines. Cancer Lett. 2012 Feb 1;315(1):1-11. PMID: 22033245.

 

Xiao X, Liu J, Hu J, et al. Protective effects of protopine on hydrogen peroxide-induced oxidative injury of PC12 cells via Ca(2+) antagonism and antioxidant mechanisms. Eur J Pharmacol. 2008 Sep 4;591(1-3):21-7. PMID: 18602385.

 

Xu Q, Jin RL, Wu YY. Opioid, calcium, and adrenergic receptor involvement in protopine analgesia. Zhongguo Yao Li Xue Bao. 1993 Nov;14(6):495-500. PMID: 8010045.

 

Ko FN, Wu TS, Lu ST, et al. Ca(2+)-channel blockade in rat thoracic aorta by protopine isolated from Corydalis tubers. Jpn J Pharmacol. 1992 Jan;58(1):1-9. PMID: 1322473.

" "UN number: 2811     Class: 6.1     Packing Group: III

Proper shipping name: Toxic solid, organic, n.o.s. (Protopine)"

LKT S0253 Sanguinarine 1 mg 36.4 Benzophenanthridine alkaloid found in various plant sources; potential AMPK activator, potential amino acid carboxylase inhibitor. 2447-54-3 ≥98% 332.33 C20H14NO4 C[N+]1=C2C(=C3C=CC4=C(C3=C1)OCO4)C=CC5=CC6=C(C=C52)OCO6 Ambient 4°C "Park SY, Jin ML, Kim YH, et al. Sanguinarine inhibits invasiveness and the MMP 9 and COX 2 expression in TPA-induced breast cancer cells by inducing HO-1 expression. Oncol Rep. 2014 Jan;31(1):497-504. PMID: 24220687.

 

Shao J, Liu D, Gong D, et al. Inhibitory effects of sanguinarine against the cyanobacterium Microcystis aeruginosa NIES-843 and possible mechanisms of action. Aquat Toxicol. 2013 Oct 15;142-143:257-63. PMID: 24060579.

 

Dong XZ, Zhang M, Wang K, et al. Sanguinarine inhibits vascular endothelial growth factor release by generation of reactive oxygen species in MCF-7 human mammary adenocarcinoma cells. Biomed Res Int. 2013;2013:517698. PMID: 23762849.

 

Niu X, Fan T, Li W, et al. Protective effect of sanguinarine against acetic acid-induced ulcerative colitis in mice. Toxicol Appl Pharmacol. 2013 Mar 15;267(3):256-65. PMID: 23352506.

 

Foss MH, Eun YJ, Grove CI, et al. Inhibitors of bacterial tubulin target bacterial membranes in vivo. Medchemcomm. 2013 Jan 1;4(1):112-119. PMID: 23539337.

 

Choi J, He N, Sung MK, et al. Sanguinarine is an allosteric activator of AMP-activated protein kinase. Biochem Biophys Res Commun. 2011 Sep 23;413(2):259-63. PMID: 21884681.

 

Drsata J, Ulrichová J, Walterová D. Sanguinarine and chelerythrine as inhibitors of aromatic amino acid decarboxylase. J Enzyme Inhib. 1996;10(4):231-237. PMID: 8872743.

 

Wolff J, Knipling L. Antimicrotubule properties of benzophenanthridine alkaloids. Biochemistry. 1993 Dec 7;32(48):13334-9. PMID: 7902132.

" Not dangerous goods.

LKT S0253 Sanguinarine 5 mg 78.9 Benzophenanthridine alkaloid found in various plant sources; potential AMPK activator, potential amino acid carboxylase inhibitor. 2447-54-3 ≥98% 332.33 C20H14NO4 C[N+]1=C2C(=C3C=CC4=C(C3=C1)OCO4)C=CC5=CC6=C(C=C52)OCO6 Ambient 4°C "Park SY, Jin ML, Kim YH, et al. Sanguinarine inhibits invasiveness and the MMP 9 and COX 2 expression in TPA-induced breast cancer cells by inducing HO-1 expression. Oncol Rep. 2014 Jan;31(1):497-504. PMID: 24220687.

 

Shao J, Liu D, Gong D, et al. Inhibitory effects of sanguinarine against the cyanobacterium Microcystis aeruginosa NIES-843 and possible mechanisms of action. Aquat Toxicol. 2013 Oct 15;142-143:257-63. PMID: 24060579.

 

Dong XZ, Zhang M, Wang K, et al. Sanguinarine inhibits vascular endothelial growth factor release by generation of reactive oxygen species in MCF-7 human mammary adenocarcinoma cells. Biomed Res Int. 2013;2013:517698. PMID: 23762849.

 

Niu X, Fan T, Li W, et al. Protective effect of sanguinarine against acetic acid-induced ulcerative colitis in mice. Toxicol Appl Pharmacol. 2013 Mar 15;267(3):256-65. PMID: 23352506.

 

Foss MH, Eun YJ, Grove CI, et al. Inhibitors of bacterial tubulin target bacterial membranes in vivo. Medchemcomm. 2013 Jan 1;4(1):112-119. PMID: 23539337.

 

Choi J, He N, Sung MK, et al. Sanguinarine is an allosteric activator of AMP-activated protein kinase. Biochem Biophys Res Commun. 2011 Sep 23;413(2):259-63. PMID: 21884681.

 

Drsata J, Ulrichová J, Walterová D. Sanguinarine and chelerythrine as inhibitors of aromatic amino acid decarboxylase. J Enzyme Inhib. 1996;10(4):231-237. PMID: 8872743.

 

Wolff J, Knipling L. Antimicrotubule properties of benzophenanthridine alkaloids. Biochemistry. 1993 Dec 7;32(48):13334-9. PMID: 7902132.

" Not dangerous goods.

LKT D1720 Deferiprone 5 g 60.7 Iron chelator. 3-Hydroxy-1,2-dimethyl-4(1H)-pyridone Ferriprox 30652-11-0 ≥97% 139.15 C7H9NO2 CC1=C(C(=O)C=CN1C)O Ambient Ambient "Prasanthi JR, Schrag M, Dasari B, et al. Deferiprone reduces amyloid-β and tau phosphorylation levels but not reactive oxygen species generation in hippocampus of rabbits fed a cholesterol-enriched diet. J Alzheimers Dis. 2012;30(1):167-82. PMID: 22406440.

 

Sweeney ME, Slusser JG, Lynch SG, et al. Deferiprone modulates in vitro responses by peripheral blood T cells from control and relapsing-remitting multiple sclerosis subjects. Int Immunopharmacol. 2011 Nov;11(11):1796-801. PMID: 21807124.

 

Kolnagou A, Michaelides Y, Kontos C, et al. Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone. Hemoglobin. 2008;32(1-2):17-28. PMID: 18274979.

 

Wiwanitkit V. Quantum chemical analysis of the deferiprone-iron binding reaction. Int J Nanomedicine. 2006;1(1):111-3. PMID: 17722270.

" Not dangerous goods.

LKT D1720 Deferiprone 25 g 236.6 Iron chelator. 3-Hydroxy-1,2-dimethyl-4(1H)-pyridone Ferriprox 30652-11-0 ≥97% 139.15 C7H9NO2 CC1=C(C(=O)C=CN1C)O Ambient Ambient "Prasanthi JR, Schrag M, Dasari B, et al. Deferiprone reduces amyloid-β and tau phosphorylation levels but not reactive oxygen species generation in hippocampus of rabbits fed a cholesterol-enriched diet. J Alzheimers Dis. 2012;30(1):167-82. PMID: 22406440.

 

Sweeney ME, Slusser JG, Lynch SG, et al. Deferiprone modulates in vitro responses by peripheral blood T cells from control and relapsing-remitting multiple sclerosis subjects. Int Immunopharmacol. 2011 Nov;11(11):1796-801. PMID: 21807124.

 

Kolnagou A, Michaelides Y, Kontos C, et al. Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone. Hemoglobin. 2008;32(1-2):17-28. PMID: 18274979.

 

Wiwanitkit V. Quantum chemical analysis of the deferiprone-iron binding reaction. Int J Nanomedicine. 2006;1(1):111-3. PMID: 17722270.

" Not dangerous goods.

LKT N7208 NSC-74859 5 mg 78.9 STAT3 inhibitor. 2-Hydroxy-4-[[[[(4-methylphenyl)sulfonyl]oxy]acetyl]amino]-benzoic acid S3I-201 501919-59-1 ≥95% 365.36 C16H15NO7S CC1=CC=C(C=C1)S(=O)(=O)OCC(=O)NC2=CC(=C(C=C2)C(=O)O)O Ambient Ambient "Kim CK, Ryu WS, Choi IY, et al. Detrimental effects of leptin on intracerebral hemorrhage via the STAT3 signal pathway. J Cereb Blood Flow Metab. 2013 Jun;33(6):944-53. PMID: 23462572.

 

Hu QD, Chen W, Yan TL, et al. NSC 74859 enhances doxorubicin cytotoxicity via inhibition of epithelial-mesenchymal transition in hepatocellular carcinoma cells. Cancer Lett. 2012 Dec 28;325(2):207-13. PMID: 22781398.

 

Sen N, Che X, Rajamani J, et al. Signal transducer and activator of transcription 3 (STAT3) and survivin induction by varicella-zoster virus promote replication and skin pathogenesis. Proc Natl Acad Sci U S A. 2012 Jan 10;109(2):600-5. PMID: 22190485.

 

Chen W, Shen X, Xia X, et al. NSC 74859-mediated inhibition of STAT3 enhances the anti-proliferative activity of cetuximab in hepatocellular carcinoma. Liver Int. 2012 Jan;32(1):70-7. PMID: 22098470.

 

Pang M, Ma L, Gong R, et al. A novel STAT3 inhibitor, S3I-201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy. Kidney Int. 2010 Aug;78(3):257-68. PMID: 20520592.

 

Lin L, Amin R, Gallicano GI, et al. The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling. Oncogene. 2009 Feb 19;28(7):961-72. PMID: 19137011.

 

Siddiquee K, Zhang S, Guida WC, et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci U S A. 2007 May 1;104(18):7391-6. PMID: 17463090.

" Not dangerous goods.

LKT N7208 NSC-74859 25 mg 333.7 STAT3 inhibitor. 2-Hydroxy-4-[[[[(4-methylphenyl)sulfonyl]oxy]acetyl]amino]-benzoic acid S3I-201 501919-59-1 ≥95% 365.36 C16H15NO7S CC1=CC=C(C=C1)S(=O)(=O)OCC(=O)NC2=CC(=C(C=C2)C(=O)O)O Ambient Ambient "Kim CK, Ryu WS, Choi IY, et al. Detrimental effects of leptin on intracerebral hemorrhage via the STAT3 signal pathway. J Cereb Blood Flow Metab. 2013 Jun;33(6):944-53. PMID: 23462572.

 

Hu QD, Chen W, Yan TL, et al. NSC 74859 enhances doxorubicin cytotoxicity via inhibition of epithelial-mesenchymal transition in hepatocellular carcinoma cells. Cancer Lett. 2012 Dec 28;325(2):207-13. PMID: 22781398.

 

Sen N, Che X, Rajamani J, et al. Signal transducer and activator of transcription 3 (STAT3) and survivin induction by varicella-zoster virus promote replication and skin pathogenesis. Proc Natl Acad Sci U S A. 2012 Jan 10;109(2):600-5. PMID: 22190485.

 

Chen W, Shen X, Xia X, et al. NSC 74859-mediated inhibition of STAT3 enhances the anti-proliferative activity of cetuximab in hepatocellular carcinoma. Liver Int. 2012 Jan;32(1):70-7. PMID: 22098470.

 

Pang M, Ma L, Gong R, et al. A novel STAT3 inhibitor, S3I-201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy. Kidney Int. 2010 Aug;78(3):257-68. PMID: 20520592.

 

Lin L, Amin R, Gallicano GI, et al. The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling. Oncogene. 2009 Feb 19;28(7):961-72. PMID: 19137011.

 

Siddiquee K, Zhang S, Guida WC, et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci U S A. 2007 May 1;104(18):7391-6. PMID: 17463090.

" Not dangerous goods.

LKT N7208 NSC-74859 100 mg 1274.1 STAT3 inhibitor. 2-Hydroxy-4-[[[[(4-methylphenyl)sulfonyl]oxy]acetyl]amino]-benzoic acid S3I-201 501919-59-1 ≥95% 365.36 C16H15NO7S CC1=CC=C(C=C1)S(=O)(=O)OCC(=O)NC2=CC(=C(C=C2)C(=O)O)O Ambient Ambient "Kim CK, Ryu WS, Choi IY, et al. Detrimental effects of leptin on intracerebral hemorrhage via the STAT3 signal pathway. J Cereb Blood Flow Metab. 2013 Jun;33(6):944-53. PMID: 23462572.

 

Hu QD, Chen W, Yan TL, et al. NSC 74859 enhances doxorubicin cytotoxicity via inhibition of epithelial-mesenchymal transition in hepatocellular carcinoma cells. Cancer Lett. 2012 Dec 28;325(2):207-13. PMID: 22781398.

 

Sen N, Che X, Rajamani J, et al. Signal transducer and activator of transcription 3 (STAT3) and survivin induction by varicella-zoster virus promote replication and skin pathogenesis. Proc Natl Acad Sci U S A. 2012 Jan 10;109(2):600-5. PMID: 22190485.

 

Chen W, Shen X, Xia X, et al. NSC 74859-mediated inhibition of STAT3 enhances the anti-proliferative activity of cetuximab in hepatocellular carcinoma. Liver Int. 2012 Jan;32(1):70-7. PMID: 22098470.

 

Pang M, Ma L, Gong R, et al. A novel STAT3 inhibitor, S3I-201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy. Kidney Int. 2010 Aug;78(3):257-68. PMID: 20520592.

 

Lin L, Amin R, Gallicano GI, et al. The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling. Oncogene. 2009 Feb 19;28(7):961-72. PMID: 19137011.

 

Siddiquee K, Zhang S, Guida WC, et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci U S A. 2007 May 1;104(18):7391-6. PMID: 17463090.

" Not dangerous goods.

LKT T6803 Trandolapril 25 mg 87.4 ACE inhibitor. 87679-37-6 ≥98% 430.54 C24H34N2O5 CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2C3CCCCC3CC2C(=O)O Ambient Ambient Soluble in methanol, dichloromethane, DMSO, and ethanol "Tanaka H, Takai S, Jin D, et al. Inhibition of matrix metalloproteinase-9 activity by trandolapril after middle cerebral artery occlusion in rats. Hypertens Res. 2007 May;30(5):469-75. PMID: 17587759.

 

Toyoshima H, Nasa Y, Kohsaka Y, et al. The effect of chronic treatment with trandolapril on cyclic AMP-and cyclic GMP-dependent relaxations in aortic segments of rats with chronic heart failure. Br J Pharmacol. 1998 Jan;123(2):344-52. PMID: 9489624.

 

Sanbe A, Tanonaka K, Kobayasi R, et al. Effects of long-term therapy with ACE inhibitors, captopril, enalapril and trandolapril, on myocardial energy metabolism in rats with heart failure following myocardial infarction. J Mol Cell Cardiol. 1995 Oct;27(10):2209-22. PMID: 8576937.

" Not dangerous goods.

LKT P0392 Paxilline 1 mg 54.1 Neuroactive mycotoxin produced by Penicillum and Aspergillus; BK K+ channel inhibitor, SERCA inhibitor. 57186-25-1 ≥98% 435.56 C27H33NO4 CC12CCC3C(=CC(=O)C(O3)C(C)(C)O)C1(CCC4C2(C5=C(C4)C6=CC=CC=C6N5)C)O Ambient 4°C Acetone, Methanol, and DMSO. "Borchert GH, Hlaváčková M, Kolář F. Pharmacological activation of mitochondrial BK(Ca) channels protects isolated cardiomyocytes against simulated reperfusion-induced injury. Exp Biol Med (Maywood). 2013 Feb;238(2):233-41. PMID: 23576804.

 

Bilmen JG, Wootton LL, Michelangeli F. The mechanism of inhibition of the sarco/endoplasmic reticulum Ca2+ ATPase by paxilline. Arch Biochem Biophys. 2002 Oct 1;406(1):55-64. PMID: 12234490." T, Xi "UN number: 2811     Class: 6.1     Packing Group: III

Proper shipping name: Toxic solid, organic, n.o.s. (Paxilline)"

LKT E7579 Estramustine Phosphate Disodium 25 mg 54.6 Nitrogen mustard and estradiol derivative; microtubule depolymerization inducer. 52205-73-9  ≥95% 564.35 C23H32Cl2NO6PNa2 CC12CCC3C(C1CCC2OP(=O)([O-])[O-])CCC4=C3C=CC(=C4)OC(=O)N(CCCl)CCCl.[Na+].[Na+] Ambient 4°C "Matsumoto K, Tanaka N, Hayakawa N, et al. Efficacy of estramustine phosphate sodium hydrate (EMP) monotherapy in castration-resistant prostate cancer patients: report of 102 cases and review of literature. Med Oncol. 2013 Dec;30(4):717. PMID: 24005812.

 

Mohan R, Panda D. Kinetic stabilization of microtubule dynamics by estramustine is associated with tubulin acetylation, spindle abnormalities, and mitotic arrest. Cancer Res. 2008 Aug 1;68(15):6181-9. PMID: 18676841.

 

Yoshida D, Hoshino S, Shimura T, et al. Drug-induced apoptosis by anti-microtubule agent, estramustine phosphate on human malignant glioma cell line, U87MG; in vitro study. J Neurooncol. 2000 Apr;47(2):133-40. PMID: 10982154.

 

Panda D, Miller HP, Islam K, et al. Stabilization of microtubule dynamics by estramustine by binding to a novel site in tubulin: a possible mechanistic basis for its antitumor action. Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10560-4. PMID: 9380674.

 

Punzi JS, Duax WL, Strong P, et al. Molecular conformation of estramustine and two analogues. Mol Pharmacol. 1992 Mar;41(3):569-76. PMID: 1545778.

" Not dangerous goods.

LKT G7345 GSK-2606414 1 mg 54.6 PERK inhibitor. 1337531-89-1 ≥98% 451.44 C24H20F3N5O CN1C=C(C2=C1N=CN=C2N)C3=CC4=C(C=C3)N(CC4)C(=O)CC5=CC(=CC=C5)C(F)(F)F Ambient -20°C Axten JM, Medina JR, Feng Y, et al. Discovery of 7-methyl-5-(1--2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK). J Med Chem. 2012 Aug 23;55(16):7193-207. PMID: 22827572. Not dangerous goods.

LKT G7345 GSK-2606414 5 mg 151.7 PERK inhibitor. 1337531-89-1 ≥98% 451.44 C24H20F3N5O CN1C=C(C2=C1N=CN=C2N)C3=CC4=C(C=C3)N(CC4)C(=O)CC5=CC(=CC=C5)C(F)(F)F Ambient -20°C Axten JM, Medina JR, Feng Y, et al. Discovery of 7-methyl-5-(1--2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK). J Med Chem. 2012 Aug 23;55(16):7193-207. PMID: 22827572. Not dangerous goods.

LKT G7345 GSK-2606414 25 mg 485.3 PERK inhibitor. 1337531-89-1 ≥98% 451.44 C24H20F3N5O CN1C=C(C2=C1N=CN=C2N)C3=CC4=C(C=C3)N(CC4)C(=O)CC5=CC(=CC=C5)C(F)(F)F Ambient -20°C Axten JM, Medina JR, Feng Y, et al. Discovery of 7-methyl-5-(1--2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK). J Med Chem. 2012 Aug 23;55(16):7193-207. PMID: 22827572. Not dangerous goods.

LKT S6236 13-Desmethyl Spirolide C 100 µg 485.3 Cyclic imine marine toxin produced by Alexandrium;nAChR and mAChR antagonist. 334974-07-1 ≥95% 691.94 C42H61NO7 Blue Ice -20°C "Marrouchi R, Rome G, Kharrat R, et al. Analysis of the action of gymnodimine-A and 13-desmethyl spirolide C on the mouse neuromuscular system in vivo. Toxicon. 2013 Dec 1;75:27-34. PMID: 23954513.

 

Alonso E, Otero P, Vale C, et al. Benefit of 13-desmethyl spirolide C treatment in triple transgenic mouse model of Alzheimer disease: beta-amyloid and neuronal markers improvement. Curr Alzheimer Res. 2013 Mar;10(3):279-89. PMID: 23036025.

 

Hauser TA, Hepler CD, Kombo DC, et al. Comparison of acetylcholine receptor interactions of the marine toxins, 13-desmethylspirolide C and gymnodimine. Neuropharmacology. 2012 Jun;62(7):2239-50. PMID: 22306792.

 

Otero A, Chapela MJ, Atanassova M, et al. Cyclic imines: chemistry and mechanism of action: a review. Chem Res Toxicol. 2011 Nov 21;24(11):1817-29. PMID: 21739960.

 

Wandscheer CB, Vilariño N, Espiña B, et al. Human muscarinic acetylcholine receptors are a target of the marine toxin 13-desmethyl C spirolide. Chem Res Toxicol. 2010 Nov 15;23(11):1753-61. PMID: 20954707.

"

LKT M3206 Microginin 511 50 µg 521.7 Found in Microcystis; protein phosphatase, ACE, leucine aminopeptidase inhibitor. ≥95% 511.67 C25H41N3O6S Blue Ice -20°C "Schatz D, Keren Y, Vardi A, et al. Towards clarification of the biological role of microcystins, a family of cyanobacterial toxins. Environ Microbiol. 2007 Apr;9(4):965-70. PMID: 17359268.

 

Kraft M, Schleberger C, Weckesser J, et al. Binding structure of the leucine aminopeptidase inhibitor microginin FR1. FEBS Lett. 2006 Dec 22;580(30):6943-7. PMID: 17157838.

 

Runnage ME, Burke AJ, Davies SG, et al. Asymmetric Synthesis of the N-terminal component of Microginin: (2S,3R)-3-Amino-2-Hydroxydecanoic Acid, its (2R,3R)-Epimer and (3R)-3-Aminodecanoic Acid. Tetrahedron: Asymmetry. 1995;6(1):165-176. 

"

LKT M3207 Microginin 674 50 µg 521.7 Found in Microcystis; protein phosphatase, ACE, leucine aminopeptidase inhibitor. ≥95% 674.85 C34H50N4O8S Blue Ice -20°C "Schatz D, Keren Y, Vardi A, et al. Towards clarification of the biological role of microcystins, a family of cyanobacterial toxins. Environ Microbiol. 2007 Apr;9(4):965-70. PMID: 17359268.

 

Kraft M, Schleberger C, Weckesser J, et al. Binding structure of the leucine aminopeptidase inhibitor microginin FR1. FEBS Lett. 2006 Dec 22;580(30):6943-7. PMID: 17157838.

 

Runnage ME, Burke AJ, Davies SG, et al. Asymmetric Synthesis of the N-terminal component of Microginin: (2S,3R)-3-Amino-2-Hydroxydecanoic Acid, its (2R,3R)-Epimer and (3R)-3-Aminodecanoic Acid. Tetrahedron: Asymmetry. 1995;6(1):165-176. 

"

LKT M3209 Microginin 688 50 µg 521.7 Found in Microcystis; protein phosphatase, ACE, leucine aminopeptidase inhibitor. ≥95% 688.87 C35H52N4O8S Blue Ice -20°C "Schatz D, Keren Y, Vardi A, et al. Towards clarification of the biological role of microcystins, a family of cyanobacterial toxins. Environ Microbiol. 2007 Apr;9(4):965-70. PMID: 17359268.

 

Kraft M, Schleberger C, Weckesser J, et al. Binding structure of the leucine aminopeptidase inhibitor microginin FR1. FEBS Lett. 2006 Dec 22;580(30):6943-7. PMID: 17157838.

 

Runnage ME, Burke AJ, Davies SG, et al. Asymmetric Synthesis of the N-terminal component of Microginin: (2S,3R)-3-Amino-2-Hydroxydecanoic Acid, its (2R,3R)-Epimer and (3R)-3-Aminodecanoic Acid. Tetrahedron: Asymmetry. 1995;6(1):165-176. 

"

LKT M3406 Microcystin-LR 100 µg 121.4 Cyclic heptapeptide produced by Microcystis; PP1/2A inhibitor, potential GSK-3β activator. 101043-37-2 ≥95% 995.17 C49H74N10O12 CC1C(NC(=O)C(NC(=O)C(C(NC(=O)C(NC(=O)C(NC(=O)C(=C)N(C(=O)CCC(NC1=O)C(=O)O)C)C)CC(C)C)C(=O)O)C)CCCN=C(N)N)C=CC(=CC(C)C(CC2=CC=CC=C2)OC)C Blue Ice -20°C "Zhou Y, Chen Y, Yuan M, et al. In vivo study on the effects of microcystin-LR on the apoptosis, proliferation and differentiation of rat testicular spermatogenic cells of male rats injected i.p. with toxins. J Toxicol Sci. 2013;38(5):661-70. PMID: 24025782.

 

Sun Y, Liu JH, Huang P, et al. Alterations of tau and VASP during microcystin-LR-induced cytoskeletal reorganization in a human liver cell line. Environ Toxicol. 2013 Aug 9. doi:. [Epub ahead of print]. PMID: 23929704.

 

Zhang H, Cai C, Fang W, et al. Oxidative damage and apoptosis induced by microcystin-LR in the liver of Rana nigromaculata in vivo. Aquat Toxicol. 2013 Sep 15;140-141:11-8. PMID: 23747548.

 

Wang J, Lin F, Cai F, et al. Microcystin-LR inhibited hippocampal long-term potential via regulation of the glycogen synthase kinase-3β pathway. Chemosphere. 2013 Sep;93(2):223-9. PMID: 23701903.

 

Liang J, Li T, Zhang YL, et al. Effect of microcystin-LR on protein phosphatase 2A and its function in human amniotic epithelial cells. J Zhejiang Univ Sci B. 2011 Dec;12(12):951-60. PMID: 22135143.

 

Gan N, Sun X, Song L. Activation of Nrf2 by microcystin-LR provides advantages for liver cancer cell growth. Chem Res Toxicol. 2010 Sep 20;23(9):1477-84. PMID: 20722399.

" "UN number: 2811     Class:  6.1     Packing group I

Proper shipping name:  Toxic solid, organic, n.o.s. (Microcystin LR)"

LKT M3407 Microcystin-RR 100 µg 165.1 Cyclic heptapeptide produced by Microcystis; PP1/2A inhibitor, potential GSK-3β activator. 111755-37-4 ≥95% 1038.2 C49H75N13O12 CC1C(NC(=O)C(NC(=O)C(C(NC(=O)C(NC(=O)C(NC(=O)C(=C)N(C(=O)CCC(NC1=O)C(=O)O)C)C)CCCN=C(N)N)C(=O)O)C)CCCN=C(N)N)C=CC(=CC(C)C(CC2=CC=CC=C2)OC)C Blue Ice -20°C "Pavagadhi S, Natera S, Roessner U, et al. Insights into Lipidomic Perturbations in Zebrafish Tissues upon Exposure to Microcystin-LR and Microcystin-RR. Environ Sci Technol. 2013 Dec 17;47(24):14376-84. PMID: 24152164.

 

Zhao S, Xie P, Li G, et al. The proteomic study on cellular responses of the testes of zebrafish (Danio rerio) exposed to microcystin-RR. Proteomics. 2012 Jan;12(2):300-12. PMID: 22140076.

 

Huang P, Zheng Q, Xu LH. The apoptotic effect of oral administration of microcystin-RR on mice liver. Environ Toxicol. 2011 Oct;26(5):443-52. PMID: 20196164.

" "UN number: 2811     Class:  6.1     Packing group I(

Proper shipping name:  Toxic solid, organic, n.o.s. (Microcystin RR)"

LKT M3412 [D-Asp3, (E)-Dhb7]-Microcystin-HphR 25 µg 558.2 Cyclic homophenylalanine heptapeptide produced by Microcystis; potential PP1/2A inhibitor, potential GSK-3β activator. 1430108-50-1 ≥95% 1029.19 C52H72N10O12 Blue Ice -20°C Namikoshi M, Sivonen K, Evans WR, et al. Structures of three new homotyrosine-containing microcystins and a new homophenylalanine variant from Anabaena sp. strain 66. Chem Res Toxicol. 1992 Sep-Oct;5(5):661-6. PMID: 1446006. "UN number: 3462     Class:  6.1     Packing group:  I

Proper shipping name:  Toxins, extracted from living sources, solid, n.o.s. ([D-Asp3, (E)-Dhb7]-Microcystin-HphR)"

LKT M3414 [D-Asp3, (E)-Dhb7]-Microcystin-HtyR 100 µg 485.3 Cyclic homotyrosine heptapeptide produced by Microcystis; potential PP1/2A inhibitor, potential GSK-3β activator. 913178-65-1 ≥95% 1045.19 C52H72N10O13 Blue Ice -20°C "Shimizu K, Sano T, Kubota R, et al. Effects of the amino Acid constituents of microcystin variants on cytotoxicity to primary cultured rat hepatocytes. Toxins (Basel). 2013 Dec 30;6(1):168-79. PMID: 24380975.

 

Hastie CJ, Borthwick EB, Morrison LF, et al. Inhibition of several protein phosphatases by a non-covalently interacting microcystin and a novel cyanobacterial peptide, nostocyclin. Biochim Biophys Acta. 2005 Nov 15;1726(2):187-93. PMID: 16046071.

 

Beattie KA, Ressler J, Wiegand C, et al. Comparative effects and metabolism of two microcystins and nodularin in the brine shrimp Artemia salina. Aquat Toxicol. 2003 Feb 12;62(3):219-26. PMID: 12560170.

 

Namikoshi M, Sivonen K, Evans WR, et al. Structures of three new homotyrosine-containing microcystins and a new homophenylalanine variant from Anabaena sp. strain 66. Chem Res Toxicol. 1992 Sep-Oct;5(5):661-6. PMID: 1446006.

" "UN number: 3462     Class:  6.1     Packing group:  I

Proper shipping name:  Toxins, extracted from living sources, solid, n.o.s. ([D-Asp3, (E)-Dhb7]-Microcystin-HtyR)"

LKT C9603 Cyanopeptolin 1007 MB1 50 µg 546 Cyclic peptide produced by Microcystis; serine protease inhibitor. 912460-65-2 ≥95% 1007.18 C51H74N8O13 Blue Ice -20°C "Silva-Stenico ME, Rigonato J, Leal MG, et al. Non-ribosomal halogenated protease inhibitors from cyanobacterial isolates as attractive drug targets. Curr Med Chem. 2012;19(30):5205-13. PMID: 22934766.

 

Gademann K, Portmann C, Blom JF, et al. Multiple toxin production in the cyanobacterium microcystis: isolation of the toxic protease inhibitor cyanopeptolin 1020. J Nat Prod. 2010 May 28;73(5):980-4. PMID: 20405925.

 

Choi H, Oh SK, Yih W, et al. Cyanopeptoline CB071: a cyclic depsipeptide isolated from the freshwater cyanobacterium Aphanocapsa sp. Chem Pharm Bull (Tokyo). 2008 Aug;56(8):1191-3. PMID: 18670126.

 

von Elert E, Oberer L, Merkel P, et al. Cyanopeptolin 954, a chlorine-containing chymotrypsin inhibitor of Microcystis aeruginosa NIVA Cya 43. J Nat Prod. 2005 Sep;68(9):1324-7. PMID: 16180807.

 

Neumann U, Campos V, Cantarero S, et al. Co-occurrence of non-toxic (cyanopeptolin) and toxic (microcystin) peptides in a bloom of Microcystis sp. from a Chilean lake. Syst Appl Microbiol. 2000 Jun;23(2):191-7. PMID: 10930070.

"

LKT C9604 Cyanopeptolin 1007 MB2 25 µg 485.3 Cyclic peptide produced by Microcystis; serine protease inhibitor. ≥95% 1007.61 C48H75ClN8O13 Blue Ice -20°C "Silva-Stenico ME, Rigonato J, Leal MG, et al. Non-ribosomal halogenated protease inhibitors from cyanobacterial isolates as attractive drug targets. Curr Med Chem. 2012;19(30):5205-13. PMID: 22934766.

 

Gademann K, Portmann C, Blom JF, et al. Multiple toxin production in the cyanobacterium microcystis: isolation of the toxic protease inhibitor cyanopeptolin 1020. J Nat Prod. 2010 May 28;73(5):980-4. PMID: 20405925.

 

Choi H, Oh SK, Yih W, et al. Cyanopeptoline CB071: a cyclic depsipeptide isolated from the freshwater cyanobacterium Aphanocapsa sp. Chem Pharm Bull (Tokyo). 2008 Aug;56(8):1191-3. PMID: 18670126.

 

von Elert E, Oberer L, Merkel P, et al. Cyanopeptolin 954, a chlorine-containing chymotrypsin inhibitor of Microcystis aeruginosa NIVA Cya 43. J Nat Prod. 2005 Sep;68(9):1324-7. PMID: 16180807.

 

Neumann U, Campos V, Cantarero S, et al. Co-occurrence of non-toxic (cyanopeptolin) and toxic (microcystin) peptides in a bloom of Microcystis sp. from a Chilean lake. Syst Appl Microbiol. 2000 Jun;23(2):191-7. PMID: 10930070.

"

LKT C9601 Cyanopeptolin 1040 MB 100 µg 485.3 Cyclic peptide produced by Microcystis; serine protease inhibitor. ≥95% 1041.62 C51H73ClN8O13 Blue Ice -20°C "Silva-Stenico ME, Rigonato J, Leal MG, et al. Non-ribosomal halogenated protease inhibitors from cyanobacterial isolates as attractive drug targets. Curr Med Chem. 2012;19(30):5205-13. PMID: 22934766.

 

Gademann K, Portmann C, Blom JF, et al. Multiple toxin production in the cyanobacterium microcystis: isolation of the toxic protease inhibitor cyanopeptolin 1020. J Nat Prod. 2010 May 28;73(5):980-4. PMID: 20405925.

 

Choi H, Oh SK, Yih W, et al. Cyanopeptoline CB071: a cyclic depsipeptide isolated from the freshwater cyanobacterium Aphanocapsa sp. Chem Pharm Bull (Tokyo). 2008 Aug;56(8):1191-3. PMID: 18670126.

 

von Elert E, Oberer L, Merkel P, et al. Cyanopeptolin 954, a chlorine-containing chymotrypsin inhibitor of Microcystis aeruginosa NIVA Cya 43. J Nat Prod. 2005 Sep;68(9):1324-7. PMID: 16180807.

 

Neumann U, Campos V, Cantarero S, et al. Co-occurrence of non-toxic (cyanopeptolin) and toxic (microcystin) peptides in a bloom of Microcystis sp. from a Chilean lake. Syst Appl Microbiol. 2000 Jun;23(2):191-7. PMID: 10930070.

"

LKT C9605 Cyanopeptolin 1020 25 µg 563 Cyclic peptide produced by Microcystis; serine protease inhibitor. ≥95% 1021.17 C50H72N10O13 Blue Ice -20°C "Silva-Stenico ME, Rigonato J, Leal MG, et al. Non-ribosomal halogenated protease inhibitors from cyanobacterial isolates as attractive drug targets. Curr Med Chem. 2012;19(30):5205-13. PMID: 22934766.

 

Gademann K, Portmann C, Blom JF, et al. Multiple toxin production in the cyanobacterium microcystis: isolation of the toxic protease inhibitor cyanopeptolin 1020. J Nat Prod. 2010 May 28;73(5):980-4. PMID: 20405925.

 

Choi H, Oh SK, Yih W, et al. Cyanopeptoline CB071: a cyclic depsipeptide isolated from the freshwater cyanobacterium Aphanocapsa sp. Chem Pharm Bull (Tokyo). 2008 Aug;56(8):1191-3. PMID: 18670126.

 

von Elert E, Oberer L, Merkel P, et al. Cyanopeptolin 954, a chlorine-containing chymotrypsin inhibitor of Microcystis aeruginosa NIVA Cya 43. J Nat Prod. 2005 Sep;68(9):1324-7. PMID: 16180807.

 

Neumann U, Campos V, Cantarero S, et al. Co-occurrence of non-toxic (cyanopeptolin) and toxic (microcystin) peptides in a bloom of Microcystis sp. from a Chilean lake. Syst Appl Microbiol. 2000 Jun;23(2):191-7. PMID: 10930070.

"

LKT C9606 Cyanopeptolin 1054 MB1 50 µg 485.3 Cyclic peptide produced by Microcystis; serine protease inhibitor. ≥95% 1055.61 C50H71ClN10O13 Blue Ice -20°C "Silva-Stenico ME, Rigonato J, Leal MG, et al. Non-ribosomal halogenated protease inhibitors from cyanobacterial isolates as attractive drug targets. Curr Med Chem. 2012;19(30):5205-13. PMID: 22934766.

 

Gademann K, Portmann C, Blom JF, et al. Multiple toxin production in the cyanobacterium microcystis: isolation of the toxic protease inhibitor cyanopeptolin 1020. J Nat Prod. 2010 May 28;73(5):980-4. PMID: 20405925.

 

Choi H, Oh SK, Yih W, et al. Cyanopeptoline CB071: a cyclic depsipeptide isolated from the freshwater cyanobacterium Aphanocapsa sp. Chem Pharm Bull (Tokyo). 2008 Aug;56(8):1191-3. PMID: 18670126.

 

von Elert E, Oberer L, Merkel P, et al. Cyanopeptolin 954, a chlorine-containing chymotrypsin inhibitor of Microcystis aeruginosa NIVA Cya 43. J Nat Prod. 2005 Sep;68(9):1324-7. PMID: 16180807.

 

Neumann U, Campos V, Cantarero S, et al. Co-occurrence of non-toxic (cyanopeptolin) and toxic (microcystin) peptides in a bloom of Microcystis sp. from a Chilean lake. Syst Appl Microbiol. 2000 Jun;23(2):191-7. PMID: 10930070.

"

LKT C9607 Cyanopeptolin 1054 MB2 25 µg 485.3 Cyclic peptide produced by Microcystis; serine protease inhibitor. ≥95% 1055.65 C52H75ClN8O13 Blue Ice -20°C "Silva-Stenico ME, Rigonato J, Leal MG, et al. Non-ribosomal halogenated protease inhibitors from cyanobacterial isolates as attractive drug targets. Curr Med Chem. 2012;19(30):5205-13. PMID: 22934766.

 

Gademann K, Portmann C, Blom JF, et al. Multiple toxin production in the cyanobacterium microcystis: isolation of the toxic protease inhibitor cyanopeptolin 1020. J Nat Prod. 2010 May 28;73(5):980-4. PMID: 20405925.

 

Choi H, Oh SK, Yih W, et al. Cyanopeptoline CB071: a cyclic depsipeptide isolated from the freshwater cyanobacterium Aphanocapsa sp. Chem Pharm Bull (Tokyo). 2008 Aug;56(8):1191-3. PMID: 18670126.

 

von Elert E, Oberer L, Merkel P, et al. Cyanopeptolin 954, a chlorine-containing chymotrypsin inhibitor of Microcystis aeruginosa NIVA Cya 43. J Nat Prod. 2005 Sep;68(9):1324-7. PMID: 16180807.

 

Neumann U, Campos V, Cantarero S, et al. Co-occurrence of non-toxic (cyanopeptolin) and toxic (microcystin) peptides in a bloom of Microcystis sp. from a Chilean lake. Syst Appl Microbiol. 2000 Jun;23(2):191-7. PMID: 10930070.

"

LKT C9616 Cyanopeptolin 1068 MB 25 µg 485.3 Cyclic peptide produced by Microcystis; serine protease inhibitor. ≥95% 1069.68 C53H77ClN8O13 Blue Ice -20°C "Silva-Stenico ME, Rigonato J, Leal MG, et al. Non-ribosomal halogenated protease inhibitors from cyanobacterial isolates as attractive drug targets. Curr Med Chem. 2012;19(30):5205-13. PMID: 22934766.

 

Gademann K, Portmann C, Blom JF, et al. Multiple toxin production in the cyanobacterium microcystis: isolation of the toxic protease inhibitor cyanopeptolin 1020. J Nat Prod. 2010 May 28;73(5):980-4. PMID: 20405925.

 

Choi H, Oh SK, Yih W, et al. Cyanopeptoline CB071: a cyclic depsipeptide isolated from the freshwater cyanobacterium Aphanocapsa sp. Chem Pharm Bull (Tokyo). 2008 Aug;56(8):1191-3. PMID: 18670126.

 

von Elert E, Oberer L, Merkel P, et al. Cyanopeptolin 954, a chlorine-containing chymotrypsin inhibitor of Microcystis aeruginosa NIVA Cya 43. J Nat Prod. 2005 Sep;68(9):1324-7. PMID: 16180807.

 

Neumann U, Campos V, Cantarero S, et al. Co-occurrence of non-toxic (cyanopeptolin) and toxic (microcystin) peptides in a bloom of Microcystis sp. from a Chilean lake. Syst Appl Microbiol. 2000 Jun;23(2):191-7. PMID: 10930070.

"

LKT M3430 Micropeptin 1106 100 µg 558.2 Cyclic peptide produced by Microcystis; serine protease and PP inhibitor. ≥95% 1106.27 C54H79N11O14 Blue Ice -20°C "Schwarzenberger A, Sadler T, Von Elert E. Effect of nutrient limitation of cyanobacteria on protease inhibitor production and fitness of Daphnia magna. J Exp Biol. 2013 Oct 1;216(Pt 19):3649-55. PMID: 23788705.

 

Yamaki H, Sitachitta N, Sano T, et al. Two new chymotrypsin inhibitors isolated from the Cyanobacterium Microcystis aeruginosa NIES-88. J Nat Prod. 2005 Jan;68(1):14-8. PMID: 15679310.

 

Ploutno A, Shoshan M, Carmeli S. Three novel protease inhibitors from a natural bloom of the cyanobacterium Microcystis aeruginosa. J Nat Prod. 2002 Jul;65(7):973-8. PMID: 12141855.

"

LKT A1890 Aeruginosin 722 100 µg 570.3 Tetrapeptide produced by Microcystis; serine protease and PP inhibitor. ≥95% 723.24 C32H43CLN6O9S Blue Ice -20°C "Kapuścik A, Hrouzek P, Kuzma M, et al. Novel Aeruginosin-865 from Nostoc sp. as a potent anti-inflammatory agent. Chembiochem. 2013 Nov 25;14(17):2329-37. PMID: 24123716.

 

Silva-Stenico ME, Silva CS, Lorenzi AS, et al. Non-ribosomal peptides produced by Brazilian cyanobacterial isolates with antimicrobial activity. Microbiol Res. 2011 Mar 20;166(3):161-75. PMID: 20630723.

 

Wang G, Goyal N. Aeruginosin analogs and other compounds with rigid bicyclic structure as potential antithrombotic agents. Cardiovasc Hematol Agents Med Chem. 2009 Apr;7(2):147-65. PMID: 19355876.

 

Radau G, Gebel J, Rauh D. New cyanopeptide-derived low molecular weight thrombin inhibitors. Arch Pharm (Weinheim). 2003 Aug;336(8):372-80. PMID: 14502757.

"

LKT A1895 Aeruginosamide B 100 µg 242.7 Linear peptide produced by Microcystis; potential serine protease and PP inhibitor. ≥95% 574.73 C32H38N4O4S Blue Ice -20°C Leikoski N, Liu L, Jokela J, et al. Genome mining expands the chemical diversity of the cyanobactin family to include highly modified linear peptides. Chem Biol. 2013 Aug 22;20(8):1033-43. PMID: 23911585.

LKT A1896 Aeruginosamide C 100 µg 242.7 Linear peptide produced by Microcystis; potential serine protease and PP inhibitor. ≥95% 673.86 C37H47N5O5S Blue Ice -20°C Leikoski N, Liu L, Jokela J, et al. Genome mining expands the chemical diversity of the cyanobactin family to include highly modified linear peptides. Chem Biol. 2013 Aug 22;20(8):1033-43. PMID: 23911585.

LKT A1897 Aeruginosamide D 100 µg 364 Linear peptide produced by Microcystis; potential serine protease and PP inhibitor. ≥95% 560.71 C31H36N4O4S Blue Ice -20°C Leikoski N, Liu L, Jokela J, et al. Genome mining expands the chemical diversity of the cyanobactin family to include highly modified linear peptides. Chem Biol. 2013 Aug 22;20(8):1033-43. PMID: 23911585.

LKT A1898 Aeruginosamide E 100 µg 364 Linear peptide produced by Microcystis; potential serine protease and PP inhibitor. ≥95% 659.84 C36H45N5O5S Blue Ice -20°C Leikoski N, Liu L, Jokela J, et al. Genome mining expands the chemical diversity of the cyanobactin family to include highly modified linear peptides. Chem Biol. 2013 Aug 22;20(8):1033-43. PMID: 23911585.

LKT A5200 Anabaenopeptin A 100 µg 242.7 Linear peptide produced by Microcystis; serine protease and PP inhibitor, potential carboxypeptidase inhibitor. 161897-73-0 ≥95% 843.96 C44H57N7O10 Blue Ice -20°C "Gesner-Apter S, Carmeli S. Protease inhibitors from a water bloom of the cyanobacterium Microcystis aeruginosa. J Nat Prod. 2009 Aug;72(8):1429-36. PMID: 19650639.

 

Okumura HS, Philmus B, Portmann C, et al. Homotyrosine-containing cyanopeptolins 880 and 960 and anabaenopeptins 908 and 915 from Planktothrix agardhii CYA 126/8. J Nat Prod. 2009 Jan;72(1):172-6. PMID: 19115837.

 

Sedmak B, Carmeli S, Elersek T. ""Non-toxic"" cyclic peptides induce lysis of cyanobacteria-an effective cell population density control mechanism in cyanobacterial blooms. Microb Ecol. 2008 Aug;56(2):201-9. PMID: 18008101.

 

Itou Y, Suzuki S, Ishida K, et al. Anabaenopeptins G and H, potent carboxypeptidase A inhibitors from the cyanobacterium Oscillatoria agardhii (NIES-595). Bioorg Med Chem Lett. 1999 May 3;9(9):1243-6. PMID: 10340607.

"

LKT A5201 Anabaenopeptin B 100 µg 242.7 Linear peptide produced by Microcystis; serine protease and PP inhibitor, potential carboxypeptidase inhibitor. 161897-74-1 ≥95% 836.98 C41H60N10O9 CC1C(=O)NC(C(=O)NCCCCC(C(=O)NC(C(=O)NC(C(=O)N1C)CCC2=CC=C(C=C2)O)C(C)C)NC(=O)NC(CCCN=C(N)N)C(=O)O)CC3=CC=CC=C3 Blue Ice -20°C "Gesner-Apter S, Carmeli S. Protease inhibitors from a water bloom of the cyanobacterium Microcystis aeruginosa. J Nat Prod. 2009 Aug;72(8):1429-36. PMID: 19650639.

 

Okumura HS, Philmus B, Portmann C, et al. Homotyrosine-containing cyanopeptolins 880 and 960 and anabaenopeptins 908 and 915 from Planktothrix agardhii CYA 126/8. J Nat Prod. 2009 Jan;72(1):172-6. PMID: 19115837.

 

Sedmak B, Carmeli S, Elersek T. ""Non-toxic"" cyclic peptides induce lysis of cyanobacteria-an effective cell population density control mechanism in cyanobacterial blooms. Microb Ecol. 2008 Aug;56(2):201-9. PMID: 18008101.

 

Itou Y, Suzuki S, Ishida K, et al. Anabaenopeptins G and H, potent carboxypeptidase A inhibitors from the cyanobacterium Oscillatoria agardhii (NIES-595). Bioorg Med Chem Lett. 1999 May 3;9(9):1243-6. PMID: 10340607.

"

LKT A5203 Anabaenopeptin F 50 µg 570.3 Linear peptide produced by Microcystis; serine protease and PP inhibitor, potential carboxypeptidase inhibitor. 226416-60-0 ≥95% 851 C42H62N10O9 CCC(C)C1C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NCCCCC(C(=O)N1)NC(=O)NC(CCCN=C(N)N)C(=O)O)CC2=CC=CC=C2)C)C)CCC3=CC=C(C=C3)O Blue Ice -20°C "Gesner-Apter S, Carmeli S. Protease inhibitors from a water bloom of the cyanobacterium Microcystis aeruginosa. J Nat Prod. 2009 Aug;72(8):1429-36. PMID: 19650639.

 

Okumura HS, Philmus B, Portmann C, et al. Homotyrosine-containing cyanopeptolins 880 and 960 and anabaenopeptins 908 and 915 from Planktothrix agardhii CYA 126/8. J Nat Prod. 2009 Jan;72(1):172-6. PMID: 19115837.

 

Sedmak B, Carmeli S, Elersek T. ""Non-toxic"" cyclic peptides induce lysis of cyanobacteria-an effective cell population density control mechanism in cyanobacterial blooms. Microb Ecol. 2008 Aug;56(2):201-9. PMID: 18008101.

 

Itou Y, Suzuki S, Ishida K, et al. Anabaenopeptins G and H, potent carboxypeptidase A inhibitors from the cyanobacterium Oscillatoria agardhii (NIES-595). Bioorg Med Chem Lett. 1999 May 3;9(9):1243-6. PMID: 10340607.

"

LKT A5205 Anabaenopeptin 872 50 µg 485.3 Linear peptide produced by Microcystis; serine protease and PP inhibitor, potential carboxypeptidase inhibitor. ≥95% 872.02 C46H61N7O10 Blue Ice -20°C "Gesner-Apter S, Carmeli S. Protease inhibitors from a water bloom of the cyanobacterium Microcystis aeruginosa. J Nat Prod. 2009 Aug;72(8):1429-36. PMID: 19650639.

 

Okumura HS, Philmus B, Portmann C, et al. Homotyrosine-containing cyanopeptolins 880 and 960 and anabaenopeptins 908 and 915 from Planktothrix agardhii CYA 126/8. J Nat Prod. 2009 Jan;72(1):172-6. PMID: 19115837.

 

Sedmak B, Carmeli S, Elersek T. ""Non-toxic"" cyclic peptides induce lysis of cyanobacteria-an effective cell population density control mechanism in cyanobacterial blooms. Microb Ecol. 2008 Aug;56(2):201-9. PMID: 18008101.

 

Itou Y, Suzuki S, Ishida K, et al. Anabaenopeptins G and H, potent carboxypeptidase A inhibitors from the cyanobacterium Oscillatoria agardhii (NIES-595). Bioorg Med Chem Lett. 1999 May 3;9(9):1243-6. PMID: 10340607.

"

LKT C9644 Cylindrospermopsin 100 µg 242.7 Cyanotoxin produced by Cylindrospermopsis; protein and glutathione synthesis inhibitor. 143545-90-8 ≥95% 415.42 C15H21N5O7S CC1C(CC2CC(NC3=NCC1N23)C(C4=CC(=O)NC(=O)N4)O)OS(=O)(=O)O Blue Ice -20°C "Gutiérrez-Praena D, Risalde MA, Pichardo S, et al. Histopathological and immunohistochemical analysis of Tilapia (Oreochromis niloticus) exposed to cylindrospermopsin and the effectiveness of N-Acetylcysteine to prevent its toxic effects. Toxicon. 2013 Nov 28;78C:18-34. [Epub ahead of print]. PMID: 24291634.

 

Guzmán-Guillén R, Prieto AI, Moreno I, et al. Cyanobacterium producing cylindrospermopsin cause histopathological changes at environmentally relevant concentrations in subchronically exposed tilapia (Oreochromis niloticus). Environ Toxicol. 2013 Sep 2. [Epub ahead of print]. PMID: 24000190.

 

Alja Š, Filipič M, Novak M, et al. Double strand breaks and cell-cycle arrest induced by the cyanobacterial toxin cylindrospermopsin in HepG2 cells. Mar Drugs. 2013 Aug 21;11(8):3077-90. PMID: 23966038.

 

López-Alonso H, Rubiolo JA, Vega F, et al. Protein synthesis inhibition and oxidative stress induced by cylindrospermopsin elicit apoptosis in primary rat hepatocytes. Chem Res Toxicol. 2013 Feb 18;26(2):203-12. PMID: 23270326.

" "UN number: 2811     Class: 6.1     Packing Group: II

Proper shipping name: Toxic solid, organic, n.o.s. (Cylindrospermopsin)"

LKT G9648 12-Methyl Gymnodimine 100 µg 364 Cyclic imine marine toxin produced by Karenia; nAChR antagonist. 1330004-64-2 ≥95% 521.73 C33H47NO4 Blue Ice -20°C "Marrouchi R, Rome G, Kharrat R, et al. Analysis of the action of gymnodimine-A and 13-desmethyl spirolide C on the mouse neuromuscular system in vivo. Toxicon. 2013 Dec 1;75:27-34. PMID: 23954513.

 

Hauser TA, Hepler CD, Kombo DC, et al. Comparison of acetylcholine receptor interactions of the marine toxins, 13-desmethylspirolide C and gymnodimine. Neuropharmacology. 2012 Jun;62(7):2239-50. PMID: 22306792.

 

Otero A, Chapela MJ, Atanassova M, et al. Cyclic imines: chemistry and mechanism of action: a review. Chem Res Toxicol. 2011 Nov 21;24(11):1817-29. PMID: 21739960.

 

Alonso E, Vale C, Vieytes MR, et al. The cholinergic antagonist gymnodimine improves Aβ and tau neuropathology in an in vitro model of Alzheimer disease. Cell Physiol Biochem. 2011;27(6):783-94. PMID: 21691095.

 

Dragunow M, Trzoss M, Brimble MA, et al. Investigations into the cellular actions of the shellfish toxin gymnodimine and analogues. Environ Toxicol Pharmacol. 2005 Sep;20(2):305-12. PMID: 21783605.

" Not dangerous goods.

LKT O7208 Oscillaginin A 100 µg 242.7 Linear peptide found in Oscillatoria; potential PP inhibitor. 189438-19-5 ≥95% 615.16 C29H47ClN4O8 CC(C)C(C(=O)NC(CCC1=CC=C(C=C1)O)C(=O)O)N(C)C(=O)C(CO)NC(=O)C(C(CCCCCCCCl)N)O Blue Ice -20°C Sano T and Kaya K. A 3-amino-10-chloro-2-hydroxydecanoic acid-containing tetrapeptide from Oscillatoria agardhii. Phytochemistry.1997 Apr;44(8):1503-05.

LKT O7209 Oscillaginin A Methyl Ester 100 µg 242.7 Linear peptide found in Oscillatoria; potential PP inhibitor. ≥95% 629.19 C30H49ClN4O8 Blue Ice -20°C Sano T and Kaya K. A 3-amino-10-chloro-2-hydroxydecanoic acid-containing tetrapeptide from Oscillatoria agardhii. Phytochemistry.1997 Apr;44(8):1503-05.

LKT O7210 Oscillaginin B 100 µg 242.7 Linear peptide found in Oscillatoria; potential PP inhibitor. 189438-21-9 ≥95% 580.71 C29H48N4O8 CCCCCCCC(C(C(=O)NC(CO)C(=O)N(C)C(C(C)C)C(=O)NC(CCC1=CC=C(C=C1)O)C(=O)O)O)N Blue Ice -20°C Sano T and Kaya K. A 3-amino-10-chloro-2-hydroxydecanoic acid-containing tetrapeptide from Oscillatoria agardhii. Phytochemistry.1997 Apr;44(8):1503-05.

LKT O7211 Oscillaginin B Methyl Ester 100 µg 485.3 Linear peptide found in Oscillatoria; potential PP inhibitor. ≥95% 594.74 C30H50N4O8 Blue Ice -20°C Sano T and Kaya K. A 3-amino-10-chloro-2-hydroxydecanoic acid-containing tetrapeptide from Oscillatoria agardhii. Phytochemistry.1997 Apr;44(8):1503-05.

LKT O7212 Oscillaginin C 25 µg 533.9 Linear peptide found in Oscillatoria; potential PP inhibitor. ≥95% 649.6 C29H46Cl2N4O8 CC(C)C(C(=O)NC(CCC1=CC=C(C=C1)O)C(=O)O)N(C)C(=O)C(CO)NC(=O)C(C(CCCCCCC(Cl)Cl)N)O Blue Ice -20°C Sano T and Kaya K. A 3-amino-10-chloro-2-hydroxydecanoic acid-containing tetrapeptide from Oscillatoria agardhii. Phytochemistry.1997 Apr;44(8):1503-05.

LKT O7213 Oscillamide Y 100 µg 242.7 Linear peptide found in Oscillatoria; PP1/2A inhibitor. 189438-19-5 ≥95% 857.99 C45H59N7O10 CCC(C)C1C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NCCCCC(C(=O)N1)NC(=O)NC(CC2=CC=C(C=C2)O)C(=O)O)CC3=CC=CC=C3)C)C)CCC4=CC=C(C=C4)O Blue Ice -20°C "Barco M, Flores C, Rivera J, et al. Determination of microcystin variants and related peptides present in a water bloom of Planktothrix (Oscillatoria) rubescens in a Spanish drinking water reservoir by LC/ESI-MS. Toxicon. 2004 Dec 15;44(8):881-6. PMID: 15530970.

 

Sano T, Usui T, Ueda K, et al. Isolation of new protein phosphatase inhibitors from two cyanobacteria species, Planktothrix spp. J Nat Prod. 2001 Aug;64(8):1052-5. PMID: 11520225.

"

LKT H1862 Heptaplatin 1 mg 88.3 Pt-based DNA cross-linker. [SP-4-2-[4R-(2a,4a,5b)]]-[2-(1-Methylethyl)-1,3-dioxolane-4,5-dimethanamine-N,N'][propanedioato(2-)-O,O']-platinum Eptaplatin 146665-77-2 ≥98% 471.36 C11H20N2O6Pt CC(C)C1OC(C(O1)CN)CN.C(C(=O)O)C(=O)O.[Pt] Ambient -20°C "Lee JW, Park JK, Lee SH, et al. Anti-tumor activity of heptaplatin in combination with 5-fluorouracil or paclitaxel against human head and neck cancer cells in vitro. Anticancer Drugs. 2006 Apr;17(4):377-84. PMID: 16549994.

 

Kim NK, Im SA, Kim DW, et al. Phase II clinical trial of SKI-2053R, a new platinum analog, in the treatment of patients with advanced gastric adenocarcinoma. Cancer. 1999 Oct 1;86(7):1109-15. PMID: 10506693.

 

Kim DK, Kim HT, Tai JH, et al. Pharmacokinetics and antitumor activity of a new platinum compound, cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1, 3- dioxolane]platinum(II), as determined by ex vivo pharmacodynamics. Cancer Chemother Pharmacol. 1995;37(1-2):1-6. PMID: 7497577.

" Not dangerous goods.

LKT R1877 all-trans-Retinol, ≥98 % 100 mg 78.9 Diterpene vitamin A; RAR/RXR agonist. 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclchexen-1-yl)-2,4,6,8-nonatetraen-1-ol Alphasterol; Retinol; Avitol; Vitamin A 68-26-8 ≥98% 286.45 C20H30O CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CCO)C)C Blue Ice -20°C "Friedman MD, Jeevan DS, Tobias M, et al. Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid. Oncol Rep. 2013 Oct;30(4):1645-50. PMID: 23877261.

 

Farhangi MA, Keshavarz SA, Eshraghian M, et al. Vitamin a supplementation and serum Th1- and th2-associated cytokine response in women. J Am Coll Nutr. 2013 Aug;32(4):280-5. PMID: 24024773.

 

Sharma RB, Wang Q, Khillan JS. Amplification of tumor inducing putative cancer stem cells (CSCs) by vitamin A/retinol from mammary tumors. Biochem Biophys Res Commun. 2013 Jul 12;436(4):625-31. PMID: 23764401.

 

Zhan XX, Liu Y, Yang JF, et al. All-trans-retinoic acid ameliorates experimental allergic encephalomyelitis by affecting dendritic cell and monocyte development. Immunology. 2013 Apr;138(4):333-45. PMID: 23181531.

 

Duester G. Retinoic acid synthesis and signaling during early organogenesis. Cell. 2008 Sep 19;134(6):921-31. PMID: 18805086.

 

" Not dangerous goods.

LKT M0255 Manzamine A 10 mg 1195.2 Alkaloid found in marine sponges; vacuolar ATPase uncoupler, GSK3 inhibitor. 104196-68-1 ≥98% 548.76 C36H44N4O C1CCN2CCC3C(=CC(CCC=CC1)(C4C3(C2)CC5N4CCCCC=C5)O)C6=NC=CC7=C6NC8=CC=CC=C78 Ambient -20°C "Kallifatidis G, Hoepfner D, Jaeg T, et al. The marine natural product manzamine A targets vacuolar ATPases and inhibits autophagy in pancreatic cancer cells. Mar Drugs. 2013 Sep 17;11(9):3500-16. PMID: 24048269.

 

Eguchi K, Fujiwara Y, Hayashida A, et al. Manzamine A, a marine-derived alkaloid, inhibits accumulation of cholesterol ester in macrophages and suppresses hyperlipidemia and atherosclerosis in vivo. Bioorg Med Chem. 2013 Jul 1;21(13):3831-8. PMID: 23665143.

 

Aqil F, Zahin M, El Sayed KA, et al. Antimicrobial, antioxidant, and antimutagenic activities of selected marine natural products and tobacco cembranoids. Drug Chem Toxicol. 2011 Apr;34(2):167-79. PMID: 21314466.

 

Palem JR, Bedadala GR, El Sayed KA, et al. Manzamine A as a novel inhibitor of herpes simplex virus type-1 replication in cultured corneal cells. Planta Med. 2011 Jan;77(1):46-51. PMID: 20645244.

 

Hamann M, Alonso D, Martín-Aparicio E, et al. Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for Alzheimer's disease. J Nat Prod. 2007 Sep;70(9):1397-405. PMID: 17708655.

 

Winkler JD, Londregan AT, Hamann MT. Antimalarial activity of a new family of analogues of manzamine A. Org Lett. 2006 Jun 8;8(12):2591-4. PMID: 16737321.

" Not dangerous goods.

LKT Z7477 ZSTK474 5 mg 42.4 PI3K inhibitor. 475110-96-4 ≥98% 417.41 C19H21F2N7O2 C1COCCN1C2=NC(=NC(=N2)N3C4=CC=CC=C4N=C3C(F)F)N5CCOCC5 Ambient -20°C "Zhao W, Guo W, Zhou Q, et al. In Vitro Antimetastatic Effect of Phosphatidylinositol 3-Kinase Inhibitor ZSTK474 on Prostate Cancer PC3 Cells. Int J Mol Sci. 2013 Jun 28;14(7):13577-91. PMID: 23812078.

 

Haruta K, Mori S, Tamura N, et al. Inhibitory effects of ZSTK474, a phosphatidylinositol 3-kinase inhibitor, on adjuvant-induced arthritis in rats. Inflamm Res. 2012 Jun;61(6):551-62. PMID: 22349137.

 

Dan S, Okamura M, Mukai Y, et al. ZSTK474, a specific phosphatidylinositol 3-kinase inhibitor, induces G1 arrest of the cell cycle in vivo. Eur J Cancer. 2012 Apr;48(6):936-43. PMID: 22088482.

" Not dangerous goods.

LKT Z7477 ZSTK474 10 mg 84.9 PI3K inhibitor. 475110-96-4 ≥98% 417.41 C19H21F2N7O2 C1COCCN1C2=NC(=NC(=N2)N3C4=CC=CC=C4N=C3C(F)F)N5CCOCC5 Ambient -20°C "Zhao W, Guo W, Zhou Q, et al. In Vitro Antimetastatic Effect of Phosphatidylinositol 3-Kinase Inhibitor ZSTK474 on Prostate Cancer PC3 Cells. Int J Mol Sci. 2013 Jun 28;14(7):13577-91. PMID: 23812078.

 

Haruta K, Mori S, Tamura N, et al. Inhibitory effects of ZSTK474, a phosphatidylinositol 3-kinase inhibitor, on adjuvant-induced arthritis in rats. Inflamm Res. 2012 Jun;61(6):551-62. PMID: 22349137.

 

Dan S, Okamura M, Mukai Y, et al. ZSTK474, a specific phosphatidylinositol 3-kinase inhibitor, induces G1 arrest of the cell cycle in vivo. Eur J Cancer. 2012 Apr;48(6):936-43. PMID: 22088482.

" Not dangerous goods.

LKT Z7477 ZSTK474 25 mg 254.8 PI3K inhibitor. 475110-96-4 ≥98% 417.41 C19H21F2N7O2 C1COCCN1C2=NC(=NC(=N2)N3C4=CC=CC=C4N=C3C(F)F)N5CCOCC5 Ambient -20°C "Zhao W, Guo W, Zhou Q, et al. In Vitro Antimetastatic Effect of Phosphatidylinositol 3-Kinase Inhibitor ZSTK474 on Prostate Cancer PC3 Cells. Int J Mol Sci. 2013 Jun 28;14(7):13577-91. PMID: 23812078.

 

Haruta K, Mori S, Tamura N, et al. Inhibitory effects of ZSTK474, a phosphatidylinositol 3-kinase inhibitor, on adjuvant-induced arthritis in rats. Inflamm Res. 2012 Jun;61(6):551-62. PMID: 22349137.

 

Dan S, Okamura M, Mukai Y, et al. ZSTK474, a specific phosphatidylinositol 3-kinase inhibitor, induces G1 arrest of the cell cycle in vivo. Eur J Cancer. 2012 Apr;48(6):936-43. PMID: 22088482.

" Not dangerous goods.

LKT Y4802 YM-201636 1 mg 97 PIKfyve inhibitor. 371942-69-7 ≥98% 469.5 C25H23N7O3 C1COCCN1C2=NC(=NC3=C2OC4=C3C=CC=N4)C5=CC(=CC=C5)NC(=O)C6=CN=C(C=C6)N Ambient -20°C "Liu Y, Lai YC, Hill EV, et al. Phosphatidylinositol 3-phosphate 5-kinase (PIKfyve) is an AMPK target participating in contraction-stimulated glucose uptake in skeletal muscle. Biochem J. 2013 Oct 15;455(2):195-206. PMID: 23905686.

 

Martin S, Harper CB, May LM, et al. Inhibition of PIKfyve by YM-201636 dysregulates autophagy and leads to apoptosis-independent neuronal cell death. PLoS One. 2013;8(3):e60152. PMID: 23544129.

 

Jefferies HB, Cooke FT, Jat P, et al. A selective PIKfyve inhibitor blocks PtdIns(3,5)P(2) production and disrupts endomembrane transport and retroviral budding. EMBO Rep. 2008 Feb;9(2):164-70. PMID: 18188180.

" Not dangerous goods.

LKT Y4802 YM-201636 5 mg 248.7 PIKfyve inhibitor. 371942-69-7 ≥98% 469.5 C25H23N7O3 C1COCCN1C2=NC(=NC3=C2OC4=C3C=CC=N4)C5=CC(=CC=C5)NC(=O)C6=CN=C(C=C6)N Ambient -20°C "Liu Y, Lai YC, Hill EV, et al. Phosphatidylinositol 3-phosphate 5-kinase (PIKfyve) is an AMPK target participating in contraction-stimulated glucose uptake in skeletal muscle. Biochem J. 2013 Oct 15;455(2):195-206. PMID: 23905686.

 

Martin S, Harper CB, May LM, et al. Inhibition of PIKfyve by YM-201636 dysregulates autophagy and leads to apoptosis-independent neuronal cell death. PLoS One. 2013;8(3):e60152. PMID: 23544129.

 

Jefferies HB, Cooke FT, Jat P, et al. A selective PIKfyve inhibitor blocks PtdIns(3,5)P(2) production and disrupts endomembrane transport and retroviral budding. EMBO Rep. 2008 Feb;9(2):164-70. PMID: 18188180.

" Not dangerous goods.

LKT Y4802 YM-201636 10 mg 398 PIKfyve inhibitor. 371942-69-7 ≥98% 469.5 C25H23N7O3 C1COCCN1C2=NC(=NC3=C2OC4=C3C=CC=N4)C5=CC(=CC=C5)NC(=O)C6=CN=C(C=C6)N Ambient -20°C "Liu Y, Lai YC, Hill EV, et al. Phosphatidylinositol 3-phosphate 5-kinase (PIKfyve) is an AMPK target participating in contraction-stimulated glucose uptake in skeletal muscle. Biochem J. 2013 Oct 15;455(2):195-206. PMID: 23905686.

 

Martin S, Harper CB, May LM, et al. Inhibition of PIKfyve by YM-201636 dysregulates autophagy and leads to apoptosis-independent neuronal cell death. PLoS One. 2013;8(3):e60152. PMID: 23544129.

 

Jefferies HB, Cooke FT, Jat P, et al. A selective PIKfyve inhibitor blocks PtdIns(3,5)P(2) production and disrupts endomembrane transport and retroviral budding. EMBO Rep. 2008 Feb;9(2):164-70. PMID: 18188180.

" Not dangerous goods.

LKT T2402 TG100-115 1 mg 97 p110δ and p110γ PI3K inhibitor. 677297-51-7 ≥98% 346.34 C18H14N6O2 C1=CC(=CC(=C1)O)C2=NC3=C(N=C2C4=CC(=CC=C4)O)N=C(N=C3N)N Ambient -20°C "Doukas J, Eide L, Stebbins K, et al. Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease. J Pharmacol Exp Ther. 2009 Mar;328(3):758-65. PMID: 19056934.

 

Doukas J, Wrasidlo W, Noronha G, et al. Isoform-selective PI3K inhibitors as novel therapeutics for the treatment of acute myocardial infarction. Biochem Soc Trans. 2007 Apr;35(Pt 2):204-6. PMID: 17371238.

 

Doukas J, Wrasidlo W, Noronha G, et al. Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury. Proc Natl Acad Sci U S A. 2006 Dec 26;103(52):19866-71. PMID: 17172449.

" Not dangerous goods.

LKT T2402 TG100-115 5 mg 194.1 p110δ and p110γ PI3K inhibitor. 677297-51-7 ≥98% 346.34 C18H14N6O2 C1=CC(=CC(=C1)O)C2=NC3=C(N=C2C4=CC(=CC=C4)O)N=C(N=C3N)N Ambient -20°C "Doukas J, Eide L, Stebbins K, et al. Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease. J Pharmacol Exp Ther. 2009 Mar;328(3):758-65. PMID: 19056934.

 

Doukas J, Wrasidlo W, Noronha G, et al. Isoform-selective PI3K inhibitors as novel therapeutics for the treatment of acute myocardial infarction. Biochem Soc Trans. 2007 Apr;35(Pt 2):204-6. PMID: 17371238.

 

Doukas J, Wrasidlo W, Noronha G, et al. Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury. Proc Natl Acad Sci U S A. 2006 Dec 26;103(52):19866-71. PMID: 17172449.

" Not dangerous goods.

LKT T2402 TG100-115 10 mg 313 p110δ and p110γ PI3K inhibitor. 677297-51-7 ≥98% 346.34 C18H14N6O2 C1=CC(=CC(=C1)O)C2=NC3=C(N=C2C4=CC(=CC=C4)O)N=C(N=C3N)N Ambient -20°C "Doukas J, Eide L, Stebbins K, et al. Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease. J Pharmacol Exp Ther. 2009 Mar;328(3):758-65. PMID: 19056934.

 

Doukas J, Wrasidlo W, Noronha G, et al. Isoform-selective PI3K inhibitors as novel therapeutics for the treatment of acute myocardial infarction. Biochem Soc Trans. 2007 Apr;35(Pt 2):204-6. PMID: 17371238.

 

Doukas J, Wrasidlo W, Noronha G, et al. Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury. Proc Natl Acad Sci U S A. 2006 Dec 26;103(52):19866-71. PMID: 17172449.

" Not dangerous goods.

LKT P9200 PX-866 1 mg 50.6 Wortmannin analog; PI3K inhibitor. (1E,​4S,​4aR,​5R,​6aS,​9aR)-​5-​(acetyloxy)-​1-​[(di-​2-​propen-​1-​ylamino)methylene]-​4,​4a,​5,​6,​6a,​8,​9,​9a-​octahydro-​11-​hydroxy-​4-​(methoxymethyl)-​4a,​6a-​dimethyl-​cyclopenta[5,​6]naphtho[1,​2-​c]pyran-​2,​7,​10(1H)-​trione Sonolisib 502632-66-8 ≥98% 525.59 C29H35NO8 CC(=O)OC1CC2(C(CCC2=O)C3=C1C4(C(OC(=O)C(=CN(CC=C)CC=C)C4=C(C3=O)O)COC)C)C Ambient -20°C Methanol , DMSO, Ethyl acetate, Ethanol "Bowles DW, Ma WW, Senzer N, et al. A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours. Br J Cancer. 2013 Sep 3;109(5):1085-92. PMID: 23942080.

 

Koul D, Shen R, Kim YW, et al. Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. Neuro Oncol. 2010 Jun;12(6):559-69. PMID: 20156803.

 

Howes AL, Chiang GG, Lang ES, et al. The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures. Mol Cancer Ther. 2007 Sep;6(9):2505-14. PMID: 17766839.

" Not dangerous goods.

LKT P9200 PX-866 5 mg 163 Wortmannin analog; PI3K inhibitor. (1E,​4S,​4aR,​5R,​6aS,​9aR)-​5-​(acetyloxy)-​1-​[(di-​2-​propen-​1-​ylamino)methylene]-​4,​4a,​5,​6,​6a,​8,​9,​9a-​octahydro-​11-​hydroxy-​4-​(methoxymethyl)-​4a,​6a-​dimethyl-​cyclopenta[5,​6]naphtho[1,​2-​c]pyran-​2,​7,​10(1H)-​trione Sonolisib 502632-66-8 ≥98% 525.59 C29H35NO8 CC(=O)OC1CC2(C(CCC2=O)C3=C1C4(C(OC(=O)C(=CN(CC=C)CC=C)C4=C(C3=O)O)COC)C)C Ambient -20°C Methanol , DMSO, Ethyl acetate, Ethanol "Bowles DW, Ma WW, Senzer N, et al. A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours. Br J Cancer. 2013 Sep 3;109(5):1085-92. PMID: 23942080.

 

Koul D, Shen R, Kim YW, et al. Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. Neuro Oncol. 2010 Jun;12(6):559-69. PMID: 20156803.

 

Howes AL, Chiang GG, Lang ES, et al. The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures. Mol Cancer Ther. 2007 Sep;6(9):2505-14. PMID: 17766839.

" Not dangerous goods.

LKT P9200 PX-866 10 mg 280.9 Wortmannin analog; PI3K inhibitor. (1E,​4S,​4aR,​5R,​6aS,​9aR)-​5-​(acetyloxy)-​1-​[(di-​2-​propen-​1-​ylamino)methylene]-​4,​4a,​5,​6,​6a,​8,​9,​9a-​octahydro-​11-​hydroxy-​4-​(methoxymethyl)-​4a,​6a-​dimethyl-​cyclopenta[5,​6]naphtho[1,​2-​c]pyran-​2,​7,​10(1H)-​trione Sonolisib 502632-66-8 ≥98% 525.59 C29H35NO8 CC(=O)OC1CC2(C(CCC2=O)C3=C1C4(C(OC(=O)C(=CN(CC=C)CC=C)C4=C(C3=O)O)COC)C)C Ambient -20°C Methanol , DMSO, Ethyl acetate, Ethanol "Bowles DW, Ma WW, Senzer N, et al. A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours. Br J Cancer. 2013 Sep 3;109(5):1085-92. PMID: 23942080.

 

Koul D, Shen R, Kim YW, et al. Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. Neuro Oncol. 2010 Jun;12(6):559-69. PMID: 20156803.

 

Howes AL, Chiang GG, Lang ES, et al. The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures. Mol Cancer Ther. 2007 Sep;6(9):2505-14. PMID: 17766839.

" Not dangerous goods.

LKT P6002 PP-121 1 mg 42.4 p110α PI3K, DNA-PK, mTOR, Abl, Hck, Src, VEGFR2, PDGFR inhibitor. 1092788-83-4 ≥98% 319.36 C17H17N7 C1CCC(C1)N2C3=C(C(=N2)C4=CN=C5C(=C4)C=CN5)C(=NC=N3)N Ambient -20°C Apsel B, Blair JA, Gonzalez B, et al. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9. PMID: 18849971. Not dangerous goods.

LKT P6002 PP-121 5 mg 82.4 p110α PI3K, DNA-PK, mTOR, Abl, Hck, Src, VEGFR2, PDGFR inhibitor. 1092788-83-4 ≥98% 319.36 C17H17N7 C1CCC(C1)N2C3=C(C(=N2)C4=CN=C5C(=C4)C=CN5)C(=NC=N3)N Ambient -20°C Apsel B, Blair JA, Gonzalez B, et al. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9. PMID: 18849971. Not dangerous goods.

LKT P6002 PP-121 10 mg 133.5 p110α PI3K, DNA-PK, mTOR, Abl, Hck, Src, VEGFR2, PDGFR inhibitor. 1092788-83-4 ≥98% 319.36 C17H17N7 C1CCC(C1)N2C3=C(C(=N2)C4=CN=C5C(=C4)C=CN5)C(=NC=N3)N Ambient -20°C Apsel B, Blair JA, Gonzalez B, et al. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9. PMID: 18849971. Not dangerous goods.

LKT P4132 PKI-402 1 mg 103.1 p110α PI3K and mTOR inhibitor. 1173204-81-3 ≥98% 570.65 C29H34N10O3 CCN1C2=C(C(=NC(=N2)C3=CC=C(C=C3)NC(=O)NC4=CC=C(C=C4)C(=O)N5CCN(CC5)C)N6CCOCC6)N=N1 Ambient -20°C "Mallon R, Hollander I, Feldberg L, et al. Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor. Mol Cancer Ther. 2010 Apr;9(4):976-84. PMID: 20371716.

 

Dehnhardt CM, Venkatesan AM, Delos Santos E, et al. Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors: discovery of PKI-402. J Med Chem. 2010 Jan 28;53(2):798-810. PMID: 19968288.

" "UN number: 3077     Class: 9     Packing Group: III

Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (PKI-402)"

LKT P4132 PKI-402 5 mg 303.3 p110α PI3K and mTOR inhibitor. 1173204-81-3 ≥98% 570.65 C29H34N10O3 CCN1C2=C(C(=NC(=N2)C3=CC=C(C=C3)NC(=O)NC4=CC=C(C=C4)C(=O)N5CCN(CC5)C)N6CCOCC6)N=N1 Ambient -20°C "Mallon R, Hollander I, Feldberg L, et al. Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor. Mol Cancer Ther. 2010 Apr;9(4):976-84. PMID: 20371716.

 

Dehnhardt CM, Venkatesan AM, Delos Santos E, et al. Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors: discovery of PKI-402. J Med Chem. 2010 Jan 28;53(2):798-810. PMID: 19968288.

" "UN number: 3077     Class: 9     Packing Group: III

Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (PKI-402)"

LKT P4132 PKI-402 10 mg 485.3 p110α PI3K and mTOR inhibitor. 1173204-81-3 ≥98% 570.65 C29H34N10O3 CCN1C2=C(C(=NC(=N2)C3=CC=C(C=C3)NC(=O)NC4=CC=C(C=C4)C(=O)N5CCN(CC5)C)N6CCOCC6)N=N1 Ambient -20°C "Mallon R, Hollander I, Feldberg L, et al. Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor. Mol Cancer Ther. 2010 Apr;9(4):976-84. PMID: 20371716.

 

Dehnhardt CM, Venkatesan AM, Delos Santos E, et al. Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors: discovery of PKI-402. J Med Chem. 2010 Jan 28;53(2):798-810. PMID: 19968288.

" "UN number: 3077     Class: 9     Packing Group: III

Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (PKI-402)"

LKT P3542 PIK-93 1 mg 103.1 p110α and p110γ PI3K inhibitor. PIK93 593960-11-3 ≥98% 389.88 C14H16ClN3O4S2 CC1=C(SC(=N1)NC(=O)C)C2=CC(=C(C=C2)Cl)S(=O)(=O)NCCO Ambient -20°C Monet M, Francoeur N, Boulay G. Involvement of phosphoinositide 3-kinase and PTEN protein in mechanism of activation of TRPC6 protein in vascular smooth muscle cells. J Biol Chem. 2012 May 18;287(21):17672-81. PMID: 22493444. Not dangerous goods.

LKT P3542 PIK-93 5 mg 303.3 p110α and p110γ PI3K inhibitor. PIK93 593960-11-3 ≥98% 389.88 C14H16ClN3O4S2 CC1=C(SC(=N1)NC(=O)C)C2=CC(=C(C=C2)Cl)S(=O)(=O)NCCO Ambient -20°C Monet M, Francoeur N, Boulay G. Involvement of phosphoinositide 3-kinase and PTEN protein in mechanism of activation of TRPC6 protein in vascular smooth muscle cells. J Biol Chem. 2012 May 18;287(21):17672-81. PMID: 22493444. Not dangerous goods.

LKT P3542 PIK-93 10 mg 485.3 p110α and p110γ PI3K inhibitor. PIK93 593960-11-3 ≥98% 389.88 C14H16ClN3O4S2 CC1=C(SC(=N1)NC(=O)C)C2=CC(=C(C=C2)Cl)S(=O)(=O)NCCO Ambient -20°C Monet M, Francoeur N, Boulay G. Involvement of phosphoinositide 3-kinase and PTEN protein in mechanism of activation of TRPC6 protein in vascular smooth muscle cells. J Biol Chem. 2012 May 18;287(21):17672-81. PMID: 22493444. Not dangerous goods.

LKT P3540 PIK-75 Hydrochloride 5 mg 54.6 p110α PI3K inhibitor. PIK-75 HCl 372196-77-5 ≥98% 488.74 C16H14BrN5O4S HCl CC1=C(C=C(C=C1)[N+](=O)[O-])S(=O)(=O)N(C)N=CC2=CN=C3N2C=C(C=C3)Br.Cl Ambient -20°C Soluble in DMSO, DMF "Buchanan CM, Dickson JM, Lee WJ, et al. Oncogenic mutations of p110α isoform of PI 3-kinase upregulate its protein kinase activity. PLoS One. 2013 Aug 1;8(8):e71337. PMID: 23936502.

 

Aoyagi K, Ohara-Imaizumi M, Nishiwaki C, et al. Acute inhibition of PI3K-PDK1-Akt pathway potentiates insulin secretion through upregulation of newcomer granule fusions in pancreatic β-cells. PLoS One. 2012;7(10):e47381. PMID: 23077605.

 

Smirnova T, Zhou ZN, Flinn RJ, et al. Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis. Oncogene. 2012 Feb 9;31(6):706-15. PMID: 21725367.

 

Dagia NM, Agarwal G, Kamath DV, et al. A preferential p110alpha/gamma PI3K inhibitor attenuates experimental inflammation by suppressing the production of proinflammatory mediators in a NF-kappaB-dependent manner. Am J Physiol Cell Physiol. 2010 Apr;298(4):C929-41. PMID: 20089935.

" Not dangerous goods.

LKT P3540 PIK-75 Hydrochloride 25 mg 218.4 p110α PI3K inhibitor. PIK-75 HCl 372196-77-5 ≥98% 488.74 C16H14BrN5O4S HCl CC1=C(C=C(C=C1)[N+](=O)[O-])S(=O)(=O)N(C)N=CC2=CN=C3N2C=C(C=C3)Br.Cl Ambient -20°C Soluble in DMSO, DMF "Buchanan CM, Dickson JM, Lee WJ, et al. Oncogenic mutations of p110α isoform of PI 3-kinase upregulate its protein kinase activity. PLoS One. 2013 Aug 1;8(8):e71337. PMID: 23936502.

 

Aoyagi K, Ohara-Imaizumi M, Nishiwaki C, et al. Acute inhibition of PI3K-PDK1-Akt pathway potentiates insulin secretion through upregulation of newcomer granule fusions in pancreatic β-cells. PLoS One. 2012;7(10):e47381. PMID: 23077605.

 

Smirnova T, Zhou ZN, Flinn RJ, et al. Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis. Oncogene. 2012 Feb 9;31(6):706-15. PMID: 21725367.

 

Dagia NM, Agarwal G, Kamath DV, et al. A preferential p110alpha/gamma PI3K inhibitor attenuates experimental inflammation by suppressing the production of proinflammatory mediators in a NF-kappaB-dependent manner. Am J Physiol Cell Physiol. 2010 Apr;298(4):C929-41. PMID: 20089935.

" Not dangerous goods.

LKT P3540 PIK-75 Hydrochloride 100 mg 697.7 p110α PI3K inhibitor. PIK-75 HCl 372196-77-5 ≥98% 488.74 C16H14BrN5O4S HCl CC1=C(C=C(C=C1)[N+](=O)[O-])S(=O)(=O)N(C)N=CC2=CN=C3N2C=C(C=C3)Br.Cl Ambient -20°C Soluble in DMSO, DMF "Buchanan CM, Dickson JM, Lee WJ, et al. Oncogenic mutations of p110α isoform of PI 3-kinase upregulate its protein kinase activity. PLoS One. 2013 Aug 1;8(8):e71337. PMID: 23936502.

 

Aoyagi K, Ohara-Imaizumi M, Nishiwaki C, et al. Acute inhibition of PI3K-PDK1-Akt pathway potentiates insulin secretion through upregulation of newcomer granule fusions in pancreatic β-cells. PLoS One. 2012;7(10):e47381. PMID: 23077605.

 

Smirnova T, Zhou ZN, Flinn RJ, et al. Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis. Oncogene. 2012 Feb 9;31(6):706-15. PMID: 21725367.

 

Dagia NM, Agarwal G, Kamath DV, et al. A preferential p110alpha/gamma PI3K inhibitor attenuates experimental inflammation by suppressing the production of proinflammatory mediators in a NF-kappaB-dependent manner. Am J Physiol Cell Physiol. 2010 Apr;298(4):C929-41. PMID: 20089935.

" Not dangerous goods.

LKT P3441 PIK-294 1 mg 103.1 p110δ PI3K inhibitor. 900185-02-6 ≥98% 489.53 C28H23N7O2 CC1=C2C(=CC=C1)N=C(N(C2=O)C3=CC=CC=C3C)CN4C5=C(C(=N4)C6=CC(=CC=C6)O)C(=NC=N5)N Ambient -20°C DMSO (98 mg/ml), insoluble in water Not dangerous goods.

LKT P3441 PIK-294 5 mg 303.3 p110δ PI3K inhibitor. 900185-02-6 ≥98% 489.53 C28H23N7O2 CC1=C2C(=CC=C1)N=C(N(C2=O)C3=CC=CC=C3C)CN4C5=C(C(=N4)C6=CC(=CC=C6)O)C(=NC=N5)N Ambient -20°C DMSO (98 mg/ml), insoluble in water Not dangerous goods.

LKT P3441 PIK-294 10 mg 485.3 p110δ PI3K inhibitor. 900185-02-6 ≥98% 489.53 C28H23N7O2 CC1=C2C(=CC=C1)N=C(N(C2=O)C3=CC=CC=C3C)CN4C5=C(C(=N4)C6=CC(=CC=C6)O)C(=NC=N5)N Ambient -20°C DMSO (98 mg/ml), insoluble in water Not dangerous goods.

LKT P3440 PIK-293 1 mg 103.1 p110δ PI3K inhibitor. 900185-01-5 ≥98% 397.43 C22H19N7O CC1=C2C(=CC=C1)N=C(N(C2=O)C3=CC=CC=C3C)CN4C5=C(C=N4)C(=NC=N5)N Ambient -20°C Not dangerous goods.

LKT P3440 PIK-293 5 mg 303.3 p110δ PI3K inhibitor. 900185-01-5 ≥98% 397.43 C22H19N7O CC1=C2C(=CC=C1)N=C(N(C2=O)C3=CC=CC=C3C)CN4C5=C(C=N4)C(=NC=N5)N Ambient -20°C Not dangerous goods.

LKT P3440 PIK-293 10 mg 485.3 p110δ PI3K inhibitor. 900185-01-5 ≥98% 397.43 C22H19N7O CC1=C2C(=CC=C1)N=C(N(C2=O)C3=CC=CC=C3C)CN4C5=C(C=N4)C(=NC=N5)N Ambient -20°C Not dangerous goods.

LKT P0246 Palomid 529 1 mg 42.4 mTOR inhibitor. P529 914913-88-5 ≥98% 406.43 C24H22O6 CC(C1=CC2=C(C=C1)C3=CC(=C(C=C3OC2=O)OCC4=CC=C(C=C4)OC)OC)O Ambient -20°C "Dalal M, Jacobs-El N, Nicholson B, et al. Subconjunctival Palomid 529 in the treatment of neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2013 Dec;251(12):2705-9. PMID: 23689994. 

 

Xiang T, Jia Y, Sherris D, et al. Targeting the Akt/mTOR pathway in Brca1-deficient cancers. Oncogene. 2011 May 26;30(21):2443-50. PMID: 21242970.

 

Xue Q, Hopkins B, Perruzzi C, et al. Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability. Cancer Res. 2008 Nov 15;68(22):9551-7. PMID: 19010932.

" "UN numer: 2811     Class: 6.1     Packing Group: III

Proper shipping name: Toxic solid, organic, n.o.s. (Palomid 529)"

LKT P0246 Palomid 529 5 mg 140.8 mTOR inhibitor. P529 914913-88-5 ≥98% 406.43 C24H22O6 CC(C1=CC2=C(C=C1)C3=CC(=C(C=C3OC2=O)OCC4=CC=C(C=C4)OC)OC)O Ambient -20°C "Dalal M, Jacobs-El N, Nicholson B, et al. Subconjunctival Palomid 529 in the treatment of neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2013 Dec;251(12):2705-9. PMID: 23689994. 

 

Xiang T, Jia Y, Sherris D, et al. Targeting the Akt/mTOR pathway in Brca1-deficient cancers. Oncogene. 2011 May 26;30(21):2443-50. PMID: 21242970.

 

Xue Q, Hopkins B, Perruzzi C, et al. Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability. Cancer Res. 2008 Nov 15;68(22):9551-7. PMID: 19010932.

" "UN numer: 2811     Class: 6.1     Packing Group: III

Proper shipping name: Toxic solid, organic, n.o.s. (Palomid 529)"

LKT P0246 Palomid 529 10 mg 225.8 mTOR inhibitor. P529 914913-88-5 ≥98% 406.43 C24H22O6 CC(C1=CC2=C(C=C1)C3=CC(=C(C=C3OC2=O)OCC4=CC=C(C=C4)OC)OC)O Ambient -20°C "Dalal M, Jacobs-El N, Nicholson B, et al. Subconjunctival Palomid 529 in the treatment of neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2013 Dec;251(12):2705-9. PMID: 23689994. 

 

Xiang T, Jia Y, Sherris D, et al. Targeting the Akt/mTOR pathway in Brca1-deficient cancers. Oncogene. 2011 May 26;30(21):2443-50. PMID: 21242970.

 

Xue Q, Hopkins B, Perruzzi C, et al. Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability. Cancer Res. 2008 Nov 15;68(22):9551-7. PMID: 19010932.

" "UN numer: 2811     Class: 6.1     Packing Group: III

Proper shipping name: Toxic solid, organic, n.o.s. (Palomid 529)"

LKT N8604 NVP-BGT226 1 mg 103.1 PI3K and mTOR inhibitor. BGT226 1245537-68-1 ≥98% 650.6 C32H29F3N6O6 CN1C2=CN=C3C=CC(=CC3=C2N(C1=O)C4=CC(=C(C=C4)N5CCNCC5)C(F)(F)F)C6=CN=C(C=C6)OC.C(=CC(=O)O)C(=O)O Ambient -20°C Not dangerous goods.

LKT N8604 NVP-BGT226 5 mg 303.3 PI3K and mTOR inhibitor. BGT226 1245537-68-1 ≥98% 650.6 C32H29F3N6O6 CN1C2=CN=C3C=CC(=CC3=C2N(C1=O)C4=CC(=C(C=C4)N5CCNCC5)C(F)(F)F)C6=CN=C(C=C6)OC.C(=CC(=O)O)C(=O)O Ambient -20°C Not dangerous goods.

LKT N8604 NVP-BGT226 10 mg 485.3 PI3K and mTOR inhibitor. BGT226 1245537-68-1 ≥98% 650.6 C32H29F3N6O6 CN1C2=CN=C3C=CC(=CC3=C2N(C1=O)C4=CC(=C(C=C4)N5CCNCC5)C(F)(F)F)C6=CN=C(C=C6)OC.C(=CC(=O)O)C(=O)O Ambient -20°C Not dangerous goods.

LKT C0396 CAY10505 5 mg 42.4 p110γ PI3K inhibitor. 1218777-13-9 ≥98% 289.28 C14H8FNO3S C1=CC(=CC=C1C2=CC=C(O2)C=C3C(=O)NC(=O)S3)F Ambient -20°C Tyagi S, Sharma S, Budhiraja RD. Effect of phosphatidylinositol 3-kinase-γ inhibitor CAY10505 in hypertension, and its associated vascular endothelium dysfunction in rats. Can J Physiol Pharmacol. 2012 Jul;90(7):881-5. PMID: 22731503. Not dangerous goods.

LKT C0396 CAY10505 10 mg 66.8 p110γ PI3K inhibitor. 1218777-13-9 ≥98% 289.28 C14H8FNO3S C1=CC(=CC=C1C2=CC=C(O2)C=C3C(=O)NC(=O)S3)F Ambient -20°C Tyagi S, Sharma S, Budhiraja RD. Effect of phosphatidylinositol 3-kinase-γ inhibitor CAY10505 in hypertension, and its associated vascular endothelium dysfunction in rats. Can J Physiol Pharmacol. 2012 Jul;90(7):881-5. PMID: 22731503. Not dangerous goods.

LKT C0396 CAY10505 25 mg 145.6 p110γ PI3K inhibitor. 1218777-13-9 ≥98% 289.28 C14H8FNO3S C1=CC(=CC=C1C2=CC=C(O2)C=C3C(=O)NC(=O)S3)F Ambient -20°C Tyagi S, Sharma S, Budhiraja RD. Effect of phosphatidylinositol 3-kinase-γ inhibitor CAY10505 in hypertension, and its associated vascular endothelium dysfunction in rats. Can J Physiol Pharmacol. 2012 Jul;90(7):881-5. PMID: 22731503. Not dangerous goods.

LKT B1996 BEZ235 10 mg 42.4 PI3K and mTOR inhibitor. NVP-BEZ235, Dactolisib 915019-65-7 ≥98% 469.54 C30H23N5O CC(C)(C#N)C1=CC=C(C=C1)N2C3=C4C=C(C=CC4=NC=C3N(C2=O)C)C5=CC6=CC=CC=C6N=C5 Ambient -20°C "Ma BB, Lui VW, Hui CW, et al. Preclinical evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal cancer models. Cancer Lett. 2014 Feb 1;343(1):24-32. PMID: 24041865.

 

Yothaisong S, Dokduang H, Techasen A, et al. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy. Tumour Biol. 2013 Dec;34(6):3637-48. PMID: 23832540.

 

Chang Z, Shi G, Jin J, et al. Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy. Int J Mol Med. 2013 Jun;31(6):1449-56. PMID: 23588698.

" Not dangerous goods.

LKT B1996 BEZ235 25 mg 91 PI3K and mTOR inhibitor. NVP-BEZ235, Dactolisib 915019-65-7 ≥98% 469.54 C30H23N5O CC(C)(C#N)C1=CC=C(C=C1)N2C3=C4C=C(C=CC4=NC=C3N(C2=O)C)C5=CC6=CC=CC=C6N=C5 Ambient -20°C "Ma BB, Lui VW, Hui CW, et al. Preclinical evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal cancer models. Cancer Lett. 2014 Feb 1;343(1):24-32. PMID: 24041865.

 

Yothaisong S, Dokduang H, Techasen A, et al. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy. Tumour Biol. 2013 Dec;34(6):3637-48. PMID: 23832540.

 

Chang Z, Shi G, Jin J, et al. Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy. Int J Mol Med. 2013 Jun;31(6):1449-56. PMID: 23588698.

" Not dangerous goods.

LKT B1996 BEZ235 100 mg 273 PI3K and mTOR inhibitor. NVP-BEZ235, Dactolisib 915019-65-7 ≥98% 469.54 C30H23N5O CC(C)(C#N)C1=CC=C(C=C1)N2C3=C4C=C(C=CC4=NC=C3N(C2=O)C)C5=CC6=CC=CC=C6N=C5 Ambient -20°C "Ma BB, Lui VW, Hui CW, et al. Preclinical evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal cancer models. Cancer Lett. 2014 Feb 1;343(1):24-32. PMID: 24041865.

 

Yothaisong S, Dokduang H, Techasen A, et al. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy. Tumour Biol. 2013 Dec;34(6):3637-48. PMID: 23832540.

 

Chang Z, Shi G, Jin J, et al. Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy. Int J Mol Med. 2013 Jun;31(6):1449-56. PMID: 23588698.

" Not dangerous goods.

LKT B0396 BAY80-6946 1 mg 224.5 p110α PI3K inhibitor. Copanlisib 1032568-63-0 ≥98% 480.52 C23H28N8O4 COC1=C(C=CC2=C1N=C(N3C2=NCC3)NC(=O)C4=CN=C(N=C4)N)OCCCN5CCOCC5 Ambient -20°C "Due to its chemical nature, pure BAY80-6946 solid powder was found to have very low solubility in common organic solvents. This has been reported in the literature. User may use the following method as a reference when making stock solution: 2 mg BAY80-6946 is placed in a clear vial. To this vial, 10 µL 10% HCl is added. The vial is capped and shaken for a few seconds to allow HCl solution to wet the crystals of BAY80-6946. Then 90 µL water is added, and shaken for a few second, which will give a clear stock solution at 20 mg /mL. This solution can be further diluted using 0.5% HCl water solution.

 

Pure BAY80-6946 has very low solubility, because of its chemical property, not because of the poor quality of our product. Molecule of BAY80-6946 contains several basic nitrogen atoms, after protonated by HCl, its solubility will be enhanced. For in vitro studies, 5 mmol/L stock solution of BAY 80-6946 (in dimethyl sulfoxide with 10 mmol/L trifluoroacetic acid) was used - see Mol Cancer Ther. 2013 Nov;12(11):2319-30." "Glauer J, Pletz N, Schön M, et al. A novel selective small-molecule PI3K inhibitor is effective against human multiple myeloma in vitro and in vivo. Blood Cancer J. 2013 Sep 6;3:e141. PMID: 24013662.

 

Cheng H, Merika E, Syrigos KN, et al. Novel agents for the treatment of pancreatic adenocarcinoma. Highlights from the ""2011 ASCO Annual Meeting"". Chicago, IL, USA; June 3-7, 2011. JOP. 2011 Jul 8;12(4):334-8. PMID: 21737890.

" Not dangerous goods.

LKT B0396 BAY80-6946 5 mg 442.9 p110α PI3K inhibitor. Copanlisib 1032568-63-0 ≥98% 480.52 C23H28N8O4 COC1=C(C=CC2=C1N=C(N3C2=NCC3)NC(=O)C4=CN=C(N=C4)N)OCCCN5CCOCC5 Ambient -20°C "Due to its chemical nature, pure BAY80-6946 solid powder was found to have very low solubility in common organic solvents. This has been reported in the literature. User may use the following method as a reference when making stock solution: 2 mg BAY80-6946 is placed in a clear vial. To this vial, 10 µL 10% HCl is added. The vial is capped and shaken for a few seconds to allow HCl solution to wet the crystals of BAY80-6946. Then 90 µL water is added, and shaken for a few second, which will give a clear stock solution at 20 mg /mL. This solution can be further diluted using 0.5% HCl water solution.

 

Pure BAY80-6946 has very low solubility, because of its chemical property, not because of the poor quality of our product. Molecule of BAY80-6946 contains several basic nitrogen atoms, after protonated by HCl, its solubility will be enhanced. For in vitro studies, 5 mmol/L stock solution of BAY 80-6946 (in dimethyl sulfoxide with 10 mmol/L trifluoroacetic acid) was used - see Mol Cancer Ther. 2013 Nov;12(11):2319-30." "Glauer J, Pletz N, Schön M, et al. A novel selective small-molecule PI3K inhibitor is effective against human multiple myeloma in vitro and in vivo. Blood Cancer J. 2013 Sep 6;3:e141. PMID: 24013662.

 

Cheng H, Merika E, Syrigos KN, et al. Novel agents for the treatment of pancreatic adenocarcinoma. Highlights from the ""2011 ASCO Annual Meeting"". Chicago, IL, USA; June 3-7, 2011. JOP. 2011 Jul 8;12(4):334-8. PMID: 21737890.

" Not dangerous goods.

LKT B0396 BAY80-6946 10 mg 722 p110α PI3K inhibitor. Copanlisib 1032568-63-0 ≥98% 480.52 C23H28N8O4 COC1=C(C=CC2=C1N=C(N3C2=NCC3)NC(=O)C4=CN=C(N=C4)N)OCCCN5CCOCC5 Ambient -20°C "Due to its chemical nature, pure BAY80-6946 solid powder was found to have very low solubility in common organic solvents. This has been reported in the literature. User may use the following method as a reference when making stock solution: 2 mg BAY80-6946 is placed in a clear vial. To this vial, 10 µL 10% HCl is added. The vial is capped and shaken for a few seconds to allow HCl solution to wet the crystals of BAY80-6946. Then 90 µL water is added, and shaken for a few second, which will give a clear stock solution at 20 mg /mL. This solution can be further diluted using 0.5% HCl water solution.

 

Pure BAY80-6946 has very low solubility, because of its chemical property, not because of the poor quality of our product. Molecule of BAY80-6946 contains several basic nitrogen atoms, after protonated by HCl, its solubility will be enhanced. For in vitro studies, 5 mmol/L stock solution of BAY 80-6946 (in dimethyl sulfoxide with 10 mmol/L trifluoroacetic acid) was used - see Mol Cancer Ther. 2013 Nov;12(11):2319-30." "Glauer J, Pletz N, Schön M, et al. A novel selective small-molecule PI3K inhibitor is effective against human multiple myeloma in vitro and in vivo. Blood Cancer J. 2013 Sep 6;3:e141. PMID: 24013662.

 

Cheng H, Merika E, Syrigos KN, et al. Novel agents for the treatment of pancreatic adenocarcinoma. Highlights from the ""2011 ASCO Annual Meeting"". Chicago, IL, USA; June 3-7, 2011. JOP. 2011 Jul 8;12(4):334-8. PMID: 21737890.

" Not dangerous goods.

LKT A9712 AZD-6482 1 mg 103.1 p110β PI3K inhibitor. 1173900-33-8 ≥98% 408.45 C22H24N4O4 CC1=CN2C(=O)C=C(N=C2C(=C1)C(C)NC3=CC=CC=C3C(=O)O)N4CCOCC4 Ambient -20°C "Weigelt B, Warne PH, Lambros MB, et al. PI3K pathway dependencies in endometrioid endometrial cancer cell lines. Clin Cancer Res. 2013 Jul 1;19(13):3533-44. PMID: 23674493.

 

Nylander S, Kull B, Björkman JA, et al. Human target validation of phosphoinositide 3-kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor. J Thromb Haemost. 2012 Oct;10(10):2127-36. PMID: 22906130.

" Not dangerous goods.

LKT A9712 AZD-6482 5 mg 291.2 p110β PI3K inhibitor. 1173900-33-8 ≥98% 408.45 C22H24N4O4 CC1=CN2C(=O)C=C(N=C2C(=C1)C(C)NC3=CC=CC=C3C(=O)O)N4CCOCC4 Ambient -20°C "Weigelt B, Warne PH, Lambros MB, et al. PI3K pathway dependencies in endometrioid endometrial cancer cell lines. Clin Cancer Res. 2013 Jul 1;19(13):3533-44. PMID: 23674493.

 

Nylander S, Kull B, Björkman JA, et al. Human target validation of phosphoinositide 3-kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor. J Thromb Haemost. 2012 Oct;10(10):2127-36. PMID: 22906130.

" Not dangerous goods.

LKT A9712 AZD-6482 10 mg 468.4 p110β PI3K inhibitor. 1173900-33-8 ≥98% 408.45 C22H24N4O4 CC1=CN2C(=O)C=C(N=C2C(=C1)C(C)NC3=CC=CC=C3C(=O)O)N4CCOCC4 Ambient -20°C "Weigelt B, Warne PH, Lambros MB, et al. PI3K pathway dependencies in endometrioid endometrial cancer cell lines. Clin Cancer Res. 2013 Jul 1;19(13):3533-44. PMID: 23674493.

 

Nylander S, Kull B, Björkman JA, et al. Human target validation of phosphoinositide 3-kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor. J Thromb Haemost. 2012 Oct;10(10):2127-36. PMID: 22906130.

" Not dangerous goods.

LKT A7204 AS-605240 1 mg 42.4 p110δ PI3K inhibitor. AS605240 648450-29-7 ≥98% 257.27 C12H7N3O2S C1=CC2=NC=CN=C2C=C1C=C3C(=O)NC(=O)S3 Ambient -20°C "Comerford I, Litchfield W, Kara E, et al. PI3Kγ drives priming and survival of autoreactive CD4(+) T celLSuring experimental autoimmune encephalomyelitis. PLoS One. 2012;7(9):e45095. PMID: 23028778.

 

Azzi J, Moore RF, Elyaman W, et al. The novel therapeutic effect of phosphoinositide 3-kinase-γ inhibitor AS605240 in autoimmune diabetes. Diabetes. 2012 Jun;61(6):1509-18. PMID: 22403300.

 

Kim DI, Kim SR, Kim HJ, et al. PI3K-γ inhibition ameliorates acute lung injury through regulation of IκBα/NF-κB pathway and innate immune responses. J Clin Immunol. 2012 Apr;32(2):340-51. PMID: 22198681.

" Not dangerous goods.

LKT A7204 AS-605240 5 mg 84.9 p110δ PI3K inhibitor. AS605240 648450-29-7 ≥98% 257.27 C12H7N3O2S C1=CC2=NC=CN=C2C=C1C=C3C(=O)NC(=O)S3 Ambient -20°C "Comerford I, Litchfield W, Kara E, et al. PI3Kγ drives priming and survival of autoreactive CD4(+) T celLSuring experimental autoimmune encephalomyelitis. PLoS One. 2012;7(9):e45095. PMID: 23028778.

 

Azzi J, Moore RF, Elyaman W, et al. The novel therapeutic effect of phosphoinositide 3-kinase-γ inhibitor AS605240 in autoimmune diabetes. Diabetes. 2012 Jun;61(6):1509-18. PMID: 22403300.

 

Kim DI, Kim SR, Kim HJ, et al. PI3K-γ inhibition ameliorates acute lung injury through regulation of IκBα/NF-κB pathway and innate immune responses. J Clin Immunol. 2012 Apr;32(2):340-51. PMID: 22198681.

" Not dangerous goods.

LKT A7204 AS-605240 10 mg 121.4 p110δ PI3K inhibitor. AS605240 648450-29-7 ≥98% 257.27 C12H7N3O2S C1=CC2=NC=CN=C2C=C1C=C3C(=O)NC(=O)S3 Ambient -20°C "Comerford I, Litchfield W, Kara E, et al. PI3Kγ drives priming and survival of autoreactive CD4(+) T celLSuring experimental autoimmune encephalomyelitis. PLoS One. 2012;7(9):e45095. PMID: 23028778.

 

Azzi J, Moore RF, Elyaman W, et al. The novel therapeutic effect of phosphoinositide 3-kinase-γ inhibitor AS605240 in autoimmune diabetes. Diabetes. 2012 Jun;61(6):1509-18. PMID: 22403300.

 

Kim DI, Kim SR, Kim HJ, et al. PI3K-γ inhibition ameliorates acute lung injury through regulation of IκBα/NF-κB pathway and innate immune responses. J Clin Immunol. 2012 Apr;32(2):340-51. PMID: 22198681.

" Not dangerous goods.

LKT A7202 AS-604850 1 mg 42.4 p110γ PI3K inhibitor. 48449-76-7 ≥98% 285.22 C11H5F2NO4S Ambient -20°C "Li H, Park D, Abdul-Muneer PM, et al. PI3Kγ inhibition alleviates symptoms and increases axon number in experimental autoimmune encephalomyelitis mice. Neuroscience. 2013 Dec 3;253:89-99. PMID: 24012746.

 

Hasan AM, Mourtada-Maarabouni M, Hameed MS, et al. Phosphoinositide 3-kinase gamma mediates chemotactic responses of human eosinophils to platelet-activating factor. Int Immunopharmacol. 2010 Sep;10(9):1017-21. PMID: 20685403.

" Not dangerous goods.

LKT A7202 AS-604850 5 mg 139.5 p110γ PI3K inhibitor. 48449-76-7 ≥98% 285.22 C11H5F2NO4S Ambient -20°C "Li H, Park D, Abdul-Muneer PM, et al. PI3Kγ inhibition alleviates symptoms and increases axon number in experimental autoimmune encephalomyelitis mice. Neuroscience. 2013 Dec 3;253:89-99. PMID: 24012746.

 

Hasan AM, Mourtada-Maarabouni M, Hameed MS, et al. Phosphoinositide 3-kinase gamma mediates chemotactic responses of human eosinophils to platelet-activating factor. Int Immunopharmacol. 2010 Sep;10(9):1017-21. PMID: 20685403.

" Not dangerous goods.

LKT A7202 AS-604850 10 mg 242.7 p110γ PI3K inhibitor. 48449-76-7 ≥98% 285.22 C11H5F2NO4S Ambient -20°C "Li H, Park D, Abdul-Muneer PM, et al. PI3Kγ inhibition alleviates symptoms and increases axon number in experimental autoimmune encephalomyelitis mice. Neuroscience. 2013 Dec 3;253:89-99. PMID: 24012746.

 

Hasan AM, Mourtada-Maarabouni M, Hameed MS, et al. Phosphoinositide 3-kinase gamma mediates chemotactic responses of human eosinophils to platelet-activating factor. Int Immunopharmacol. 2010 Sep;10(9):1017-21. PMID: 20685403.

" Not dangerous goods.

LKT A7200 AS-252424 1 mg 42.4 p110γ PI3K inhibitor, potential TRPC1/5/6 negative modulator, potential TRPC3/7 positive modulator. 900515-16-4 ≥98% 305.28 C14H8FNO4S C1=CC(=C(C=C1F)O)C2=CC=C(O2)C=C3C(=O)NC(=O)S3 Ambient -20°C "Shi J, Ju M, Large WA, et al. Pharmacological profile of phosphatidylinositol 3-kinases and related phosphatidylinositols mediating endothelin(A) receptor-operated native TRPC channels in rabbit coronary artery myocytes. Br J Pharmacol. 2012 Aug;166(7):2161-75. PMID: 22404177.

 

Pomel V, Klicic J, Covini D, et al. Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma. J Med Chem. 2006 Jun 29;49(13):3857-71. PMID: 16789742.

" Not dangerous goods.

LKT A7200 AS-252424 5 mg 139.5 p110γ PI3K inhibitor, potential TRPC1/5/6 negative modulator, potential TRPC3/7 positive modulator. 900515-16-4 ≥98% 305.28 C14H8FNO4S C1=CC(=C(C=C1F)O)C2=CC=C(O2)C=C3C(=O)NC(=O)S3 Ambient -20°C "Shi J, Ju M, Large WA, et al. Pharmacological profile of phosphatidylinositol 3-kinases and related phosphatidylinositols mediating endothelin(A) receptor-operated native TRPC channels in rabbit coronary artery myocytes. Br J Pharmacol. 2012 Aug;166(7):2161-75. PMID: 22404177.

 

Pomel V, Klicic J, Covini D, et al. Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma. J Med Chem. 2006 Jun 29;49(13):3857-71. PMID: 16789742.

" Not dangerous goods.

LKT A7200 AS-252424 10 mg 242.7 p110γ PI3K inhibitor, potential TRPC1/5/6 negative modulator, potential TRPC3/7 positive modulator. 900515-16-4 ≥98% 305.28 C14H8FNO4S C1=CC(=C(C=C1F)O)C2=CC=C(O2)C=C3C(=O)NC(=O)S3 Ambient -20°C "Shi J, Ju M, Large WA, et al. Pharmacological profile of phosphatidylinositol 3-kinases and related phosphatidylinositols mediating endothelin(A) receptor-operated native TRPC channels in rabbit coronary artery myocytes. Br J Pharmacol. 2012 Aug;166(7):2161-75. PMID: 22404177.

 

Pomel V, Klicic J, Covini D, et al. Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma. J Med Chem. 2006 Jun 29;49(13):3857-71. PMID: 16789742.

" Not dangerous goods.

LKT A0002 A66 1 mg 94.6 p110α PI3K inhibitor. 1166227-08-2 ≥98% 393.53 C17H23N5O2S2 CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CSC(=N3)C(C)(C)C Ambient -20°C "Weigelt B, Warne PH, Lambros MB, et al. PI3K pathway dependencies in endometrioid endometrial cancer cell lines. Clin Cancer Res. 2013 Jul 1;19(13):3533-44. PMID: 23674493.

 

Smith GC, Ong WK, Rewcastle GW, et al. Effects of acutely inhibiting PI3K isoforms and mTOR on regulation of glucose metabolism in vivo. Biochem J. 2012 Feb 15;442(1):161-9. PMID: 22142257.

 

" Not dangerous goods.

LKT A0002 A66 5 mg 266.9 p110α PI3K inhibitor. 1166227-08-2 ≥98% 393.53 C17H23N5O2S2 CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CSC(=N3)C(C)(C)C Ambient -20°C "Weigelt B, Warne PH, Lambros MB, et al. PI3K pathway dependencies in endometrioid endometrial cancer cell lines. Clin Cancer Res. 2013 Jul 1;19(13):3533-44. PMID: 23674493.

 

Smith GC, Ong WK, Rewcastle GW, et al. Effects of acutely inhibiting PI3K isoforms and mTOR on regulation of glucose metabolism in vivo. Biochem J. 2012 Feb 15;442(1):161-9. PMID: 22142257.

 

" Not dangerous goods.

LKT A0002 A66 10 mg 455.1 p110α PI3K inhibitor. 1166227-08-2 ≥98% 393.53 C17H23N5O2S2 CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CSC(=N3)C(C)(C)C Ambient -20°C "Weigelt B, Warne PH, Lambros MB, et al. PI3K pathway dependencies in endometrioid endometrial cancer cell lines. Clin Cancer Res. 2013 Jul 1;19(13):3533-44. PMID: 23674493.

 

Smith GC, Ong WK, Rewcastle GW, et al. Effects of acutely inhibiting PI3K isoforms and mTOR on regulation of glucose metabolism in vivo. Biochem J. 2012 Feb 15;442(1):161-9. PMID: 22142257.

 

" Not dangerous goods.

LKT L9600 LY-2090314 1 mg 118.9 GSK-3 inhibitor. 603288-22-8 ≥98% 512.53 C28H25FN6O3 C1CCN(CC1)C(=O)N2CCN3C=C(C4=CC(=CC(=C43)C2)F)C5=C(C(=O)NC5=O)C6=CN=C7N6C=CC=C7 Ambient 4°C Zamek-Gliszczynski MJ, Abraham TL, Alberts JJ, et al. Pharmacokinetics, metabolism, and excretion of the glycogen synthase kinase-3 inhibitor LY2090314 in rats, dogs, and humans: a case study in rapid clearance by extensive metabolism with low circulating metabolite exposure. Drug Metab Dispos. 2013 Apr;41(4):714-26. PMID: 23305709. Not dangerous goods.

LKT L9600 LY-2090314 5 mg 333.7 GSK-3 inhibitor. 603288-22-8 ≥98% 512.53 C28H25FN6O3 C1CCN(CC1)C(=O)N2CCN3C=C(C4=CC(=CC(=C43)C2)F)C5=C(C(=O)NC5=O)C6=CN=C7N6C=CC=C7 Ambient 4°C Zamek-Gliszczynski MJ, Abraham TL, Alberts JJ, et al. Pharmacokinetics, metabolism, and excretion of the glycogen synthase kinase-3 inhibitor LY2090314 in rats, dogs, and humans: a case study in rapid clearance by extensive metabolism with low circulating metabolite exposure. Drug Metab Dispos. 2013 Apr;41(4):714-26. PMID: 23305709. Not dangerous goods.

LKT L9600 LY-2090314 10 mg 630.9 GSK-3 inhibitor. 603288-22-8 ≥98% 512.53 C28H25FN6O3 C1CCN(CC1)C(=O)N2CCN3C=C(C4=CC(=CC(=C43)C2)F)C5=C(C(=O)NC5=O)C6=CN=C7N6C=CC=C7 Ambient 4°C Zamek-Gliszczynski MJ, Abraham TL, Alberts JJ, et al. Pharmacokinetics, metabolism, and excretion of the glycogen synthase kinase-3 inhibitor LY2090314 in rats, dogs, and humans: a case study in rapid clearance by extensive metabolism with low circulating metabolite exposure. Drug Metab Dispos. 2013 Apr;41(4):714-26. PMID: 23305709. Not dangerous goods.

LKT T4400 TL-32711 1 mg 115.3 Smac mimetic; IAP inhibitor. Birinapant 1260251-31-7 ≥98% 806.94 C42H56F2N8O6 CCC(C(=O)N1CC(CC1CC2=C(NC3=C2C=CC(=C3)F)C4=C(C5=C(N4)C=C(C=C5)F)CC6CC(CN6C(=O)C(CC)NC(=O)C(C)NC)O)O)NC(=O)C(C)NC Ambient 4°C "Ebert G, Allison C, Preston S, et al. Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis. Proc Natl Acad Sci U S A. 2015 May 5;112(18):5803-8. PMID: 25902530.

 

Benetatos CA, Mitsuuchi Y, Burns JM, et al. Birinapant(TL32711), a Bivalent Smac Mimetic, Targets TRAF2-associated cIAPs, Abrogates TNF-induced NF-κB Activation and is Active in Patient-Derived Xenograft Models. Mol Cancer Ther. 2014 Feb 21. [Epub ahead of print]. PMID: 24563541.

 

Carter BZ, Mak PY, Mak DH, et al. Synergistic Targeting of AML Stem/Progenitor Cells With IAP Antagonist Birinapant and Demethylating Agents. J Natl Cancer Inst. 2014 Feb 1;106(2):djt440. PMID: 24526787.

" Not dangerous goods.

LKT T4400 TL-32711 5 mg 333.7 Smac mimetic; IAP inhibitor. Birinapant 1260251-31-7 ≥98% 806.94 C42H56F2N8O6 CCC(C(=O)N1CC(CC1CC2=C(NC3=C2C=CC(=C3)F)C4=C(C5=C(N4)C=C(C=C5)F)CC6CC(CN6C(=O)C(CC)NC(=O)C(C)NC)O)O)NC(=O)C(C)NC Ambient 4°C "Ebert G, Allison C, Preston S, et al. Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis. Proc Natl Acad Sci U S A. 2015 May 5;112(18):5803-8. PMID: 25902530.

 

Benetatos CA, Mitsuuchi Y, Burns JM, et al. Birinapant(TL32711), a Bivalent Smac Mimetic, Targets TRAF2-associated cIAPs, Abrogates TNF-induced NF-κB Activation and is Active in Patient-Derived Xenograft Models. Mol Cancer Ther. 2014 Feb 21. [Epub ahead of print]. PMID: 24563541.

 

Carter BZ, Mak PY, Mak DH, et al. Synergistic Targeting of AML Stem/Progenitor Cells With IAP Antagonist Birinapant and Demethylating Agents. J Natl Cancer Inst. 2014 Feb 1;106(2):djt440. PMID: 24526787.

" Not dangerous goods.

LKT T4400 TL-32711 10 mg 588.5 Smac mimetic; IAP inhibitor. Birinapant 1260251-31-7 ≥98% 806.94 C42H56F2N8O6 CCC(C(=O)N1CC(CC1CC2=C(NC3=C2C=CC(=C3)F)C4=C(C5=C(N4)C=C(C=C5)F)CC6CC(CN6C(=O)C(CC)NC(=O)C(C)NC)O)O)NC(=O)C(C)NC Ambient 4°C "Ebert G, Allison C, Preston S, et al. Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis. Proc Natl Acad Sci U S A. 2015 May 5;112(18):5803-8. PMID: 25902530.

 

Benetatos CA, Mitsuuchi Y, Burns JM, et al. Birinapant(TL32711), a Bivalent Smac Mimetic, Targets TRAF2-associated cIAPs, Abrogates TNF-induced NF-κB Activation and is Active in Patient-Derived Xenograft Models. Mol Cancer Ther. 2014 Feb 21. [Epub ahead of print]. PMID: 24563541.

 

Carter BZ, Mak PY, Mak DH, et al. Synergistic Targeting of AML Stem/Progenitor Cells With IAP Antagonist Birinapant and Demethylating Agents. J Natl Cancer Inst. 2014 Feb 1;106(2):djt440. PMID: 24526787.

" Not dangerous goods.

LKT M4455 MLN-2238 1 mg 118.9 Proteasome inhibitor, miR33b modulator. Ixazomib 1072833-77-2 ≥99% 361.03 C14H19BCl2N2O4 B(C(CC(C)C)NC(=O)CNC(=O)C1=C(C=CC(=C1)Cl)Cl)(O)O Ambient 4°C Tian Z, Zhao JJ, Tai YT, et al. Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells. Blood. 2012 Nov 8;120(19):3958-67. PMID: 22983447. Not dangerous goods.

LKT M4455 MLN-2238 5 mg 333.7 Proteasome inhibitor, miR33b modulator. Ixazomib 1072833-77-2 ≥99% 361.03 C14H19BCl2N2O4 B(C(CC(C)C)NC(=O)CNC(=O)C1=C(C=CC(=C1)Cl)Cl)(O)O Ambient 4°C Tian Z, Zhao JJ, Tai YT, et al. Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells. Blood. 2012 Nov 8;120(19):3958-67. PMID: 22983447. Not dangerous goods.

LKT M4455 MLN-2238 10 mg 630.9 Proteasome inhibitor, miR33b modulator. Ixazomib 1072833-77-2 ≥99% 361.03 C14H19BCl2N2O4 B(C(CC(C)C)NC(=O)CNC(=O)C1=C(C=CC(=C1)Cl)Cl)(O)O Ambient 4°C Tian Z, Zhao JJ, Tai YT, et al. Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells. Blood. 2012 Nov 8;120(19):3958-67. PMID: 22983447. Not dangerous goods.

LKT L9602 LY-2874455 1 mg 118.9 FGFR inhibitor. 1254473-64-7 ≥98% 444.31 C21H19Cl2N5O2 CC(C1=C(C=NC=C1Cl)Cl)OC2=CC3=C(C=C2)NN=C3C=CC4=CN(N=C4)CCO Ambient 4°C Zhao G, Li WY, Chen D, et al. A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models. Mol Cancer Ther. 2011 Nov;10(11):2200-10. PMID: 21900693. Not dangerous goods.

LKT L9602 LY-2874455 5 mg 333.7 FGFR inhibitor. 1254473-64-7 ≥98% 444.31 C21H19Cl2N5O2 CC(C1=C(C=NC=C1Cl)Cl)OC2=CC3=C(C=C2)NN=C3C=CC4=CN(N=C4)CCO Ambient 4°C Zhao G, Li WY, Chen D, et al. A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models. Mol Cancer Ther. 2011 Nov;10(11):2200-10. PMID: 21900693. Not dangerous goods.

LKT L9602 LY-2874455 10 mg 630.9 FGFR inhibitor. 1254473-64-7 ≥98% 444.31 C21H19Cl2N5O2 CC(C1=C(C=NC=C1Cl)Cl)OC2=CC3=C(C=C2)NN=C3C=CC4=CN(N=C4)CCO Ambient 4°C Zhao G, Li WY, Chen D, et al. A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models. Mol Cancer Ther. 2011 Nov;10(11):2200-10. PMID: 21900693. Not dangerous goods.

LKT I5208 INCB-28060 1 mg 78.9 c-MET inhibitor. INC-280, Capmatinib 1029712-80-8 ≥98% 412.42 C23H17FN6O CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F Ambient 4°C Liu X, Wang Q, Yang G, et al. A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3. Clin Cancer Res. 2011 Nov 15;17(22):7127-38. PMID: 21918175. Not dangerous goods.

LKT I5208 INCB-28060 5 mg 212.3 c-MET inhibitor. INC-280, Capmatinib 1029712-80-8 ≥98% 412.42 C23H17FN6O CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F Ambient 4°C Liu X, Wang Q, Yang G, et al. A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3. Clin Cancer Res. 2011 Nov 15;17(22):7127-38. PMID: 21918175. Not dangerous goods.

LKT I5208 INCB-28060 10 mg 345.8 c-MET inhibitor. INC-280, Capmatinib 1029712-80-8 ≥98% 412.42 C23H17FN6O CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F Ambient 4°C Liu X, Wang Q, Yang G, et al. A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3. Clin Cancer Res. 2011 Nov 15;17(22):7127-38. PMID: 21918175. Not dangerous goods.

留言框

  • 产品:

  • 留言内容:

  • 您的单位:

  • 您的姓名:

  • 联系电话:

  • 常用邮箱:

  • 详细地址:

  • 省份:

  • 验证码:

    请输入计算结果(填写阿拉伯数字),如:三加四=7
网站首页 公司简介 产品中心 招聘中心 技术支持 企业动态 联系我们 管理登陆
上海易汇生物科技有限公司主营:Eaivelly封板膜|Eaivelly八联管|Eaivelly针式过滤器|Eaivelly光学平盖|Eaivelly荧光定量|代理GE
GoogleSitemap ICP备案号:沪ICP备16010708号-3 技术支持:化工仪器网
张经理
  • 电话

    021-62962298

在线客服
扫一扫访问手机站扫一扫访问手机站
访问手机站